WO2024073507A1 - Macrocyclic compounds and uses thereof - Google Patents
Macrocyclic compounds and uses thereof Download PDFInfo
- Publication number
- WO2024073507A1 WO2024073507A1 PCT/US2023/075262 US2023075262W WO2024073507A1 WO 2024073507 A1 WO2024073507 A1 WO 2024073507A1 US 2023075262 W US2023075262 W US 2023075262W WO 2024073507 A1 WO2024073507 A1 WO 2024073507A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- independently
- alkyl
- compound
- membered
- unsubstituted
- Prior art date
Links
- 150000002678 macrocyclic compounds Chemical class 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 254
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 80
- 201000011510 cancer Diseases 0.000 claims abstract description 55
- 238000000034 method Methods 0.000 claims abstract description 40
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims abstract description 36
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims abstract description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 27
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims abstract 8
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims abstract 8
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims abstract 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 154
- 125000001424 substituent group Chemical group 0.000 claims description 134
- 125000005647 linker group Chemical group 0.000 claims description 129
- 125000000623 heterocyclic group Chemical group 0.000 claims description 109
- 125000001072 heteroaryl group Chemical group 0.000 claims description 89
- 150000003839 salts Chemical class 0.000 claims description 86
- 229910052736 halogen Inorganic materials 0.000 claims description 82
- 150000002367 halogens Chemical class 0.000 claims description 82
- 125000001931 aliphatic group Chemical group 0.000 claims description 76
- 125000000217 alkyl group Chemical group 0.000 claims description 71
- 239000003446 ligand Substances 0.000 claims description 68
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 63
- 230000035772 mutation Effects 0.000 claims description 55
- 125000004429 atom Chemical group 0.000 claims description 54
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 51
- 229910052757 nitrogen Inorganic materials 0.000 claims description 49
- 125000001624 naphthyl group Chemical group 0.000 claims description 45
- 229910052760 oxygen Inorganic materials 0.000 claims description 44
- 229910052799 carbon Inorganic materials 0.000 claims description 42
- 125000002947 alkylene group Chemical group 0.000 claims description 39
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 33
- 125000002619 bicyclic group Chemical group 0.000 claims description 33
- 229910052717 sulfur Inorganic materials 0.000 claims description 33
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 31
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 31
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 29
- 208000020816 lung neoplasm Diseases 0.000 claims description 27
- 125000005549 heteroarylene group Chemical group 0.000 claims description 26
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 25
- 229910052739 hydrogen Inorganic materials 0.000 claims description 25
- 239000001257 hydrogen Substances 0.000 claims description 25
- 201000005202 lung cancer Diseases 0.000 claims description 23
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 22
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 21
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 19
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 19
- 241000282414 Homo sapiens Species 0.000 claims description 18
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims description 15
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 claims description 15
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 claims description 15
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 15
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims description 14
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims description 14
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 12
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 12
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 11
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 10
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 9
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims description 7
- 125000006585 (C6-C10) arylene group Chemical group 0.000 claims description 6
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 6
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 108091000080 Phosphotransferase Proteins 0.000 abstract description 25
- 102000020233 phosphotransferase Human genes 0.000 abstract description 25
- 238000011282 treatment Methods 0.000 abstract description 19
- 102200048955 rs121434569 Human genes 0.000 abstract description 17
- 238000002560 therapeutic procedure Methods 0.000 abstract description 14
- 238000002360 preparation method Methods 0.000 abstract description 7
- 230000002265 prevention Effects 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 102000001301 EGF receptor Human genes 0.000 description 116
- 108060006698 EGF receptor Proteins 0.000 description 115
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 95
- 239000012634 fragment Substances 0.000 description 84
- -1 digluconate Chemical compound 0.000 description 81
- 235000002639 sodium chloride Nutrition 0.000 description 75
- 239000001064 degrader Substances 0.000 description 64
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 48
- 125000003118 aryl group Chemical group 0.000 description 44
- 125000002950 monocyclic group Chemical group 0.000 description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 39
- 239000000203 mixture Substances 0.000 description 39
- 125000005842 heteroatom Chemical group 0.000 description 36
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 32
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 32
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 27
- 239000001301 oxygen Substances 0.000 description 27
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 25
- 229910052805 deuterium Inorganic materials 0.000 description 25
- 125000003226 pyrazolyl group Chemical group 0.000 description 25
- 201000010099 disease Diseases 0.000 description 24
- 125000004076 pyridyl group Chemical group 0.000 description 24
- 125000003342 alkenyl group Chemical group 0.000 description 22
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 22
- 229920006395 saturated elastomer Polymers 0.000 description 22
- 125000000753 cycloalkyl group Chemical group 0.000 description 21
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 21
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 20
- 208000009956 adenocarcinoma Diseases 0.000 description 20
- 239000000523 sample Substances 0.000 description 20
- 239000011593 sulfur Chemical group 0.000 description 20
- 125000000714 pyrimidinyl group Chemical group 0.000 description 19
- 125000000335 thiazolyl group Chemical group 0.000 description 19
- 125000000304 alkynyl group Chemical group 0.000 description 18
- 125000004432 carbon atom Chemical group C* 0.000 description 18
- 239000000460 chlorine Substances 0.000 description 18
- 229910052801 chlorine Inorganic materials 0.000 description 18
- 125000004122 cyclic group Chemical group 0.000 description 18
- 229910052731 fluorine Inorganic materials 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 17
- 229910052794 bromium Inorganic materials 0.000 description 17
- 125000004093 cyano group Chemical group *C#N 0.000 description 17
- 206010041823 squamous cell carcinoma Diseases 0.000 description 17
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 16
- 101150058395 US22 gene Proteins 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- 125000003545 alkoxy group Chemical group 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 15
- 208000035475 disorder Diseases 0.000 description 15
- 125000003710 aryl alkyl group Chemical group 0.000 description 14
- 150000002431 hydrogen Chemical class 0.000 description 14
- 125000002883 imidazolyl group Chemical group 0.000 description 14
- 125000002971 oxazolyl group Chemical group 0.000 description 14
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 13
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 12
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 12
- 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 12
- 125000004404 heteroalkyl group Chemical group 0.000 description 12
- 208000016992 lung adenocarcinoma in situ Diseases 0.000 description 12
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 238000006467 substitution reaction Methods 0.000 description 12
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 11
- 125000000168 pyrrolyl group Chemical group 0.000 description 11
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 10
- 125000006580 bicyclic heterocycloalkyl group Chemical group 0.000 description 10
- 238000010348 incorporation Methods 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 125000006732 (C1-C15) alkyl group Chemical group 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 150000007523 nucleic acids Chemical group 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 201000009030 Carcinoma Diseases 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
- 210000000349 chromosome Anatomy 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 208000005017 glioblastoma Diseases 0.000 description 8
- 150000002430 hydrocarbons Chemical group 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 206010025323 Lymphomas Diseases 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 7
- 239000012472 biological sample Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 230000000155 isotopic effect Effects 0.000 description 7
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 125000006519 CCH3 Chemical group 0.000 description 6
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- 206010033128 Ovarian cancer Diseases 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- 206010039491 Sarcoma Diseases 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 150000004677 hydrates Chemical class 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 6
- 102200048928 rs121434568 Human genes 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 6
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 6
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 5
- 206010060862 Prostate cancer Diseases 0.000 description 5
- 102000001253 Protein Kinase Human genes 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 5
- 125000004450 alkenylene group Chemical group 0.000 description 5
- 125000004419 alkynylene group Chemical group 0.000 description 5
- 125000003368 amide group Chemical group 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 238000009739 binding Methods 0.000 description 5
- 238000001574 biopsy Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000002648 combination therapy Methods 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 229960001433 erlotinib Drugs 0.000 description 5
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 208000003849 large cell carcinoma Diseases 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 108060006633 protein kinase Proteins 0.000 description 5
- 102200048951 rs121913465 Human genes 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 4
- 206010024612 Lipoma Diseases 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 229960001686 afatinib Drugs 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 125000000732 arylene group Chemical group 0.000 description 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 125000004452 carbocyclyl group Chemical group 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 238000001516 cell proliferation assay Methods 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 229950002205 dacomitinib Drugs 0.000 description 4
- 125000004663 dialkyl amino group Chemical group 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229940093476 ethylene glycol Drugs 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 229960002584 gefitinib Drugs 0.000 description 4
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 4
- 125000001041 indolyl group Chemical group 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- 125000004957 naphthylene group Chemical group 0.000 description 4
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 4
- 229960003278 osimertinib Drugs 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- 238000003566 phosphorylation assay Methods 0.000 description 4
- 239000003380 propellant Substances 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 239000008247 solid mixture Substances 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 125000003003 spiro group Chemical group 0.000 description 4
- 125000000565 sulfonamide group Chemical group 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 3
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 101150039808 Egfr gene Proteins 0.000 description 3
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 3
- 201000008808 Fibrosarcoma Diseases 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 241000239226 Scorpiones Species 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 206010043276 Teratoma Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 3
- 150000001345 alkine derivatives Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical compound C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 description 3
- 208000037765 diseases and disorders Diseases 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 108700021358 erbB-1 Genes Proteins 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 206010016629 fibroma Diseases 0.000 description 3
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 201000010536 head and neck cancer Diseases 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 201000011066 hemangioma Diseases 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 125000005956 isoquinolyl group Chemical group 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 125000005493 quinolyl group Chemical group 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 102200048929 rs121913444 Human genes 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 229910052710 silicon Chemical group 0.000 description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229940124530 sulfonamide Drugs 0.000 description 3
- 150000003456 sulfonamides Chemical class 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PXVFFBGSTYQHRO-REQIQPEASA-N (2S,4R)-1-[(2S)-2-[[7-[4-[(3R)-3-[4-[[4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]benzoyl]sulfamoyl]-2-(trifluoromethylsulfonyl)anilino]-4-phenylsulfanylbutyl]piperazin-1-yl]-7-oxoheptanoyl]amino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide Chemical compound C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)CCCCCC(=O)N1CCN(CC[C@H](CSc2ccccc2)Nc2ccc(cc2S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)c2ccc(cc2)N2CCN(CC3=C(CCC(C)(C)C3)c3ccc(Cl)cc3)CC2)CC1)C(C)(C)C)c1ccc(cc1)-c1scnc1C PXVFFBGSTYQHRO-REQIQPEASA-N 0.000 description 2
- TZZDVPMABRWKIZ-XMOGEVODSA-N (3S)-3-[6-[4-[[1-[4-[(1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl]phenyl]piperidin-4-yl]methyl]piperazin-1-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound OC=1C=C2CC[C@@H]([C@@H](C2=CC=1)C1=CC=C(C=C1)N1CCC(CC1)CN1CCN(CC1)C=1C=C2CN(C(C2=CC=1)=O)[C@@H]1C(NC(CC1)=O)=O)C1=CC=CC=C1 TZZDVPMABRWKIZ-XMOGEVODSA-N 0.000 description 2
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- GNRGNRCQXHMQQV-ZQAZVOLISA-N C1N(CC[C@@H](C1(F)F)N1CCN(C2=CC=C(N[C@H]3CCC(=O)NC3=O)C=C2F)CC1)CC1=C(C=C(C2=CN(C(=O)C(=C2C)C)C)C=C1OC)OC Chemical compound C1N(CC[C@@H](C1(F)F)N1CCN(C2=CC=C(N[C@H]3CCC(=O)NC3=O)C=C2F)CC1)CC1=C(C=C(C2=CN(C(=O)C(=C2C)C)C)C=C1OC)OC GNRGNRCQXHMQQV-ZQAZVOLISA-N 0.000 description 2
- 229940126268 CFT8634 Drugs 0.000 description 2
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 2
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 2
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 2
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 2
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 2
- 102100023263 Cyclin-dependent kinase 10 Human genes 0.000 description 2
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 2
- 102100036329 Cyclin-dependent kinase 3 Human genes 0.000 description 2
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 2
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 2
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 description 2
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 description 2
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 2
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 101100503636 Danio rerio fyna gene Proteins 0.000 description 2
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 2
- 101100314281 Danio rerio trappc11 gene Proteins 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 101100066566 Drosophila melanogaster FER gene Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 101150036586 FES gene Proteins 0.000 description 2
- 101150017750 FGFRL1 gene Proteins 0.000 description 2
- 101150106356 FPS gene Proteins 0.000 description 2
- 101150018370 FRK gene Proteins 0.000 description 2
- 101150018272 FYN gene Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 101150040897 Fgr gene Proteins 0.000 description 2
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 2
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 2
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 2
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 2
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 2
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 2
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 2
- 102100026149 Fibroblast growth factor receptor-like 1 Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 101150004849 HCK gene Proteins 0.000 description 2
- 208000002927 Hamartoma Diseases 0.000 description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000908138 Homo sapiens Cyclin-dependent kinase 10 Proteins 0.000 description 2
- 101000715946 Homo sapiens Cyclin-dependent kinase 3 Proteins 0.000 description 2
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 description 2
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 description 2
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 2
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 2
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 description 2
- 101000878540 Homo sapiens Protein-tyrosine kinase 2-beta Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
- 101000850794 Homo sapiens Tropomyosin alpha-3 chain Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- 102000009308 Mechanistic Target of Rapamycin Complex 2 Human genes 0.000 description 2
- 108010034057 Mechanistic Target of Rapamycin Complex 2 Proteins 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101100268648 Mus musculus Abl1 gene Proteins 0.000 description 2
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 description 2
- CLCTZVRHDOAUGJ-UHFFFAOYSA-N N-[4-(3-chloro-4-cyanophenoxy)cyclohexyl]-6-[4-[[4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindol-5-yl]piperazin-1-yl]methyl]piperidin-1-yl]pyridazine-3-carboxamide Chemical compound FC1=CC2=C(C=C1N1CCN(CC3CCN(CC3)C3=CC=C(N=N3)C(=O)NC3CCC(CC3)OC3=CC(Cl)=C(C=C3)C#N)CC1)C(=O)N(C1CCC(=O)NC1=O)C2=O CLCTZVRHDOAUGJ-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 101100381429 Oryza sativa subsp. japonica BADH2 gene Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000009328 Perro Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 2
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 2
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 2
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 2
- 102000001332 SRC Human genes 0.000 description 2
- 108060006706 SRC Proteins 0.000 description 2
- 101150001535 SRC gene Proteins 0.000 description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000004479 aerosol dispenser Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000006350 alkyl thio alkyl group Chemical group 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000008512 biological response Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 150000005829 chemical entities Chemical class 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 2
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 229940121647 egfr inhibitor Drugs 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000007824 enzymatic assay Methods 0.000 description 2
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 125000005553 heteroaryloxy group Chemical group 0.000 description 2
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 201000010260 leiomyoma Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- ZAJXXUDARPGGOC-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-[3-methyl-3-(4-methylpiperazin-1-yl)but-1-ynyl]quinazolin-6-yl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C)(C)C#CC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1NC(=O)C=C ZAJXXUDARPGGOC-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000002088 nanocapsule Substances 0.000 description 2
- JWNPDZNEKVCWMY-VQHVLOKHSA-N neratinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 JWNPDZNEKVCWMY-VQHVLOKHSA-N 0.000 description 2
- 201000011682 nervous system cancer Diseases 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 125000003566 oxetanyl group Chemical group 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 201000001514 prostate carcinoma Diseases 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 102220014428 rs121913229 Human genes 0.000 description 2
- 102200048795 rs121913428 Human genes 0.000 description 2
- 102220014442 rs147149347 Human genes 0.000 description 2
- 102200048796 rs28929495 Human genes 0.000 description 2
- 230000007781 signaling event Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000000707 stereoselective effect Effects 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 230000034512 ubiquitination Effects 0.000 description 2
- 238000010798 ubiquitination Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- HCMJWOGOISXSDL-UHFFFAOYSA-N (2-isothiocyanato-1-phenylethyl)benzene Chemical compound C=1C=CC=CC=1C(CN=C=S)C1=CC=CC=C1 HCMJWOGOISXSDL-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- XZNORRXEBCTXPB-KHBXAZQSSA-N (2S,4R)-1-[(2S)-2-[[2-[2-[2-[2-[4-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]quinazolin-6-yl]phenoxy]ethoxy]ethoxy]ethoxy]acetyl]amino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide Chemical class CC1=C(SC=N1)C1=CC=C(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)COCCOCCOCCOC2=CC=C(C=C2)C2=CC3=C(C=C2)N=CN=C3NC2=CC(Cl)=C(OCC3=CC(F)=CC=C3)C=C2)C(C)(C)C)C=C1 XZNORRXEBCTXPB-KHBXAZQSSA-N 0.000 description 1
- PQOGZKGXGLHDGS-QQRWPDCKSA-N (2S,4R)-1-[(2S)-2-[[2-[3-[2-[[2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]acetyl]amino]ethoxy]propoxy]acetyl]amino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide Chemical compound C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)COCCCOCCNC(=O)C[C@@H]1N=C(C2=C(SC(C)=C2C)N2C(C)=NN=C12)C1=CC=C(Cl)C=C1)C(C)(C)C)C1=CC=C(C=C1)C1=C(C)N=CS1 PQOGZKGXGLHDGS-QQRWPDCKSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- 102100039126 5-hydroxytryptamine receptor 7 Human genes 0.000 description 1
- 101710150237 5-hydroxytryptamine receptor 7 Proteins 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- ULXXDDBFHOBEHA-ONEGZZNKSA-N Afatinib Chemical compound N1=CN=C2C=C(OC3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-ONEGZZNKSA-N 0.000 description 1
- 241000576133 Alphasatellites Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 206010073106 Bone giant cell tumour malignant Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 201000005262 Chondroma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 101710099953 DNA mismatch repair protein msh3 Proteins 0.000 description 1
- 238000013382 DNA quantification Methods 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 208000007033 Dysgerminoma Diseases 0.000 description 1
- 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 description 1
- 101710201734 E3 protein Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 102220541677 Epidermal growth factor receptor_G873E_mutation Human genes 0.000 description 1
- 102220542395 Epidermal growth factor receptor_V689M_mutation Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 208000007659 Fibroadenoma Diseases 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000000527 Germinoma Diseases 0.000 description 1
- 208000007569 Giant Cell Tumors Diseases 0.000 description 1
- 201000005409 Gliomatosis cerebri Diseases 0.000 description 1
- 206010018404 Glucagonoma Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019629 Hepatic adenoma Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000005045 Interdigitating dendritic cell sarcoma Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000002404 Liver Cell Adenoma Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 230000037364 MAPK/ERK pathway Effects 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 102220483920 N-alpha-acetyltransferase 15, NatA auxiliary subunit_L814P_mutation Human genes 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- BTYYWOYVBXILOJ-UHFFFAOYSA-N N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide Chemical compound C12=CC(NC(=O)C#CC)=CC=C2N=CN=C1NC1=CC=CC(Br)=C1 BTYYWOYVBXILOJ-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091005461 Nucleic proteins Chemical group 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000000035 Osteochondroma Diseases 0.000 description 1
- 208000027067 Paget disease of bone Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102220474480 Protection of telomeres protein 1_K806E_mutation Human genes 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 241000720974 Protium Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102000002490 Rad51 Recombinase Human genes 0.000 description 1
- 108010068097 Rad51 Recombinase Proteins 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 208000005678 Rhabdomyoma Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 1
- 229910007157 Si(OH)3 Inorganic materials 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102220466979 Tetratricopeptide repeat protein 21B_K846R_mutation Human genes 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102000018478 Ubiquitin-Activating Enzymes Human genes 0.000 description 1
- 108010091546 Ubiquitin-Activating Enzymes Proteins 0.000 description 1
- 102000003431 Ubiquitin-Conjugating Enzyme Human genes 0.000 description 1
- 108060008747 Ubiquitin-Conjugating Enzyme Proteins 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 208000009311 VIPoma Diseases 0.000 description 1
- 206010048214 Xanthoma Diseases 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000002718 adenomatoid tumor Diseases 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000003140 astrocytic effect Effects 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 208000016738 bone Paget disease Diseases 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 201000009480 botryoid rhabdomyosarcoma Diseases 0.000 description 1
- 238000002725 brachytherapy Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000003149 breast fibroadenoma Diseases 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 201000002143 bronchus adenoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 102220364104 c.2407C>T Human genes 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 241000902900 cellular organisms Species 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 201000005217 chondroblastoma Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 201000010305 cutaneous fibrous histiocytoma Diseases 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 125000004976 cyclobutylene group Chemical group 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004979 cyclopentylene group Chemical group 0.000 description 1
- 125000004980 cyclopropylene group Chemical group 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 125000005508 decahydronaphthalenyl group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 238000009261 endocrine therapy Methods 0.000 description 1
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N gamma-butyrolactam Natural products O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 201000003911 head and neck carcinoma Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 201000002735 hepatocellular adenoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000004405 heteroalkoxy group Chemical group 0.000 description 1
- 125000005114 heteroarylalkoxy group Chemical group 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000005020 hydroxyalkenyl group Chemical group 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 201000005264 laryngeal carcinoma Diseases 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 201000004593 malignant giant cell tumor Diseases 0.000 description 1
- 201000000289 malignant teratoma Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 201000004662 neurofibroma of spinal cord Diseases 0.000 description 1
- 208000004649 neutrophil actin dysfunction Diseases 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 208000003388 osteoid osteoma Diseases 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000005564 oxazolylene group Chemical group 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000002661 proton therapy Methods 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000005551 pyridylene group Chemical group 0.000 description 1
- HNJBEVLQSNELDL-YZRHJBSPSA-N pyrrolidin-2-one Chemical group O=C1CC[14CH2]N1 HNJBEVLQSNELDL-YZRHJBSPSA-N 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 102200048976 rs1051753269 Human genes 0.000 description 1
- 102220198016 rs1057519828 Human genes 0.000 description 1
- 102220198017 rs1057519829 Human genes 0.000 description 1
- 102200110940 rs121912714 Human genes 0.000 description 1
- 102220197915 rs121913231 Human genes 0.000 description 1
- 102220014433 rs121913418 Human genes 0.000 description 1
- 102220197916 rs121913418 Human genes 0.000 description 1
- 102220197912 rs121913430 Human genes 0.000 description 1
- 102200048948 rs121913443 Human genes 0.000 description 1
- 102220197911 rs121913446 Human genes 0.000 description 1
- 102220198062 rs121913464 Human genes 0.000 description 1
- 102220197913 rs121913466 Human genes 0.000 description 1
- 102220198020 rs139236063 Human genes 0.000 description 1
- 102220344457 rs139429793 Human genes 0.000 description 1
- 102220198150 rs149840192 Human genes 0.000 description 1
- 102200163521 rs16885 Human genes 0.000 description 1
- 102220074259 rs180177181 Human genes 0.000 description 1
- 102220180550 rs372150492 Human genes 0.000 description 1
- 102220014449 rs397517116 Human genes 0.000 description 1
- 102200048946 rs397517126 Human genes 0.000 description 1
- 102200048950 rs397517128 Human genes 0.000 description 1
- 102220028266 rs398122743 Human genes 0.000 description 1
- 102220035909 rs483352806 Human genes 0.000 description 1
- 102220035912 rs483352807 Human genes 0.000 description 1
- 102200048797 rs727504256 Human genes 0.000 description 1
- 102220055958 rs727504263 Human genes 0.000 description 1
- 102220122598 rs76625876 Human genes 0.000 description 1
- 102220071724 rs794728408 Human genes 0.000 description 1
- 102200048947 rs864621996 Human genes 0.000 description 1
- 102220315803 rs866926882 Human genes 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000008684 selective degradation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 208000004548 serous cystadenocarcinoma Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000010703 silicon Chemical group 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
- 125000005557 thiazolylene group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 150000003556 thioamides Chemical class 0.000 description 1
- 150000003558 thiocarbamic acid derivatives Chemical class 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000004952 trihaloalkoxy group Chemical group 0.000 description 1
- 125000004385 trihaloalkyl group Chemical group 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 208000022271 tubular adenoma Diseases 0.000 description 1
- 230000014848 ubiquitin-dependent protein catabolic process Effects 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 208000009540 villous adenoma Diseases 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- MACROCYCLIC COMPOUNDS AND USES THEREOF CROSS-REFERENCE TO RELATED APPLICATIONS [0001]
- the present application claims priority to U.S. Provisional Application No. 63/410,823, filed on September 28, 2022, and which is hereby incorporated by reference in its entirety.
- FIELD OF THE INVENTION [0002] Described herein are macrocyclic compounds that can be used as kinase inhibitors.
- compounds described herein can inhibit epidermal growth factor receptor (EGFR), including mutant forms of EGFR.
- Compounds described herein can be effective for treating various disorders that include cancers such as EGFR-driven cancers (e.g., non-small cell lung cancer (NSCLC) characterized by mutant EGFR).
- NSCLC non-small cell lung cancer
- Signal transduction refers to the transmission of stimulatory or inhibitory signals into and within a cell leading, often via a cascade of signal transmission events, to a biological response within the cell. Defects in various components of signal transduction pathways have been found to account for a large number of diseases, including numerous forms of cancer, inflammatory disorders, metabolic disorders, vascular and neuronal diseases. [0004] Signal transduction is often mediated by certain proteins called kinases. Kinases can generally be classified into protein kinases and lipid kinases, and certain kinases exhibit dual specificities.
- epidermal growth factor receptor belongs to a family of receptor tyrosine kinases (RTKs) that include EGFR/ERBB1, HER2/ERBB2/NEU, HER3/ERBB3, and HER4/ERBB4.
- RTKs receptor tyrosine kinases
- EGF epidermal growth factor
- Activated EGFR then phosphorylates its substrates, resulting in activation of multiple downstream pathways within the cell, including the PI3K-AKT-mTOR pathway, which is involved in cell survival, and the RAS-RAF-MEK-ERK pathway, which is involved in cell proliferation.
- PI3K-AKT-mTOR pathway which is involved in cell survival
- RAS-RAF-MEK-ERK pathway which is involved in cell proliferation.
- the first step in selective degradation is the ligation of one or more ubiquitin molecules to a protein substrate.
- Ubiquitination occurs through the activity of ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2), and ubiquitin-protein ligases (E3), which act sequentially to catalyze the attachment of ubiquitin to lysine residues of substrate proteins (see Ciechanover A., et al., BioEssays, 22:442–451 (2000)).
- E3 protein ligases confer specificity to ubiquitination reactions by binding directly to substrate.
- New therapeutic methods therefore remain necessary for treating cancers associated with defective signal transduction pathways, including EGFR-driven cancers and cancers which develop resistance to one or more therapies.
- EGFR-driven cancers such as non-small cell lung cancer (NSCLC) characterized by mutant EGFR.
- NSCLC non-small cell lung cancer
- the present compounds can be useful as proteolysis-targetic chimera (PROTAC) therapies for the treatment of mutant EGFR, including EGFR comprising one or more resistance mutations.
- PROTAC proteolysis-targetic chimera
- a compound of Formula (AI) has a structure selected from the group consisting of: or a pharmaceutically acceptable salt thereof, wherein R 2 is H, unsubstituted C 1-6 alkyl or C 1-6 alkyl substituted by a group that is unsubstituted C 3-6 cycloalkyl; each X 8 , X 9 , and X 10 , when present, is CH or N.
- L 1 -L 2 -X 5 when present is CH(CH 3 )-(CH 2 ) 2 -O, CH(CH 3 )-(CH 2 ) 3 -O, CH(CH 2 CH 3 )-(CH 2 ) 2 -O, C(CH 3 ) 2 -(CH 2 ) 2 -O, (CH 2 ) 3 -O, CH 2 -CH(CH 3 )CH 2 -O, CH 2 - CH 2 CH(CH 3 )-O, CH(CH 3 )-(CH 2 ) 2 -NH, CH(CH 3 )-(CH 2 ) 2 -NCH 3 , CH(CH 3 )-(CH 2 ) 3 - NH, CH(CH 3 )-(CH 2 ) 3 -NCH 3 , CH(CH 3 )-(CH 2 ) 3 , or CH(CH 3 )-(CH 2 ) 4 , or L 1 -L 2 -X 5 is [0012
- a compound is selected from the group consisting of the compounds of Table A2, or a pharmaceutically acceptable salt thereof.
- the invention features a compound having a structure according to Formula (BI): or a pharmaceutically acceptable salt thereof, wherein A 1 is independently phenylene or 5- or 6-membered heteroarylene; A 2 is independently phenyl, naphthyl, or a 5- to 13-membered heteroaryl; X 1 is independently O or X 1A ; X 1A is a covalent bond, S, NR 4 , C 1-6 alkylene, C 2-6 alkenylene, or C 2-6 alkynylene; each of X 2 and X 3 is independently N or CR 1B ; L 1 is independently a covalent bond or C 1-6 alkylene; L 2 is independently a covalent bond, C 2-6 alkenylene, C 2-6 alkynylene, C 3-6 cycloalkylene, 3- to 10-membered heterocycl
- a compound of Formula (BI) has a structure selected from the group consisting of: or a pharmaceutically acceptable salt thereof.
- the compound is according to Formula (BIX), (BX), or (BXI), or a pharmaceutically acceptable salt thereof, wherein L 1 is C 1 -C 6 alkylene optionally substituted by 1, 2, or 3 R 13 ; each R 13 is independently unsubstituted C 1 -C 3 alkyl; and R 1A is independently unsubstitued C 1 -C 6 alkyl or C 1 -C 6 haloalkyl;
- the compound is according to Formula (BXII), or a pharmaceutically acceptable salt thereof, wherein R 1A is independently unsubstitued C 1 -C 6 alkyl or C 1 -C 6 haloalkyl; or
- the compound is according to Formula (BXIII) or (BXIV), or a pharmaceutically acceptable salt thereof, wherein L
- a compound is selected from the group consisting of the compounds of Table B2, or a pharmaceutically acceptable salt thereof.
- the invention features a compound having a structure according to Formula (CI): or a pharmaceutically acceptable salt thereof, wherein X 2 is independently N or CR 5 ; each of X 3 and X 4 is independently a covalent bond, O, S, NR 6 , C(O)NR 6 , NR 6 C(O), NR 6 C(O)NR 6 , or (C(R 7 ) 2 ) q ; L 1 is independently a covalent bond, C 1-6 heteroalkylene, C 1-6 alkylene, C 2-6 alkenylene, C 2-6 alkynylene, C 3-6 cycloalkylene, 3- to 10-membered heterocyclylene, phenylene, or 5- to 10-membered heteroarylene; each R 1 is independently L P -E, (Substructure A), OH, CN, halogen, C
- R 4A is a first R 4 group
- R 4B is a second R 4 group
- R 4C is a third R 4 group
- R 4D is a fourth R 4 group, preferably R 4 is unsubstituted C 1-6 alkyl if one or more of R 4A , R 4B , and R 4C is also present
- p is 0 or 1.
- a compound is selected from the group consisting of the compounds of Table C2 and Table C3, or a pharmaceutically acceptable salt thereof.
- E is selected from the group consisting of:
- a linker L P is a covalent bond.
- a linker L P comprises a C 1 -C 20 alkylene, a C 2 -C 20 heteroalkylene, a C 2 -C 20 monoalkynylene, and/or one or more ethyleneglycol moieties.
- a linker L P comprises a heterocyclyl moiety that is attached to the EGFR ligand moiety of the compound via a covalent bond or via a CH 2 or C(O) linker.
- a linker L P comprises a substructure F1 or a substructure F2 , wherein * denotes the point of attachment to the EGFR ligand moiety of the compound.
- a linker L P does not comprise a heterocyclyl moiety that is attached to the EGFR ligand moiety of the compound via a covalent bond or via a CH 2 or C(O) linker.
- –L P -E comprises a structure or is a structure selected from the group consisting of:
- –L P -E is a structure selected from the group consisting of:
- the invention features a pharmaceutical composition comprising any compound described herein, or a pharmaceutically acceptable salt thereof.
- the invention features a method of treating cancer comprising administering to a human in need thereof an effective amount of any compound described herein, or a pharmaceutically acceptable salt thereof, in a pharmaceutical composition.
- a cancer is a lung cancer.
- a cancer is non-small cell lung cancer.
- a cancer e.g., a lung cancer such as non-small cell lung cancer
- a cancer is an EGFR-driven cancer.
- a cancer e.g., a lung cancer such as non-small cell lung cancer
- a cancer is characterized by an EGFR mutation.
- animal refers to any member of the animal kingdom. In some embodiments, “animal” refers to humans, at any stage of development. In some embodiments, “animal” refers to non-human animals, at any stage of development.
- the non-human animal is a mammal (e.g., a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a sheep, a bovine, a primate, and/or a pig).
- animals include, but are not limited to, mammals, birds, reptiles, amphibians, fish, insects, and/or worms.
- an animal may be a transgenic animal, genetically-engineered animal, and/or a clone.
- the terms “improve,” “increase,” or “reduce,” or grammatical equivalents indicate values that are relative to a baseline measurement, such as a measurement in the same individual prior to initiation of the treatment described herein, or a measurement in a control subject (or multiple control subject) in the absence of the treatment described herein.
- a “control subject” is a subject afflicted with the same form of disease as the subject being treated, who is about the same age as the subject being treated.
- in vitro refers to events that occur in an artificial environment, e.g., in a test tube or reaction vessel, in cell culture, etc., rather than within a multi-cellular organism.
- in Vivo refers to events that occur within a multi- cellular organism, such as a human and a non-human animal. In the context of cell-based systems, the term may be used to refer to events that occur within a living cell (as opposed to, for example, in vitro systems).
- a patient refers to any organism to which a provided composition may be administered, e.g., for experimental, diagnostic, prophylactic, cosmetic, and/or therapeutic purposes. Typical patients include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and/or humans). In some embodiments, a patient is a human. A human includes pre- and post-natal forms.
- compositions are pharmaceutically acceptable.
- pharmaceutically acceptable refers to substances that, within the scope of sound medical judgment, are suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. Accordingly, pharmaceutically acceptable relates to substances that are not biologically or otherwise undesirable, i.e., the material can be administered to an individual along with the relevant active compound without causing clinically unacceptable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained.
- Pharmaceutically acceptable salt Pharmaceutically acceptable salts are well known in the art. For example, S. M.
- Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases.
- suitable inorganic and organic acids and bases examples include those derived from suitable inorganic and organic acids and bases.
- pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid, or by using other methods used in the art such as ion exchange.
- salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2- naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate
- Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C 1–4 -alkyl) 4 salts.
- Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
- Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium. quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, sulfonate, and aryl sulfonate.
- compositions include salts formed from the quarternization of an amine using an appropriate electrophile, e.g., an alkyl halide, to form a quarternized alkylated amino salt.
- subject refers to a human or any non-human animal (e.g., mouse, rat, rabbit, dog, cat, cattle, swine, sheep, horse or primate).
- a human includes pre- and post-natal forms.
- a subject is a human being.
- a subject can be a patient, which refers to a human presenting to a medical provider for diagnosis or treatment of a disease.
- subject is used herein interchangeably with “individual” or “patient.”
- a subject can be afflicted with or is susceptible to a disease or disorder but may or may not display symptoms of the disease or disorder.
- Substantially refers to the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest.
- biological and chemical phenomena rarely, if ever, go to completion and/or proceed to completeness or achieve or avoid an absolute result.
- the term “substantially” is therefore used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.
- therapeutically effective amount As used herein, the term “therapeutically effective amount” of a therapeutic agent means an amount that is sufficient, when administered to a subject suffering from or susceptible to a disease, disorder, and/or condition, to treat, diagnose, prevent, and/or delay the onset of the symptom(s) of the disease, disorder, and/or condition. It will be appreciated by those of ordinary skill in the art that a therapeutically effective amount is typically administered via a dosing regimen comprising at least one unit dose.
- Treating refers to any method used to partially or completely alleviate, ameliorate, relieve, inhibit, prevent, delay onset of, reduce severity of and/or reduce incidence of one or more symptoms or features of a particular disease, disorder, and/or condition. Treatment may be administered to a subject who does not exhibit signs of a disease and/or exhibits only early signs of the disease for the purpose of decreasing the risk of developing pathology associated with the disease.
- a term e.g., alkyl or aryl
- prefix roots e.g., alk- or ar-
- affixing the suffix “-ene” to a group indicates the group is a divalent moiety, e.g., arylene is the divalent moiety of aryl
- heteroarylene is the divalent moiety of heteroaryl
- heterocycloalkylene is the divalent moiety of heterocycloalkyl.
- Alkyl As used herein, the term “alkyl” means acyclic linear and branched hydrocarbon groups, e.g. “C 1 -C 20 alkyl” refers to alkyl groups having 1–20 carbons and “ C 1 –C 4 alkyl” refers to alkyl groups having 1–4 carbons. Alkyl groups include C 1 -C 20 alkyl, C 1 -C 15 alkyl, C 1 –C 10 alkyl, C 1 –C 4 alkyl, and C 1 –C 3 alkyl).
- an alkyl group is C 1 –C 4 alkyl.
- An alkyl group may be linear or branched. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl tert-pentylhexyl, isohexyl, etc.
- the term “lower alkyl” means an alkyl group straight chain or branched alkyl having 1 to 6 carbon atoms. Other alkyl groups will be readily apparent to those of skill in the art given the benefit of the present disclosure.
- An alkyl group may be unsubstituted or substituted with one or more substituent groups as described herein.
- an alkyl group may be substituted with one or more (e.g., 1, 2, 3, 4, 5, or 6 independently selected substituents) of halogen, -COR’, -CO 2 H, -CO 2 R’, -CN, -OH, -OR’, - OCOR’, -OCO 2 R’, -NH 2 , -NHR’, -N(R’) 2 , -SR’ or-SO 2 R’, wherein each instance of R’ independently is C 1 -C 20 aliphatic (e.g., C 1 -C 20 alkyl, C 1 -C 15 alkyl, C 1 –C 10 alkyl, C 1 –C 4 alkyl, or C 1 –C 3 alkyl).
- R’ independently is an unsubstituted alkyl (e.g., unsubstituted C 1 -C 20 alkyl, C 1 -C 15 alkyl, C 1 –C 10 alkyl, or C 1 –C 3 alkyl). In some embodiments, R’ independently is unsubstituted C 1 –C 3 alkyl. In some embodiments, the alkyl is substituted (e.g., with 1, 2, 3, 4, 5, or 6 substituent groups as described herein).
- an alkyl group is substituted with a–OH group and may also be referred to herein as a “hydroxyalkyl” group, where the prefix denotes the –OH group and “alkyl” is as described herein.
- an alkyl group is substituted with a–OR’ group.
- Alkylene represents a saturated divalent straight or branched chain hydrocarbon group and is exemplified by methylene, ethylene, isopropylene and the like.
- alkenylene represents an unsaturated divalent straight or branched chain hydrocarbon group having one or more unsaturated carbon-carbon double bonds that may occur in any stable point along the chain
- alkynylene herein represents an unsaturated divalent straight or branched chain hydrocarbon group having one or more unsaturated carbon-carbon triple bonds that may occur in any stable point along the chain.
- an alkylene, alkenylene, or alkynylene group may comprise one or more cyclic aliphatic and/or one or more heteroatoms such as oxygen, nitrogen, or sulfur and may optionally be substituted with one or more substituents such as alkyl, halo, alkoxyl, hydroxy, amino, aryl, ether, ester or amide.
- an alkylene, alkenylene, or alkynylene may be substituted with one or more (e.g., 1, 2, 3, 4, 5, or 6 independently selected substituents) of halogen, -COR’, -CO 2 H, -CO 2 R’, -CN, -OH, -OR’, -OCOR’, -OCO 2 R’, -NH 2 , -NHR’, -N(R’) 2 , -SR’ or -SO 2 R’, wherein each instance of R’ independently is C 1 –C 20 aliphatic (e.g., C 1 -C 20 alkyl, C 1 -C 15 alkyl, C 1 –C 10 alkyl, or C 1 –C 3 alkyl).
- R independently is C 1 –C 20 aliphatic (e.g., C 1 -C 20 alkyl, C 1 -C 15 alkyl, C 1 –C 10 alkyl, or C 1 –C 3 alky
- R’ independently is an unsubstituted alkyl (e.g., unsubstituted C 1 -C 20 alkyl, C 1 – C 15 alkyl, C 1 –C 10 alkyl, or C 1 –C 3 alkyl). In some embodiments, R’ independently is unsubstituted C 1 –C 3 alkyl. In certain embodiments, an alkylene, alkenylene, or alkynylene is unsubstituted. In certain embodiments, an alkylene, alkenylene, or alkynylene does not include any heteroatoms.
- alkenyl means any linear or branched hydrocarbon chains having one or more unsaturated carbon-carbon double bonds that may occur in any stable point along the chain, e.g. “C 2 -C 20 alkenyl” refers to an alkenyl group having 2–20 carbons.
- an alkenyl group includes prop-2-enyl, but-2-enyl, but-3-enyl, 2-methylprop-2- enyl, hex-2-enyl, hex-5-enyl, 2,3-dimethylbut-2-enyl, and the like.
- the alkenyl comprises 1, 2, or 3 carbon-carbon double bond.
- the alkenyl comprises a single carbon-carbon double bond. In some embodiments, multiple double bonds (e.g., 2 or 3) are conjugated.
- An alkenyl group may be unsubstituted or substituted with one or more substituent groups as described herein.
- an alkenyl group may be substituted with one or more (e.g., 1, 2, 3, 4, 5, or 6 independently selected substituents) of halogen, -COR’, -CO 2 H, -CO 2 R’, -CN, -OH, -OR’, -OCOR’, -OCO 2 R’, -NH 2 , -NHR’, - N(R’) 2 , -SR’ or-SO 2 R’, wherein each instance of R’ independently is C 1 –C 20 aliphatic (e.g., C 1 -C 20 alkyl, C 1 -C 15 alkyl, C 1 –C 10 alkyl, or C 1 –C 3 alkyl).
- R independently is C 1 –C 20 aliphatic (e.g., C 1 -C 20 alkyl, C 1 -C 15 alkyl, C 1 –C 10 alkyl, or C 1 –C 3 alkyl).
- R’ independently is an unsubstituted alkyl (e.g., unsubstituted C 1 -C 20 alkyl, C 1 -C 15 alkyl, C 1 –C 10 alkyl, or C 1 –C 3 alkyl). In some embodiments, R’ independently is unsubstituted C 1 -C 3 alkyl. In some embodiments, the alkenyl is unsubstituted. In some embodiments, the alkenyl is substituted (e.g., with 1, 2, 3, 4, 5, or 6 substituent groups as described herein).
- alkenyl group is substituted with a–OH group and may also be referred to herein as a “hydroxyalkenyl” group, where the prefix denotes the –OH group and “alkenyl” is as described herein.
- alkynyl means any hydrocarbon chain of either linear or branched configuration, having one or more carbon-carbon triple bonds occurring in any stable point along the chain, e.g. “C 2 -C 20 alkynyl” refers to an alkynyl group having 2–20 carbons.
- an alkynyl group examples include prop-2-ynyl, but-2-ynyl, but-3-ynyl, pent-2- ynyl, 3-methylpent-4-ynyl, hex-2-ynyl, hex-5-ynyl, etc.
- an alkynyl comprises one carbon-carbon triple bond.
- An alkynyl group may be unsubstituted or substituted with one or more substituent groups as described herein.
- an alkynyl group may be substituted with one or more (e.g., 1, 2, 3, 4, 5, or 6 independently selected substituents) of halogen, -COR’, -CO 2 H, -CO 2 R’, -CN, -OH, -OR’, -OCOR’, -OCO 2 R’, -NH 2 , -NHR’, -N(R’) 2 , -SR’ or-SO 2 R’, wherein each instance of R’ independently is C 1 -C 20 aliphatic (e.g., C 1 -C 20 alkyl, C 1 -C 15 alkyl, C 1 –C 10 alkyl, or C 1 –C 3 alkyl).
- R independently is C 1 -C 20 aliphatic (e.g., C 1 -C 20 alkyl, C 1 -C 15 alkyl, C 1 –C 10 alkyl, or C 1 –C 3 alkyl).
- R’ independently is an unsubstituted alkyl (e.g., unsubstituted C 1 -C 20 alkyl, C 1 – C 15 alkyl, C 1 –C 10 alkyl, or C 1 –C 3 alkyl). In some embodiments, R’ independently is unsubstituted C 1 –C 3 alkyl. In some embodiments, the alkynyl is unsubstituted. In some embodiments, the alkynyl is substituted (e.g., with 1, 2, 3, 4, 5, or 6 substituent groups as described herein).
- Alkoxy refers to the group -O-alkyl, including from 1 to 10 carbon atoms of a straight, branched, saturated cyclic configuration and combinations thereof, attached to the parent molecular structure through an oxygen. Examples include methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, pentoxy, cyclopropyloxy, cyclohexyloxy and the like. “Lower alkoxy” refers to alkoxy groups containing one to six carbons. In some embodiments, C 1-4 alkoxy is an alkoxy group which encompasses both straight and branched chain alkyls of from 1 to 4 carbon atoms.
- alkoxy group can be optionally substituted by one or more substituents (e.g., as described herein for alkyl).
- substituents e.g., as described herein for alkyl.
- alkenoxy and alkynoxy mirror the above description of “alkoxy” wherein the prefix “alk” is replaced with “alken” or “alkyn” respectively, and the parent “alkenyl” or “alkynyl” terms are as described herein.
- amide refers to a chemical moiety with formula -C(O)N(R’) 2 , -C(O)N(R’)-, -NR’C(O)R’, or -NR’C(O)-, where each R’ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl (bonded through a chain carbon), cycloalkyl, aryl, arylalkyl, heteroaryl (bonded through a ring carbon), heteroarylalkyl, or heterocycloalkyl (bonded through a ring carbon), unless stated other-wise in the specification, each of which moiety can itself be optionally substituted as described herein, or two R’ can combine with the nitrogen atom to form a 3-, 4-, 5-, 6-, or 7-membered ring.
- amino refers to a -N(R’) 2 group, where each R’ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl (bonded through a chain carbon), cycloalkyl, aryl, arylalkyl, heteroaryl (bonded through a ring carbon), heteroarylalkyl, or heterocycloalkyl (bonded through a ring carbon), unless stated otherwise in the specification, each of which moiety can itself be optionally substituted as described herein, or two R’ can combine with the nitrogen atom to form a 3-, 4-, 5-, 6-, or 7-membered ring.
- an amino group is –NHR’, where R’ is aryl (“arylamino”), heteroaryl (“heteroarylamino”), or alkyl (“alkylamino”).
- R’ is aryl (“arylamino”), heteroaryl (“heteroarylamino”), or alkyl (“alkylamino”).
- Aryl used alone or as part of a larger moiety as in “aralkyl,” refers to a monocyclic, bicyclic, or tricyclic carbocyclic ring system having a total of six to fourteen ring members, wherein said ring system has a single point of attachment to the rest of the molecule, wherein at least one ring in the system is aromatic, and wherein each ring in the system contains 4 to 7 ring members.
- an aryl group has 6 ring carbon atoms (“C 6 aryl,” e.g., phenyl). In some embodiments, an aryl group has 10 ring carbon atoms (“C 10 aryl,” e.g., naphthyl such as 1-naphthyl and 2-naphthyl). In some embodiments, an aryl group has 14 ring carbon atoms (“C 14 aryl,” e.g., anthracyl).
- Aryl also includes ring systems wherein the aryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the radical or point of attachment is on the aryl ring, and in such instances, the number of carbon atoms continue to designate the number of carbon atoms in the aryl ring system.
- Exemplary aryls include phenyl, naphthyl, and anthracene.
- Arylalkyl refers to an –(alkylene)-aryl radical where aryl and alkylene are as disclosed herein and which are optionally substituted by one or more of the exemplary substituent groups described herein.
- arylalkyl is bonded to the parent molecular structure through the alkylene moiety.
- arylalkoxy refers to an -O- [arylalkyl] radical (-O-[(alkylene)-aryl]), which is attached to the parent molecular structure through the oxygen.
- Arylene refers to an aryl group that is divalent (that is, having two points of attachment to the molecule). Exemplary arylenes include phenylene (e.g., unsubstituted phenylene or substituted phenylene).
- Cyclic The term “cyclic” as used herein, refers to any covalently closed structure.
- Cyclic moieties include, for example, carbocycles (e.g., aryls and cycloalkyls), heterocycles (e.g., heteroaryls and heterocycloalkyls), aromatics (e.g. aryls and heteroaryls), and non- aromatics (e.g., cycloalkyls and heterocycloalkyls).
- cyclic moieties are optionally substituted.
- cyclic moieties form part of a ring system.
- Cycloaliphatic The term “cycloaliphatic” refers to a monocyclic or polycyclic radical that contains only carbon and hydrogen, and can be saturated or partially unsaturated.
- Fully saturated cycloaliphatics can be termed “cycloalkyl”.
- Partially unsaturated cycloalkyl groups can be termed “cycloalkenyl” if the carbocycle contains at least one double bond, or "cycloalkynyl” if the carbocycle contains at least one triple bond.
- Cycloaliphatic groups include groups having from 3 to 13 ring atoms (e.g., C 3–13 cycloalkyl).
- a numerical range such as “3 to 10” refers to each integer in the given range; e.g., “3 to 10 carbon atoms” means that the cycloaliphatic group (e.g., cycloalkyl) can consist of 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, etc., up to and including 10 carbon atoms.
- the term “cycloaliphatic” also includes bridged and spiro-fused cyclic structures containing no heteroatoms.
- the term also includes monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of ring atoms) groups.
- Polycyclic cycloaliphatic groups include bicycles, tricycles, tetracycles, and the like.
- cycloalkyl can be a C 3-8 cycloalkyl group.
- cycloalkyl can be a C 3-5 cycloalkyl group.
- C 3–6 cycloaliphatic groups include, without limitation, cyclopropyl (C 3 ), cyclobutyl (C 4 ), cyclopentyl (C 5 ), cyclopentenyl (C 5 ), cyclohexyl (C 6 ), cyclohexenyl (C 6 ), cyclohexadienyl (C 6 ) and the like.
- C 3–7 cycloaliphatic groups include norbornyl (C 7 ).
- C 3-8 cycloaliphatic groups include the aforementioned C3–7 carbocyclyl groups as well as cycloheptyl(C 7 ), cycloheptadienyl (C 7 ), cyclohept-atrienyl (C 7 ), cyclooctyl (C 8 ), bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, and the like.
- Examples of C 3-13 cycloaliphatic groups include the aforementioned C 3-8 carbocyclyl groups as well as octahydro-1H indenyl, decahydronaphthalenyl, spiro[4.5]decanyl, and the like.
- Cyano refers to a –CN group.
- Deuterium The term “deuterium” is also called heavy hydrogen. Deuterium is isotope of hydrogen with a nucleus consisting of one proton and one neutron, which is double the mass of the nucleus of ordinary hydrogen (one proton). In embodiments, deuterium can also be identified as 2 H.
- Ester refers to a group of formula –C(O)OR’ or –R’OC(O)-, where R’ is selected from alkyl, alkenyl, alkynyl, heteroalkyl (bonded through a chain carbon), cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, or heterocycloalkyl as described herein.
- R is selected from alkyl, alkenyl, alkynyl, heteroalkyl (bonded through a chain carbon), cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, or heterocycloalkyl as described herein.
- Halogen or Halo As used herein, the term “halogen” or “halo” means fluorine, chlorine, bromine, or iodine.
- Heteroalkyl is meant a branched or unbranched alkyl, alkenyl, or alkynyl group having from 1 to 14 carbon atoms in addition to 1, 2, 3 or 4 heteroatoms independently selected from the group consisting of N, O, S, and P.
- Heteroalkyls include tertiary amines, secondary amines, ethers, thioethers, amides, thioamides, carbamates, thiocarbamates, hydrazones, imines, phosphodiesters, phosphoramidates, sulfonamides, and disulfides.
- a heteroalkyl group may optionally include monocyclic, bicyclic, or tricyclic rings, in which each ring desirably has three to six members.
- heteroalkyls include polyethers, such as methoxymethyl and ethoxyethyl. Accordingly, the term “heteroalkoxy” refers to the group -O-heteroalkyl, where the group is attached to the parent molecular structure via the oxygen.
- Heteroalkylene The term “heteroalkylene,” as used herein, represents a divalent form of a heteroalkyl group as described herein.
- Heteroaryl refers to a monocyclic, bicyclic, or tricyclic carbocyclic ring system having a total of six to fourteen ring members, wherein said ring system has a single point of attachment to the rest of the molecule, wherein at least one ring in the system is aromatic, wherein each ring in the system contains 4 to 7 ring members, and wherein at least one ring atom is a heteroatom such as, but not limited to, nitrogen and oxygen.
- heteroaryl groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxal
- heteroaryloxy refers to the group -O-heteroaryl, where the group is attached to the parent molecular structure via the oxygen.
- Heteroarylalkyl refers to an –(alkylene)-heteroaryl radical where heteroaryl and alkylene are as disclosed herein and which are optionally substituted by one or more of the exemplary substituent groups described herein.
- the “heteroarylalkyl” group is bonded to the parent molecular structure through the alkylene moiety.
- heteroarylalkoxy refers to an -O-[heteroarylalkyl] radical (-O-[(alkylene)-heteroaryl]), which is attached to the parent molecular structure through the oxygen.
- Heterocycloalkyl is a non-aromatic ring wherein at least one atom is a heteroatom such as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus, and the remaining atoms are carbon.
- heterocycloalkyl groups are pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H- pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithiany
- heterocycloalkyl group can be substituted or unsubstituted.
- Heterocycle refers to groups containing one to four heteroatoms each selected from O, S and N, wherein each heterocycle group has from 4 to 10 atoms in its ring system, and with the proviso that the ring of said group does not contain two adjacent O or S atoms.
- the number of carbon atoms in a heterocycle is indicated (e.g., C 1 –C 6 -heterocycle), at least one other atom (the heteroatom) must be present in the ring.
- Designations such as “C 1 –C 6 -heterocycle” refer only to the number of carbon atoms in the ring and do not refer to the total number of atoms in the ring. In some embodiments, it is understood that the heterocycle ring has additional heteroatoms in the ring. Designations such as “4–6-membered heterocycle” refer to the total number of atoms that are contained in the ring (i.e., a four, five, or six membered ring, in which at least one atom is a carbon atom, at least one atom is a heteroatom and the remaining two to four atoms are either carbon atoms or heteroatoms).
- heterocycles that have two or more heteroatoms, those two or more heteroatoms are the same or different from one another.
- heterocycles are optionally substituted.
- binding to a heterocycle is at a heteroatom or via a carbon atom.
- Heterocycloalkyl groups include groups having only 4 atoms in their ring system, but heteroaryl groups must have at least 5 atoms in their ring system.
- the heterocycle groups include benzo-fused ring systems.
- An example of a 4-membered heterocycle group is azetidinyl (derived from azetidine).
- An example of a 5-membered heterocycle group is thiazolyl.
- a 6-membered heterocycle group is pyridyl
- an example of a 10-membered heterocycle group is quinolinyl.
- the foregoing groups are C-attached or N-attached where such is possible.
- a group derived from pyrrole is pyrrol-1-yl (N-attached) or pyrrol-3-yl (C- attached).
- a group derived from imidazole is imidazol-1-yl or imidazol-3-yl (both N-attached) or imidazol-2-yl, imidazol-4-yl or imidazol-5-yl (all C- attached).
- a heterocycle group is a monoradical or a diradical (i.e., a heterocyclene group).
- the heterocycles described herein are substituted with 0, 1, 2, 3, or 4 substituents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylthio, alkylthioalkyl, alynyl, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxyl, hydroxyalkylene, mercapto, nitro, amino, and amido moities.
- Isotope refers to a variant of a particular chemical element which differs in neutron number, and consequently in nucleon number.
- Nitro refers to a –NO 2 group.
- Moiety refers to a specific segment or functional group of a molecule. Chemical moieties are often recognized chemical entities embedded in or appended to a molecule. [0079] Molecular groups herein may be substituted or unsubstituted (e.g., as described herein).
- substituted means that the specified group or moiety bears one or more substituents: at least one hydrogen present on a group atom (e.g., a carbon or nitrogen atom) is replaced with a permissible substituent, e.g., a substituent which upon substitution for the hydrogen results in a stable compound, e.g., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction.
- a permissible substituent e.g., a substituent which upon substitution for the hydrogen results in a stable compound, e.g., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction.
- unsubstituted means that the specified group bears no substituents.
- optionally substituted means that the specified group is unsubstituted or substituted by one or more substituents.
- substituted is used to describe a structural system, the substitution is meant to occur at any valency-allowed position on the system.
- a group described herein is substituted.
- a group described herein is unsubstituted.
- a specified moiety or group is not expressly noted as being optionally substituted or substituted with any specified substituent, it is understood that such a moiety or group is intended to be unsubstituted.
- substituents include but are not limited to alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, arylalkyl, alkylaryl, aryl, heteroaryl, heterocycloalkyl, hydroxyalkyl, arylalkyl, aminoalkyl, haloalkyl, thioalkyl, alkylthioalkyl, carboxyalkyl, imidazolylalkyl, indolylalkyl, mono-, di- and trihaloalkyl, mono-, di- and trihaloalkoxy, amino, alkylamino, dialkylamino, alkoxy, hydroxy, halo (e.g., —Cl and —Br), nitro, oximino, —COOR 50 , —COR 50 , —SO 0-2 R 50 , —SO 2 NR 50 R 51 , —NR 52 SO 2 R 50 , ⁇ C(
- R 50 and R 51 can be joined together to form a carbocyclic or heterocyclic ring system.
- the substituent is selected from halogen, -COR’, -CO 2 H, - CO 2 R’, -CN, -OH, -OR’, -OCOR’, -OCO 2 R’, -NH 2 , -NHR’, -N(R’) 2 , -SR’, and -SO 2 R’, wherein each instance of R’ independently is C 1 -C 20 aliphatic (e.g., C 1 -C 20 alkyl, C 1 -C 15 alkyl, C 1 –C 10 alkyl, or C 1 –C 3 alkyl).
- R’ independently is an unsubstituted alkyl (e.g., unsubstituted C 1 –C 20 alkyl, C 1 –C 15 alkyl, C 1 –C 10 alkyl, or C 1 –C 3 alkyl).
- R’ independently is unsubstituted C 1 –C 3 alkyl.
- any formula given herein is intended to represent a racemate, one or more enantiomeric forms, one or more diastereomeric forms, one or more atropisomeric forms, and mixtures thereof.
- certain structures may exist as geometric isomers (i.e., cis and trans isomers), as tautomers, or as atropisomers.
- any formula given herein is intended to embrace hydrates, solvates, and polymorphs of such compounds, and mixtures thereof.
- EGFR Inhibitors Compounds of the invention can be be effective as as proteolysis-targetic chimera (PROTAC) therapies, including for the treatment of cancers characterized by mutant EGFR, including EGFR comprising one or more resistance mutations.
- PROTAC proteolysis-targetic chimera
- EGFR PROTAC compounds described herein comprise the following structural features: (1) a ligand targeting EGFR; (2) a linker L P , wherein the linker is covalently attached to the ligand and an E3 ubiquitin ligase ligand; and (3) a moiety E, which is an E3 ubiquitin ligase ligand.
- a linker L P wherein the linker is covalently attached to the ligand and an E3 ubiquitin ligase ligand
- E which is an E3 ubiquitin ligase ligand.
- any exemplary permitted feature for ligands, linkers L P , and moieties E can be used in any combination to arrive at suitable compounds.
- Exemplary ligands Exemplary ligands
- Exemplary EGFR ligands that can be incorporated into the compounds described herein include any of the EGFR inhibitor formulas and compounds described in any of the below disclosures, each of which is incorporated in its reference in its entirety: • International Patent Publication No. WO2021/168074 (“Class A ligands”); • International Patent Application No. PCT/US22/21999 (“Class B ligands”); and • International Patent Application No. PCT/US22/28755 (“Class C ligands”).
- a compound of the invention as described herein comprises or is derived from a Class A ligand, including any formulae or specific compound as described in WO2021/168074, including any compound according to any one of Formulas (I), (I’), (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (I-H), and (I-J), such as any one of Compounds (1)-(58), (61)-(71), (73)-(80), and (82)-(193), or a pharmaceutically acceptable salt thereof.
- a Class A ligand including any formulae or specific compound as described in WO2021/168074, including any compound according to any one of Formulas (I), (I’), (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (I-H), and (I-J), such as any one of Compounds (1)-(58), (61)-(
- a compound of the invention as described herein comprises or is derived from a Class B ligand, including any formulae or specific compound as described in PCT/US22/21999, including any compound according to any one of Formulas (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII), and (XIV) such as any one of Compounds (1)-(71), or a pharmaceutically acceptable salt thereof.
- a compound of the invention as described herein comprises or is derived from a Class C ligand, including any formulae or specific compound as described in PCT/US22/28755, including any compound according to Formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII), (XIV), (XV), (XVI), (XVII), (XVIII), (XIX), (XX), (XXI), (XXII), and (XXIII), such as any one of Compounds (1)-(169), or a pharmaceutically acceptable salt thereof.
- a derivative of a formula or compound described in any of WO2021/168074, PCT/US22/21999, and PCT/US22/28755 includes modification of a formula or compound to include a functional group for covalent attachment to the L P -E moiety (e.g., as described herein).
- An exemplary derivative includes modification of any formula or compound described in WO2021/168074, PCT/US22/21999, and PCT/US22/28755 to comprise a piperazine or piperazine-containing group that is covalently attached to an L P -E moiety.
- a compound of the invention as described herein comprises or is derived from a Class A ligand, wherein said ligand is according to or derived from any one of Formulas (I), (I’), (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (I-H), and (I-J) of WO2021/168074, such as any one of Compounds (1)-(58), (61)-(71), (73)-(80), and (82)- (193), or a pharmaceutically acceptable salt thereof.
- the invention features a compound having a structure according to Formula (AI), or a pharmaceutically acceptable salt thereof, wherein: A is C 6-10 arylene, 5-12-membered heteroarylene, or 5-12-membered heterocycloalkylene; X 1 is N or CR X ; X 2 is N or CR X ; X 3 is N or CR X” ; X 4 is N or CR X” ; X 6 is N or CR X’ ; X 7 is N or CR X’ ; ------ represents an optional double bond between X 7 and X 4 or X 4 and X 6 , wherein one and only one double bond is present; X 5 is a covalent bond, CH 2 , O, NR 4 , C(O)NR 4 , or NR 4 C(O); L 1 is a covalent bond or C(R 5 ) 2 , and L 2 is C 1-4 alkylene, or L 1 and L 2 combine
- X 7 is N and X 4 is CR X .
- X 7 is C and X 4 is CR X .
- X 7 is N and X 4 is N.
- X 6 is N.
- X 6 is CR X (e.g., C-H).
- ------ represents a double bond between X 6 and X 4 , and there is a single bond between X 7 and X 4 .
- X 6 is C
- X 4 is CR X .
- X 6 is C
- X 4 is N.
- X 7 is N.
- X 7 is CR X (e.g., C-H).
- A is C 6-10 arylene.
- A is unsubstituted C 6-10 arylene.
- A is substituted C 6-10 arylene (e.g., comprising 1, 2, 3, or 4 substituents as described herein).
- A is 5-12-membered heteroarylene. In embodiments, A is unsubstituted 5-12-membered heteroarylene. In embodiments, A is substituted 5-12-membered heteroarylene (e.g., comprising 1, 2, 3, or 4 substituents as described herein). [0102] In embodiments, A is 5-12-membered heterocycloalkylene. In embodiments, A is unsubstituted 5-12-membered heterocycloalkylene. In embodiments, A is substituted 5-12- membered heterocycloalkylene (e.g., comprising 1, 2, 3, or 4 substituents as described herein). [0103] In embodiments, X 1 is N.
- X 1 is CR X (e.g., C-H or C-CH 3 ).
- X 2 is N.
- X 2 is CR X (e.g., C-H or C-CH 3 ).
- X 3 is N.
- X 3 is CR X” (e.g., C-H or C-CH 3 ).
- X 4 is N.
- X 4 is CR X” (e.g., C-H or C-CH 3 ).
- X 6 is N.
- X 6 is CR X’ (e.g., C, C-H, or C-CH 3 ).
- X 7 is N.
- X 7 is CR X’ (e.g., C, C-H, or C-CH 3 ).
- X 5 is a covalent bond.
- X 5 is CH 2 .
- X 5 is O.
- X 5 is NR 4 (e.g., NH or NCH 3 ).
- X 5 is C(O)NR 4 (e.g., C(O)NH or C(O)CH 3 ).
- X 5 is NR 4 C(O) (e.g., NHC(O) or NCH 3 C(O)).
- L 1 is a covalent bond or C(R 5 ) 2
- L 2 is C 1-4 alkylene.
- L 1 is a covalent bond.
- L 1 is C(R 5 ) 2 (e.g., CH 2 , CHCH 3 , CH(CH 2 CH 3 ), or C(CH 3 ) 2 ).
- L 2 is unsubstituted C 1-4 alkylene (e.g. CH 2 , (CH 2 ) 2 , (CH 2 ) 3 , or (CH 2 ) 4 ).
- L 1 and L 2 combine to form a C 3-6 cycloalkyl or a 4- to 6-membered heterocycloalkyl.
- L 1 and L 2 combine to form a C 3-6 cycloalkyl.
- L 1 and L 2 combine to form cyclopropyl.
- L 1 and L 2 combine to form cyclobutyl.
- L 1 and L 2 combine to form cyclopentyl.
- L 1 and L 2 combine to form cyclohexyl. In embodiments, L 1 and L 2 combine to form an unsubstituted C 4-6 cycloalkyl. In embodiments, L 1 and L 2 combine to form a substituted C 4-6 cycloalkyl (e.g., comprising 1, 2, or 3 substituents as described herein). In embodiments, L 1 and L 2 combine to form a 4- to 6-membered heterocycloalkyl. In embodiments, L 1 and L 2 combine to form tetrahydropyranyl. In embodiments, L 1 and L 2 combine to form an unsubstituted 4- to 6-membered heterocycloalkyl.
- L 1 and L 2 combine to form a substituted 4- to 6-membered heterocycloalkyl (e.g., comprising 1, 2, or 3 substituents as described herein).
- R 1 is halogen.
- R 1 is C 1-6 alkyl.
- R 1 is C 3-7 cycloalkyl.
- R 1 is C 6-10 aryl.
- R 1 is 5- to 10-membered heteroaryl (e.g., monocyclic or bicyclic heteroaryl).
- R 1 is 3- to 10-membered heterocycloalkyl (e.g., monocyclic or bicyclic heterocycloalkyl).
- R 1 is CN.
- R 1 is NR 6 R 7 . In embodiments, R 1 is NR 6 C(O)R 7 . In embodiments, R 1 is NR 6 C(O)NH 2 . In embodiments, R 1 is OR 8 . In embodiments, R 1 is C(O)NR 6 R 7 . [0113] In embodiments, R 1 is unsubstituted C 1-6 alkyl. In embodiments, R 1 is unsubstituted C 3-7 cycloalkyl. In embodiments, R 1 is unsubstituted C 6-10 aryl. In embodiments, R 1 is unsubstituted 5- to 10-membered heteroaryl (e.g., unsubstituted monocyclic or bicyclic heteroaryl).
- R 1 is unsubstituted 3- to 10-membered heterocycloalkyl (e.g., unsubstituted monocyclic or bicyclic heterocycloalkyl).
- R 1 is –L P -E.
- R 1 optionally further comprises -L P -E.
- R 1 further comprises -L P -E.
- R 1 is substituted C 1-6 alkyl.
- R 1 is substituted C 3-7 cycloalkyl.
- R 1 is substituted C 6-10 aryl.
- R 1 is substituted 5- to 10-membered heteroaryl (e.g., substituted monocyclic or bicyclic heteroaryl). In embodiments, R 1 is substituted 3- to 10-membered heterocycloalkyl (e.g., substituted monocyclic or bicyclic heterocycloalkyl). In embodiments, a substituted group comprises 1, 2, or 3 substituent groups as described herein.
- R 1 is a substituted or unsubstituted 5- or 6-membered heteroarylene; a substituted or unsubstituted 5- or 6-membered heterocycloalkyl, C 1-6 alkyl substituted by a 5- or 6-membered heteroarylene that is substituted or unsubstituted; or C 1-6 alkyl substituted by a 5- or 6-membered heterocycloalkyl that is substituted or unsubstituted, or substituted phenyl.
- R 2 is absent.
- R 2 is H.
- R 2 is C 1-6 alkyl.
- R 2 is halogen.
- R 2 is CN.
- R 2 is C 1-6 alkoxy. In embodiments, R 2 is unsubstituted C 1-6 alkyl. In embodiments, R 2 is substituted C 1-6 alkyl (e.g., comprising 1, 2, or 3 substituent groups as described herein). In embodiments, R 2 is unsubstituted C 1-6 alkoxy. In embodiments, R 2 is substituted C 1-6 alkoxy (e.g., comprising 1, 2, or 3 substituent groups as described herein). [0117] In embodiments, R 3 is not present. In embodiments, R 3 is present. In embodiments, R 3 is OH. In embodiments, R 3 is CN. In embodiments, R 3 is halogen. In embodiments, R 3 is C 1-6 alkyl.
- R 3 is C 1-6 alkoxy. In embodiments, R 3 is unsubstituted C 1-6 alkyl. In embodiments, R 3 is substituted C 1-6 alkyl (e.g., comprising 1, 2, or 3 substituent groups as described herein). In embodiments, R 3 is unsubstituted C 1-6 alkoxy. In embodiments, R 3 is substituted C 1-6 alkoxy (e.g., comprising 1, 2, or 3 substituent groups as described herein). [0118] In embodiments, n is 0. In embodiments, n is 1. In embodiments, n is 2. [0119] In embodiments, R X is H. In embodiments, R X is OR X1 . In embodiments, R X is CN.
- R X is halogen. In embodiments, R X is C 1-6 alkyl. In embodiments, R X is unsubstituted C 1-6 alkyl. In embodiments, R X is substituted C 1-6 alkyl (e.g., comprising 1, 2, or 3 substituent groups as described herein). [0120] In embodiments, R X’ is H. In embodiments, R X’ is OR X1 . In embodiments, R X’ is CN. In embodiments, R X’ is halogen. In embodiments, R X’ is C 1-6 alkyl. In embodiments, R X’ is absent if the carbon to which it is attached is part of a double bond.
- R X is H. In embodiments, R X” is OR X1 . In embodiments, R X” is CN. In embodiments, R X” is halogen. In embodiments, R X” is C 1-6 alkyl. In embodiments, R X” is absent if the carbon to which it is attached is part of a double bond. In embodiments, R X” is – L P -E. In embodiments, when R X” is not –L P -E, R 1 optionally further comprises -L P -E. In embodiments, R X” further comprises -L P -E. [0122] In embodiments, R X1 is H.
- R X1 is C 1-6 alkyl. In embodiments, R X1 is unsubstituted C 1-6 alkyl. In embodiments, R X1 is substituted C 1-6 alkyl (e.g., comprising 1, 2, or 3 substituent groups as described herein). [0123] In embodiments, R 4 is H. embodiments, R 4 is C 1-6 alkyl. In embodiments, R 4 is unsubstituted C 1-6 alkyl. In embodiments, R 4 is substituted C 1-6 alkyl (e.g., comprising 1, 2, or 3 substituent groups as described herein). [0124] In embodiments, R 5 is H. embodiments, R 5 is C 1-6 alkyl.
- R 5 is unsubstituted C 1-6 alkyl. In embodiments, R 5 is substituted C 1-6 alkyl (e.g., comprising 1, 2, or 3 substituent groups as described herein).
- R 6 is H. In embodiments, R 6 is C 1-6 alkyl. In embodiments, R 6 is C 3-7 cycloalkyl. In embodiments, R 6 is 3- to 10-membered heterocycloalkyl (e.g. monocyclic or bicyclic heterocycloalkyl). In embodiments, R 6 is unsubstituted C 1-6 alkyl. In embodiments, R 6 is unsubstituted C 3-7 cycloalkyl.
- R 6 is unsubstituted 3- to 10-membered heterocycloalkyl (e.g. monocyclic or bicyclic heterocycloalkyl).
- R 6 is substituted C 1-6 alkyl (e.g., comprising 1, 2, or 3 substituent groups as described herein).
- R 6 is substituted C 3-7 cycloalkyl (e.g., comprising 1, 2, or 3 substituent groups as described herein).
- R 6 is substituted 3- to 10-membered heterocycloalkyl (e.g. a monocyclic or bicyclic heterocycloalkyl comprising 1, 2, or 3 substituent groups as described herein).
- R 7 is H.
- R 7 is C 1-6 alkyl. In embodiments, R 7 is C 3-7 cycloalkyl. In embodiments, R 7 is 3- to 10-membered heterocycloalkyl (e.g. monocyclic or bicyclic heterocycloalkyl). In embodiments, R 7 is unsubstituted C 1-6 alkyl. In embodiments, R 7 is unsubstituted C 3-7 cycloalkyl. In embodiments, R 7 is unsubstituted 3- to 10-membered heterocycloalkyl (e.g. monocyclic or bicyclic heterocycloalkyl). In embodiments, R 7 is substituted C 1-6 alkyl (e.g., comprising 1, 2, or 3 substituent groups as described herein).
- R 7 is substituted C 3-7 cycloalkyl (e.g., comprising 1, 2, or 3 substituent groups as described herein).
- R 7 is substituted 3- to 10-membered heterocycloalkyl (e.g. a monocyclic or bicyclic heterocycloalkyl comprising 1, 2, or 3 substituent groups as described herein).
- R 6 and R 7 together with the nitrogen atom to which they are attached form a 3- to 8-membered heterocycloalkyl ring (e.g., monocyclic or bicyclic heterocycloalkyl).
- R 8 is H.
- R 8 is C 1-6 alkyl.
- R 8 is 4- to 6-membered heterocycloalkyl.
- R 8 is unsubstituted C 1-6 alkyl.
- R 8 is substituted C 1-6 alkyl (e.g., comprising 1, 2, or 3 substituent groups as described herein).
- R 8 is a substituted C 1-6 alkyl that is piperidinyl substituted C 1-6 alkyl (e.g., -CH 2 CH 2 (piperidinyl)).
- R 8 is unsubstituted 4- to 6- membered heterocycloalkyl.
- R 8 is substituted 4- to 6-membered heterocycloalkyl (e.g., comprising 1, 2, or 3 substituent groups as described herein).
- a compound of the invention comprising a Class A ligand has a structure selected from the following formulas selected from Table A1.
- an E moiety is selected from those described in Table D, where shows the point of covalent attachment to moiety L P .
- -L P -E is according to any of substructures (D1)- (D49) as described herein.
- -L P -E is according to any of substructures (D1)’- (D49)’ as described herein. Table A1.
- R 2 is H, unsubstituted C 1-6 alkyl or C 1-6 alkyl substituted by a group that is unsubstituted C 3-6 cycloalkyl.
- each X 8 , X 9 , and X 10 when present, is CH or N.
- L 1 -L 2 -X 5 when present is CH(CH 3 )-(CH 2 ) 2 -O, CH(CH 3 )-(CH 2 ) 3 -O, CH(CH 2 CH 3 )-(CH 2 ) 2 -O, C(CH 3 ) 2 -(CH 2 ) 2 -O, (CH 2 ) 3 -O, CH 2 -CH(CH 3 )CH 2 -O, CH 2 - CH 2 CH(CH 3 )-O, CH(CH 3 )-(CH 2 ) 2 -NH, CH(CH 3 )-(CH 2 ) 2 -NCH 3 , CH(CH 3 )-(CH 2 ) 3 - NH, CH(CH 3 )-(CH 2 ) 3 -NCH 3 , CH(CH 3 )-(CH 2 ) 3 , or CH(CH 3 )-(CH 2 ) 4 , or L 1 -L 2 -X 5 is [0133
- R 2 is unsubstituted C 1-6 alkyl or C 1-6 alkyl substituted by a group that is unsubstituted C 3-6 cycloalkyl.
- the compound comprises a ligand formed from any one Compounds (1)-(58), (61)-(71), (73)-(80), and (82)-(193) of WO2021/168074, or a pharmaceutically acceptable salt thereof.
- the compound comprises a ligand derived from any one of Compounds (1)-(58), (61)-(71), (73)-(80), and (82)-(193) of WO2021/168074, or a pharmaceutically acceptable salt thereof.
- the compound of WO2021/168074 is modified to include a piperazine- or piperazine-containing group covalently attached to the -L P -E group as described herein.
- the compound is selected from any of the following compounds of Table A2, or a pharmaceutically acceptable salt thereof.
- an E moiety is selected from those described in Table D, where shows the point of covalent attachment to moiety L P .
- -L P -E is according to any of substructures (D1)-(D49) as described herein. Table A2.
- the invention features compounds comprising a Class B ligand.
- a compound of the invention as described herein comprises or is derived from a Class B ligand, wherein said ligand is according to or derived from any one of Formulas (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII), and (XIV) of PCT/US22/21999 such as any one of Compounds (1)-(71), or a pharmaceutically acceptable salt thereof.
- Certain exemplary structure features are described herein.
- Exemplary structural formulae and compounds can feature any combination of features as described herein.
- E and L P are according to any embodiments described herein, as well as any combinations thereof.
- the invention features a compound having a structure according to Formula (BI), or a pharmaceutically acceptable salt thereof, wherein A 1 is independently phenylene or 5- or 6-membered heteroarylene; A 2 is independently phenyl, naphthyl, or a 5- to 13-membered heteroaryl; X 1 is independently O or X 1A ; X 1A is a covalent bond, S, NR 4 , C 1-6 alkylene, C 2-6 alkenylene, or C 2-6 alkynylene; each of X 2 and X 3 is independently N or CR 1B ; L 1 is independently a covalent bond or C 1-6 alkylene; L 2 is independently a covalent bond, C 2-6 alkenylene, C
- a 2 is naphthyl or a bicyclic 8- to 12-membered heteroaryl.
- X 2 is N.
- X 2 is CR 1B (e.g., CH).
- X 3 is N.
- X 3 is CR 1B (e.g., CH).
- each of X 2 and X 3 is N.
- each of X 2 and X 3 is CR 1B .
- each of X 2 and X 3 is CH.
- one of X 2 and X 3 is N, and the other is CR 1B (e.g., CH). In embodiments, at least one of X 2 and X 3 is N.
- X 1 is X 1A .
- X 1A is a covalent bond.
- X 1A is S or NR 4 .
- X 1A is C 1-6 alkylene, C 2-6 alkenylene, or C 2-6 alkynylene.
- L 1 is a covalent bond.
- L 1 is unsubstituted branched C 1-6 alkylene, or linear C 1-6 alkylene optionally comprising a -OH substituent.
- X 1 is X 1A , wherein X 1A is a covalent bond, C 1-6 alkylene, C 2-6 alkenylene, or C 2-6 alkynylene; L 1 is independently a covalent bond or C 1-6 alkylene; L 2 is independently a covalent bond, C 2-6 alkenylene, C 2-6 alkynylene, C 3-6 cycloalkylene, 3- to 10-membered heterocyclylene, phenylene, or 5- or 6-membered heteroarylene; and where at least one of X 1A , L 1 , and L 2 is a covalent bond.
- one X 1A and L 1 is a covalent bond and the other is C 1-6 alkylene; and L 2 is a covalent bond.
- each of L 1 and L 2 is a covalent bond.
- each of X 1A and L 2 is a covalent bond.
- each of X 1A and L 1 is a covalent bond.
- X 2 is N.
- X 2 is CR 1B (e.g., CH).
- X 3 is N.
- X 3 is CR 1B (e.g., CH).
- each of X 2 and X 3 is N.
- each of X 2 and X 3 is CR 1B . In embodiments, each of X 2 and X 3 is CH. In embodiments, one of X 2 and X 3 is N, and the other is CR 1B (e.g., CH). In embodiments, at least one of X 2 and X 3 is N.
- a 1 is phenylene. In embodiments, A 1 is unsubstituted phenylene. In embodiments, A 1 is substituted phenylene (e.g., comprising 1 or 2 substituents as described herein). In embodiments, A 1 is 5- or 6-membered heteroarylene.
- Examplary 5- to 6-membered heteroarylene includes but is not limited to pyridylene, pyrimidylene, pyrazolylene, thiazolylene, oxazolylene, and imidazolylene.
- a 1 is unsubstituted 5- or 6- membered heteroarylene.
- a 1 is substituted 5- or 6-membered heteroarylene (e.g., comprising 1 or 2 substituents as described herein).
- a 1 is pyrazolylene.
- a 1 is unsubstituted pyrazolylene.
- a 1 is substituted pyrazolylene (e.g., comprising 1 or 2 substituents as described herein).
- a 1 is N-substituted pyrazolylene (e.g., N-methyl pyrazolylene).
- a 2 is phenyl. In embodiments, A 2 is unsubstituted phenyl. In embodiments, A 2 is substituted phenyl (e.g., comprising 1 or 2 substituents as described herein).
- a 2 is naphthyl. In embodiments, A 2 is unsubstituted naphthyl. In embodiments, A 2 is substituted naphthyl (e.g., comprising 1 or 2 substituents as described herein).
- a 2 is 5- to 13-membered heteroaryl (e.g., monocyclic or bicyclic heteroaryl).
- a 2 is a monocyclic 5- to 6-membered heteroaryl.
- Examplary monocyclic 5- to 6-membered heteroaryls include but are not limited to pyridyl, pyrimidyl, pyrazolyl, thiazolyl, oxazolyl, and imidazolyl.
- a 2 is a bicyclic 8- to 12-membered heteroaryl (e.g., nitrogen-containing, bicyclic 8- to 12-membered heteroaryl).
- Examplary bicyclic 8- to 12-membered heteroaryls include but are not limited to indolyl, benzimidazolyl, indazolyl, isoindolyl, pyrrolopyrimidyl, pyrrolopyridinyl, pyrazolopyrimidyl, pyrazolopyridinyl, benzotriazolyl, quinolyl, and isoquinolyl.
- a 2 is pyrazolyl.
- a 2 is unsubstituted 5- to 13-membered heteroaryl (e.g., unsubstituted monocyclic or bicyclic heteroaryl).
- a 2 is unsubstituted monocyclic 5- to 6-membered heteroaryls.
- a 2 is unsubstituted pyridyl, unsubstituted pyrimidyl, unsubstituted pyrazolyl, unsubstituted thiazolyl, unsubstituted oxazolyl, or unsubstituted imidazolyl.
- a 2 is unsubstituted bicyclic 8- to 12-membered heteroaryl (e.g., unsubstituted nitrogen-containing, bicyclic 8- to 12-membered heteroaryl).
- a 2 is unsubstituted indolyl, unsubstituted benzimidazolyl, unsubstituted indazolyl, unsubstituted isoindolyl, unsubstituted pyrrolopyrimidyl, unsubstituted pyrrolopyridinyl, unsubstituted pyrazolopyrimidyl, unsubstituted pyrazolopyridinyl, unsubstituted benzotriazolyl, unsubstituted quinolyl, or unsubstituted isoquinolyl.
- a 2 is unsubstituted pyrazolyl.
- a 2 is substituted 5- to 13-membered heteroaryl (e.g., substituted monocyclic or bicyclic heteroaryl comprising 1 or 2 substituents as described herein). In embodiments, A 2 is substituted monocyclic 5- to 6-membered heteroaryls. In embodiments, A 2 is substituted pyridyl, substituted pyrimidyl, substituted pyrazolyl, substituted thiazolyl, substituted oxazolyl, or substituted imidazolyl. In embodiments, A 2 is substituted bicyclic 8- to 12- membered heteroaryl (e.g., substituted nitrogen-containing, bicyclic 8- to 12-membered heteroaryl).
- a 2 is substituted indolyl, substituted benzimidazolyl, substituted indazolyl, substituted isoindolyl, substituted pyrrolopyrimidyl, substituted pyrrolopyridinyl, substituted pyrazolopyrimidyl, substituted pyrazolopyridinyl, substituted benzotriazolyl, substituted quinolyl, or substituted isoquinolyl.
- Examplary substituent groups include but are not limited to methyl, halogen (e.g. F, Cl, Br, or I), and CN.
- a 2 is substituted pyrazolyl (e.g, N-substituted pyrazolyl such as N-methyl pyrazolyl).
- a 2 is naphthyl or a bicyclic 8- to 12-membered heteroaryl.
- X 1 is not O.
- R 1A is H.
- R 1A is OH.
- R 1A is CN.
- R 1A is halogen (e.g., F, Cl, Br, or I).
- R 1A is C 1-6 aliphatic.
- R 1A is unsubstituted C 1-6 aliphatic. In embodiments, R 1A is substituted C 1-6 aliphatic (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R 1A is C 1-6 alkoxy. In embodiments, R 1A is unsubstituted C 1-6 alkoxy. In embodiments, R 1A is substituted C 1-6 alkoxy (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R 1A is NR 6 R 7 . In embodiments, R 1A is C(O)R 8 . In embodiments, R 1A is CO 2 R 8 . In embodiments, R 1A is C(O)NR 6 R 7 .
- R 1A is NR 9 C(O)R 8 . In embodiments, R 1A is NR 9 CO 2 R 8 . In embodiments, R 1A is NR 9 C(O)NR 6 R 7 . In embodiments, R 1A is R 10 . In embodiments, R 1A is CH 3 , CH 2 F, CHF 2 , or CF 3 . In embodiments, R 1A is CH 3 . In embodiments, R 1A is CH 2 F, CHF 2 , or CF 3 . In embodiments, R 1B is H. In embodiments, R 1B is OH. In embodiments, R 1B is CN. In embodiments, R 1B is halogen (e.g., F, Cl, Br, or I).
- R 1B is C 1-6 aliphatic. In embodiments, R 1B is unsubstituted C 1-6 aliphatic. In embodiments, R 1B is substituted C 1-6 aliphatic (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R 1B is C 1-6 alkoxy. In embodiments, R 1B is unsubstituted C 1-6 alkoxy. In embodiments, R 1B is substituted C 1-6 alkoxy (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R 1B is NR 6 R 7 . In embodiments, R 1B is C(O)R 8 . In embodiments, R 1B is CO 2 R 8 .
- R 1B is C(O)NR 6 R 7 . In embodiments, R 1B is NR 9 C(O)R 8 . In embodiments, R 1B is NR 9 CO 2 R 8 . In embodiments, R 1B is NR 9 C(O)NR 6 R 7 . In embodiments, R 1B is R 10 .
- R 2 is OH. In embodiments, R 2 is CN. In embodiments, R 2 is halogen (e.g., F, Cl, Br, or I). In embodiments, R 2 is C 1-6 aliphatic (e.g., methyl). In embodiments, R 2 is unsubstituted C 1-6 aliphatic (e.g., methyl).
- R 2 is substituted C 1-6 aliphatic (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R 2 is C 1-6 alkoxy. In embodiments, R 2 is unsubstituted C 1-6 alkoxy. In embodiments, R 2 is substituted C 1-6 alkoxy (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R 2 is NR 6 R 7 . In embodiments, R 2 is C(O)R 8 . In embodiments, R 2 is CO 2 R 8 . In embodiments, R 2 is C(O)NR 6 R 7 . In embodiments, R 2 is NR 9 C(O)R 8 . In embodiments, R 2 is NR 9 CO 2 R 8 .
- R 2 is NR 9 C(O)NR 6 R 7 .
- R 2 is R 10 .
- R 2 is OR 10 .
- R 2 is CH 2 R 10 .
- R 2 is CH 2 CH 2 R 10 .
- R 2 is OCH 2 R 10 .
- R 2 is OCH 2 CH 2 R 10 .
- R 2 is methyl.
- R 3 is–L P -E.
- R 3 is not –L P -E.
- R 3 further comprises -L P -E.
- R 3 is OH.
- R 3 is CN.
- R 3 is halogen (e.g., F, Cl, Br, or I). In embodiments, R 3 is C 1-6 aliphatic. In embodiments, R 3 is unsubstituted C 1-6 aliphatic. In embodiments, R 3 is substituted C 1-6 aliphatic (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R 3 is C 1-6 alkoxy. In embodiments, R 3 is unsubstituted C 1-6 alkoxy. In embodiments, R 3 is substituted C 1-6 alkoxy (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R 3 is NR 6 R 7 . In embodiments, R 3 is C(O)R 8 .
- R 3 is halogen (e.g., F, Cl, Br, or I). In embodiments, R 3 is C 1-6 aliphatic. In embodiments, R 3 is unsubstituted C 1-6 aliphatic. In embodiments, R 3 is substituted C 1-6
- R 3 is CO 2 R 8 . In embodiments, R 3 is C(O)NR 6 R 7 . In embodiments, R 3 is NR 9 C(O)R 8 . In embodiments, R 3 is NR 9 CO 2 R 8 . In embodiments, R 3 is NR 9 C(O)NR 6 R 7 . In embodiments, R 3 is R 10 . In embodiments, R 3 is OR 10 . In embodiments, R 3 is CH 2 R 10 . In embodiments, R 3 is CH 2 CH 2 R 10 . In embodiments, R 3 is OCH 2 R 10 . In embodiments, R 3 is OCH 2 CH 2 R 10 . In embodiments, R 3 is is halogen.
- R 3 is NR 6 R 7 , where R 6 and R 7 , together with the nitrogen atom to which they are attached, form a 5- to 6-membered heterocyclyl.
- R 3 is NR 6 R 7 , wherein each R 6 and R 7 is independently C 1 -C 6 alkyl (e.g., one R 6 and R 7 is unsubstituted C 1 -C 6 alkyl, and the other is C 1 -C 6 alkyl comprising an amino group, a monoalkylamino group, or a dialkylamino group).
- R 3 is unsubstituted or substituted phenyl or pyridyl.
- R 3 is unsubstituted or substituted phenyl. In embodiments, R 3 is unsubstituted or substituted pyridyl. In embodiments, R 3 is unsubstituted or substituted pyrrolidine, morpholine, piperidine, or piperazine. In embodiments, R 3 is C(O)R 8 , wherein R 8 is unsubstituted or substituted pyrrolidine, morpholine, piperidine, or piperazine.
- R 3 is R 10 , OR 10 , CH 2 R 10 , CH 2 CH 2 R 10 , or OCH 2 CH 2 R 10 , wherein R 10 is unsubstituted or substituted pyrrolidine, morpholine, piperidine, or piperazine. In embodiments, R 3 is an unsubstituted group. In embodiments, R 3 is a group comprising 1, 2, 3, or 4 substituent groups.
- a cyclic group (e.g., a C 3-6 cycloaliphatic, a 3- to 6-membered heterocyclyl, a pyridyl, or a phenyl) comprises 1, 2, or 3 substituent groups (e.g., 1, 2, or 3 substituent groups selected from halogen (e.g., F, Cl, Br, or I), C 1-6 aliphatic (e.g., methyl, monofluoromethyl, difluoromethyl, trifluoromethyl, ethyl, monofluoroethyl, propyl (e.g., n-propyl or isopropyl), butyl (e.g., n-butyl, sec-butyl, isobutyl, or tert-butyl)), amino ( _ NH 2 ), monoalkylamino (e.g., -NHCH 3 ), dialkylamino (e.g., -N(CH 3 )
- R 4 is H. In embodiments, R 4 is an N-protecting group (e.g., an amide group, a carbamate group, or a sulfonamide group). In embodiments, R 4 is C 1-6 alkyl. In embodiments, a C 1-6 alkyl is unsubstituted. In embodiments, a C 1-6 alkyl is substituted (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R 5 is H. In embodiments, R 6 is H. In embodiments, R 6 is C 1-6 alkyl. In embodiments, a C 1-6 alkyl is unsubstituted.
- a C 1-6 alkyl is substituted (e.g., comprising 1, 2, or 3 substituent groups).
- R 7 is H. In embodiments, R 7 is C 1-6 alkyl. In embodiments, a C 1-6 alkyl is unsubstituted. In embodiments, a C 1-6 alkyl is substituted (e.g., comprising 1, 2, or 3 substituent groups).
- R 9 is H. In embodiments, R 9 is C 1-6 alkyl. In embodiments, a C 1-6 alkyl is unsubstituted. In embodiments, a C 1-6 alkyl is substituted (e.g., comprising 1, 2, or 3 substituent groups).
- R 6 and R 7 together with the nitrogen atom to which they are attached, form a 3- to 10-membered heterocyclyl (e.g., monocyclic or bicyclic heterocyclyl). In embodiments, a 3- to 10-membered heterocyclyl is unsubstituted. In embodiments, a 3- to 10-membered heterocyclyl is substituted (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R 6 and R 9 , together with the atoms to which they are attached, form a 3- to 10-membered heterocyclyl (e.g., monocyclic or bicyclic heterocyclyl). In embodiments, a 3- to 10-membered heterocyclyl is unsubstituted.
- a 3- to 10-membered heterocyclyl is unsubstituted.
- a 3- to 10-membered heterocyclyl is substituted (e.g., comprising 1, 2, or 3 substituent groups).
- R 8 is C 1-6 aliphatic.
- R 8 is C 3 -C 10 cycloaliphatic (e.g., monocyclic or bicyclic cycloaliphatic).
- R 8 is 3- to 10-membered heterocyclyl (e.g., monocyclic or bicyclic heterocyclyl).
- R 8 is phenyl.
- R 8 is naphthyl.
- R 8 is 5- to 12-membered heteroaryl (e.g., monocyclic or bicyclic heteroaryl).
- R 8 is unsubstituted C 1-6 aliphatic. In embodiments, R 8 is unsubstituted C 3 -C 10 cycloaliphatic. In embodiments, R 8 is unsubstituted 3- to 10-membered heterocyclyl. In embodiments, R 8 is unsubstituted phenyl. In embodiments, R 8 is unsubstituted naphthyl. In embodiments, R 8 is unsubstituted 5- to 12-membered heteroaryl. In embodiments, R 8 is substituted C 1-6 aliphatic. In embodiments, R 8 is substituted C 3 -C 10 cycloaliphatic. In embodiments, R 8 is substituted 3- to 10-membered heterocyclyl.
- R 8 is substituted phenyl. In embodiments, R 8 is substituted naphthyl. In embodiments, R 8 is substituted 5- to 12-membered heteroaryl. In embodiments, a substituted group comprises 1, 2, or 3 substituent groups as described herein. In embodiments, R 8 and R 9 , together with the atoms to which they are attached, form a 3- to 10-membered heterocyclyl (e.g., monocyclic or bicyclic heterocyclyl). In embodiments, a 3- to 10-membered heterocyclyl is unsubstituted. In embodiments, a 3- to 10-membered heterocyclyl is substituted (e.g., comprising 1, 2, or 3 substituent groups).
- R 10 is C 3 -C 10 cycloaliphatic (e.g., monocyclic or bicyclic cycloaliphatic). In embodiments, R 10 is 3- to 10-membered heterocyclyl (e.g., monocyclic or bicyclic heterocyclyl). In embodiments, R 10 is phenyl. In embodiments, R 10 is naphthyl. In embodiments, R 10 is 5- to 12-membered heteroaryl (e.g., monocyclic or bicyclic heteroaryl). In embodiments, R 10 is unsubstituted C 3 -C 10 cycloaliphatic. In embodiments, R 10 is unsubstituted 3- to 10-membered heterocyclyl.
- R 10 is unsubstituted phenyl. In embodiments, R 10 is unsubstituted naphthyl. In embodiments, R 10 is unsubstituted 5- to 12- membered heteroaryl. In embodiments, R 10 is substituted C 3 -C 10 cycloaliphatic. In embodiments, R 10 is substituted 3- to 10-membered heterocyclyl. In embodiments, R 10 is substituted phenyl. In embodiments, R 10 is substituted naphthyl. In embodiments, R 10 is substituted 5- to 12-membered heteroaryl. In embodiments, a substituted group comprises 1, 2, or 3 substituent groups as described herein. In embodiments, n is 0. In embodiments, n is 1.
- n is 2. In embodiments, n is 1 or 2. In embodiments, o is 0. In embodiments, o is 1. In embodiments, o is 2. In embodiments, o is 1 or 2. [0142] in embodiments, a compound of the invention comprising a Class B ligand has a structure selected from the following formulas selected from Table B1. In embodiments, an E moiety is selected from those described in Table D, where shows the point of covalent attachment to moiety L P . In embodiments, -L P -E is according to any of substructures (D1)- (D49) as described herein. In embodiments, -L P -E is according to any of substructures (D1)’- (D49)’ as described herein. Table B1.
- Exemplary Formulas Comprising Class B Ligands or a pharmaceutically acceptable salt thereof.
- the compound is according to Formula (BIX), (BX), or (BXI), or a pharmaceutically acceptable salt thereof, wherein L 1 is C 1 -C 6 alkylene optionally substituted by 1, 2, or 3 R 13 ; each R 13 is independently unsubstituted C 1 -C 3 alkyl; and R 1A is independently unsubstitued C 1 -C 6 alkyl or C 1 -C 6 haloalkyl.
- the compound is according to Formula (BXII), or a pharmaceutically acceptable salt thereof, wherein R 1A is independently unsubstitued C 1 -C 6 alkyl or C 1 -C 6 haloalkyl.
- R 1A is independently unsubstitued C 1 -C 6 alkyl or C 1 -C 6 haloalkyl.
- the compound is according to Formula (BXIII) or (BXIV), or a pharmaceutically acceptable salt thereof, wherein L 1 is C 1 -C 6 alkylene optionally substituted by 1 or 2 R 13 ; each R 13 is independently unsubstituted C 1 -C 3 alkyl; and R 1A is independently unsubstitued C 1 -C 6 alkyl or C 1 -C 6 haloalkyl.
- L 1 is selected from: –(CH 2 ) 3 –; –(CH 2 ) 4 –; wherein a carbon marked by an asterisk (*) is racemic or has the (R)- or (S)- stereochemistry.
- a carbon marked by an asterisk (*) is racemic.
- a carbon marked by an asterisk (*) has the (R)-stereochemistry.
- a carbon marked by an asterisk (*) has the (S)-stereochemistry.
- -L 1 -L 2 -X 1 - or -L 1 -L 2 -X 1A - is [0002] In embodiments, -L 1 -L 2 -X 1 - or -L 1 -L 2 -X 1A - is [0003] In embodiments, -L 1 -L 2 -X 1 - or -L 1 -L 2 -X 1A - is [0004] In embodiments, -L 1 -L 2 -X 1 - or -L 1 -L 2 -X 1A - is [0005] In embodiments, -L 1 -L 2 -X 1 - or -L 1 -L 2 -X 1A - is substructure (S1).
- - L 1 -L 2 -X 1 - or -L 1 -L 2 -X 1A - is substructure (S2).
- -L 1 -L 2 -X 1 - or -L 1 -L 2 -X 1A - is substructure (S3).
- -L 1 -L 2 -X 1 - or -L 1 -L 2 -X 1A - is substructure (S4).
- -L 1 -L 2 -X 1 - or -L 1 -L 2 -X 1A - is substructure (S5).
- -L 1 -L 2 -X 1 - or - L 1 -L 2 -X 1A - is substructure (S6). In embodiments, -L 1 -L 2 -X 1 - or -L 1 -L 2 -X 1A - is substructure (S7). In embodiments, -L 1 -L 2 -X 1 - or -L 1 -L 2 -X 1A - is substructure (S8). [0147] In embodiments, the compound comprises a ligand formed from any one Compounds (1)-(71) of PCT/US22/21999, or a pharmaceutically acceptable salt thereof.
- the compound comprises a ligand derived from any one of Compounds (1)-(71) of PCT/US22/21999, or a pharmaceutically acceptable salt thereof.
- the compound of PCT/US22/21999 is modified to include a piperazine- or piperazine-containing group covalently attached to the -L P -E group as described herein.
- the compound is selected from any of the following compounds of Table B2, or a pharmaceutically acceptable salt thereof.
- an E moiety is selected from those described in Table D, where shows the point of covalent attachment to moiety L P .
- -L P -E is according to any of substructures (D1)-(D49) as described herein. Table B2.
- the invention features compounds comprising a Class C ligand.
- a compound of the invention as described herein comprises or is derived from a Class C ligand, wherein said ligand is according to or derived from any one of Formulas (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII), (XIV), (XV), (XVI), (XVII), (XVIII), (XIX), (XX), (XXI), (XXII), and (XXIII) as described in PCT/US22/28755, such as any one of Compounds (1)-(169), or a pharmaceutically acceptable salt thereof.
- the invention features a compound having a structure according to Formula (CI), or a pharmaceutically acceptable salt thereof, wherein X 2 is independently N or CR 5 ; each of X 3 and X 4 is independently a covalent bond, O, S, NR 6 , C(O)NR 6 , NR 6 C(O), NR 6 C(O)NR 6 , or (C(R 7 ) 2 ) q ; L 1 is independently a covalent bond, C 1-6 heteroalkylene, C 1-6 alkylene, C 2-6 alkenylene, C 2-6 alkynylene, C 3-6 cycloalkylene, 3- to 10-membered heterocyclylene, phenylene, naphthylene, or 5- to 10-membered heteroarylene; each R 1 is independently L P -E, (Substructure A), OH, CN, halogen, C 1-6 aliphatic, C 1-6 alkoxy, NR 8 R 9 , C(O)R 10 ,
- each R 4 is independently H, OH, CN, halogen, C 1-6 aliphatic, C 1-6 alkoxy, NR 8 R 9 , C(O)R 10 , CO 2 R 10 , C(O)NR 8 R 9 , NR 11 C(O)R 10 , NR 11 CO 2 R 10 , NR 11 C(O)NR 8 R 9 , NR 11 (CH 2 ) s NR 8 R 9 , (CH 2 ) t NR 8 R 9 , or (CH 2 ) r R 12 ; or R 4 and R 6 , or R 4 and R 7 , together with the atoms to which they are attached, form a 5- to 6-membered ring.
- m is 0.
- m is 1. In embodiments, m is 2. In embodiments, m is 1 or 2. In embodiments, n is 0. In embodiments, n is 1. In embodiments, n is 2. In embodiments, n is 1 or 2. In embodiments, m is not 0. In embodiments, n is not 0. In embodiments, at least one m or n is not 0. In embodiments, m is 1, and n is 0. In embodiments, n is 1, and m is 0. In embodiments, p is 0. In embodiments, p is 1. In embodiments, p is 2. In embodiments, p is 3. In embodiments, p is 4. In embodiments, R 1 is present. In embodiments, R 2 is present.
- R 1 and R 2 is present. In embodiments, one of R 1 and R 2 is present. In embodiments, no more than one of R 1 and R 2 is present. In embodiments, one of R 1 and R 2 is present and is Substructure A ( ) or halogen (e.g., F, Cl, Br, or I). In embodiments, one of R 1 and R 2 is present and is Substructure A ( ). In embodiments, Substructure A ( ) is not present. In embodiments, one Substructure A group is present. In embodiments, no more than one Substructure A is present. In embodiments, two Substructure A groups are present (e.g., two Substructure A groups with identical or different structures).
- C is 5- or 6-membered N-containing heteroaryl.
- C is pyridyl, pyrimidyl, pyrazolyl, pyrrolyl, thiazolyl, oxazolyl, or imidazolyl.
- A is pyridyl, pyrimidyl, pyrazolyl, pyrrolyl, thiazolyl, oxazolyl, or imidazolyl.
- B is pyridyl, pyrimidyl, pyrazolyl, pyrrolyl, thiazolyl, oxazolyl, or imidazolyl.
- each of A and B is pyrazolyl.
- A is pyridyl or pyrimidyl.
- X 1 is N.
- X 2 is CR 5 (e.g., CH).
- X 2 is N.
- X 2 is CR 5 (e.g., CH).
- X 3 is a covalent bond.
- X 3 is O.
- X 3 is S.
- X 3 is NR 6 , C(O)NR 6 , NR 6 C(O), or NR 6 C(O)NR 6 .
- R 6 is H.
- R 6 is an N-protecting group (e.g., an amide group, a carbamate group, or a sulfonamide group).
- R 6 is C 1-6 alkyl.
- a C 1-6 alkyl is unsubstituted.
- a C 1-6 alkyl is substituted (e.g., comprising 1, 2, or 3 substituent groups).
- X 3 is (C(R 7 ) 2 ) q .
- q is 1.
- X 3 is C(O), CH 2 , CHCH 3 , or C(CH 3 ) 2 .
- X 4 is a covalent bond. In embodiments, X 4 is O. In embodiments, X 4 is S.
- X 4 is NR 6 , C(O)NR 6 , NR 6 C(O), or NR 6 C(O)NR 6 .
- R 6 is H.
- R 6 is an N-protecting group (e.g., an amide group, a carbamate group, or a sulfonamide group).
- R 6 is C 1-6 alkyl.
- a C 1-6 alkyl is unsubstituted.
- a C 1-6 alkyl is substituted (e.g., comprising 1, 2, or 3 substituent groups).
- X 4 is (C(R 7 ) 2 ) q .
- q is 1.
- X 4 is C(O), CH 2 , CHCH 3 , or C(CH 3 ) 2 . In embodiments, X 3 is O and X 4 is O. In embodiments, X 2 is CH, X 3 is O, and X 4 is O. In embodiments, X 1 is N.
- R 6 and R 4 together with the atoms to which they are attached, form a 5- to 6-membered ring.
- a 5- to 6-membered ring has a structure of where the M ring is the newly-formed A ring.
- L is a covalent bond.
- L A is an alkylene (e.g., -CH 2 -).
- an alkylene is unsubstituted.
- an alkylene is substituted (e.g., comprising 1 or 2 substituent groups).
- R 7 and R 4 together with the atoms to which they are attached, form a 5- to 6-membered ring.
- a 5- to 6-membered ring has a structure of where the M ring is the newly-formed ring.
- L A is a covalent bond.
- L A is an alkylene (e.g., -CH 2 -).
- an alkylene is unsubstituted.
- an alkylene is substituted (e.g., comprising 1 or 2 substituent groups).
- X 3 and X 4 are the same.
- X 3 and X 4 are different.
- X 3 and X 4 are both O.
- L 1 is a covalent bond.
- L 1 is a C 1-6 heteroalkylene (e.g., comprises 1, 2, or 3 heteroatoms that are independently oxygen or nitrogen). In embodiments, L 1 is a branched C 1-6 heteroalkylene. In embodiments, L 1 is a linear C 1-6 heteroalkylene. In embodiments, L 1 is unsubstituted C 1-6 heteroalkylene. In embodiments, L 1 is unsubstituted branched C 1-6 heteroalkylene. In embodiments, L 1 is unsubstituted linear C 1-6 heteroalkylene.
- a C 1-6 heteroalkylene is -O(CH 2 )u-, - (CH 2 )uO-, -O(CH 2 )uO-, -OCH 2 OCH 2 CH 2 OCH 2 –, -CH 2 OCH 2 CH 2 O-, -OCH 2 CH 2 OCH 2 - , -NH(CH 2 ) u -, - (CH 2 ) u NH-, or -NH(CH 2 ) u NH-, and wherein u is an integer of 1-4.
- u is 1.
- u is 2.
- u is 3.
- u is 4.
- L 1 is a C 1-6 alkylene (e.g., CH 2 , (CH 2 ) 2 , (CH 2 ) 3 , (CH 2 ) 4 , (CH 2 ) 5 , or (CH 2 ) 6 ).
- L 1 is a branched C 1-6 alkylene.
- L 1 is a linear C 1-6 alkylene.
- L 1 is unsubstituted C 1-6 alkylene.
- L 1 is unsubstituted branched C 1-6 alkylene.
- L 1 is unsubstituted linear C 1-6 alkylene.
- L 1 is unsubstituted C 1-6 alkylene. In embodiments, L 1 is unsubstituted branched C 2-6 alkylene. In embodiments, L 1 is unsubstituted linear C 2-6 alkylene. In embodiments, L 1 is a C 2-6 alkenylene (e.g., C 2 H 4 , C 3 H 6 , C 4 H 8 , C 5 H 10 , or C 6 H 12 ). In embodiments, L 1 is unsubstituted C 2-6 alkenylene. In embodiments, L 1 is substituted C 2-6 alkenylene (e.g., comprising 1, 2, or 3 substituent groups).
- L 1 is a C 2-6 alkynylene (e.g., C 2 H 2 , C 3 H 4 , C 4 H 6 , C 5 H 8 , or C 6 H 10 ). In embodiments, L 1 is unsubstituted C 2-6 alkynylene. In embodiments, L 1 is substituted C 2-6 alkynylene (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, L 1 is a C 3-6 cycloalkylene (e.g., cyclopropylene, cyclobutylene, cyclopentylene, or cyclohexylene). In embodiments, L 1 is unsubstituted C 3-6 cycloalkylene.
- L 1 is substituted C 3-6 cycloalkylene (e.g., comprising 1, 2, or 3 substituent groups).
- the sp 3 carbon of a L 1 group has the (R)-configuration.
- the sp 3 carbon of a L 1 group has the (S)-configuration.
- L 1 is a 3- to 10-membered heterocyclylene (e.g., monocyclic or bicyclic heterocyclylene).
- L 1 is unsubstituted 3- to 10-membered heterocyclylene.
- L 1 is substituted 3- to 10-membered heterocyclylene (e.g., comprising 1, 2, or 3 substituent groups).
- L 1 is a phenylene or naphthylene. In embodiments, L 1 is unsubstituted phenylene or unsubstituted naphthylene. In embodiments, L 1 is substituted phenylene or substituted naphthylene (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, L 1 is a 5- to 10-membered heteroarylene. In embodiments, L 1 is unsubstituted 5- to 10-membered heteroarylene. In embodiments, L 1 is substituted 5- to 10-membered heteroarylene (e.g., comprising 1, 2, or 3 substituent groups).
- L 1 is an unsubstituted linear C 4-6 alkylene or an unsubstituted branched C 4-6 alkylene.
- L 1 is -(CH 2 ) 3 -.
- L 1 is -CH(CH 3 )CH 2 CH 2 -.
- L 1 is In embodiments, L 1 is where * denotes the point of covalent attachment to X 4 , and ** denotes the point of covalent attachment to X 3 .
- -X 4 -L 1 -X 3 - is -O-L 1 -O-.
- -X 4 -L 1 -X 3 - is -O(CH 2 ) 3 O-.
- -X 4 -L 1 -X 3 - is -OCH(CH 3 )CH 2 CH 2 O-. In embodiments, -X 4 -L 1 -X 3 - is In embodiments, X 4 -L 1 -X 3 forms or comprises a urea group (e.g., NHC(O)NH). In embodiments, X 3 and/or X 4 is NR 6 C(O)NR 6 . In embodiments, one of X 3 and X 4 is NR 6 C(O)NR 6 . In embodiments, X 4 -L 1 -X 3 forms or comprises a carboxamide group (e.g., C(O)NH or NH(CO)).
- a carboxamide group e.g., C(O)NH or NH(CO)
- X 3 and/or X 4 is C(O)NR 6 or NR 6 C(O). In embodiments, one of X 3 and X 4 is C(O)NR 6 or NR 6 C(O). In embodiments, X 4 -L 1 -X 3 is -CHR 7 -O(C 1-2 alkylene)-OCHR 7 - or -CHR 7 -O(C 1-2 alkylene)-O-.
- B is phenyl. In embodiments, B is naphthyl. In embodiments, B is 5- to 13- membered heteroaryl (e.g., monocyclic or bicyclic heteroaryl).
- B is a bicyclic 8- to 12-membered heteroaryl (e.g., nitrogen-containing, bicyclic 8- to 12-membered heteroaryl).
- B is a monocyclic 5- to 6-membered heteroaryl.
- Examplary monocyclic 5- to 6-membered heteroaryls include but are not limited to pyridyl, pyrimidyl, pyrazolyl, pyrrolyl, thiazolyl, oxazolyl, and imidazolyl.
- B is phenyl or 5- to 6-membered heteroaryl.
- B is phenyl, pyridyl, pyrimidyl, pyrazolyl, pyrrolyl, thiazolyl, oxazolyl, or imidazolyl.
- B is pyrazolyl.
- B is unsubstituted phenyl.
- B is unsubstituted naphthyl.
- B is unsubstituted 5- to 13-membered heteroaryl (e.g., unsubstituted monocyclic or bicyclic heteroaryl).
- B is unsubstituted bicyclic 8- to 12- membered heteroaryl (e.g., unsubstituted nitrogen-containing, bicyclic 8- to 12-membered heteroaryl). In embodiments, B is unsubstituted monocyclic 5- to 6-membered heteroaryls. In embodiments, B is unsubstituted pyridyl, unsubstituted pyrimidyl, unsubstituted pyrazolyl, unsubstituted pyrrolyl, unsubstituted thiazolyl, unsubstituted oxazolyl, or unsubstituted imidazolyl.
- B is substituted phenyl (e.g., comprising 1 or 2 substituents as described herein). In embodiments, B is substituted naphthyl (e.g., comprising 1 or 2 substituents as described herein). In embodiments, B is substituted 5- to 13-membered heteroaryl (e.g., substituted monocyclic or bicyclic heteroaryl comprising 1 or 2 substituents as described herein). B is substituted bicyclic 8- to 12-membered heteroaryl (e.g., substituted nitrogen- containing, bicyclic 8- to 12-membered heteroaryl). In embodiments, B is substituted monocyclic 5- to 6-membered heteroaryls.
- B is substituted pyridyl, substituted pyrimidyl, substituted pyrazolyl, substituted pyrrolyl, substituted thiazolyl, substituted oxazolyl, or substituted imidazolyl.
- B is substituted pyrazolyl (e.g., N-substituted pyrazolyl such as N-methyl pyrazolyl).
- B is substituted with one or more R 3 groups as described herein (e.g., methyl, halogen, or CN).
- B is where * denotes the point of covalent attachment to C, and ** denotes the point of covalent attachment to X 3 .
- C is 5- or 6-membered heteroaryl. In embodiments, C is 5- or 6-membered N-containing heteroaryl. Examplary 5- or 6-membered heteroaryls include but are not limited to pyridyl, pyrimidyl, pyrazolyl, pyrrolyl, thiazolyl, oxazolyl, and imidazolyl. In embodiments, C is pyridyl or pyrimidyl. In embodiments, C is pyrazolyl or thiazolyl. In embodiments, C is unsubstituted 5- or 6-membered heteroaryl. In embodiments, C is unsubstituted 5- or 6-membered N-containing heteroaryl.
- Examplary unsubstituted 5- or 6-membered heteroaryls include but are not limited to unsubstituted pyridyl, unsubstituted pyrimidyl, unsubstituted pyrazolyl, unsubstituted pyrrolyl, unsubstituted thiazolyl, unsubstituted oxazolyl, and unsubstituted imidazolyl.
- C is unsubstituted pyridyl or pyrimidyl.
- C is unsubstituted pyrazolyl or thiazolyl.
- C is substituted 5- or 6-membered heteroaryl (e.g., comprising 1 or 2 substituents as described herein). In embodiments, C is substituted 5- or 6-membered N- containing heteroaryl (e.g., comprising 1 or 2 substituents as described herein). In embodiments, C is substituted pyridyl, substituted pyrimidyl, substituted pyrazolyl, substituted pyrrolyl, substituted thiazolyl, substituted oxazolyl, or substituted imidazolyl. In embodiments, C is substituted pyridyl (e.g., substituted with Substructure A).
- C is substituted pyrimidyl (e.g., substituted with Substructure A).
- C is substituted pyrazolyl (e.g., N-substituted pyrazolyl such as N-methyl pyrazolyl).
- C is substituted thiazolyl (e.g., methyl substituted thiazolyl).
- C is substituted with one or more R 1 groups as described herein (e.g., Substructure A or methyl).
- A is pyrazolyl
- B is pyrazolyl
- C is pyridyl or pyrimidyl.
- a and B are substituted.
- m is 0.
- m is 1. In embodiments, m is 2. In embodiments, m is 1 or 2. In embodiments, m is not 0. In embodiments, R 1 is present. In embodiments, R 1 is (Substructure A).
- L 2 is independently a covalent bond, O, NR L , C(O), C(O)NR L , NR L C(O), CR L 2 , wherein R L is independently H or C 1-6 alkyl. In embodiments, R L is unsubstituted C 1-6 alkyl. In embodiments, R L is substituted C 1-6 alkyl (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, L 2 is covalent bond.
- each R 4 is independently H, OH, CN, halogen, C 1-6 aliphatic, C 1-6 alkoxy, NR 8 R 9 , C(O)R 10 , CO 2 R 10 , C(O)NR 8 R 9 , NR 11 C(O)R 10 , NR 11 CO 2 R 10 , NR 11 C(O)NR 8 R 9 , NR 11 (CH 2 ) s NR 8 R 9 , (CH 2 ) t NR 8 R 9 , or (CH 2 ) r R 12 .
- p is 0.
- p is 1.
- p is 2.
- R 4 is–L P -E.
- R 4 is not –L P -E. In embodiments, R 4 further comprises -L P -E. In embodiments, R 1 is–L P -E. In embodiments, R 1 is not –L P -E. In embodiments, R 1 further comprises -L P -E. In embodiments, R 1 is OH. In embodiments, R 1 is CN. In embodiments, R 1 is halogen (e.g., F, Cl, Br, or I). In embodiments, R 1 is C 1-6 aliphatic. In embodiments, R 1 is unsubstituted C 1-6 aliphatic. In embodiments, R 1 is substituted C 1-6 aliphatic (e.g., comprising 1, 2, or 3 substituent groups).
- R 1 is C 1-6 alkoxy. In embodiments, R 1 is unsubstituted C 1-6 alkoxy. In embodiments, R 1 is substituted C 1-6 alkoxy (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R 1 is NR 8 R 9 . In embodiments, R 1 is C(O)R 10 . In embodiments, R 1 is CO 2 R 10 . In embodiments, R 1 is C(O)NR 8 R 9 . In embodiments, R 1 is NR 11 C(O)R 10 . In embodiments, R 1 is NR 11 CO 2 R 10 . In embodiments, R 1 is NR 11 C(O)NR 8 R 9 .
- R 1 is (CH 2 ) r R 12 . In embodiments, r is 0. In embodiments, r is 1. In embodiments, r is 2. In embodiments, r is 3. In embodiments, r is 4. In embodiments, r is 0 or 1. In embodiments, R 1 is halogen (e.g., F, Cl, Br, or I). In embodiments, n is 0. In embodiments, n is 1. In embodiments, n is 2. In embodiments, n is 1 or 2. In embodiments, n is not 0. In embodiments, R 2 is present. In embodiments, R 2 is (Substructure A).
- L 2 is independently a covalent bond, O, NR L , C(O), C(O)NR L , NR L C(O), CR L 2, wherein R L is independently H or C 1-6 alkyl.
- R L is unsubstituted C 1-6 alkyl.
- R L is substituted C 1-6 alkyl (e.g., comprising 1, 2, or 3 substituent groups).
- L 2 is covalent bond.
- each R 4 is independently H, OH, CN, halogen, C 1-6 aliphatic, C 1-6 alkoxy, NR 8 R 9 , C(O)R 10 , CO 2 R 10 , C(O)NR 8 R 9 , NR 11 C(O)R 10 , NR 11 CO 2 R 10 , NR 11 C(O)NR 8 R 9 , NR 11 (CH 2 ) s NR 8 R 9 , (CH 2 ) t NR 8 R 9 , or (CH 2 )rR 12 .
- p is 0.
- p is 1.
- p is 2.
- R 4 is–L P -E.
- R 4 is not –L P -E. In embodiments, R 4 further comprises -L P -E. In embodiments, R 2 is–L P -E. In embodiments, R 2 is not –L P -E. In embodiments, R 2 further comprises -L P -E. In embodiments, R 2 is OH. In embodiments, R 2 is CN. In embodiments, R 2 is halogen (e.g., F, Cl, Br, or I). In embodiments, R 2 is C 1-6 aliphatic. In embodiments, R 2 is unsubstituted C 1-6 aliphatic. In embodiments, R 2 is substituted C 1-6 aliphatic (e.g., comprising 1, 2, or 3 substituent groups).
- R 2 is C 1-6 alkoxy. In embodiments, R 2 is unsubstituted C 1-6 alkoxy. In embodiments, R 2 is substituted C 1-6 alkoxy (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R 2 is NR 8 R 9 . In embodiments, R 2 is C(O)R 10 . In embodiments, R 2 is CO 2 R 10 . In embodiments, R 2 is C(O)NR 8 R 9 . In embodiments, R 2 is NR 11 C(O)R 10 . In embodiments, R 2 is NR 11 CO 2 R 10 . In embodiments, R 2 is NR 11 C(O)NR 8 R 9 .
- R 2 is (CH 2 )rR 12 . In embodiments, r is 0. In embodiments, r is 1. In embodiments, r is 2. In embodiments, r is 3. In embodiments, r is 4. In embodiments, r is 0 or 1. In embodiments, R 2 is halogen (e.g., F, Cl, Br, or I). In embodiments, R 1 is present. In embodiments, R 2 is present. In embodiments, one of R 1 and R 2 is present. In embodiments, one of R 1 and R 2 is present and is Substructure A ( ) or halogen (e.g., F, Cl, Br, or I). In embodiments, one of R 1 and R 2 is present and is Substructure A ( ).
- two R 1 or two R 2 together to which the atoms they are attached form a 5- to 10-membered ring (e.g., 5- to 10-membered carbocyclic, heterocyclic, aryl, or heteroaryl ring).
- o is 0. In embodiments, o is 1. In embodiments, o is 2. In embodiments, o is 1 or 2. In embodiments, o is 0 or 1. In embodiments, o is not 0.
- R 3 is present. In embodiments, R 3 is OH. In embodiments, R 3 is CN. In embodiments, R 3 is halogen (e.g., F, Cl, Br, or I). In embodiments, R 3 is C 1-6 aliphatic.
- R 3 is unsubstituted C 1-6 aliphatic. In embodiments, R 3 is substituted C 1-6 aliphatic (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R 3 is C 1-6 alkoxy. In embodiments, R 3 is unsubstituted C 1-6 alkoxy. In embodiments, R 3 is substituted C 1-6 alkoxy (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R 3 is NR 8 R 9 . In embodiments, R 3 is C(O)R 10 . In embodiments, R 3 is CO 2 R 10 . In embodiments, R 3 is C(O)NR 8 R 9 .
- R 3 is NR 11 C(O)R 10 . In embodiments, R 3 is NR 11 CO 2 R 10 . In embodiments, R 3 is NR 11 C(O)NR 8 R 9 . In embodiments, R 3 is (CH 2 )rR 12 . In embodiments, r is 0. In embodiments, r is 1. In embodiments, r is 2. In embodiments, r is 3. In embodiments, r is 4. In embodiments, r is 0 or 1. In embodiments, R 3 is methyl, halogen, or CN. In embodiments, R 3 is methyl. In embodiments, R 5 is H. In embodiments, R 5 is OH. In embodiments, R 5 is CN.
- R 5 is halogen (e.g., F, Cl, Br, or I). In embodiments, R 5 is C 1-6 aliphatic. In embodiments, R 5 is unsubstituted C 1-6 aliphatic. In embodiments, R 5 is substituted C 1-6 aliphatic (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R 5 is C 1-6 alkoxy. In embodiments, R 5 is unsubstituted C 1-6 alkoxy. In embodiments, R 5 is substituted C 1-6 alkoxy (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R 5 is NR 8 R 9 . In embodiments, R 5 is C(O)R 10 .
- R 5 is halogen (e.g., F, Cl, Br, or I). In embodiments, R 5 is C 1-6 aliphatic. In embodiments, R 5 is unsubstituted C 1-6 aliphatic. In embodiments, R 5 is substituted C 1-6
- R 5 is CO 2 R 10 . In embodiments, R 5 is C(O)NR 8 R 9 . In embodiments, R 5 is NR 11 C(O)R 10 . In embodiments, R 5 is NR 11 CO2R 10 . In embodiments, R 5 is NR 11 C(O)NR 8 R 9 . In embodiments, R 5 is (CH 2 ) r R 12 . In embodiments, r is 0. In embodiments, r is 1. In embodiments, r is 2. In embodiments, r is 3. In embodiments, r is 4. In embodiments, r is 0 or 1. In embodiments, R 8 is H. In embodiments, R 8 is C 1-6 alkyl.
- a C 1-6 alkyl is unsubstituted. In embodiments, a C 1-6 alkyl is substituted (e.g., comprising 1, 2, or 3 substituent groups).
- R 9 is H. In embodiments, R 9 is C 1-6 alkyl. In embodiments, a C 1-6 alkyl is unsubstituted. In embodiments, a C 1-6 alkyl is substituted (e.g., comprising 1, 2, or 3 substituent groups).
- R 11 is H. In embodiments, R 11 is C 1-6 alkyl. In embodiments, a C 1-6 alkyl is unsubstituted.
- a C 1-6 alkyl is substituted (e.g., comprising 1, 2, or 3 substituent groups).
- R 8 and R 9 together with the nitrogen atom to which they are attached, form a 3- to 10-membered heterocyclyl.
- a 3- to 10-membered heterocyclyl is unsubstituted.
- a 3- to 10-membered heterocyclyl is unsubstituted (e.g., comprising 1, 2, or 3 substituent groups).
- R 8 and R 11 together with the atoms to which they are attached, form a 3- to 10-membered heterocyclyl.
- a 3- to 10-membered heterocyclyl is unsubstituted.
- a 3- to 10-membered heterocyclyl is unsubstituted (e.g., comprising 1, 2, or 3 substituent groups).
- R 10 is C 1-6 aliphatic.
- R 10 is C 3 -C 10 cycloaliphatic (e.g., monocyclic or bicyclic cycloaliphatic).
- R 10 is 3- to 10-membered heterocyclyl (e.g., monocyclic or bicyclic heterocyclyl).
- R 10 is phenyl.
- R 10 is naphthyl.
- R 10 is 5- to 12-membered heteroaryl (e.g., monocyclic or bicyclic heteroaryl).
- R 10 is unsubstituted C 1-6 aliphatic. In embodiments, R 10 is unsubstituted C 3 - C 10 cycloaliphatic. In embodiments, R 10 is unsubstituted 3- to 10-membered heterocyclyl. In embodiments, R 10 is unsubstituted phenyl. In embodiments, R 10 is unsubstituted naphthyl. In embodiments, R 10 is unsubstituted 5- to 12-membered heteroaryl. In embodiments, R 10 is substituted C 1-6 aliphatic. In embodiments, R 10 is substituted C 3 -C 10 cycloaliphatic. In embodiments, R 10 is substituted 3- to 10-membered heterocyclyl.
- R 10 is substituted phenyl. In embodiments, R 10 is substituted naphthyl. In embodiments, R 10 is substituted 5- to 12-membered heteroaryl. In embodiments, a substituted group comprises 1, 2, or 3 substituent groups as described herein. In embodiments, R 10 and R 11 , together with the atoms to which they are attached, form a 3- to 10-membered heterocyclyl. In embodiments, a 3- to 10-membered heterocyclyl is unsubstituted. In embodiments, a 3- to 10-membered heterocyclyl is substituted (e.g., comprising 1, 2, or 3 substituent groups).
- R 12 is C 3 -C 10 cycloaliphatic (e.g., monocyclic or bicyclic cycloaliphatic). In embodiments, R 12 is 3- to 10-membered heterocyclyl (e.g., monocyclic or bicyclic heterocyclyl). In embodiments, R 12 is phenyl. In embodiments, R 12 is naphthyl. In embodiments, R 12 is 5- to 12-membered heteroaryl (e.g., monocyclic or bicyclic heteroaryl). In embodiments, R 12 is unsubstituted C 3 -C 10 cycloaliphatic. In embodiments, R 12 is unsubstituted 3- to 10-membered heterocyclyl.
- R 12 is unsubstituted phenyl. In embodiments, R 12 is unsubstituted naphthyl. In embodiments, R 12 is unsubstituted 5- to 12- membered heteroaryl. In embodiments, R 12 is substituted C 3 -C 10 cycloaliphatic. In embodiments, R 12 is substituted 3- to 10-membered heterocyclyl. In embodiments, R 12 is substituted phenyl. In embodiments, R 12 is substituted naphthyl. In embodiments, R 12 is substituted 5- to 12-membered heteroaryl. In embodiments, a substituted group comprises 1, 2, or 3 substituent groups as described herein.
- a compound of the invention comprising a Class C ligand has a structure selected from the following formulas selected from Table C1.
- an E moiety is selected from those described in Table D, where shows the point of covalent attachment to moiety L P .
- -L P -E is according to any of substructures (D1)- (D49) as described herein.
- -L P -E is according to any of substructures (D1)’- (D49)’ as described herein. Table C1.
- Exemplary Formulas Comprising Class C Ligands or a pharmaceutically acceptable salt thereof, wherein R 4A is a first R 4 group, R 4B is a second R 4 group, R 4C is a third R 4 group, R 4D is a fourth R 4 group, preferably R 4 is unsubstituted C 1-6 alkyl if one or more of R 4A , R 4B , and R 4C is also present; and p is 0 or 1.
- the compound comprises a ligand formed from any one Compounds (1)-(169) of PCT/US22/28755, or a pharmaceutically acceptable salt thereof.
- the compound comprises a ligand derived from any one of Compounds (1)-(169) of PCT/US22/28755, or a pharmaceutically acceptable salt thereof.
- the compound of PCT/US22/28755 is modified to include a piperazine- or piperazine-containing group covalently attached to the -L P -E group as described herein.
- the compound is selected from any of the following compounds of Table C2 and C3, or a pharmaceutically acceptable salt thereof.
- an E moiety is selected from those described in Table D, where shows the point of covalent attachment to moiety L P .
- -L P -E is according to any of substructures (D1)- (D49) as described herein. Table C2.
- Exemplary L P and E Groups Exemplary linkers (L P ) and E3 ubiquitin ligase ligands (E) suitable for inclusion in the compounds of the invention include any known in the art. Exemplary structures for L P and/or E include those described in the below, each of which is incorporated by reference in its entirety. [0159] In embodiments, a linker L P is a covalent bond. [0160] In embodiments, a linker L P comprises a heterocycyl directly attached to the Ligand or attached to Ligand via a methylene (CH 2 ) moiety. In embodiments, a linker L P comprises a substructure F1 or a substructure F2 where * indicates the point of covalent attachment to the Ligand.
- a linker L P comprises a C 1 -C 20 alkylene.
- a linker L P is a C 1 -C 20 alkylene.
- a linker L P comprises an unsubstituted C 1 -C 20 alkylene.
- a linker L P comprises an unsubstituted C 2 -C 10 alkylene.
- a linker L P comprises an unsubstituted, linear C 2 -C 10 alkylene.
- a linker L P is comprises unsubstituted C 3 -C 10 alkylene.
- a linker L P is an unsubstituted C 1 -C 20 alkylene. In embodiments, a linker L P is an unsubstituted C 2 -C 10 alkylene. In embodiments, a linker L P is an unsubstituted, linear C 2 -C 10 alkylene. In embodiments, a linker L P is an unsubstituted C 3 -C 10 alkylene.
- a linker L P comprises a C 2 -C 20 heteroalkylene.
- a linker L P is a C 2 -C 20 heteroalkylene.
- a linker L P comprises an unsubstituted C 2 -C 20 heteroalkylene.
- a linker L P comprises an unsubstituted C 2 -C 10 heteroalkylene.
- a linker L P comprises an unsubstituted, linear C 2 -C 10 heteroalkylene.
- a linker L P comprises an unsubstituted C 3 -C 10 heteroalkylene.
- a linker L P is an unsubstituted C 2 -C 20 heteroalkylene.
- a linker L P comprises a C 2 -C 20 monoalkynylene.
- a linker L P is a C 2 -C 20 monoalkynylene.
- a linker L P comprises an unsubstituted C 2 -C 20 monoalkynylene.
- a linker L P comprises an unsubstituted C 2 -C 10 monoalkynylene. In embodiments, a linker L P comprises an unsubstituted, linear C 2 -C 10 monoalkynylene. In embodiments, a linker L P comprises an unsubstituted, branched C 4 -C 10 monoalkynylene. [0176] In embodiments, a linker L P is an unsubstituted C 2 -C 20 monoalkynylene. In embodiments, a linker L P is an unsubstituted C 2 -C 10 monoalkynylene.
- a linker L P comprises one or more ethyleneglycol moieties.
- a linker L P comprises 1, 2, 3, 4, or 5 ethyleneglycol repeating units.
- a linker L P comprises (1) an alkylene moiety (CH 2 ), (CH 2 ) 2 , (CH 2 ) 3 , (CH 2 ) 4 , (CH 2 ) 5 , (CH 2 ) 6 , (CH 2 ) 7 , (CH 2 ) 8 , (CH 2 ) 9 , or (CH 2 ) 10 ; and (2) substructure F1 or substructure F2.
- a linker L P is (CH 2 ), (CH 2 ) 2 , (CH 2 ) 3 , (CH 2 ) 4 , (CH 2 ) 5 , (CH 2 ) 6 , (CH 2 ) 7 , (CH 2 ) 8 , (CH 2 ) 9 , or (CH 2 ) 10 .
- a linker L P comprises –O(CH 2 CH 2 O) 2 (CH 2 ) 2 -, -O(CH 2 CH 2 O)(CH 2 ) 2 -, -O(CH 2 CH 2 O) 3 (CH 2 ) 2 -, -O(CH 2 CH 2 O) 4 (CH 2 ) 2 -, or -O(CH 2 CH 2 O) 5 (CH 2 ) 2 -.
- a linker L P comprises (1) –O(CH 2 CH 2 O) 2 (CH 2 ) 2 -, -O(CH 2 CH 2 O)(CH 2 ) 2 -, -O(CH 2 CH 2 O) 3 (CH 2 ) 2 -, -O(CH 2 CH 2 O) 4 (CH 2 ) 2 -, or -O(CH 2 CH 2 O) 5 (CH 2 ) 2 -; and (2) substructure F1 or substructure F2.
- a linker L P is –O(CH 2 CH 2 O) 2 (CH 2 ) 2 -, -O(CH 2 CH 2 O)(CH 2 ) 2 -, -O(CH 2 CH 2 O) 3 (CH 2 ) 2 -, -O(CH 2 CH 2 O) 4 (CH 2 ) 2 -, or -O(CH 2 CH 2 O) 5 (CH 2 ) 2 -.
- a linker L P comprises —O(CH 2 CH 2 O)CH 2 C(O)-, –O(CH 2 CH 2 O) 2 CH 2 C(O)-, –O(CH 2 CH 2 O) 3 CH 2 C(O)-, –O(CH 2 CH 2 O) 4 CH 2 C(O)-, or – O(CH 2 CH 2 O) 5 CH 2 C(O)-.
- a linker L P comprises: (1) –O(CH 2 CH 2 O)CH 2 C(O)-, –O(CH 2 CH 2 O) 2 CH 2 C(O)-, –O(CH 2 CH 2 O) 3 CH 2 C(O)-, –O(CH 2 CH 2 O) 4 CH 2 C(O)-, or – O(CH 2 CH 2 O) 5 CH 2 C(O)-; and (2) substructure F1 or substructure F2.
- a linker L P is –O(CH 2 CH 2 O)CH 2 C(O)-, –O(CH 2 CH 2 O) 2 CH 2 C(O)-, –O(CH 2 CH 2 O) 3 CH 2 C(O)-, –O(CH 2 CH 2 O) 4 CH 2 C(O)-, or – O(CH 2 CH 2 O) 5 CH 2 C(O)-.
- a linker L P comprises -NHC(O)CH 2 O(CH 2 CH 2 O)(CH 2 ) 2 -, -NHC(O)CH 2 O(CH 2 CH 2 O) 2 (CH 2 ) 2 -, -NHC(O)CH 2 O(CH 2 CH 2 O) 3 (CH 2 ) 2 -, -NHC(O)CH 2 O(CH 2 CH 2 O) 4 (CH 2 ) 2 -, or -NHC(O)CH 2 O(CH 2 CH 2 O) 5 (CH 2 ) 2 -.
- a linker L P comprises: (1) -NHC(O)CH 2 O(CH 2 CH 2 O)(CH 2 ) 2 -, -NHC(O)CH 2 O(CH 2 CH 2 O) 2 (CH 2 ) 2 -, -NHC(O)CH 2 O(CH 2 CH 2 O) 3 (CH 2 ) 2 -, -NHC(O)CH 2 O(CH 2 CH 2 O) 4 (CH 2 ) 2 -, or -NHC(O)CH 2 O(CH 2 CH 2 O) 5 (CH 2 ) 2 -; and (2) substructure F1 or substructure F2.
- a linker L P is -NHC(O)CH 2 O(CH 2 CH 2 O)(CH 2 ) 2 -, -NHC(O)CH 2 O(CH 2 CH 2 O) 2 (CH 2 ) 2 -, -NHC(O)CH 2 O(CH 2 CH 2 O) 3 (CH 2 ) 2 -, -NHC(O)CH 2 O(CH 2 CH 2 O) 4 (CH 2 ) 2 -, or -NHC(O)CH 2 O(CH 2 CH 2 O) 5 (CH 2 ) 2 -.
- a linker L P comprises -NHC(O)CH 2 O(CH 2 CH 2 O)(CH 2 ) 2 C(O)-, -NHC(O)CH 2 O(CH 2 CH 2 O) 2 (CH 2 ) 2 C(O)-, -NHC(O) CH 2 O(CH 2 CH 2 O) 3 (CH 2 ) 2 C(O)-, -NHC(O)CH 2 O(CH 2 CH 2 O) 4 (CH 2 ) 2 C(O)-, or -NHC(O)CH 2 O(CH 2 CH 2 O) 5 (CH 2 ) 2 C(O)-.
- a linker L P comprises (1) -NHC(O)CH 2 O(CH 2 CH 2 O)(CH 2 ) 2 C(O)-, -NHC(O)CH 2 O(CH 2 CH 2 O) 2 (CH 2 ) 2 C(O)-, -NHC(O) CH 2 O(CH 2 CH 2 O) 3 (CH 2 ) 2 C(O)-, -NHC(O)CH 2 O(CH 2 CH 2 O) 4 (CH 2 ) 2 C(O)-, or -NHC(O)CH 2 O(CH 2 CH 2 O) 5 (CH 2 ) 2 C(O)-; and (2) substructure F1 or substructure F2.
- a linker L P is: -NHC(O)CH 2 O(CH 2 CH 2 O)(CH 2 ) 2 C(O)-, -NHC(O)CH 2 O(CH 2 CH 2 O) 2 (CH 2 ) 2 C(O)-, -NHC(O) CH 2 O(CH 2 CH 2 O) 3 (CH 2 ) 2 C(O)-, -NHC(O)CH 2 O(CH 2 CH 2 O) 4 (CH 2 ) 2 C(O)-, or -NHC(O)CH 2 O(CH 2 CH 2 O) 5 (CH 2 ) 2 C(O)-.
- a linker L P comprises –NH(CH 2 )C(O)-, -NH(CH 2 ) 2 C(O)-, -NH(CH 2 ) 3 C(O)-, -NH(CH 2 ) 4 C(O)-, or -NH(CH 2 ) 5 C(O)-.
- a linker L P comprises: (1) –NH(CH 2 )C(O)-, -NH(CH 2 ) 2 C(O)-, -NH(CH 2 ) 3 C(O)-, -NH(CH 2 ) 4 C(O)-, or -NH(CH 2 ) 5 C(O)-; and (2) substructure F1 or substructure F2.
- a linker L P is –NH(CH 2 )C(O)-, -NH(CH 2 ) 2 C(O)-, -NH(CH 2 ) 3 C(O)-, -NH(CH 2 ) 4 C(O)-, or -NH(CH 2 ) 5 C(O)-.
- a linker L P comprises -(NHCH 2 C(O)NH)(CH 2 )(NHCH 2 C(O)-, -(NHCH 2 C(O)NH)(CH 2 ) 2 (NHCH 2 C(O)-, - (NHCH 2 C(O)NH)(CH 2 ) 3 (NHCH 2 C(O)-, -(NHCH 2 C(O)NH)(CH 2 ) 4 (NHCH 2 C(O)-, or -(NHCH 2 C(O)NH)(CH 2 ) 5 (NHCH 2 C(O)-.
- a linker L P comprises: (1) -(NHCH 2 C(O)NH)(CH 2 )(NHCH 2 C(O)-, -(NHCH 2 C(O)NH)(CH 2 ) 2 (NHCH 2 C(O)-, -(NHC H 2 C(O)NH)(CH 2 ) 3 (NHCH 2 C(O)-, -(NHCH 2 C(O)NH)(CH 2 ) 4 (NHCH 2 C(O)-, or -(NHCH 2 C(O)NH)(CH 2 ) 5 (NHCH 2 C(O)-; and (2) substructure F1 or substructure F2.
- a linker L P is -(NHCH 2 C(O)NH)(CH 2 )(NHCH 2 C(O)-, -(NHCH 2 C(O)NH)(CH 2 ) 2 (NHCH 2 C(O)-, -(NHCH 2 C(O)NH)(CH 2 ) 3 (NHCH 2 C(O)-, -(NHCH 2 C(O)NH)(CH 2 ) 4 (NHCH 2 C(O)-, or -(NHCH 2 C(O)NH)(CH 2 ) 5 (NHCH 2 C(O)-.
- a linker L P comprises –NH(CH 2 )C(O)-, -NH(CH 2 ) 2 C(O)-, -NH(CH 2 ) 3 C(O)-, -NH(CH 2 ) 4 C(O)-, or -NH(CH 2 ) 5 C(O)-.
- a linker L P comprises: (1) –NH(CH 2 )C(O)-, -NH(CH 2 ) 2 C(O)-, -NH(CH 2 ) 3 C(O)-, -NH(CH 2 ) 4 C(O)-, or -NH(CH 2 ) 5 C(O)-; and (2) substructure F1 or substructure F2.
- a linker L P is –NH(CH 2 )C(O)-, -NH(CH 2 ) 2 C(O)-, -NH(CH 2 ) 3 C(O)-, -NH(CH 2 ) 4 C(O)-, or -NH(CH 2 ) 5 C(O)-.
- a linker L P comprises -NHC(O)CH 2 O(CH 2 ) 2 C(O)-, -NHC(O)CH 2 O(CH 2 ) 3 C(O)-, -NHC(O)CH 2 O(CH 2 ) 4 C (O)-, -NHC(O)CH 2 O(CH 2 ) 5 C(O)-, or -NHC(O)CH 2 O(CH 2 ) 6 C(O)-.
- a linker L P comprises: (1) -NHC(O)CH 2 O(CH 2 ) 2 C(O)-, -NHC(O)CH 2 O(CH 2 ) 3 C(O)-, -NHC(O)CH 2 O(CH 2 ) 4 C(O)-, - NHC(O)CH 2 O(CH 2 ) 5 C(O)-, or -NHC(O)CH 2 O(CH 2 ) 6 C(O)-; and (2) substructure F1 or substructure F2.
- a linker L P is -NHC(O)CH 2 O(CH 2 ) 2 C(O)-, -NHC(O)CH 2 O(CH 2 ) 3 C(O)-, -NHC(O)CH 2 O(CH 2 ) 4 C(O)-, -N HC(O)CH 2 O(CH 2 ) 5 C(O)-, or -NHC(O)CH 2 O(CH 2 ) 6 C(O)-.
- a linker L P comprises - ⁇ -(CH 2 )-, - ⁇ -(CH 2 ) 2 -, - ⁇ -(CH 2 ) 3 -, - ⁇ -(CH 2 ) 4 -, - ⁇ -(CH 2 ) 5 -, - ⁇ -(CH 2 ) 6 , - ⁇ -(CH 2 ) 7 , or - ⁇ -(CH 2 ) 8 .
- a linker L P comprises: (1) - ⁇ -(CH 2 )-, - ⁇ -(CH 2 ) 2 -, - ⁇ -(CH 2 ) 3 -, - ⁇ -(CH 2 ) 4 -, - ⁇ -(CH 2 ) 5 -, - ⁇ -(CH 2 ) 6 , - ⁇ -(CH 2 ) 7 , or - ⁇ -(CH 2 ) 8 ; and (2) substructure F1 or substructure F2.
- a linker L P is - ⁇ -(CH 2 )-, - ⁇ -(CH 2 ) 2 -, - ⁇ -(CH 2 ) 3 -, - ⁇ -(CH 2 ) 4 -, - ⁇ -(CH 2 ) 5 -, - ⁇ -(CH 2 ) 6 , - ⁇ -(CH 2 ) 7 , or - ⁇ -(CH 2 ) 8 .
- a linker L P comprises - ⁇ -(CH 2 )OCH 2 CH 2 OCH 2 C(O)-, - ⁇ -(CH 2 )NHCH 2 CH 2 NHCH 2 C(O)-, or - ⁇ -(CH 2 )OCH 2 CH 2 NHC(O)CH 2 -.
- a linker L P comprises: (1) - ⁇ -(CH 2 )OCH 2 CH 2 OCH 2 C(O)-, - ⁇ -(CH 2 )NHCH 2 CH 2 NHCH 2 C(O)-, or - ⁇ -(CH 2 )OCH 2 CH 2 NHC(O)CH 2 -; and (2) substructure F1 or substructure F2.
- a linker L P is - ⁇ -(CH 2 )OCH 2 CH 2 OCH 2 C(O)-, - ⁇ -(CH 2 )NHCH 2 CH 2 NHCH 2 C(O)-, or - ⁇ -(CH 2 )OCH 2 CH 2 NHC(O)CH 2 -.
- an E moiety is selected from those described in Table D, where shows the point of covalent attachment to moiety L P . Table D. Exemplary E Moieties
- an L P -E moiety is selected from those described in Table E1.
- an L P -E moiety is selected from those described in Table E2.
- an L P -E moiety is selected from those described in Table E3.
- an L P -E moiety comprises, corresponds to, or is derived from that present in ARV-110, ARV-471, AC682, ARV-766, CC-94676, DT2216, FHD-609, KT- 474, KT-413, KT-333, NX-2127, NX-5948, CFT8634, CFT8919, or CG001419, including any fragments thereof.
- an L P -E moiety comprises, corresponds to, or is derived from that present in BGB-16673, HK29116, LNK-01002, AC682, HP618, or GT- 20029, including fragments thereof.
- L P -E moieties include any of those described in WO2021121261, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described at pages 28-30 of WO2021121261.
- L P -E moieties include any of those described in US20190106417, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of those described in WO2018119441, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in WO2022047145A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20220259154A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20220162163A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20220144809A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20220127279A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20220089570A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20210187108A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20210145832A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20210040081A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20200392131A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20200155690A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20180346461A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20180237418A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20180193470, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20180155322A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20180147202A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20180072711A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20170327469A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20160272639A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20160214972A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20160058872A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20160045607A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20210220475A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20180193470A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- E comprises, corresponds to, or is derived from a moiety described therein (e.g., those described at paragraphs [0654]-[0953] of US20180193470A1such as Formulas (a)-(f): wherein: W of Formulas (a) through (e) is independently selected from the group CH 2 , CHR, C ⁇ O, SO 2 , NH, and N-alkyl; X of Formulas (a) through (e) is independently selected from the group O, S and H2; Y of Formulas (a) through (e) is independently selected from the group CH 2 , —C ⁇ CR′, NH, N-alkyl, N-aryl, N-hetaryl, N-cycloalkyl, N-heterocyclyl, O, and S; Z of Formulas (a) through (e) is independently selected from the group O, and S or H2 except that both X and Z cannot be H2; G and G′ of Formulas (a) through (e)
- L P comprises, corresponds to, or is derived from a moiety described therein (e.g., those described at paragraphs [0954]-[0993] of US20180193470A1, include those described at paragraphs [0969]-[0977], particularly those described at paragraphs [0975]-[0977]).
- a linker L P may be described by: one or more covalently connected structural units (e.g., —A L 1... (A L ) q - or -(A L ) q -), wherein A1 is a group coupled to the ligand moiety, and (A L ) q is a group coupled to the E moiety.
- the linker group L is selected from -(A L ) q -, wherein (A L ) q is a group which is connected to at least one of a ULM, a PTM moiety, or a combination thereof; q of the linker is an integer greater than or equal to 1; each A L q is independently selected from the group consisting of, a bond, CR L1 R L2 , O, S, SO, SO 2 , NR L3 , SO 2 NR L3 , SONR L3 , CONR L3 , NR L3 CONR L4 , NR L3 SO 2 NR L4 , CO, CR L1 ⁇ CR L2 , C ⁇ C, SiR L1 R L2 , P(O)R L1 , P(O)OR L1 , NR L3 C( ⁇ NCN)NR L4 , NR L3 C( ⁇ NCN), NR L3 C( ⁇ CNO 2 )NR L4
- q of the linker is an integer greater than or equal to 0. In certain embodiments, q is an integer greater than or equal to 1. [0247] In certain embodiments, e.g., where q of the linker is greater than 2, (A L ) q is a group which is connected to ULM, and A L 1 and (A L ) q are connected via structural units of the linker (L). [0248] In certain embodiments, e.g., where q of the linker is 2, (A L ) q is a group which is connected to A L 1 and to a ULM.
- the structure of the linker group L is -A L 1 -, and A L 1 is a group which is connected to a ULM moiety and a PTM moiety.
- the linker (L) comprises a group represented by a general structure selected from the group consisting of: —NR(CH 2 ) n -(lower alkyl)-, —NR(CH 2 ) n -(lower alkoxyl)-, —NR(CH 2 ) n - (lower alkoxyl)-OCH 2 —, —NR(CH 2 ) n -(lower alkoxyl)-(lower alkyl)-OCH 2 —, — NR(CH 2 ) n -(cycloalkyl)-(lower alkyl)-OCH 2 -, —NR(CH 2 ) n -(hetero cycloalkyl)-, — NR(CH 2 CH 2 O) n -(lower alkyl)-O—CH 2 —, NR(CH 2 CH 2 O) n -(lower alkyl)-O—CH 2 —, NR(CH 2 CH 2
- an L P -E moiety comprises, corresponds to, or is derived from that present in ARV-471, including any fragments thereof.
- an L P -E moiety has a structure according to (D46), (D46)’, or (D46)”.
- an L P -E moiety comprises, corresponds to, or is derived from that present in ARV-110, including any fragments thereof.
- an L P -E moiety has a structure according to (D47), (D47)’, or (D47)”.
- an L P -E moiety comprises, corresponds to, or is derived from that present in ARV-771 or ARV-766, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20220274993A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20220054453A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20210395273A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20210228562A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20220281831A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20210002296A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US11318205B1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US11117889B1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20200010468A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in WO2022178532A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- -L P -E comprises, corresponds to, or is derived from a moiety having the following structure: , wherein L is a covalent bond or a bivalent, saturated or partially unsaturated, straight or branched C1-50 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by –Cy-, -O-, -N(R)-, –Si(R) 2 –, –Si(OH)(R)–, –Si(OH) 2 –, –P(O)(OR)–, –P(O)(R)–, – P(O)(NR2)–, -S-, - OC(O)-, -C(O)O-, -C(O)-, -S(O)-, -S(O) 2 -, -N(R)S(O) 2 -, -S(O) 2 N(R)-, - N(R)C(O)-
- a point of attachment of –(R 2 )m is depicted on Ring B, it is intended, and one of ordinary skill in the art would appreciate, that the point of attachment of –(R 2 )m may be on Ring A and may also be at any available carbon or nitrogen atom on Ring A including the ring to which Ring B is fused. Where - R 2 is attached to a nitrogen atom bound to R 4 or R 5 , R 4 or R 5 is absent and -R 2 takes the place of the R 4 or R 5 group.
- L is a covalent bond.
- each –Cy— is independently an optionally substituted bivalent phenylenyl.
- each – Cy– is independently an optionally substituted 8-10 membered bicyclic arylenyl. In some embodiments, each –Cy— is independently an optionally substituted 4-7 membered saturated or partially unsaturated carbocyclylenyl. In some embodiments, each –Cy— is independently an optionally substituted 4-7 membered saturated or partially unsaturated spiro carbocyclylenyl. In some embodiments, each –Cy— is independently an optionally substituted 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl.
- each –Cy– is independently an optionally substituted 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each –Cy– is independently an optionally substituted 4-7 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each –Cy– is independently an optionally substituted 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
- each –Cy– is independently an optionally substituted 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each –Cy– is independently an optionally substituted 8-10 membered bicyclic heteroarylenyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- a linker is as described at, e.g., paragraphs [00478]-[0486] and Table 1 or Table B of WO2022178532A1 (e.g., exemplified linkers (1)-(650) of Table B).
- -L P -E comprises, corresponds to, or is derived from a moiety found in any of the exemplary compounds of Table 1 of WO2022178532A1 (e.g., a moiety found in any of Compounds I-1 to I-100 as described therein).
- an L P -E moiety comprises, corresponds to, or is derived from that present in KT-474, including any fragments thereof.
- an L P -E moiety comprises, corresponds to, or is derived from that present in KT-413, including any fragments thereof.
- an L P -E moiety comprises, corresponds to, or is derived from that present in KT-333, including any fragments thereof.
- Exemplary Group 3 L P -E moieties include any of the PROTAC degraders described in US20220098194A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in WO2022081927A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in WO2022081925A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in WO2022081928A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US11407732B1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in WO2022032132A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in WO2022032026A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in WO2021255213A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in WO2021255212A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20210198256A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in WO2021127561A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20210070763A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in WO2021083949A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in WO2021086785A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20210032245A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20210009559A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20200361930A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20220251061A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US10905768B1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in WO2020181232A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20200207733A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US11254672B2, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20200207783A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in WO2020132561A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20200140456A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US10849982B2, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20190076539A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US20190070185A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- L P -E moieties include any of the PROTAC degraders described in US11185592B2, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- -L P -E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
- a linker L P moiety is a chain of 2 to 14, 15, 16, 17, 18 or 20 or more carbon atoms of which one or more carbons can be replaced by a heteroatom such as O, N, S, or P.
- the chain has 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 contiguous atoms in the chain.
- the chain may include 1 or more ethylene glycol units that can be contiguous, partially contiguous or non-contiguous (for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 ethylene glycol units).
- the chain has at least 1, 2, 3, 4, 5, 6, 7, or 8 contiguous chains which can have branches which can be independently alkyl, heteroalkyl, aryl, heteroaryl, alkenyl, or alkynyl, aliphatic, heteroaliphatic, cycloalkyl or heterocyclic substituents.
- a linker L P moiety can include or be comprised of one or more of ethylene glycol, propylene glycol, lactic acid and/or glycolic acid.
- propylene glycol adds hydrophobicity, while propylene glycol adds hydrophilicity.
- Lactic acid segments tend to have a longer half-life than glycolic acid segments.
- Block and random lactic acid-co-glycolic acid moieties, as well as ethylene glycol and propylene glycol, are known in the art to be pharmaceutically acceptable and can be modified or arranged to obtain the desired half-life and hydrophilicity.
- these units can be flanked or interspersed with other moieties, such as aliphatic, including alkyl, heteroaliphatic, aryl, heteroaryl, heterocyclic, cycloalkyl, etc., as desired to achieve the appropriate drug properties.
- a linker L P moiety is selected from the following formulas:
- X 1 and X 2 are independently selected from bond, NH, NR 25 , CH 2 , CHR 25 , C(R 25 ) 2 , O, and S;
- R 20 , R 21 , R 22 , R 23 , and R 24 are independently selected from bond, alkyl, —C(O)— — C(O)O—, —OC(O)—, —C(O)alkyl, —C(O)Oalkyl, —C(S)—, —SO 2 —, —S(O)—, — C(S)—, —C(O)NH—, —NHC(O)—, —N(alkyl)C(O)—, —C(O)N(alkyl)-, —O—, —S—, — NH—, —N(alkyl)-, —CH(—O—R 26 )—, —CH(—NHR 25 )—, —CH(—NH
- Certain nonlimiting examples include —O—CH(CH 3 )—CH(CH 3 )CH—O—, —O—CH 2 — CH(CH 3 )CH—O—, —O—CH(CH 3 )—CH 2 CH—O—, etc. each of which R 20 , R 21 , R 22 , R 23 , and R 24 is optionally substituted with one or more substituents selected from R 101 or alternatively as described in Section 1.
- R 25 is selected at each instance from: alkyl, —C(O)H, —C(O)OH, —C(O)alkyl, — C(O)Oalkyl, alkenyl, or alkynyl or alternatively can be aliphatic, heteroaliphatic, aryl, heteroaryl or heterocyclic;
- R 26 is hydrogen, alkyl, silane, arylalkyl, heteroarylalkyl, alkene, and alkyne; or in addition to these can also be selected from aryl, heteroaryl, heterocyclic, aliphatic and heteroaliphatic;
- R 27 and R 28 are independently selected from hydrogen, alkyl, amine, or together with the carbon atom to which they are attached, form C(O), C(S), C ⁇ CH 2 , a C 3 - C 6 spirocarbocycle, or a 4-, 5-, or 6-membered spiroheterocycle comprising 1 or 2 heteroatoms selected from N
- a linker L P moiety is an optionally substituted (poly)ethylene glycol having at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, ethylene glycol units, or optionally substituted alkyl groups interspersed with optionally substituted, O, N, S, P or Si atoms.
- the Linker is flanked, substituted, or interspersed with an aryl, phenyl, benzyl, alkyl, alkylene, or heterocycle group.
- the Linker may be asymmetric or symmetrical.
- the Linker is a substituted or unsubstituted polyethylene glycol group ranging in size from about 1 to about 12 ethylene glycol units, between 1 and about 10 ethylene glycol units, about 2 about 6 ethylene glycol units, between about 2 and 5 ethylene glycol units, between about 2 and 4 ethylene glycol units.
- the linker L P moiety may be any suitable moiety as described herein.
- the linker L P moiety is selected from: —NR 61 (CH 2 ) n1 -(lower alkyl)-, —NR 61 (CH 2 ) n1 -(lower alkoxyl)-, —NR 61 (CH 2 ) n1 -(lower alkoxyl)-OCH 2 —, —NR 61 (CH 2 ) n1 - (lower alkoxyl)-(lower alkyl)-OCH 2 —, —NR 61 (CH 2 ) n1 -(cycloalkyl)-(lower alkyl)-OCH 2 —, —NR 61 (CH 2 ) n1 -(heterocycloalkyl)-, —NR 61 (CH 2 CH 2 O) n1 -(lower alkyl)-O—CH 2 —, — NR 61 (CH 2 CH 2 O) n1 -(lower alkyl)-O—CH 2
- the linker L P moiety is selected from: —N(R 61 )—(CH 2 ) m1 —O(CH 2 ) n2 —O(CH 2 ) o1 —O(CH 2 ) p1 —O(CH 2 ) q1 —O(CH 2 ) r1 —OCH 2 —O— (CH 2 ) m1 —O(CH 2 ) n2 —O(CH 2 ) o1 —O(CH 2 ) p1 —O(CH 2 ) q1 —O(CH 2 ) r1 —OCH 2 —, —O— (CH 2 ) m1 —O(CH 2 ) n2 —O(CH 2 ) o1 —O(CH 2 ) p1 —O(CH 2 ) q1 —O(CH 2 ) r1 —OCH 2 —, —O— (CH 2 ) m1 —O
- a L P moiety includes any of the strctures described in US11185592B2 at cols.97-148.
- an E moiety includes any of the strctures described in US11185592B2 as the fragments according to Formula (I) and Formula (II) cols.61-74 or according to Formula III and IV at cols.74-84.
- L P -E moieties include any of the PROTAC degraders described in US20200308171A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to L P and/or E described therein.
- L P , E, and/or L P -E moieties include those according to the following formula, where Y is covalently attached to the the Ligand moiety, Y is absent or heterocyclyl (e.g., pyrrolidinyl); and L is selected from the group consisting of i) —C( ⁇ O)—(CH 2 ) 2-10 —NH—, in particular —C( ⁇ O)—(CH 2 ) 5 —NH—; ii) —(CH 2 ) 2-10 —NH—, in particular —(CH 2 ) 6 —NH—, —(CH 2 ) 5 —NH— or — (CH 2 ) 4 —NH—; iii) —(CH 2 ) 2-10 -heterocyclyl-, in particular a.
- an L P -E moiety comprises, corresponds to, or is derived from that present in CFT8919, including any fragments thereof.
- an L P -E moiety comprises, corresponds to, or is derived from that present in CFT8634, including any fragments thereof.
- an L P -E moiety has a structure according to (D48), (D48)’, or (D48)”.
- Exemplary Group 4 [0312]
- an L P -E moiety comprises, corresponds to, or is derived from that present in DT2216, including any fragments thereof.
- an L P -E moiety comprises, corresponds to, or is derived from that present in AC682, including any fragments thereof.
- an L P -E moiety comprises, corresponds to, or is derived from that present in CC-94676, including any fragments thereof. [0315] In certain embodiments, an L P -E moiety comprises, corresponds to, or is derived from that present in FHD-609, including any fragments thereof. [0316] In certain embodiments, an L P -E moiety comprises, corresponds to, or is derived from that present in NX-2127, including any fragments thereof. [0317] In certain embodiments, an L P -E moiety comprises, corresponds to, or is derived from that present in NX-5948, including any fragments thereof.
- an L P -E moiety comprises, corresponds to, or is derived from that present in CG001419, including any fragments thereof.
- Deuterated Compounds [0319] Compounds described herein can comprise atoms that exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominately found in nature.
- isotopologue refers to a species that has the same chemical structure and formula as a specific compound provided herein, with the exception of the positions of isotopic substitution and/or level of isotopic enrichment at one or more positions, e.g., hydrogen vs. deuterium.
- the present invention is meant to include all suitable isotopic variations of the compounds of the compounds described herein.
- different isotopic forms of hydrogen (H) include protium ( 1 H), deuterium ( 2 H), and tritium ( 3 H), as well as compositions enriched in isotopologues of any compound described herein.
- one or more of the hydrogens of the compounds described herein is replaced by a deuterium.
- the position When a position is designated as “H” or “hydrogen”, the position is understood to have hydrogen at its natural abundance isotopic composition.
- a position When a position is designated as “ 2 H” or “deuterium”, the position is understood to have deuterium at an abundance that is at least 3340 times greater than the natural abundance of deuterium, which is 0.015% (i.e., the term “ 2 H” or “deuterium” indicates at least 50.1% incorporation of deuterium).
- the invention also features compositions enriched in deuterated compounds.
- compositions of any compound provided herein may have an isotopic enrichment factor for each deuterium present at a site designated as a potential site of deuteration on the compound of at least 3500 (52.5% deuterium incorporation), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
- compositions comprising any compound herein, or a pharmaceutically acceptable form thereof.
- a pharmaceutical composition comprises a therapeutically effective amount of any compound described herein, or any pharmaceutically acceptable form thereof.
- a pharmaceutically acceptable form of a compound includes any pharmaceutically acceptable salts, hydrates, solvates, isomers, prodrugs, and isotopically labeled derivatives thereof.
- a pharmaceutical composition comprises any compound described herein, or a pharmaceutically acceptable salt thereof.
- a pharmaceutical composition comprises a pharmaceutically acceptable excipient.
- excipient and “carrier” are used interchangeably throughout the description of the present invention and said terms are defined herein as, “ingredients which are used in the practice of formulating a safe and effective pharmaceutical composition.”
- excipients are used primarily to serve in delivering a safe, stable, and functional pharmaceutical, serving not only as part of the overall vehicle for delivery but also as a means for achieving effective absorption by the recipient of the active ingredient.
- An excipient may fill a role as simple and direct as being an inert filler, or an excipient as used herein may be part of a pH stabilizing system or coating to insure delivery of the ingredients safely to the stomach.
- compositions comprising one or more compounds as disclosed herein, or a pharmaceutically acceptable form thereof (e.g., pharmaceutically acceptable salts, hydrates, solvates, isomers, prodrugs, and isotopically labeled derivatives), and one or more pharmaceutically acceptable excipients, carriers, including inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants.
- pharmaceutically acceptable form thereof e.g., pharmaceutically acceptable salts, hydrates, solvates, isomers, prodrugs, and isotopically labeled derivatives
- excipients including inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants.
- a pharmaceutical composition described herein includes a second active agent such as an additional therapeutic agent, (e.g., a chemotherapeutic).
- a second active agent such as an additional therapeutic agent, (e.g., a chemotherapeutic).
- the present teachings also provide pharmaceutical compositions that include at least one compound described herein, or any pharmaceutically salt thereof thereof, and one or more pharmaceutically acceptable carriers, excipients, or diluents. Examples of such carriers are well known to those skilled in the art and can be prepared in accordance with acceptable pharmaceutical procedures, such as, for example, those described in Remington’s Pharmaceutical Sciences, 17th edition, ed. Alfonoso R. Gennaro, Mack Publishing Company, Easton, PA (1985), the entire disclosure of which is incorporated by reference herein for all purposes.
- pharmaceutically acceptable refers to a substance that is acceptable for use in pharmaceutical applications from a toxicological perspective and does not adversely interact with the active ingredient.
- pharmaceutically acceptable carriers are those that are compatible with the other ingredients in the composition and are biologically acceptable. Supplementary active ingredients can also be incorporated into the pharmaceutical compositions.
- Compounds of the present teachings can be administered orally or parenterally, neat or in combination with conventional pharmaceutical carriers.
- Applicable solid carriers can include one or more substances which can also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents, or encapsulating materials.
- the compounds can be formulated in conventional manner, for example, in a manner similar to that used for known 5-hydroxytryptamine receptor 7 activity modulators.
- Pharmaceutical compositions in the form of oral formulations containing a compound disclosed herein can comprise any conventionally used oral form, including tablets, capsules, buccal forms, troches, lozenges and oral liquids, suspensions or solutions.
- the carrier can be a finely divided solid, which is an admixture with a finely divided compound.
- a compound disclosed herein can be mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired.
- the powders and tablets can contain up to 99 % of the compound.
- Capsules can contain mixtures of one or more compound(s) disclosed herein with inert filler(s) and/or diluent(s) such as pharmaceutically acceptable starches (e.g., corn, potato or tapioca starch), sugars, artificial sweetening agents, powdered celluloses (e.g., crystalline and microcrystalline celluloses), flours, gelatins, gums, and the like.
- inert filler(s) and/or diluent(s) such as pharmaceutically acceptable starches (e.g., corn, potato or tapioca starch), sugars, artificial sweetening agents, powdered celluloses (e.g., crystalline and microcrystalline celluloses), flours, gelatins, gums, and the like.
- Useful tablet formulations can be made by conventional compression, wet granulation or dry granulation methods and utilize pharmaceutically acceptable diluents, binding agents, lubricants, disintegrants, surface modifying agents (including surfactants), suspending or stabilizing agents, including, but not limited to, magnesium stearate, stearic acid, sodium lauryl sulfate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, microcrystalline cellulose, sodium carboxymethyl cellulose, carboxymethylcellulose calcium, polyvinylpyrrolidine, alginic acid, acacia gum, xanthan gum, sodium citrate, complex silicates, calcium carbonate, glycine, sucrose, sorbitol, dicalcium phosphate, calcium sulfate, lactose, kaolin, mannitol, sodium chloride, low melting waxes, and ion exchange resins.
- pharmaceutically acceptable diluents including
- Surface modifying agents include nonionic and anionic surface modifying agents.
- Representative examples of surface modifying agents include, but are not limited to, poloxamer 188, benzalkonium chloride, calcium stearate, cetostearl alcohol, cetomacrogol emulsifying wax, sorbitan esters, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, magnesium aluminum silicate, and triethanolamine.
- Oral formulations described herein herein can utilize standard delay or time-release formulations to alter the absorption of the compound(s).
- An oral formulation can also consist of administering a compound disclosed herein in water or fruit juice, containing appropriate solubilizers or emulsifiers as needed.
- Liquid carriers can be used in preparing solutions, suspensions, emulsions, syrups, elixirs, and for inhaled delivery.
- a compound of the present teachings can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, or a mixture of both, or a pharmaceutically acceptable oils or fats.
- the liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers, and osmo-regulators.
- liquid carriers for oral and parenteral administration include, but are not limited to, water (particularly containing additives as described herein, e.g., cellulose derivatives such as a sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g., glycols) and their derivatives, and oils (e.g., fractionated coconut oil and arachis oil).
- the carrier can be an oily ester such as ethyl oleate and isopropyl myristate.
- Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration.
- the liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellants.
- Liquid pharmaceutical compositions which are sterile solutions or suspensions, can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously.
- Compositions for oral administration can be in either liquid or solid form.
- a pharmaceutical composition is in unit dosage form, for example, as tablets, capsules, powders, solutions, suspensions, emulsions, granules, or suppositories. In such form, the pharmaceutical composition can be sub-divided in unit dose(s) containing appropriate quantities of the compound.
- the unit dosage forms can be packaged compositions, for example, packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids.
- the unit dosage form can be a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.
- Such unit dosage form can contain from about 1 mg/kg of compound to about 500 mg/kg of compound, and can be given in a single dose or in two or more doses.
- Such doses can be administered in any manner useful in directing the compound(s) to the recipient’s bloodstream, including orally, via implants, parenterally (including intravenous, intraperitoneal and subcutaneous injections), rectally, vaginally, and transdermally.
- an effective dosage can vary depending upon the particular compound utilized, the mode of administration, and severity of the condition being treated, as well as the various physical factors related to the individual being treated.
- a compound of the present teachings can be provided to a patient already suffering from a disease in an amount sufficient to cure or at least partially ameliorate the symptoms of the disease and its complications.
- the dosage to be used in the treatment of a specific individual typically must be subjectively determined by the attending physician.
- the variables involved include the specific condition and its state as well as the size, age and response pattern of the patient.
- a compound directly to the airways of the patient, using devices such as, but not limited to, metered dose inhalers, breath-operated inhalers, multidose dry-powder inhalers, pumps, squeeze-actuated nebulized spray dispensers, aerosol dispensers, and aerosol nebulizers.
- devices such as, but not limited to, metered dose inhalers, breath-operated inhalers, multidose dry-powder inhalers, pumps, squeeze-actuated nebulized spray dispensers, aerosol dispensers, and aerosol nebulizers.
- the compounds of the present teachings can be formulated into a liquid composition, a solid composition, or an aerosol composition.
- the liquid composition can include, by way of illustration, one or more compounds of the present teachings dissolved, partially dissolved, or suspended in one or more pharmaceutically acceptable solvents and can be administered by, for example, a pump or a squeeze-actuated nebulized spray dispenser.
- the solvents can be, for example, isotonic saline or bacteriostatic water.
- the solid composition can be, by way of illustration, a powder preparation including one or more compounds of the present teachings intermixed with lactose or other inert powders that are acceptable for intrabronchial use, and can be administered by, for example, an aerosol dispenser or a device that breaks or punctures a capsule encasing the solid composition and delivers the solid composition for inhalation.
- the aerosol composition can include, by way of illustration, one or more compounds of the present teachings, propellants, surfactants, and co-solvents, and can be administered by, for example, a metered device.
- the propellants can be a chlorofluorocarbon (CFC), a hydrofluoroalkane (HFA), or other propellants that are physiologically and environmentally acceptable.
- CFC chlorofluorocarbon
- HFA hydrofluoroalkane
- compositions described herein can be administered parenterally or intraperitoneally. Solutions or suspensions of these compounds or a pharmaceutically acceptable salts, hydrates, or esters thereof can be prepared in water suitably mixed with a surfactant such as hydroxylpropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations typically contain a preservative to inhibit the growth of microorganisms.
- the pharmaceutical forms suitable for injection can include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
- the form can sterile and its viscosity permits it to flow through a syringe.
- the form preferably is stable under the conditions of manufacture and storage and can be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.
- Compounds described herein can be administered transdermally, i.e., administered across the surface of the body and the inner linings of bodily passages including epithelial and mucosal tissues. Such administration can be carried out using the compounds of the present teachings including pharmaceutically acceptable salts, hydrates, or esters thereof, in lotions, creams, foams, patches, suspensions, solutions, and suppositories (rectal and vaginal).
- Transdermal administration can be accomplished through the use of a transdermal patch containing a compound, such as a compound disclosed herein, and a carrier that can be inert to the compound, can be non-toxic to the skin, and can allow delivery of the compound for systemic absorption into the blood stream via the skin.
- the carrier can take any number of forms such as creams and ointments, pastes, gels, and occlusive devices.
- the creams and ointments can be viscous liquid or semisolid emulsions of either the oil-in-water or water-in- oil type. Pastes comprised of absorptive powders dispersed in petroleum or hydrophilic petroleum containing the compound can also be suitable.
- occlusive devices can be used to release the compound into the blood stream, such as a semi-permeable membrane covering a reservoir containing the compound with or without a carrier, or a matrix containing the compound.
- Other occlusive devices are known in the literature.
- Compounds described herein can be administered rectally or vaginally in the form of a conventional suppository.
- Suppository formulations can be made from traditional materials, including cocoa butter, with or without the addition of waxes to alter the suppository’s melting point, and glycerin.
- Water-soluble suppository bases such as polyethylene glycols of various molecular weights, can also be used.
- Lipid formulations or nanocapsules can be used to introduce compounds of the present teachings into host cells either in vitro or in vivo. Lipid formulations and nanocapsules can be prepared by methods known in the art. [0347] To increase the effectiveness of compounds of the present teachings, it can be desirable to combine a compound with other agents effective in the treatment of the target disease. For example, other active compounds (i.e., other active ingredients or agents) effective in treating the target disease can be administered with compounds of the present teachings. The other agents can be administered at the same time or at different times than the compounds disclosed herein. Kits [0348] In some embodiments, provided herein are kits.
- kits can include a compound or pharmaceutically acceptable form thereof, or pharmaceutical composition as described herein, in suitable packaging, and written material that can include instructions for use, discussion of clinical studies, listing of side effects, and the like.
- Kits are well suited for the delivery of solid oral dosage forms such as tablets or capsules.
- Such kits can also include information, such as scientific literature references, package insert materials, clinical trial results, and/or summaries of these and the like, which indicate or establish the activities and/or advantages of the pharmaceutical composition, and/or which describe dosing, administration, side effects, drug interactions, or other information useful to the health care provider.
- Such information can be based on the results of various studies, for example, studies using experimental animals involving in vivo models and studies based on human clinical trials.
- Compounds of the present teachings can be useful for the treatment or inhibition of a pathological condition or disorder in a mammal, for example, a human subject.
- the present teachings accordingly provide methods of treating or inhibiting a pathological condition or disorder by providing to a mammal a compound of the present teachings (including its pharmaceutically acceptable salt) or a pharmaceutical composition that includes one or more compounds of the present teachings in combination or association with pharmaceutically acceptable carriers.
- Compounds of the present teachings can be administered alone or in combination with other therapeutically effective compounds or therapies for the treatment or inhibition of the pathological condition or disorder.
- a compound described herein modulates (e.g., inhibitors) a protein kinase that is abl, Akt, bcr-abl, Blk, Brk, c-kit, c-met, c-src, CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, cRaf1, CSK, EGFR, ErbB2, ErbB3, ErbB4, Erk, Pak, fes, FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, Fgr, flt-1, Fps, Frk, Fyn, Hck, IGF-1R, INS-R, Jak, KDR, Lck, Lyn
- a compound described herein modulates (e.g., inhibits) a wild-type form of a kinase (e.g., EGFR). In embodiments, a compound described herein modulates (e.g., inhibits) a mutant form of a kinase (e.g., EGFR). [0351] In embodiments, a compound described herein, or any pharmaceutically acceptable form thereof such as a pharmaceutically acceptable salt thereof, modulates (e.g., inhibits) a kinase that is a tyrosine kinase (e.g., KIT, erb2, PDGFR, EGFR, VEGFR, src, or abl).
- a tyrosine kinase e.g., KIT, erb2, PDGFR, EGFR, VEGFR, src, or abl.
- a compound described herein, or any pharmaceutically acceptable form thereof such as a pharmaceutically acceptable salt thereof modulates (e.g., inhibits) a kinase that is a serine/threonine kinase (e.g., mTorC1, mTorC2, ATM, ATR, DNA-PK, or Akt).
- a kinase that is a serine/threonine kinase e.g., mTorC1, mTorC2, ATM, ATR, DNA-PK, or Akt.
- a compound described herein, or any pharmaceutically acceptable form thereof such as a pharmaceutically acceptable salt thereof can be used to treat or prevent a disease or disorder that is responsive to modulation (e.g., inhibition) of a protein kinase (e.g., abl, Akt, bcr-abl, Blk, Brk, c-kit, c-met, c-src, CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, cRaf1, CSK, EGFR, ErbB2, ErbB3, ErbB4, Erk, Pak, fes, FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, Fgr, flt-1, Fps, Frk, Fyn, Hck, IGF-1R, INS-R, Jak, KDR, Lck, Lyn, MEK, p38, PDGFR
- a compound described herein, or any pharmaceutically acceptable form thereof such as a pharmaceutically acceptable salt thereof can be used to treat or prevent a disease or disorder that is responsive to modulation (e.g., inhibition) of a tyrosine kinase (e.g., KIT, erb2, PDGFR, EGFR, VEGFR, src, or abl).
- a tyrosine kinase e.g., KIT, erb2, PDGFR, EGFR, VEGFR, src, or abl.
- a compound described herein, or any pharmaceutically acceptable form thereof such as a pharmaceutically acceptable salt thereof can be used to treat or prevent a disease or disorder that is responsive to modulation (e.g., inhibition) of a serine/threonine kinase (e.g., mTorC1, mTorC2, ATM, ATR, DNA-PK, or Akt).
- a compound described herein modulates (e.g., inhibits) a wild-type form of a kinase (e.g., EGFR).
- a compound described herein modulates (e.g., inhibits) a mutant form of a kinase (e.g., EGFR).
- Selective Inhibition of Kinases refers to the agent’s ability to selectively reduce the target signaling activity as compared to off-target signaling activity, via direct or interact interaction with the target.
- a compound described herein, or any pharmaceutically acceptable salt thereof selectively inhibits a kinase or kinase form over other kinases or other kinase forms.
- a compound selectively inhibits a mutant kinase form over the wild-type of the same kinase.
- a compound described herein, or any pharmaceutically acceptable salt thereof selectively inhibits a kinase (e.g., EGFR) over other kinases.
- a compound described herein, or any pharmaceutically acceptable salt thereof selectively inhibits a kinase form (e.g., mutant EGFR) over other kinase forms (e.g., wild-type EGFR).
- the ratio of selectivity can be greater than a factor of about 10, greater than a factor of about 20, greater than a factor of about 30, greater than a factor of about 40, greater than a factor of about 50, greater than a factor of about 60, greater than a factor of about 70, greater than a factor of about 80, greater than a factor of about 100, greater than a factor of about 120, or greater than a factor of about 150, where selectivity can be measured by in vitro assays known in the art.
- assays to measure selectivity include enzymatic assays, cellular proliferation assays, and EGFR phosphorylation assays.
- selectivity can be determined by cellular proliferation assays.
- selectivity can be determined by EGFR phosphorylation assays.
- the mutant EGFR inhibitory activity of a compound as disclosed herein can be less than about 1000 nM, less than about 100 nM, less than about 50 nM, less than about 30 nM, or less than about 10 nM.
- the IC50 of a kinase inhibitor compound can be less than about 100 nM, less than about 50 nM, less than about 10 nM, less than about 1 nM, less than about 0.5 nM, or less than about 1 pM.
- Determination of IC 50 values can be performed according to methods known in the art.
- a compound described herein, or any pharmaceutically acceptable form thereof such as a pharmaceutically acceptable salt thereof, can be used to treat or prevent a disease or disorder that is cancer, an inflammatory disorder, a metabolic disorder, vascular disease, or neuronal disease.
- a disease or disorder that is cancer, an inflammatory disorder, a metabolic disorder, vascular disease, or neuronal disease.
- Compounds described herein, or any pharmaceutically acceptable form thereof, or any pharmaceutical composition thereof, can be useful for treating diseases and disorders associated with abnormal cell proliferation.
- a compound described herein, or a pharmaceutically acceptable form thereof e.g., a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, can be used to treat cancer.
- compositions and methods provided herein can potentially be useful for the treatment of cancer including tumors such as astrocytic, breast, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatocellular, laryngeal, lung, oral, ovarian, prostate and thyroid carcinomas and sarcomas.
- tumors such as astrocytic, breast, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatocellular, laryngeal, lung, oral, ovarian, prostate and thyroid carcinomas and sarcomas.
- a cancer is a cardiac cancer such as sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma or teratoma.
- sarcoma angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma
- myxoma rhabdomyoma
- fibroma fibroma
- lipoma lipoma
- teratoma teratoma
- a cancer is a lung cancer such as bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, or mesothelioma.
- bronchogenic carcinoma squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma
- alveolar (bronchiolar) carcinoma bronchial adenoma
- sarcoma sarcoma
- lymphoma chondromatous hamartoma
- mesothelioma mesothelioma
- a cancer is a gastrointestinal cancer such as: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma).
- esophagus squamous cell carcinoma, adenocarcinoma, leiomyosarcoma,
- a cancer is a cancer of the genitourinary tract such as: kidney (adenocarcinoma, Wilm's tumor (nephroblastoma), lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma).
- kidney adenocarcinoma, Wilm's tumor (nephroblastoma), lymphoma, leukemia), bladder and urethra
- a cancer is a liver cancer such as hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma.
- hepatoma hepatocellular carcinoma
- cholangiocarcinoma hepatoblastoma
- angiosarcoma hepatocellular adenoma
- hemangioma hemangioma
- a cancer is a bone cancer such as: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors.
- osteogenic sarcoma osteosarcoma
- fibrosarcoma malignant fibrous histiocytoma
- chondrosarcoma chondrosarcoma
- Ewing's sarcoma malignant lymphoma
- multiple myeloma malignant giant cell tumor chordoma
- osteochronfroma osteocar
- a cancer is a cancer of the central nervous system (CNS) such as: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma).
- CNS central nervous system
- a cancer is a gynecological cancer such as: uterus (endometrial carcinoma), cervix (cervical carcinoma, pre -tumor cervical dysplasia), ovaries (ovarian carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tubes (carcinoma).
- uterus endometrial carcinoma
- cervix cervical carcinoma, pre -tumor cervical dysplasia
- ovaries
- a cancer is a hematological cancer such as: blood (myeloid leukemia (acute and chronic), acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplasia syndrome), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma).
- blood myeloid leukemia (acute and chronic), acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplasia syndrome
- Hodgkin's disease non-Hodgkin's lymphoma (malignant lymphoma).
- a cancer is a skin cancer such as: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis.
- a cancer is a cancer of the adrenal glands such as neuroblastoma.
- a cancer includes a cell afflicted by any one of or related to the above identified conditions.
- a cancer is an EGFR-driven cancer (e.g., as described herein).
- an EGFR-driven cancer is non-small cell lung cancer (NSCLC), squamous cell carcinoma, adenocarcinoma, adenocarcinoma, bronchioloalveolar carcinoma (BAC), BAC with focal invasion, adenocarcinoma with BAC features, and large cell carcinoma; neural tumors, such as glioblastomas; pancreatic cancer; head and neck cancers (e.g., squamous cell carcinoma); breast cancer; colorectal cancer; epithelial cancer, including squamous cell carcinoma; ovarian cancer; prostate cancer; or adenocarcinomas.
- NSCLC non-small cell lung cancer
- BAC bronchioloalveolar carcinoma
- BAC bronchioloalveolar carcinoma
- BAC BAC with focal invasion, adenocarcinoma with BAC features, and large cell carcinoma
- neural tumors such as glioblastomas
- pancreatic cancer head and neck cancers (e.g., squamous cell carcinoma
- a cancer is an EGFR mutant cancer (e.g., as described herein).
- an EGFR mutant cancer is non-small cell lung cancer (NSCLC), squamous cell carcinoma, adenocarcinoma, adenocarcinoma, bronchioloalveolar carcinoma (BAC), BAC with focal invasion, adenocarcinoma with BAC features, and large cell carcinoma; neural tumors, such as glioblastomas; pancreatic cancer; head and neck cancers (e.g., squamous cell carcinoma); breast cancer; colorectal cancer; epithelial cancer, including squamous cell carcinoma; ovarian cancer; prostate cancer; or adenocarcinomas.
- NSCLC non-small cell lung cancer
- BAC bronchioloalveolar carcinoma
- BAC bronchioloalveolar carcinoma
- BAC BAC with focal invasion, adenocarcinoma with BAC features, and large cell carcinoma
- neural tumors such as glioblastomas
- compositions and methods provided herein are useful for the treatment of lung cancer and pancreatic cancer, most specifically, non-small cell lung cancer (NSCLC).
- NSCLC non-small cell lung cancer
- a cancer is refractory to TKI therapies (e.g., erlotinib, gefitinib, dacomitinib, afatinib, osimertinib).
- TKI therapies e.g., erlotinib, gefitinib, dacomitinib, afatinib, osimertinib.
- a cancer is a lung cancer.
- Lung cancer is the most common cause of cancer mortality globally and the second most common cancer in both men and women. About 14% of all new cancers are lung cancers. In the United States (US), there are projected to be 222,500 new cases of lung cancer (116,990 in men and 105,510 in women) and 155,870 deaths from lung cancer (84,590 in men and 71,280 in women) in 2017.
- NSCLC non-small cell lung cancer
- small cell lung cancer small cell lung cancer
- NSCLC is a heterogeneous disease that consists of adenocarcinoma, large-cell carcinoma, and squamous cell carcinoma (sqNSCLC), and comprises approximately 80% to 85% of all lung cancers. Squamous cell carcinoma of the lung accounts for 20% to 30% of NSCLC.
- sqNSCLC squamous cell carcinoma of the lung accounts for 20% to 30% of NSCLC.
- Platinum-based doublet therapy, maintenance chemotherapy, and anti-angiogenic agents in combination with chemotherapy have contributed to improved patient outcomes in advanced NSCLC.
- an advanced lung cancer is stage III cancer or stage IV cancer. In embodiments, an advanced lung cancer is stage III cancer. In embodiments, an advanced lung cancer is stage IV cancer. In embodiments, an advanced lung cancer is locally advanced. In embodiments, an advanced lung cancer is metastatic. [0388] In embodiments, a lung cancer is small cell lung cancer (SCLC). [0389] In embodiments, a lung cancer is non-small cell lung cancer (NSCLC) such as adenocarcinoma, large-cell carcinoma, or squamous cell carcinoma (sqNSCLC). In embodiments, a NSCLC is lung adenocarcinoma. In embodiments, a NSCLC is large cell carcinoma of the lung.
- NSCLC non-small cell lung cancer
- sqNSCLC squamous cell carcinoma
- a NSCLC is squamous cell carcinoma of the lung (sqNSCLC).
- a lung cancer e.g., NSCLC
- EGFR-mutant lung cancer e.g., EGFR-mutant NSCLC
- a cancer is NSCLC (e.g., advanced NSCLC) with an identified EGFR mutation.
- the invention features compounds which can be useful for treating patients who have an EGFR-driven cancer, including cancers which are, or have become, refractory to erlotinib, gefitinib, dacomitinib, afatinib, osimertinib , or cancers which bear an EGFR mutation identified herein, by administering a compound of formula (I) to a subject.
- EGFR-driven cancers which can be treated using the compositions and method of the invention include, for example, EGFR mutants including one or more deletions, substitutions, or additions in the amino acid or nucleotide sequences of EGFR, or fragments thereof.
- An EGFR-driven cancer may result from an EGFR fusion.
- the N-terminal of EGFR can be linked to various fusion partners such as RAD51.
- Cancers e.g., lung cancers
- an EGFR-fusion e.g., an EGFR-RAD51 fusion
- Mutations in EGFR can occur in any part of the EGFR sequence.
- EGFR mutants arise from mutations in the kinase domain (i.e., exons 18-24 in the EGFR sequence) or in the extracellular domain (i.e., exons 2-16 in the EGFR sequence).
- a mutation in EGFR can be an activating mutation, which lead to a ligand- independent activation of TK activity.
- a mutation in EGFR can also be a resistance mutation, which can confer resistance to TKI therapies such as resistance to one or more of erlotinib, gefitinib, dacomitinib, afatinib, or osimertinib.
- mutations typically occur in the kinase domain, including one or more of a point mutation in exon 18 (e.g., L688P, V689M, P694L/S, N700D, L703V, E709K/Q/A/G/V, I715S, L718P, G719C/A/S/R, or S720P/F), a deletion in exon 19 that may or may not include an insertion (e.g., delG719, delE746_E749, delE746_A750, delE746_A750insRP, delE746_A750insQP, delE746_T751, delE746_T751insA/I/V, delE746_T751insVA, delE746_S752, delE746_S752insA/V/D, delE746_P53insLS,
- a mutation is a resistance mutation.
- drug resistance in 50% of lung cancers arises from the T790M point mutation.
- Other exemplary resistance mutation include point mutations such as: C797X (e.g., C797S, C797G, or C797N); G796X (e.g., G796R, G796S, or G796D); L792X (e.g. L792H, L792F, L792R, or L792Y); G724S; L718X (e.g., L718P, L718Q, or L718V); S768I; or G719A.
- C797X e.g., C797S, C797G, or C797N
- G796X e.g., G796R, G796S, or G796D
- L792X e.g. L792H, L792F, L792R, or L792Y
- glioblastoma mutations typically, but not exclusively, occur in the extracellular domain, including EGFR variant I (EGFRvI) lacking the extracellular domain and resembling the v-erbB oncoprotein; EGFRvII lacking 83 amino acids from domain IV; and EGFRvIII lacking amino acids 30-297 from domains I and II, which is the most common amplification and is reported in 30-50% of glioblastomas and 5% of squamous cell carcinoma.
- EGFRvI EGFR variant I
- EGFRvIII lacking amino acids from domain IV
- EGFRvIII lacking amino acids 30-297 from domains I and II
- glioblastoma include one or more of point mutations in exon 2 (e.g., D46N or G63R), exon 3 (e.g., R108K in domain I), exon 7 (e.g., T263P or A289D/T/V in domain II), exon 8 (e.g., R324L or E330K), exon 15 (e.g., P596L or G598V in domain IV), or exon 21 (L861Q in the kinase domain).
- EGFR mutants also include those with a combination of two or more mutations, as described herein.
- Exemplary combinations include S768I and G719A; S768I and V769L; H773R and W731Stop; R776G and L858R; R776H and L861Q; T790M and L858R; T790M and delE746_A750; R803W and delE746_T751insVA; delL747_E749 and A750P; delL747_S752 and E746V; delL747_S752 and P753S; P772_H773insYNP and H773Y; P772_H773insNP and H773Y; and D770_N771insG and N771T.
- EGFR mutants can be either activation mutants or resistant mutants. Activation mutants include those with substitutions that increase drug sensitivity (e.g., G719C/S/A, delE746_A750, or L858R). Resistant mutants include those with substitutions that increase drug resistance (e.g., T790M or any combination including T790M).
- an EGFR mutation is a deletion in exon19 (del19). In embodiments, an EGFR mutation is a T790M mutation.
- an EGFR mutation is a L858R mutation. In embodiments, an EGFR mutation is a C797S mutation. In embodiments, an EGFR-driven cancer (e.g., non-small cell lung cancer) is characterized by at least one of these mutations. In embodiments, an EGFR-driven cancer (e.g., non-small cell lung cancer) is characterized by at least two of these mutations. In embodiments, an EGFR-driven cancer (e.g., non-small cell lung cancer) is characterized by at least three of these mutations. [0403] EGFR-driven cancers include those having any mutant described herein.
- EGFRvIII is commonly found in glioblastoma and has also been reported in breast, ovarian, prostate, and lung carcinomas.
- exemplary EGFR-driven cancers glioblastoma, lung cancer (e.g., squamous cell carcinoma, non-small cell lung cancer, adenocarcinoma, bronchioloalveolar carcinoma (BAC), BAC with focal invasion, adenocarcinoma with BAC features, and large cell carcinoma), pancreatic cancer, head and neck cancers (e.g., squamous cell carcinoma), breast cancer, colorectal cancer, epithelial cancer (e.g., squamous cell carcinoma), ovarian cancer, and prostate cancer.
- lung cancer e.g., squamous cell carcinoma, non-small cell lung cancer, adenocarcinoma, bronchioloalveolar carcinoma (BAC), BAC with focal invasion, adenocarcinoma with BAC features, and large cell carcinoma
- pancreatic cancer
- the invention described herein would benefit patient populations having higher risk for TKI-resistant mutations.
- About 8,000 to 16,000 new cases per year can be estimated based on: incidence of non-small cell lung cancer (about 160,000 new cases in the U.S.), the response to erlotinib in the general population (about 10%, resulting in a sensitive population of 16,000), the presence of activation mutations (10-20% in white and 30-40% in Asian population, resulting in a sensitive population of 16,000-32,000), acquisition of secondary resistance (most if not all patients, resulting in a sensitive population of 16,000- 32,000), and percentage of patients carrying the T790M point mutations (about 50%, resulting in a sensitive population of 8,000-16,000).
- Patients having TKI-resistant mutations include those patients having cancers resistant to one or more of erlotinib, gefitinib, dacomitinib, afatinib, osimertinib, CL-387,785, BIBW 2992 (CAS Reg. No.439081-18-2), CI-1033, neratinib (HKI-272), MP-412 (AV-412), PF-299804, AEE78, and XL64.
- the inventions relate to treatment of EGFR-driven cancers having the T790M point mutation.
- an EGFR mutant also includes other amino acid and nucleotide sequences of EGFR with one or more deletions, substitutions, or additions, such as point mutations, that retain or increase tyrosine kinase or phosphorylation activity.
- substitutions are conservative substitutions, which are substitutions between amino acids similar in properties such as structural, electric, polar, or hydrophobic properties.
- the substitution can be conducted between basic amino acids (e.g., Lys, Arg, and His), or between acidic amino acids (e.g., Asp and Glu), or between amino acids having non-charged polar side chains (e.g., Gly, Asn, Gln, Ser, Thr, Tyr, and Cys), or between amino acids having hydrophobic side chains (e.g., Ala, Val, Leu, Ile, Pro, Phe, and Met), or between amino acids having branched side chains (e.g., Thr, Val, Leu, and Ile), or between amino acids having aromatic side chains (e.g., Tyr, Trp, Phe, and His).
- basic amino acids e.g., Lys, Arg, and His
- acidic amino acids e.g., Asp and Glu
- amino acids having non-charged polar side chains
- the DNA encoding an EGFR mutant protein may comprise a nucleotide sequence capable of hybridizing to a complement sequence of the nucleotide sequence encoding an EGFR mutant, as defined herein, under stringent conditions.
- the stringent conditions include low, medium or high stringent conditions.
- An example of the stringent conditions includes hybridization at approximately 42-55°C in approximately 2-6 x SSC, followed by wash at approximately 50-65°C in approximately 0.1-1 x SSC containing approximately 0.1-0.2% SDS, where 1 x SSC is a solution containing 0.15 M NaCl and 0.015 M Na citrate, pH 7.0. Wash can be performed once or more.
- stringent conditions may be set at a temperature approximately 5°C lower than a melting temperature (Tm) of a specific nucleotide sequence at defined ionic strength and pH.
- Tm melting temperature
- the amino acid and nucleotide sequences of EGFR and DNAs encoding them are available from known databases such as NCBI GenBank (USA), EMBL (Europe), etc.
- GenBank accession numbers for EGFR [Homo sapiens] include MIM131550, AAI28420, NM_005228, NP_005219.2, and GeneID: 1956.
- a compound described herein, or any pharmaceutically acceptable salt thereof selectively inhibits EGFR (including any mutant EGFR described herein) over other kinases.
- a compound described herein, or any pharmaceutically acceptable salt thereof selectively inhibits mutant EGFR (e.g., any mutant EGFR described herein) over wild-type EGFR.
- a compound described herein selectively inhibits EGFR characterized by a mutation that is: a deletion in exon19 (del19), a T790M mutation, a L858R mutation, and/or a C797S mutation, or any combination thereof.
- the ratio of selectivity can be greater than a factor of about 10, greater than a factor of about 20, greater than a factor of about 30, greater than a factor of about 40, greater than a factor of about 50, greater than a factor of about 60, greater than a factor of about 70, greater than a factor of about 80, greater than a factor of about 100, greater than a factor of about 120, or greater than a factor of about 150, where selectivity can be measured by in vitro assays known in the art.
- Non-limiting examples of assays to measure selectivity include enzymatic assays, cellular proliferation assays, and EGFR phosphorylation assays.
- selectivity can be determined by cellular proliferation assays.
- selectivity can be determined by EGFR phosphorylation assays.
- the mutant EGFR inhibitory activity of a compound as disclosed herein can be less than about 1000 nM, less than about 100 nM, less than about 50 nM, less than about 30 nM, or less than about 10 nM.
- the IC50 of a subject compound for mutant EGFR inhibition can be less than about 100 nM, less than about 50 nM, less than about 10 nM, less than about 1 nM, less than about 0.5 nM, or less than about 1 pM.
- Characterization of EGFR-driven Cancers [0413] The compositions and methods of the invention can be used to treat subjects having an EGFR-driven cancer (i.e., cancers characterized by EGFR mutant expression or overexpression).
- EGFR mutant expression or overexpression can be determined in a diagnostic or prognostic assay by evaluating levels of EGFR mutants in biological sample, or secreted by the cell (e.g., via an immunohistochemistry assay using anti-EGFR antibodies or anti-p-EGFR antibodies; FACS analysis, etc.).
- FISH fluorescent in situ hybridization using a nucleic acid based probe corresponding to an EGFR mutant-encoding nucleic acid or the complement thereof
- FISH fluorescent in situ hybridization using a nucleic acid based probe corresponding to an EGFR mutant-encoding nucleic acid or the complement thereof
- FISH fluorescent in situ hybridization using a nucleic acid based probe corresponding to an EGFR mutant-encoding nucleic acid or the complement thereof
- PCR polymerase chain reaction
- RT-PCR real time quantitative PCR
- Examples of biological properties that can be measured in isolated cells include mRNA expression, protein expression, and DNA quantification. Additionally, the DNA of cells isolated by the methods of the invention can be sequenced, or certain sequence characteristics (e.g., polymorphisms and chromosomal abnormalities) can be identified using standard techniques, e.g., FISH or PCR. The chemical components of cells, and other analytes, may also be assayed after isolation. Cells may also be assayed without lysis, e.g., using extracellular or intracellular stains or by other observation, e.g., morphology or growth characteristics in various media.
- sequence characteristics e.g., polymorphisms and chromosomal abnormalities
- FISH fluorescent in situ hybridization
- FISH is a cytogenetic technique which can be used to detect and localize the presence or absence of specific DNA or RNA sequences on chromosomes.
- FISH incorporates the use of fluorescently labeled nucleic acid probes which bind only to those parts of the chromosome with which they show a high degree of sequence similarity. Fluorescence microscopy can be used to find out where the fluorescent probe bound to the chromosome. The basic steps of FISH are outlined below.
- Exemplary FISH probes include Vysis EGFR SpectrumOrange/ CEP SpectrumGreen Probe (Abbott, Downers Grove, IL), which hybridizes to band 7p12; and ZytoLight SPEC EGFR/CEN 7 Dual Color Probe (ZytoVision), which hybridizes to the alpha-satellite sequences of the centromere of chromosome 7.
- a probe is constructed that is long enough to hybridize specifically to its target (and not to similar sequences in the genome), but not too large to impede the hybridization process. Probes are generally labeled with fluorophores, with targets for antibodies, with biotin, or any combination thereof.
- a sample or aliquot of a population of cells is used for FISH analysis.
- cells are trypsinized to disperse into single cells, cytospun onto glass slides, and then fixed with paraformaldehyde before storing in 70% ethanol.
- the chromosomes are firmly attached to a substrate, usually glass. After preparation, the probe is applied to the chromosome RNA and starts to hybridize. In several wash steps, all unhybridized or partially hybridized probes are washed away.
- FISH Fluorescence In situ hybridization
- FISH can have resolution ranging from huge chromosomes or tiny ( ⁇ 100 kilobase) sequences. The probes can be quantified simply by counting dots or comparing color.
- Allele-specific quantitative real time-PCR may also be used to identify a nucleic acid encoding a mutant EGFR protein (see, for e.g., Diagnostic Innovations DxS BCR-ABL T3151 Mutation Test Kit, and Singer et al., Methods in Molec. Biol.181:145 (2001)).
- This technique utilizes Taq DNA polymerase, which is extremely effective at distinguishing between a match and a mismatch at the 3’-end of the primer (when the 3’-base is mismatched, no efficient amplification occurs).
- the 3’-end of the primer may be designed to specifically hybridize to a nucleic acid sequence that corresponds to a codon that encodes a mutant amino acid in an EGFR mutant, as described herein. In this way, the specific mutated sequences can be selectively amplified in a patient sample.
- This technique further utilizes a Scorpion probe molecule, which is a bifunctional molecule containing a PCR primer, a fluorophore, and a quencher.
- the fluorophore in the probe interacts with a quencher, which reduces fluorescence.
- a quencher which reduces fluorescence.
- the fluorophore and quencher in the Scorpion probe become separated, which leads to an increase in fluorescence from the reaction tube.
- Any of the primers described herein may be used in allele-specific quantitative real time PCR.
- methods such as direct nucleic acid sequencing, altered hybridization, aberrant electrophoretic gel migration, binding or cleavage mediated by mismatch binding proteins, single-strand conformational polymorphism (SSCP) analysis, or restriction fragment length polymorphism (RFLP) analysis of PCR products derived from a patient sample can be used to detect a mutation in an EGFR gene; ELISA can be used to measure levels of EGFR polypeptide; and PCR can be used to measure the level of an EGFR nucleic acid molecule.
- Any of these techniques may be used to facilitate detection of a mutation in a candidate gene, and each is well known in the art; examples of particular techniques are described, without limitation, in Orita et al. (Proc. Natl.
- telomeres may be monitored by standard Northern blot analysis or may be aided by PCR (see, e.g., Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY (1995); PCR Technology: Principles and Applications for DNA Amplification, H.A. Ehrlich, Ed., Stockton Press, NY; Yap et al., Nucl. Acids. Res.19:4294 (1991)).
- One skilled in the art may identify in a nucleic acid or protein sequence a residue (e.g., amino acid or nucleotide) or codon that corresponds to a residue or codon in wild-type EGFR or EGFR mutants using a number of sequence alignment software programs (e.g., NCBI BLAST website). Such software programs may allow for gaps in the alignment of the compared sequences. Using such software, one skilled in the art may identify a nucleotide, amino acid, or amino acid that corresponding to a specific nucleotide, amino acid, or codon in wild-type EGFR or EGFR mutants.
- sequence alignment software programs e.g., NCBI BLAST website
- Levels of EGFR expression (e.g., DNA, mRNA, or protein) in a biological sample can be determined by using any of a number of standard techniques that are well known in the art or described herein.
- Exemplary biological samples include plasma, blood, sputum, pleural effusion, bronchoalveolar lavage, or biopsy, such as a lung biopsy and lymph node biopsy.
- EGFR expression in a biological sample e.g., a blood or tissue sample
- PCR Technology Principles and Applications for DNA Amplification, H.A.
- Combination Therapies [0425]
- an agent known to modulate other pathways, or other components of the same pathway, or even overlapping sets of target enzymes are used in combination with a compound as provided herein, or a pharmaceutically acceptable form (e.g., pharmaceutically acceptable salts, hydrates, solvates, isomers, prodrugs, and isotopically labeled derivatives) thereof.
- a pharmaceutically acceptable form e.g., pharmaceutically acceptable salts, hydrates, solvates, isomers, prodrugs, and isotopically labeled derivatives
- such therapy includes, but is not limited to, the combination of the subject compound with chemotherapeutic agents, therapeutic antibodies, and radiation treatment, to provide a synergistic or additive therapeutic effect.
- the therapeutic agents can be formulated as separate compositions that are administered at the same time or sequentially at different times, or the therapeutic agents can be given as a single composition.
- the phrase “combination therapy”, in referring to the use of a disclosed compound together with another pharmaceutical agent, means the coadministration of each agent in a substantially simultaneous manner as well as the administration of each agent in a sequential manner, in either case, in a regimen that will provide beneficial effects of the drug combination.
- Coadministration includes, inter alia, the simultaneous delivery, e.g., in a single tablet, capsule, injection or other dosage form having a fixed ratio of these active agents, as well as the simultaneous delivery in multiple, separate dosage forms for each agent respectively.
- additional therapies known to those skilled in the art in the prevention or treatment of cancer, such as radiation therapy or cytostatic agents, cytotoxic agents, other anti-cancer agents and other drugs to amerliorate symptoms of the cancer or side effects of any of the drugs.
- treatment can be provided in combination with one or more other cancer therapies, include surgery, radiotherapy (e.g., gamma-radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, and systemic radioactive isotopes, etc.), endocrine therapy, biologic response modifiers (e.g., interferons, interleukins, and tumor necrosis factor (TNF)), hyperthermia, cryotherapy, agents to attenuate any adverse effects (e.g., antiemetics), and other cancer chemotherapeutic drugs.
- the other agent(s) can be administered using a formulation, route of administration and dosing schedule the same or different from that used with the compounds provided herein.
- combination therapy comprises administration of a compound described herein, or any pharmaceutically acceptable form thereof (e.g., any pharmaceutically acceptable salt thereof), or a pharmaceutical composition thereof, in combination with anticancer drugs (e.g., antiproliferative agents, anti-angiogenic agents and other chemotherapeutic agents).
- anticancer drugs e.g., antiproliferative agents, anti-angiogenic agents and other chemotherapeutic agents.
- combination therapy comprises administration of a compound described herein, or any pharmaceutically acceptable form thereof (e.g., any pharmaceutically acceptable salt thereof), or a pharmaceutical composition thereof, in combination with an amount of an anti-cancer agent (e.g., a chemotherapeutic agent).
- an anti-cancer agent e.g., a chemotherapeutic agent
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Described herein are macrocyclic compounds of Formulas (Al), (BI), and (CI) which can inhibit kinases such as EGFR, including mutant forms such as T790M EGFR mutants. Also described herein are pharmaceutical compositions comprising a compound of Formula (I), or any pharmaceutically acceptable form thereof, processes for their preparation, and use in therapy for the prevention or treatment of cancer. In particular, compounds described herein can be effective for treating EGFR-driven cancers including non-small cell lung cancer (NSCLC).
Description
MACROCYCLIC COMPOUNDS AND USES THEREOF CROSS-REFERENCE TO RELATED APPLICATIONS [0001] The present application claims priority to U.S. Provisional Application No. 63/410,823, filed on September 28, 2022, and which is hereby incorporated by reference in its entirety. FIELD OF THE INVENTION [0002] Described herein are macrocyclic compounds that can be used as kinase inhibitors. In particular, compounds described herein can inhibit epidermal growth factor receptor (EGFR), including mutant forms of EGFR. Compounds described herein can be effective for treating various disorders that include cancers such as EGFR-driven cancers (e.g., non-small cell lung cancer (NSCLC) characterized by mutant EGFR). BACKGROUND [0003] Signal transduction refers to the transmission of stimulatory or inhibitory signals into and within a cell leading, often via a cascade of signal transmission events, to a biological response within the cell. Defects in various components of signal transduction pathways have been found to account for a large number of diseases, including numerous forms of cancer, inflammatory disorders, metabolic disorders, vascular and neuronal diseases. [0004] Signal transduction is often mediated by certain proteins called kinases. Kinases can generally be classified into protein kinases and lipid kinases, and certain kinases exhibit dual specificities. For example, epidermal growth factor receptor (EGFR) belongs to a family of receptor tyrosine kinases (RTKs) that include EGFR/ERBB1, HER2/ERBB2/NEU, HER3/ERBB3, and HER4/ERBB4. The binding of a ligand, such as epidermal growth factor (EGF), induces a conformational change in EGFR that facilitates receptor homo- or heterodimer formation, leading to activation of EGFR tyrosine kinase activity. Activated EGFR then phosphorylates its substrates, resulting in activation of multiple downstream pathways within the cell, including the PI3K-AKT-mTOR pathway, which is involved in cell survival, and the RAS-RAF-MEK-ERK pathway, which is involved in cell proliferation. (Chong et al. Nature Med.2013;19(11):1389-1400).
[0005] Certain cancers are characterized by mutations of EGFR, which results in increased cell proliferation. Tyrosine kinase inhibitor (TKI) therapies that inhibit EGFR can lead to clinical responses; however, mutations in EGFR can also confer resistance to such therapies. [0006] Further, one of the major pathways to regulate proteins post-translationally is ubiquitin-dependent proteolysis. The first step in selective degradation is the ligation of one or more ubiquitin molecules to a protein substrate. Ubiquitination occurs through the activity of ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2), and ubiquitin-protein ligases (E3), which act sequentially to catalyze the attachment of ubiquitin to lysine residues of substrate proteins (see Ciechanover A., et al., BioEssays, 22:442–451 (2000)). The E3 protein ligases confer specificity to ubiquitination reactions by binding directly to substrate. [0007] New therapeutic methods therefore remain necessary for treating cancers associated with defective signal transduction pathways, including EGFR-driven cancers and cancers which develop resistance to one or more therapies. SUMMARY OF THE INVENTION [0008] Described herein are new compounds that can be effective inhibitors of EGFR. Such compounds can be useful for treating various diseases and disorders, including EGFR-driven cancers such as non-small cell lung cancer (NSCLC) characterized by mutant EGFR. For example, the present compounds can be useful as proteolysis-targetic chimera (PROTAC) therapies for the treatment of mutant EGFR, including EGFR comprising one or more resistance mutations. [0009] In one aspect, the invention features a compound having a structure according to Formula (AI):
or a pharmaceutically acceptable salt thereof,
wherein: A is C6-10 arylene, 5-12-membered heteroarylene, or 5-12-membered heterocycloalkylene; X1 is N or CRX; X2 is N or CRX; X3 is N or CRX”; X4 is N or CRX”; X6 is N or CRX’; X7 is N or CRX’; ------ represents an optional double bond between X7 and X4 or X4 and X6, wherein one and only one double bond is present; X5 is a covalent bond, CH2, O, NR4, C(O)NR4, or NR4C(O); L1 is a covalent bond or C(R5)2, and L2 is C1-4 alkylene, or L1 and L2 combine to form a C3-6 cycloalkyl or a 4- to 6-membered heterocycloalkyl; R1 is –LP-E, halogen, C1-6 alkyl, C3-7 cycloalkyl, C6-10 aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocycloalkyl, CN, NR6R7, NR6C(O)R7, NR6C(O)NH2, OR8, or C(O)NR6R7, and where valency permits when R1 is not –LP-E, R1 optionally further comprises -LP-E; R2 is absent, H, C1-6 alkyl, halogen, CN, or C1-6 alkoxy; each R3, when present, is independently OH, CN, halogen, C1-6 alkyl, or C1-6 alkoxy; n is 0, 1, or 2; each RX is independently H, ORX1, CN, halogen, or C1-6 alkyl, wherein RX1 is H or C1- 6 alkyl; each RX’ is independently H, ORX1, CN, halogen, or C1-6 alkyl, wherein RX1 is H or C1- 6 alkyl, or RX’ is absent if the carbon to which it is attached is part of a double bond; each RX” is independently –LP-E, H, ORX1, CN, halogen, or C1-6 alkyl optionally comprising -LP-E, and wherein RX1 is H or C1-6 alkyl optionally comprising –LP-E; LP is a linker; E is an E3 ubiquitin ligase ligand; each R4 and R5 is independently H or C1-6 alkyl; each R6 and R7 is independently H, C1-6 alkyl, C3-7 cycloalkyl, or 3- to 10-membered heterocycloalkyl; or R6 and R7 together with the nitrogen atom to which they are attached form a 3- to 8-membered heterocycloalkyl ring; and R8 is independently H, C1-6 alkyl, or 4- to 6-membered heterocycloalkyl; and
wherein the compound comprises one and only one LP-E moiety. [0010] In embodiments, a compound of Formula (AI) has a structure selected from the group consisting of:
or a pharmaceutically acceptable salt thereof, wherein R2 is H, unsubstituted C1-6 alkyl or C1-6 alkyl substituted by a group that is unsubstituted C3-6 cycloalkyl; each X8, X9, and X10, when present, is CH or N.
[0011] In embodiments, L1-L2-X5 when present is CH(CH3)-(CH2)2-O, CH(CH3)-(CH2)3-O, CH(CH2CH3)-(CH2)2-O, C(CH3)2-(CH2)2-O, (CH2)3-O, CH2-CH(CH3)CH2-O, CH2- CH2CH(CH3)-O, CH(CH3)-(CH2)2-NH, CH(CH3)-(CH2)2-NCH3, CH(CH3)-(CH2)3- NH, CH(CH3)-(CH2)3-NCH3, CH(CH3)-(CH2)3, or CH(CH3)-(CH2)4, or L1-L2-X5 is
[0012] In embodiments, R2 is H or unsubstituted C1-6 alkyl; or R2 is unsubstituted C1-6 alkyl or C1-6 alkyl substituted by a group that is unsubstituted C3-6 cycloalkyl. [0013] In embodiments, a compound is selected from the group consisting of the compounds of Table A2, or a pharmaceutically acceptable salt thereof. [0014] In one aspect, the invention features a compound having a structure according to Formula (BI):
or a pharmaceutically acceptable salt thereof, wherein A1 is independently phenylene or 5- or 6-membered heteroarylene; A2 is independently phenyl, naphthyl, or a 5- to 13-membered heteroaryl; X1 is independently O or X1A; X1A is a covalent bond, S, NR4, C1-6 alkylene, C2-6 alkenylene, or C2-6 alkynylene;
each of X2 and X3 is independently N or CR1B; L1 is independently a covalent bond or C1-6 alkylene; L2 is independently a covalent bond, C2-6 alkenylene, C2-6 alkynylene, C3-6 cycloalkylene, 3- to 10-membered heterocyclylene, phenylene, or 5- or 6-membered heteroarylene; each R1A and R1B is independently H, OH, CN, halogen, C1-6 aliphatic, C1-6 alkoxy, NR6R7, C(O)R8, CO2R8, C(O)NR6R7, NR9C(O)R8, NR9CO2R8, NR9C(O)NR6R7, or R10; each R2, when present, is independently OH, CN, halogen, C1-6 aliphatic, C1-6 alkoxy, NR6R7, C(O)R8, CO2R8, C(O)NR6R7, NR9C(O)R8, NR9CO2R8, NR9C(O)NR6R7, R10, OR10, CH2R10, CH2CH2R10, OCH2R10, or OCH2CH2R10; each R3, when present, is independently –LP-E, OH, CN, halogen, C1-6 aliphatic, C1-6 alkoxy, NR6R7, C(O)R8, CO2R8, C(O)NR6R7, NR9C(O)R8, NR9CO2R8, NR9C(O)NR6R7, R10, OR10, CH2R10, CH2CH2R10, OCH2R10, or OCH2CH2R10, and where valency permits when R3 is not –LP-E, R3 optionally further comprises –LP-E; LP is a linker; E is an E3 ubiquitin ligase ligand; each R4 is independently H, a N-protecting group, or C1-6 alkyl; R5 is hydrogen; each R6, R7, and R9 is independently H or C1-6 alkyl; or R6 and R7, together with the nitrogen atom to which they are attached, form a 3- to 10-membered heterocyclyl, or R6 and R9, together with the atoms to which they are attached, form a 3- to 10-membered heterocyclyl; R8 is independently C1-6 aliphatic, C3-C10 cycloaliphatic, 3- to 10-membered heterocyclyl, phenyl, naphthyl, or a 5- to 12-membered heteroaryl, or R8 and R9, together with the atoms to which they are attached, form a 3- to 10-membered heterocyclyl; R10 is independently C3-C10 cycloaliphatic, 3- to 10-membered heterocyclyl, phenyl, naphthyl, or a 5- to 12-membered heteroaryl; each of n and o is independently 0, 1, or 2; wherein X1 is O, and both of X2 and X3 are not N, then A2 is naphthyl or a bicyclic 8- to 12-membered heteroaryl; and wherein the compound comprises one and only one LP-E moiety.
[0015] In embodiments, a compound of Formula (BI) has a structure selected from the group consisting of:
or a pharmaceutically acceptable salt thereof. [0016] In embodiments, (a) the compound is according to Formula (BIX), (BX), or (BXI), or a pharmaceutically acceptable salt thereof, wherein L1 is C1-C6 alkylene optionally substituted by 1, 2, or 3 R13; each R13 is independently unsubstituted C1-C3 alkyl; and R1A is independently unsubstitued C1-C6 alkyl or C1-C6 haloalkyl; (b) the compound is according to Formula (BXII), or a pharmaceutically acceptable salt thereof, wherein R1A is independently unsubstitued C1-C6 alkyl or C1-C6 haloalkyl; or (c) the compound is according to Formula (BXIII) or (BXIV), or a pharmaceutically acceptable salt thereof, wherein L1 is C1-C6 alkylene optionally substituted by 1 or 2 R13; each R13 is independently unsubstituted
C1-C3 alkyl; and R1A is independently unsubstitued C1-C6 alkyl or C1-C6 haloalkyl. [0017] In embodiments, a compound is selected from the group consisting of the compounds of Table B2, or a pharmaceutically acceptable salt thereof. [0018] In one aspect, the invention features a compound having a structure according to Formula (CI):
or a pharmaceutically acceptable salt thereof, wherein X2 is independently N or CR5; each of X3 and X4 is independently a covalent bond, O, S, NR6, C(O)NR6, NR6C(O), NR6C(O)NR6, or (C(R7)2)q; L1 is independently a covalent bond, C1-6 heteroalkylene, C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C3-6 cycloalkylene, 3- to 10-membered heterocyclylene, phenylene, or 5- to 10-membered heteroarylene; each R1 is independently LP-E,
(Substructure A), OH, CN, halogen, C1-6 aliphatic, C1-6 alkoxy, NR8R9, C(O)R10, CO2R10, C(O)NR8R9, NR11C(O)R10, NR11CO2R10, NR11C(O)NR8R9, or (CH2)rR12, or two R1 or two R2, together to which the atoms they are attached form a 5- to 10-membered ring, and where valency permits when R1 is not –LP-E, R1 optionally further comprises –LP-E;
each R2 is independently LP-E,
(Substructure A), OH, CN, halogen, C1-6 aliphatic, C1-6 alkoxy, NR8R9, C(O)R10, CO2R10, C(O)NR8R9, NR11C(O)R10, NR11CO2R10, NR11C(O)NR8R9, or (CH2)rR12, or two R1 or two R2, together to which the atoms they are attached form a 5- to 10-membered ring, and where valency permits when R2 is not –LP-E, R2 optionally further comprises –LP-E; LP is a linker; E is an E3 ubiquitin ligase ligand; L2 is independently a covalent bond, O, NRL, C(O), C(O)NRL, NRLC(O), CRL 2; RL is independently H or C1-6 alkyl; A is independently phenyl, naphthyl, 5- to 13-membered heteroaryl, C3-C10 cycloaliphatic, or 3- to 10-membered heterocyclyl; B is independently phenyl, naphthyl, 5- to 13-membered heteroaryl, C3-C10 cycloaliphatic, or 3- to 10-membered heterocyclyl; C is independently 5- or 6-membered heteroaryl; each R3 is independently OH, CN, halogen, C1-6 aliphatic, C1-6 alkoxy, NR8R9, C(O)R10, CO2R10, C(O)NR8R9, NR11C(O)R10, NR11CO2R10, NR11C(O)NR8R9, or (CH2)rR12; each R4 is independently –LP-E, H, OH, CN, halogen, C1-6 aliphatic, C1-6 alkoxy, NR8R9, C(O)R10, CO2R10, C(O)NR8R9, NR11C(O)R10, NR11CO2R10, NR11C(O)NR8R9, NR11(CH2)sNR8R9, (CH2)tNR8R9, (CH2)tOH, (CH2)tOCH3, O(CH2)tOH, O(CH2)tOCH3, O(CH2)rR12, or (CH2)rR12; or R4 and R6 or R4 and R7, together with the atoms to which they are attached, form a 5- to 6-membered ring, and where valency permits when R4 is not –LP-E, R4 optionally further comprises –LP-E; each R5 is independently H, OH, CN, halogen, C1-6 aliphatic, C1-6 alkoxy, NR8R9, C(O)R10, CO2R10, C(O)NR8R9, NR11C(O)R10, NR11CO2R10, NR11C(O)NR8R9, or (CH2)rR12; each R6 is independently H, a N-protecting group, or C1-6 alkyl; or R6 and R4, together with the atoms to which they are attached, form a 5- to 6-membered ring; each R7 is independently H or C1-6 alkyl; or two R7 on the same carbon combine to from an oxo (=O) group; or R7 and R4, together with the atoms to which they are attached, form a 5- to 6-membered ring; each R8, R9, and R11 is independently H or C1-6 alkyl; or R8 and R9, together with the nitrogen atom to which they are attached, form a 3- to 10-membered heterocyclyl, or R8 and
R11, together with the atoms to which they are attached, form a 3- to 10-membered heterocyclyl; each R10 is independently C1-6 aliphatic, C3-C10 cycloaliphatic, 3- to 10-membered heterocyclyl, phenyl, naphthyl, or a 5- to 12-membered heteroaryl, or R10 and R11, together with the atoms to which they are attached, form a 3- to 10-membered heterocyclyl; each R12 is independently C3-C10 cycloaliphatic, 3- to 10-membered heterocyclyl, phenyl, naphthyl, or a 5- to 12-membered heteroaryl; each m, n, and o, is independently 0, 1, or 2; each p is independently 0, 1, 2; 3, or 4; each q is independently 1 or 2; each r is independently an integer of 0-4; each s is independently an integer of 2-6; each t is independently an integer of 1-6; and wherein the compound comprises one and only one LP-E moiety. [0019] In embodiments, a compound of Formula (CI) has a structure selected from the group consisting of:
or a pharmaceutically acceptable salt thereof, wherein R4A is a first R4 group, R4B is a second R4 group, R4C is a third R4 group, R4D is a fourth R4 group, preferably R4 is unsubstituted C1-6 alkyl if one or more of R4A, R4B, and R4C is also present; and p is 0 or 1.
[0020] In embodiments, a compound is selected from the group consisting of the compounds of Table C2 and Table C3, or a pharmaceutically acceptable salt thereof.
15
[0022] In embodiments, a linker LP is a covalent bond. [0023] In embodiments, a linker LP comprises a C1-C20 alkylene, a C2-C20 heteroalkylene, a C2-C20 monoalkynylene, and/or one or more ethyleneglycol moieties. [0024] In embodiments, a linker LP comprises one or more oxo (=O) substituents as valency permits. [0025] In embodiments, a linker LP comprises a heterocyclyl moiety that is attached to the EGFR ligand moiety of the compound via a covalent bond or via a CH2 or C(O) linker. [0026] In embodiments, a linker LP comprises a substructure F1
or a substructure F2
, wherein * denotes the point of attachment to the EGFR ligand moiety of the compound. [0027] In embodiments, a linker LP does not comprise a heterocyclyl moiety that is attached to the EGFR ligand moiety of the compound via a covalent bond or via a CH2 or C(O) linker. [0028] In embodiments, –LP-E comprises a structure or is a structure selected from the group consisting of:
[0030] In another aspect, the invention features a pharmaceutical composition comprising any compound described herein, or a pharmaceutically acceptable salt thereof.
[0031] In another aspect, the invention features a method of treating cancer comprising administering to a human in need thereof an effective amount of any compound described herein, or a pharmaceutically acceptable salt thereof, in a pharmaceutical composition.
[0032] In embodiments, a cancer is a lung cancer.
[0033] In embodiments, a cancer is non-small cell lung cancer.
[0034] In embodiments, a cancer (e.g., a lung cancer such as non-small cell lung cancer) is an EGFR-driven cancer.
[0035] In embodiments, a cancer (e.g., a lung cancer such as non-small cell lung cancer) is characterized by an EGFR mutation.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
[0036] In order for the present invention to be more readily understood, certain terms are first defined below. Additional definitions for the following terms and other terms are set forth
throughout the specification. The publications and other reference materials referenced herein to describe the background of the invention and to provide additional detail regarding its practice are hereby incorporated by reference. [0037] Animal: As used herein, the term “animal” refers to any member of the animal kingdom. In some embodiments, “animal” refers to humans, at any stage of development. In some embodiments, “animal” refers to non-human animals, at any stage of development. In certain embodiments, the non-human animal is a mammal (e.g., a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a sheep, a bovine, a primate, and/or a pig). In some embodiments, animals include, but are not limited to, mammals, birds, reptiles, amphibians, fish, insects, and/or worms. In some embodiments, an animal may be a transgenic animal, genetically-engineered animal, and/or a clone. [0038] Approximately or about: As used herein, the term “approximately” or “about,” as applied to one or more values of interest, refers to a value that is similar to a stated reference value. In certain embodiments, the term “approximately” or “about” refers to a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value). [0039] As used in the description and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a composition” includes mixtures of two or more such compositions. [0040] Throughout the description and claims of this specification the word “comprise” and other forms of the word, such as “comprising” and “comprises,” means including but not limited to, and is not intended to exclude, for example, other additives, components, integers, or steps. [0041] “Optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not. [0042] Improve, increase, or reduce: As used herein, the terms “improve,” “increase,” or “reduce,” or grammatical equivalents, indicate values that are relative to a baseline measurement, such as a measurement in the same individual prior to initiation of the treatment described herein, or a measurement in a control subject (or multiple control subject) in the absence of the treatment described herein. A “control subject” is a subject afflicted with the
same form of disease as the subject being treated, who is about the same age as the subject being treated. [0043] In Vitro: As used herein, the term “in vitro” refers to events that occur in an artificial environment, e.g., in a test tube or reaction vessel, in cell culture, etc., rather than within a multi-cellular organism. [0044] In Vivo: As used herein, the term “in vivo” refers to events that occur within a multi- cellular organism, such as a human and a non-human animal. In the context of cell-based systems, the term may be used to refer to events that occur within a living cell (as opposed to, for example, in vitro systems). [0045] Patient: As used herein, the term “patient” or “subject” refers to any organism to which a provided composition may be administered, e.g., for experimental, diagnostic, prophylactic, cosmetic, and/or therapeutic purposes. Typical patients include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and/or humans). In some embodiments, a patient is a human. A human includes pre- and post-natal forms. [0046] Pharmaceutically acceptable: The term “pharmaceutically acceptable,” as used herein, refers to substances that, within the scope of sound medical judgment, are suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. Accordingly, pharmaceutically acceptable relates to substances that are not biologically or otherwise undesirable, i.e., the material can be administered to an individual along with the relevant active compound without causing clinically unacceptable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained. [0047] Pharmaceutically acceptable salt: Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences (1977) 66:1–19. Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid, or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate,
dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2- naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+(C1–4-alkyl)4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium. quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, sulfonate, and aryl sulfonate. Further pharmaceutically acceptable salts include salts formed from the quarternization of an amine using an appropriate electrophile, e.g., an alkyl halide, to form a quarternized alkylated amino salt. [0048] Subject: As used herein, the term “subject” refers to a human or any non-human animal (e.g., mouse, rat, rabbit, dog, cat, cattle, swine, sheep, horse or primate). A human includes pre- and post-natal forms. In many embodiments, a subject is a human being. A subject can be a patient, which refers to a human presenting to a medical provider for diagnosis or treatment of a disease. The term “subject” is used herein interchangeably with “individual” or “patient.” A subject can be afflicted with or is susceptible to a disease or disorder but may or may not display symptoms of the disease or disorder. [0049] Substantially: As used herein, the term “substantially” refers to the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest. One of ordinary skill in the biological arts will understand that biological and chemical phenomena rarely, if ever, go to completion and/or proceed to completeness or achieve or avoid an absolute result. The term “substantially” is therefore used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena. [0050] Therapeutically effective amount: As used herein, the term “therapeutically effective amount” of a therapeutic agent means an amount that is sufficient, when administered to a subject suffering from or susceptible to a disease, disorder, and/or condition, to treat, diagnose, prevent, and/or delay the onset of the symptom(s) of the disease, disorder, and/or condition. It will be appreciated by those of ordinary skill in the art that a therapeutically effective amount is typically administered via a dosing regimen comprising at least one unit dose.
[0051] Treating: As used herein, the term “treat,” “treatment,” or “treating” refers to any method used to partially or completely alleviate, ameliorate, relieve, inhibit, prevent, delay onset of, reduce severity of and/or reduce incidence of one or more symptoms or features of a particular disease, disorder, and/or condition. Treatment may be administered to a subject who does not exhibit signs of a disease and/or exhibits only early signs of the disease for the purpose of decreasing the risk of developing pathology associated with the disease. [0052] Whenever a term (e.g., alkyl or aryl) or either of their prefix roots (e.g., alk- or ar-) appear in a name of a substituent the name is to be interpreted as including those limitations provided herein. For example, affixing the suffix “-ene” to a group indicates the group is a divalent moiety, e.g., arylene is the divalent moiety of aryl, heteroarylene is the divalent moiety of heteroaryl, and heterocycloalkylene is the divalent moiety of heterocycloalkyl. Similarly, affixing the suffix “-oxy” to a group indicates the group is attached to the parent molecular structure through an oxygen atom (-O-). [0053] Alkyl: As used herein, the term “alkyl” means acyclic linear and branched hydrocarbon groups, e.g. “C1-C20 alkyl” refers to alkyl groups having 1–20 carbons and “ C1–C4 alkyl” refers to alkyl groups having 1–4 carbons. Alkyl groups include C1-C20 alkyl, C1-C15 alkyl, C1–C10 alkyl, C1–C4 alkyl, and C1–C3 alkyl). In embodiments, an alkyl group is C1–C4 alkyl. An alkyl group may be linear or branched. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl tert-pentylhexyl, isohexyl, etc. The term “lower alkyl" means an alkyl group straight chain or branched alkyl having 1 to 6 carbon atoms. Other alkyl groups will be readily apparent to those of skill in the art given the benefit of the present disclosure. An alkyl group may be unsubstituted or substituted with one or more substituent groups as described herein. For example, an alkyl group may be substituted with one or more (e.g., 1, 2, 3, 4, 5, or 6 independently selected substituents) of halogen, -COR’, -CO2H, -CO2R’, -CN, -OH, -OR’, - OCOR’, -OCO2R’, -NH2, -NHR’, -N(R’)2, -SR’ or-SO2R’, wherein each instance of R’ independently is C1-C20 aliphatic (e.g., C1-C20 alkyl, C1-C15 alkyl, C1–C10 alkyl, C1–C4 alkyl, or C1–C3 alkyl). In some embodiments, R’ independently is an unsubstituted alkyl (e.g., unsubstituted C1-C20 alkyl, C1-C15 alkyl, C1–C10 alkyl, or C1–C3 alkyl). In some embodiments, R’ independently is unsubstituted C1–C3 alkyl. In some embodiments, the alkyl is substituted (e.g., with 1, 2, 3, 4, 5, or 6 substituent groups as described herein). In some embodiments, an alkyl group is substituted with a–OH group and may also be referred to herein as a “hydroxyalkyl” group, where the prefix denotes the –OH group and “alkyl” is as described herein. In some embodiments, an alkyl group is substituted with a–OR’ group.
[0054] Alkylene: The term “alkylene,” as used herein, represents a saturated divalent straight or branched chain hydrocarbon group and is exemplified by methylene, ethylene, isopropylene and the like. Likewise, the term “alkenylene” as used herein represents an unsaturated divalent straight or branched chain hydrocarbon group having one or more unsaturated carbon-carbon double bonds that may occur in any stable point along the chain, and the term “alkynylene” herein represents an unsaturated divalent straight or branched chain hydrocarbon group having one or more unsaturated carbon-carbon triple bonds that may occur in any stable point along the chain. In certain embodiments, an alkylene, alkenylene, or alkynylene group may comprise one or more cyclic aliphatic and/or one or more heteroatoms such as oxygen, nitrogen, or sulfur and may optionally be substituted with one or more substituents such as alkyl, halo, alkoxyl, hydroxy, amino, aryl, ether, ester or amide. For example, an alkylene, alkenylene, or alkynylene may be substituted with one or more (e.g., 1, 2, 3, 4, 5, or 6 independently selected substituents) of halogen, -COR’, -CO2H, -CO2R’, -CN, -OH, -OR’, -OCOR’, -OCO2R’, -NH2, -NHR’, -N(R’)2, -SR’ or -SO2R’, wherein each instance of R’ independently is C1–C20 aliphatic (e.g., C1-C20 alkyl, C1-C15 alkyl, C1–C10 alkyl, or C1–C3 alkyl). In some embodiments, R’ independently is an unsubstituted alkyl (e.g., unsubstituted C1-C20 alkyl, C1– C15 alkyl, C1–C10 alkyl, or C1–C3 alkyl). In some embodiments, R’ independently is unsubstituted C1–C3 alkyl. In certain embodiments, an alkylene, alkenylene, or alkynylene is unsubstituted. In certain embodiments, an alkylene, alkenylene, or alkynylene does not include any heteroatoms. [0055] Alkenyl: As used herein, “alkenyl” means any linear or branched hydrocarbon chains having one or more unsaturated carbon-carbon double bonds that may occur in any stable point along the chain, e.g. “C2-C20 alkenyl” refers to an alkenyl group having 2–20 carbons. For example, an alkenyl group includes prop-2-enyl, but-2-enyl, but-3-enyl, 2-methylprop-2- enyl, hex-2-enyl, hex-5-enyl, 2,3-dimethylbut-2-enyl, and the like. In some embodiments, the alkenyl comprises 1, 2, or 3 carbon-carbon double bond. In some embodiments, the alkenyl comprises a single carbon-carbon double bond. In some embodiments, multiple double bonds (e.g., 2 or 3) are conjugated. An alkenyl group may be unsubstituted or substituted with one or more substituent groups as described herein. For example, an alkenyl group may be substituted with one or more (e.g., 1, 2, 3, 4, 5, or 6 independently selected substituents) of halogen, -COR’, -CO2H, -CO2R’, -CN, -OH, -OR’, -OCOR’, -OCO2R’, -NH2, -NHR’, - N(R’)2, -SR’ or-SO2R’, wherein each instance of R’ independently is C1–C20 aliphatic (e.g., C1-C20 alkyl, C1-C15 alkyl, C1–C10 alkyl, or C1–C3 alkyl). In some embodiments, R’ independently is an unsubstituted alkyl (e.g., unsubstituted C1-C20 alkyl, C1-C15 alkyl, C1–C10
alkyl, or C1–C3 alkyl). In some embodiments, R’ independently is unsubstituted C1-C3 alkyl. In some embodiments, the alkenyl is unsubstituted. In some embodiments, the alkenyl is substituted (e.g., with 1, 2, 3, 4, 5, or 6 substituent groups as described herein). In some embodiments, an alkenyl group is substituted with a–OH group and may also be referred to herein as a “hydroxyalkenyl” group, where the prefix denotes the –OH group and “alkenyl” is as described herein. [0056] Alkynyl: As used herein, “alkynyl” means any hydrocarbon chain of either linear or branched configuration, having one or more carbon-carbon triple bonds occurring in any stable point along the chain, e.g. “C2-C20 alkynyl” refers to an alkynyl group having 2–20 carbons. Examples of an alkynyl group include prop-2-ynyl, but-2-ynyl, but-3-ynyl, pent-2- ynyl, 3-methylpent-4-ynyl, hex-2-ynyl, hex-5-ynyl, etc. In some embodiments, an alkynyl comprises one carbon-carbon triple bond. An alkynyl group may be unsubstituted or substituted with one or more substituent groups as described herein. For example, an alkynyl group may be substituted with one or more (e.g., 1, 2, 3, 4, 5, or 6 independently selected substituents) of halogen, -COR’, -CO2H, -CO2R’, -CN, -OH, -OR’, -OCOR’, -OCO2R’, -NH2, -NHR’, -N(R’)2, -SR’ or-SO2R’, wherein each instance of R’ independently is C1-C20 aliphatic (e.g., C1-C20 alkyl, C1-C15 alkyl, C1–C10 alkyl, or C1–C3 alkyl). In some embodiments, R’ independently is an unsubstituted alkyl (e.g., unsubstituted C1-C20 alkyl, C1– C15 alkyl, C1–C10 alkyl, or C1–C3 alkyl). In some embodiments, R’ independently is unsubstituted C1–C3 alkyl. In some embodiments, the alkynyl is unsubstituted. In some embodiments, the alkynyl is substituted (e.g., with 1, 2, 3, 4, 5, or 6 substituent groups as described herein). [0057] Alkoxy: The term “alkoxy” refers to the group -O-alkyl, including from 1 to 10 carbon atoms of a straight, branched, saturated cyclic configuration and combinations thereof, attached to the parent molecular structure through an oxygen. Examples include methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, pentoxy, cyclopropyloxy, cyclohexyloxy and the like. “Lower alkoxy” refers to alkoxy groups containing one to six carbons. In some embodiments, C1-4 alkoxy is an alkoxy group which encompasses both straight and branched chain alkyls of from 1 to 4 carbon atoms. Unless stated otherwise in the specification, an alkoxy group can be optionally substituted by one or more substituents (e.g., as described herein for alkyl). The terms “alkenoxy” and “alkynoxy” mirror the above description of “alkoxy” wherein the prefix “alk” is replaced with “alken” or “alkyn” respectively, and the parent “alkenyl" or “alkynyl” terms are as described herein.
[0058] Amide: The term “amide” or “amido” refers to a chemical moiety with formula -C(O)N(R’)2, -C(O)N(R’)-, -NR’C(O)R’, or -NR’C(O)-, where each R’ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl (bonded through a chain carbon), cycloalkyl, aryl, arylalkyl, heteroaryl (bonded through a ring carbon), heteroarylalkyl, or heterocycloalkyl (bonded through a ring carbon), unless stated other-wise in the specification, each of which moiety can itself be optionally substituted as described herein, or two R’ can combine with the nitrogen atom to form a 3-, 4-, 5-, 6-, or 7-membered ring. [0059] Amino: The term “amino” or “amine” refers to a -N(R’)2 group, where each R’ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl (bonded through a chain carbon), cycloalkyl, aryl, arylalkyl, heteroaryl (bonded through a ring carbon), heteroarylalkyl, or heterocycloalkyl (bonded through a ring carbon), unless stated otherwise in the specification, each of which moiety can itself be optionally substituted as described herein, or two R’ can combine with the nitrogen atom to form a 3-, 4-, 5-, 6-, or 7-membered ring. In embodiments, an amino group is –NHR’, where R’ is aryl (“arylamino”), heteroaryl (“heteroarylamino”), or alkyl (“alkylamino”). [0060] Aryl: The term “aryl” used alone or as part of a larger moiety as in “aralkyl,” refers to a monocyclic, bicyclic, or tricyclic carbocyclic ring system having a total of six to fourteen ring members, wherein said ring system has a single point of attachment to the rest of the molecule, wherein at least one ring in the system is aromatic, and wherein each ring in the system contains 4 to 7 ring members. In some embodiments, an aryl group has 6 ring carbon atoms (“C6 aryl,” e.g., phenyl). In some embodiments, an aryl group has 10 ring carbon atoms (“C10 aryl,” e.g., naphthyl such as 1-naphthyl and 2-naphthyl). In some embodiments, an aryl group has 14 ring carbon atoms (“C14 aryl,” e.g., anthracyl). “Aryl” also includes ring systems wherein the aryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the radical or point of attachment is on the aryl ring, and in such instances, the number of carbon atoms continue to designate the number of carbon atoms in the aryl ring system. Exemplary aryls include phenyl, naphthyl, and anthracene. [0061] Arylalkyl: The term “arylalkyl” refers to an –(alkylene)-aryl radical where aryl and alkylene are as disclosed herein and which are optionally substituted by one or more of the exemplary substituent groups described herein. The “arylalkyl” group is bonded to the parent molecular structure through the alkylene moiety. The term “arylalkoxy” refers to an -O- [arylalkyl] radical (-O-[(alkylene)-aryl]), which is attached to the parent molecular structure through the oxygen.
[0062] Arylene: The term “arylene” as used herein refers to an aryl group that is divalent (that is, having two points of attachment to the molecule). Exemplary arylenes include phenylene (e.g., unsubstituted phenylene or substituted phenylene). [0063] Cyclic: The term “cyclic” as used herein, refers to any covalently closed structure. Cyclic moieties include, for example, carbocycles (e.g., aryls and cycloalkyls), heterocycles (e.g., heteroaryls and heterocycloalkyls), aromatics (e.g. aryls and heteroaryls), and non- aromatics (e.g., cycloalkyls and heterocycloalkyls). In some embodiments, cyclic moieties are optionally substituted. In some embodiments, cyclic moieties form part of a ring system. [0064] Cycloaliphatic: The term “cycloaliphatic” refers to a monocyclic or polycyclic radical that contains only carbon and hydrogen, and can be saturated or partially unsaturated. Fully saturated cycloaliphatics can be termed “cycloalkyl”. Partially unsaturated cycloalkyl groups can be termed “cycloalkenyl” if the carbocycle contains at least one double bond, or "cycloalkynyl" if the carbocycle contains at least one triple bond. Cycloaliphatic groups include groups having from 3 to 13 ring atoms (e.g., C3–13 cycloalkyl). Whenever it appears herein, a numerical range such as “3 to 10” refers to each integer in the given range; e.g., “3 to 10 carbon atoms” means that the cycloaliphatic group (e.g., cycloalkyl) can consist of 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, etc., up to and including 10 carbon atoms. The term “cycloaliphatic” also includes bridged and spiro-fused cyclic structures containing no heteroatoms. The term also includes monocyclic or fused-ring polycyclic (i.e., rings which share adjacent pairs of ring atoms) groups. Polycyclic cycloaliphatic groups include bicycles, tricycles, tetracycles, and the like. In some embodiments, “cycloalkyl” can be a C3-8 cycloalkyl group. In some embodiments, “cycloalkyl” can be a C3-5 cycloalkyl group. Illustrative examples of cycloaliphatic groups include, but are not limited to the following moieties: C3–6 cycloaliphatic groups include, without limitation, cyclopropyl (C3), cyclobutyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6) and the like. Examples of C3–7 cycloaliphatic groups include norbornyl (C7). Examples of C3-8 cycloaliphatic groups include the aforementioned C3–7 carbocyclyl groups as well as cycloheptyl(C7), cycloheptadienyl (C7), cyclohept-atrienyl (C7), cyclooctyl (C8), bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, and the like. Examples of C3-13 cycloaliphatic groups include the aforementioned C3-8 carbocyclyl groups as well as octahydro-1H indenyl, decahydronaphthalenyl, spiro[4.5]decanyl, and the like. [0065] Cyano: The term “cyano” refers to a –CN group.
[0066] Deuterium: The term “deuterium” is also called heavy hydrogen. Deuterium is isotope of hydrogen with a nucleus consisting of one proton and one neutron, which is double the mass of the nucleus of ordinary hydrogen (one proton). In embodiments, deuterium can also be identified as 2H. [0067] Ester: The term “ester” refers to a group of formula –C(O)OR’ or –R’OC(O)-, where R’ is selected from alkyl, alkenyl, alkynyl, heteroalkyl (bonded through a chain carbon), cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, or heterocycloalkyl as described herein. [0068] Halogen or Halo: As used herein, the term “halogen” or “halo” means fluorine, chlorine, bromine, or iodine. [0069] Heteroalkyl: The term “heteroalkyl” is meant a branched or unbranched alkyl, alkenyl, or alkynyl group having from 1 to 14 carbon atoms in addition to 1, 2, 3 or 4 heteroatoms independently selected from the group consisting of N, O, S, and P. Heteroalkyls include tertiary amines, secondary amines, ethers, thioethers, amides, thioamides, carbamates, thiocarbamates, hydrazones, imines, phosphodiesters, phosphoramidates, sulfonamides, and disulfides. A heteroalkyl group may optionally include monocyclic, bicyclic, or tricyclic rings, in which each ring desirably has three to six members. Examples of heteroalkyls include polyethers, such as methoxymethyl and ethoxyethyl. Accordingly, the term “heteroalkoxy” refers to the group -O-heteroalkyl, where the group is attached to the parent molecular structure via the oxygen. [0070] Heteroalkylene: The term “heteroalkylene,” as used herein, represents a divalent form of a heteroalkyl group as described herein. [0071] Heteroaryl: The term “heteroaryl,” as used herein, refers to a monocyclic, bicyclic, or tricyclic carbocyclic ring system having a total of six to fourteen ring members, wherein said ring system has a single point of attachment to the rest of the molecule, wherein at least one ring in the system is aromatic, wherein each ring in the system contains 4 to 7 ring members, and wherein at least one ring atom is a heteroatom such as, but not limited to, nitrogen and oxygen. Examples of heteroaryl groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl. Accordingly, the
term “heteroaryloxy” refers to the group -O-heteroaryl, where the group is attached to the parent molecular structure via the oxygen. [0072] Heteroarylalkyl: The term “heteroarylalkyl” refers to an –(alkylene)-heteroaryl radical where heteroaryl and alkylene are as disclosed herein and which are optionally substituted by one or more of the exemplary substituent groups described herein. The “heteroarylalkyl” group is bonded to the parent molecular structure through the alkylene moiety. The term “heteroarylalkoxy” refers to an -O-[heteroarylalkyl] radical (-O-[(alkylene)-heteroaryl]), which is attached to the parent molecular structure through the oxygen. [0073] Heterocycloalkyl: The term “heterocycloalkyl” as used herein, is a non-aromatic ring wherein at least one atom is a heteroatom such as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus, and the remaining atoms are carbon. Examples of heterocycloalkyl groups are pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H- pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, 3H-indolyl and quinolizinyl. The heterocycloalkyl group can be substituted or unsubstituted. [0074] Heterocycle: The term “heterocycle” or “heterocyclyl” refers to groups containing one to four heteroatoms each selected from O, S and N, wherein each heterocycle group has from 4 to 10 atoms in its ring system, and with the proviso that the ring of said group does not contain two adjacent O or S atoms. Herein, whenever the number of carbon atoms in a heterocycle is indicated (e.g., C1–C6-heterocycle), at least one other atom (the heteroatom) must be present in the ring. Designations such as “C1–C6-heterocycle” refer only to the number of carbon atoms in the ring and do not refer to the total number of atoms in the ring. In some embodiments, it is understood that the heterocycle ring has additional heteroatoms in the ring. Designations such as “4–6-membered heterocycle” refer to the total number of atoms that are contained in the ring (i.e., a four, five, or six membered ring, in which at least one atom is a carbon atom, at least one atom is a heteroatom and the remaining two to four atoms are either carbon atoms or heteroatoms). In some embodiments, in heterocycles that have two or more heteroatoms, those two or more heteroatoms are the same or different from one another. In some embodiments, heterocycles are optionally substituted. In some embodiments, binding
to a heterocycle is at a heteroatom or via a carbon atom. Heterocycloalkyl groups include groups having only 4 atoms in their ring system, but heteroaryl groups must have at least 5 atoms in their ring system. The heterocycle groups include benzo-fused ring systems. An example of a 4-membered heterocycle group is azetidinyl (derived from azetidine). An example of a 5-membered heterocycle group is thiazolyl. An example of a 6-membered heterocycle group is pyridyl, and an example of a 10-membered heterocycle group is quinolinyl. In some embodiments, the foregoing groups, as derived from the groups listed above, are C-attached or N-attached where such is possible. For instance, in some embodiments, a group derived from pyrrole is pyrrol-1-yl (N-attached) or pyrrol-3-yl (C- attached). Further, in some embodiments, a group derived from imidazole is imidazol-1-yl or imidazol-3-yl (both N-attached) or imidazol-2-yl, imidazol-4-yl or imidazol-5-yl (all C- attached). The heterocycle groups include benzo-fused ring systems and ring systems substituted with one or two oxo (=O) moieties such as pyrrolidin-2-one. In some embodiments, depending on the structure, a heterocycle group is a monoradical or a diradical (i.e., a heterocyclene group). The heterocycles described herein are substituted with 0, 1, 2, 3, or 4 substituents independently selected from alkenyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylthio, alkylthioalkyl, alynyl, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halogen, hydroxyl, hydroxyalkylene, mercapto, nitro, amino, and amido moities. [0075] Isotope: The term “isotope” refers to a variant of a particular chemical element which differs in neutron number, and consequently in nucleon number. All isotopes of a given element have the same number of protons but different numbers of neutrons in each atom. [0076] Nitro: The term “nitro” refers to a –NO2 group. [0077] Sulfonamide: The term “sulfonamide” or sulfonamido” refers to the following groups: -S(=O)2-(R’)2, -N(R’)-S(=O)2-R’, -S(=O)2-N(R’)-, or -N(R’)-S(=O)2-,where each R’ is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl (bonded through a chain carbon), cycloalkyl, aryl, arylalkyl, heteroaryl (bonded through a ring carbon), heteroarylalkyl, or heterocycloalkyl (bonded through a ring carbon), unless stated other-wise in the specification, each of which moiety can itself be optionally substituted as described herein, or two R’ can combine with the nitrogen atom to form a 3-, 4-, 5-, 6-, or 7-membered ring.
[0078] Moiety: The term “moiety” refers to a specific segment or functional group of a molecule. Chemical moieties are often recognized chemical entities embedded in or appended to a molecule. [0079] Molecular groups herein may be substituted or unsubstituted (e.g., as described herein). The term “substituted” means that the specified group or moiety bears one or more substituents: at least one hydrogen present on a group atom (e.g., a carbon or nitrogen atom) is replaced with a permissible substituent, e.g., a substituent which upon substitution for the hydrogen results in a stable compound, e.g., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction. The term “unsubstituted” means that the specified group bears no substituents. The term “optionally substituted” means that the specified group is unsubstituted or substituted by one or more substituents. Where the term “substituted” is used to describe a structural system, the substitution is meant to occur at any valency-allowed position on the system. In embodiments, a group described herein is substituted. In embodiments, a group described herein is unsubstituted. In cases where a specified moiety or group is not expressly noted as being optionally substituted or substituted with any specified substituent, it is understood that such a moiety or group is intended to be unsubstituted. [0080] A wide variety of substituents are well known, and methods for their formation and introduction into a variety of parent groups are also well known. Representative substituents include but are not limited to alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, arylalkyl, alkylaryl, aryl, heteroaryl, heterocycloalkyl, hydroxyalkyl, arylalkyl, aminoalkyl, haloalkyl, thioalkyl, alkylthioalkyl, carboxyalkyl, imidazolylalkyl, indolylalkyl, mono-, di- and trihaloalkyl, mono-, di- and trihaloalkoxy, amino, alkylamino, dialkylamino, alkoxy, hydroxy, halo (e.g., —Cl and —Br), nitro, oximino, —COOR50, —COR50, —SO0-2R50, —SO2NR50R51, —NR52SO2R50, ═C(R50R51), ═N—OR50, ═N—CN, ═C(halo)2, ═S, ═O, —CON(R50R51), — OCOR50, —OCON(R50R51), —N(R52)CO(R50), —N(R52)COOR50 , —N(R52)CON(R50(R51), — P(OR50)2, —P(O)R50R51, and —P(O)OR50OR51, wherein R50, R51 and R52 may be independently selected from the following: a hydrogen atom and a branched or straight-chain, C1–6-alkyl, C3–6-cycloalkyl, C4–6-heterocycloalkyl, heteroaryl and aryl group, with or without substituents. When permissible, R50 and R51can be joined together to form a carbocyclic or heterocyclic ring system. [0081] In preferred embodiments, the substituent is selected from halogen, -COR’, -CO2H, - CO2R’, -CN, -OH, -OR’, -OCOR’, -OCO2R’, -NH2, -NHR’, -N(R’)2, -SR’, and -SO2R’, wherein each instance of R’ independently is C1-C20 aliphatic (e.g., C1-C20 alkyl, C1-C15
alkyl, C1–C10 alkyl, or C1–C3 alkyl). In certain embodiments thereof, R’ independently is an unsubstituted alkyl (e.g., unsubstituted C1–C20 alkyl, C1–C15 alkyl, C1–C10 alkyl, or C1–C3 alkyl). Preferably, R’ independently is unsubstituted C1–C3 alkyl. [0082] Any formula given herein is intended to represent compounds having structures depicted by the structural formula as well as certain variations or forms. In particular, compounds of any formula given herein may have asymmetric centers and therefore exist in different enantiomeric forms. All optical isomers and stereoisomers of the compounds of the general formula, and mixtures thereof, are considered within the scope of the formula. Thus, any formula given herein is intended to represent a racemate, one or more enantiomeric forms, one or more diastereomeric forms, one or more atropisomeric forms, and mixtures thereof. Furthermore, certain structures may exist as geometric isomers (i.e., cis and trans isomers), as tautomers, or as atropisomers. Additionally, any formula given herein is intended to embrace hydrates, solvates, and polymorphs of such compounds, and mixtures thereof. EGFR Inhibitors [0083] Compounds of the invention can be be effective as as proteolysis-targetic chimera (PROTAC) therapies, including for the treatment of cancers characterized by mutant EGFR, including EGFR comprising one or more resistance mutations. [0084] Accordingly, EGFR PROTAC compounds described herein comprise the following structural features: (1) a ligand targeting EGFR; (2) a linker LP, wherein the linker is covalently attached to the ligand and an E3 ubiquitin ligase ligand; and (3) a moiety E, which is an E3 ubiquitin ligase ligand. [0085] Exemplary formulas, compounds, and structural features are described herein. [0086] Any structural feature described herein (e.g., for any exemplary formula described herein) can be used in combination with any other structural feature(s) described for any exemplary formula described herein. In particular, any exemplary permitted feature for ligands, linkers LP, and moieties E (E3 ubiquitin ligase ligand) can be used in any combination to arrive at suitable compounds.
Exemplary ligands [0087] Exemplary EGFR ligands that can be incorporated into the compounds described herein include any of the EGFR inhibitor formulas and compounds described in any of the below disclosures, each of which is incorporated in its reference in its entirety: • International Patent Publication No. WO2021/168074 (“Class A ligands”); • International Patent Application No. PCT/US22/21999 (“Class B ligands”); and • International Patent Application No. PCT/US22/28755 (“Class C ligands”). [0088] In embodiments, a compound of the invention as described herein comprises or is derived from a Class A ligand, including any formulae or specific compound as described in WO2021/168074, including any compound according to any one of Formulas (I), (I’), (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (I-H), and (I-J), such as any one of Compounds (1)-(58), (61)-(71), (73)-(80), and (82)-(193), or a pharmaceutically acceptable salt thereof. [0089] In embodiments, a compound of the invention as described herein comprises or is derived from a Class B ligand, including any formulae or specific compound as described in PCT/US22/21999, including any compound according to any one of Formulas (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII), and (XIV) such as any one of Compounds (1)-(71), or a pharmaceutically acceptable salt thereof. [0090] In embodiments, a compound of the invention as described herein comprises or is derived from a Class C ligand, including any formulae or specific compound as described in PCT/US22/28755, including any compound according to Formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII), (XIV), (XV), (XVI), (XVII), (XVIII), (XIX), (XX), (XXI), (XXII), and (XXIII), such as any one of Compounds (1)-(169), or a pharmaceutically acceptable salt thereof. [0091] In embodiments, a derivative of a formula or compound described in any of WO2021/168074, PCT/US22/21999, and PCT/US22/28755 includes modification of a formula or compound to include a functional group for covalent attachment to the LP-E moiety (e.g., as described herein). An exemplary derivative includes modification of any formula or compound described in WO2021/168074, PCT/US22/21999, and PCT/US22/28755 to comprise a piperazine or piperazine-containing group that is covalently attached to an LP-E moiety.
Exemplary Compounds Comprising a Class A Ligand [0092] In embodiments, the invention features compounds comprising a Class A ligand or comprising a moiety derived from a Class A ligand. [0093] In embodiments, a compound of the invention as described herein comprises or is derived from a Class A ligand, wherein said ligand is according to or derived from any one of Formulas (I), (I’), (I-A), (I-B), (I-C), (I-D), (I-E), (I-F), (I-G), (I-H), and (I-J) of WO2021/168074, such as any one of Compounds (1)-(58), (61)-(71), (73)-(80), and (82)- (193), or a pharmaceutically acceptable salt thereof. [0094] Certain exemplary structure features are described herein. Exemplary structural formulae and compounds can feature any combination of features as described herein. [0095] In embodiments of compounds comprising or derived from a Class A Ligand, E and LP are according to any embodiments described herein, as well as any combinations thereof. [0096] In one embodiment, the invention features a compound having a structure according to Formula (AI),
or a pharmaceutically acceptable salt thereof, wherein: A is C6-10 arylene, 5-12-membered heteroarylene, or 5-12-membered heterocycloalkylene; X1 is N or CRX; X2 is N or CRX; X3 is N or CRX”; X4 is N or CRX”; X6 is N or CRX’;
X7 is N or CRX’; ------ represents an optional double bond between X7 and X4 or X4 and X6, wherein one and only one double bond is present; X5 is a covalent bond, CH2, O, NR4, C(O)NR4, or NR4C(O); L1 is a covalent bond or C(R5)2, and L2 is C1-4 alkylene, or L1 and L2 combine to form a C3-6 cycloalkyl or a 4- to 6-membered heterocycloalkyl; R1 is –LP-E, halogen, C1-6 alkyl, C3-7 cycloalkyl, C6-10 aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocycloalkyl, CN, NR6R7, NR6C(O)R7, NR6C(O)NH2, OR8, or C(O)NR6R7, and where valency permits when R1 is not –LP-E, R1 optionally further comprises -LP-E; R2 is absent, H, C1-6 alkyl, halogen, CN, or C1-6 alkoxy; each R3, when present, is independently OH, CN, halogen, C1-6 alkyl, or C1-6 alkoxy; n is 0, 1, or 2; each RX is independently H, ORX1, CN, halogen, or C1-6 alkyl, wherein RX1 is H or C1- 6 alkyl; each RX’ is independently H, ORX1, CN, halogen, or C1-6 alkyl, wherein RX1 is H or C1- 6 alkyl, or RX’ is absent if the carbon to which it is attached is part of a double bond; each RX” is independently –LP-E, H, ORX1, CN, halogen, or C1-6 alkyl optionally comprising -LP-E, and wherein RX1 is H or C1-6 alkyl optionally comprising –LP-E; LP is a linker; E is an E3 ubiquitin ligase ligand; each R4 and R5 is independently H or C1-6 alkyl; each R6 and R7 is independently H, C1-6 alkyl, C3-7 cycloalkyl, or 3- to 10-membered heterocycloalkyl; or R6 and R7 together with the nitrogen atom to which they are attached form a 3- to 8-membered heterocycloalkyl ring; and R8 is independently H, C1-6 alkyl, or 4- to 6-membered heterocycloalkyl; and wherein the compound comprises one and only one LP-E moiety. [0097] Certain exemplary structure features are described herein. Exemplary structural formulae and compounds can feature any combination of features as described herein. [0098] In embodiments, ------ represents a double bond between X7 and X4, and there is a single bond between X6 and X4. In embodiments, X7 is N and X4 is CRX. In embodiments, X7 is C and X4 is CRX. In embodiments, X7 is N and X4 is N. In embodiments, X6 is N. In embodiments, X6 is CRX (e.g., C-H).
[0099] In embodiments, ------ represents a double bond between X6 and X4, and there is a single bond between X7 and X4. In embodiments, X6 is C, and X4 is CRX. In embodiments, X6 is C, and X4 is N. In embodiments, X7 is N. In embodiments, X7 is CRX (e.g., C-H). [0100] In embodiments, A is C6-10 arylene. In embodiments, A is unsubstituted C6-10 arylene. In embodiments, A is substituted C6-10 arylene (e.g., comprising 1, 2, 3, or 4 substituents as described herein). [0101] In embodiments, A is 5-12-membered heteroarylene. In embodiments, A is unsubstituted 5-12-membered heteroarylene. In embodiments, A is substituted 5-12-membered heteroarylene (e.g., comprising 1, 2, 3, or 4 substituents as described herein). [0102] In embodiments, A is 5-12-membered heterocycloalkylene. In embodiments, A is unsubstituted 5-12-membered heterocycloalkylene. In embodiments, A is substituted 5-12- membered heterocycloalkylene (e.g., comprising 1, 2, 3, or 4 substituents as described herein). [0103] In embodiments, X1 is N. In embodiments, X1 is CRX (e.g., C-H or C-CH3). [0104] In embodiments, X2 is N. In embodiments, X2 is CRX (e.g., C-H or C-CH3). [0105] In embodiments, X3 is N. In embodiments, X3 is CRX” (e.g., C-H or C-CH3). [0106] In embodiments, X4 is N. In embodiments, X4 is CRX” (e.g., C-H or C-CH3). [0107] In embodiments, X6 is N. In embodiments, X6 is CRX’ (e.g., C, C-H, or C-CH3). [0108] In embodiments, X7 is N. In embodiments, X7 is CRX’ (e.g., C, C-H, or C-CH3). [0109] In embodiments, X5 is a covalent bond. In embodiments, X5 is CH2. In embodiments, X5 is O. In embodiments, X5 is NR4 (e.g., NH or NCH3). In embodiments, X5 is C(O)NR4 (e.g., C(O)NH or C(O)CH3). In embodiments, X5 is NR4C(O) (e.g., NHC(O) or NCH3C(O)). [0110] In embodiments, L1 is a covalent bond or C(R5)2, and L2 is C1-4 alkylene. In embodiments, L1 is a covalent bond. In embodiments, L1 is C(R5)2 (e.g., CH2, CHCH3, CH(CH2CH3), or C(CH3)2). In embodiments, L2 is unsubstituted C1-4 alkylene (e.g. CH2, (CH2)2, (CH2)3, or (CH2)4). In embodiments, L2 is substituted C1-4 alkylene (e.g., C1-4 alkylene substituted by OH, oxo (=O), or unsubstituted C1-3 alkyl)). [0111] In embodiments, L1 and L2 combine to form a C3-6 cycloalkyl or a 4- to 6-membered heterocycloalkyl. In embodiments, L1 and L2 combine to form a C3-6 cycloalkyl. In embodiments, L1 and L2 combine to form cyclopropyl. In embodiments, L1 and L2 combine to form cyclobutyl. In embodiments, L1 and L2 combine to form cyclopentyl. In embodiments,
L1 and L2 combine to form cyclohexyl. In embodiments, L1 and L2 combine to form an unsubstituted C4-6 cycloalkyl. In embodiments, L1 and L2 combine to form a substituted C4-6 cycloalkyl (e.g., comprising 1, 2, or 3 substituents as described herein). In embodiments, L1 and L2 combine to form a 4- to 6-membered heterocycloalkyl. In embodiments, L1 and L2 combine to form tetrahydropyranyl. In embodiments, L1 and L2 combine to form an unsubstituted 4- to 6-membered heterocycloalkyl. In embodiments, L1 and L2 combine to form a substituted 4- to 6-membered heterocycloalkyl (e.g., comprising 1, 2, or 3 substituents as described herein). [0112] In embodiments, R1 is halogen. In embodiments, R1 is C1-6 alkyl. In embodiments, R1 is C3-7 cycloalkyl. In embodiments, R1 is C6-10 aryl. In embodiments, R1 is 5- to 10-membered heteroaryl (e.g., monocyclic or bicyclic heteroaryl). In embodiments, R1 is 3- to 10-membered heterocycloalkyl (e.g., monocyclic or bicyclic heterocycloalkyl). In embodiments, R1 is CN. In embodiments, R1 is NR6R7. In embodiments, R1 is NR6C(O)R7. In embodiments, R1 is NR6C(O)NH2. In embodiments, R1 is OR8. In embodiments, R1 is C(O)NR6R7. [0113] In embodiments, R1 is unsubstituted C1-6 alkyl. In embodiments, R1 is unsubstituted C3-7 cycloalkyl. In embodiments, R1 is unsubstituted C6-10 aryl. In embodiments, R1 is unsubstituted 5- to 10-membered heteroaryl (e.g., unsubstituted monocyclic or bicyclic heteroaryl). In embodiments, R1 is unsubstituted 3- to 10-membered heterocycloalkyl (e.g., unsubstituted monocyclic or bicyclic heterocycloalkyl). In embodiments, R1 is –LP-E. In embodiments, when R1 is not –LP-E, R1 optionally further comprises -LP-E. In embodiments, R1 further comprises -LP-E. [0114] In embodiments, R1 is substituted C1-6 alkyl. In embodiments, R1 is substituted C3-7 cycloalkyl. In embodiments, R1 is substituted C6-10 aryl. In embodiments, R1 is substituted 5- to 10-membered heteroaryl (e.g., substituted monocyclic or bicyclic heteroaryl). In embodiments, R1 is substituted 3- to 10-membered heterocycloalkyl (e.g., substituted monocyclic or bicyclic heterocycloalkyl). In embodiments, a substituted group comprises 1, 2, or 3 substituent groups as described herein. [0115] In embodiments, R1 is a substituted or unsubstituted 5- or 6-membered heteroarylene; a substituted or unsubstituted 5- or 6-membered heterocycloalkyl, C1-6 alkyl substituted by a 5- or 6-membered heteroarylene that is substituted or unsubstituted; or C1-6 alkyl substituted by a 5- or 6-membered heterocycloalkyl that is substituted or unsubstituted, or substituted phenyl.
[0116] In embodiments, R2 is absent. In embodiments, R2 is H. In embodiments, R2 is C1-6 alkyl. In embodiments, R2 is halogen. In embodiments, R2 is CN. In embodiments, R2 is C1-6 alkoxy. In embodiments, R2 is unsubstituted C1-6 alkyl. In embodiments, R2 is substituted C1-6 alkyl (e.g., comprising 1, 2, or 3 substituent groups as described herein). In embodiments, R2 is unsubstituted C1-6 alkoxy. In embodiments, R2 is substituted C1-6 alkoxy (e.g., comprising 1, 2, or 3 substituent groups as described herein). [0117] In embodiments, R3 is not present. In embodiments, R3 is present. In embodiments, R3 is OH. In embodiments, R3 is CN. In embodiments, R3 is halogen. In embodiments, R3 is C1-6 alkyl. In embodiments, R3 is C1-6 alkoxy. In embodiments, R3 is unsubstituted C1-6 alkyl. In embodiments, R3 is substituted C1-6 alkyl (e.g., comprising 1, 2, or 3 substituent groups as described herein). In embodiments, R3 is unsubstituted C1-6 alkoxy. In embodiments, R3 is substituted C1-6 alkoxy (e.g., comprising 1, 2, or 3 substituent groups as described herein). [0118] In embodiments, n is 0. In embodiments, n is 1. In embodiments, n is 2. [0119] In embodiments, RX is H. In embodiments, RX is ORX1. In embodiments, RX is CN. In embodiments, RX is halogen. In embodiments, RX is C1-6 alkyl. In embodiments, RX is unsubstituted C1-6 alkyl. In embodiments, RX is substituted C1-6 alkyl (e.g., comprising 1, 2, or 3 substituent groups as described herein). [0120] In embodiments, RX’ is H. In embodiments, RX’ is ORX1. In embodiments, RX’ is CN. In embodiments, RX’ is halogen. In embodiments, RX’ is C1-6 alkyl. In embodiments, RX’ is absent if the carbon to which it is attached is part of a double bond. [0121] In embodiments, RX” is H. In embodiments, RX” is ORX1. In embodiments, RX” is CN. In embodiments, RX” is halogen. In embodiments, RX” is C1-6 alkyl. In embodiments, RX” is absent if the carbon to which it is attached is part of a double bond. In embodiments, RX”is – LP-E. In embodiments, when RX”is not –LP-E, R1 optionally further comprises -LP-E. In embodiments, RX” further comprises -LP-E. [0122] In embodiments, RX1 is H. In embodiments, RX1 is C1-6 alkyl. In embodiments, RX1 is unsubstituted C1-6 alkyl. In embodiments, RX1 is substituted C1-6 alkyl (e.g., comprising 1, 2, or 3 substituent groups as described herein). [0123] In embodiments, R4 is H. embodiments, R4 is C1-6 alkyl. In embodiments, R4 is unsubstituted C1-6 alkyl. In embodiments, R4 is substituted C1-6 alkyl (e.g., comprising 1, 2, or 3 substituent groups as described herein).
[0124] In embodiments, R5 is H. embodiments, R5 is C1-6 alkyl. In embodiments, R5 is unsubstituted C1-6 alkyl. In embodiments, R5 is substituted C1-6 alkyl (e.g., comprising 1, 2, or 3 substituent groups as described herein). [0125] In embodiments, R6 is H. In embodiments, R6 is C1-6 alkyl. In embodiments, R6 is C3-7 cycloalkyl. In embodiments, R6 is 3- to 10-membered heterocycloalkyl (e.g. monocyclic or bicyclic heterocycloalkyl). In embodiments, R6 is unsubstituted C1-6 alkyl. In embodiments, R6 is unsubstituted C3-7 cycloalkyl. In embodiments, R6 is unsubstituted 3- to 10-membered heterocycloalkyl (e.g. monocyclic or bicyclic heterocycloalkyl). In embodiments, R6 is substituted C1-6 alkyl (e.g., comprising 1, 2, or 3 substituent groups as described herein). In embodiments, R6 is substituted C3-7 cycloalkyl (e.g., comprising 1, 2, or 3 substituent groups as described herein). In embodiments, R6 is substituted 3- to 10-membered heterocycloalkyl (e.g. a monocyclic or bicyclic heterocycloalkyl comprising 1, 2, or 3 substituent groups as described herein). [0126] In embodiments, R7 is H. In embodiments, R7 is C1-6 alkyl. In embodiments, R7 is C3-7 cycloalkyl. In embodiments, R7 is 3- to 10-membered heterocycloalkyl (e.g. monocyclic or bicyclic heterocycloalkyl). In embodiments, R7 is unsubstituted C1-6 alkyl. In embodiments, R7 is unsubstituted C3-7 cycloalkyl. In embodiments, R7 is unsubstituted 3- to 10-membered heterocycloalkyl (e.g. monocyclic or bicyclic heterocycloalkyl). In embodiments, R7 is substituted C1-6 alkyl (e.g., comprising 1, 2, or 3 substituent groups as described herein). In embodiments, R7 is substituted C3-7 cycloalkyl (e.g., comprising 1, 2, or 3 substituent groups as described herein). In embodiments, R7 is substituted 3- to 10-membered heterocycloalkyl (e.g. a monocyclic or bicyclic heterocycloalkyl comprising 1, 2, or 3 substituent groups as described herein). [0127] In embodiments, R6 and R7 together with the nitrogen atom to which they are attached form a 3- to 8-membered heterocycloalkyl ring (e.g., monocyclic or bicyclic heterocycloalkyl). [0128] In embodiments, R8 is H. In embodiments, R8 is C1-6 alkyl. In embodiments, R8 is 4- to 6-membered heterocycloalkyl. In embodiments, R8 is unsubstituted C1-6 alkyl. In embodiments, R8 is substituted C1-6 alkyl (e.g., comprising 1, 2, or 3 substituent groups as described herein). In embodiments, R8 is a substituted C1-6 alkyl that is piperidinyl substituted C1-6 alkyl (e.g., -CH2CH2(piperidinyl)). In embodiments, R8 is unsubstituted 4- to 6-
membered heterocycloalkyl. In embodiments, R8 is substituted 4- to 6-membered heterocycloalkyl (e.g., comprising 1, 2, or 3 substituent groups as described herein). [0129] In embodiments, a compound of the invention comprising a Class A ligand has a structure selected from the following formulas selected from Table A1. In embodiments, an E moiety is selected from those described in Table D, where
shows the point of covalent attachment to moiety LP. In embodiments, -LP-E is according to any of substructures (D1)- (D49) as described herein. In embodiments, -LP-E is according to any of substructures (D1)’- (D49)’ as described herein. Table A1. Exemplary Formulas Comprising Class A Ligands
or a pharmaceutically acceptable salt thereof. [0130] In embodiments, R2 is H, unsubstituted C1-6 alkyl or C1-6 alkyl substituted by a group that is unsubstituted C3-6 cycloalkyl. [0131] In embodiments, each X8, X9, and X10, when present, is CH or N. [0132] In embodiments, L1-L2-X5 when present is CH(CH3)-(CH2)2-O, CH(CH3)-(CH2)3-O, CH(CH2CH3)-(CH2)2-O, C(CH3)2-(CH2)2-O, (CH2)3-O, CH2-CH(CH3)CH2-O, CH2- CH2CH(CH3)-O, CH(CH3)-(CH2)2-NH, CH(CH3)-(CH2)2-NCH3, CH(CH3)-(CH2)3- NH, CH(CH3)-(CH2)3-NCH3, CH(CH3)-(CH2)3, or CH(CH3)-(CH2)4, or L1-L2-X5 is
[0133] In embodiments, R2 is H or unsubstituted C1-6 alkyl. [0134] In embodiments, R2 is unsubstituted C1-6 alkyl or C1-6 alkyl substituted by a group that is unsubstituted C3-6 cycloalkyl. [0135] In embodiments, the compound comprises a ligand formed from any one Compounds (1)-(58), (61)-(71), (73)-(80), and (82)-(193) of WO2021/168074, or a pharmaceutically acceptable salt thereof. [0136] In embodiments, the compound comprises a ligand derived from any one of Compounds (1)-(58), (61)-(71), (73)-(80), and (82)-(193) of WO2021/168074, or a pharmaceutically acceptable salt thereof. In embodiments, the compound of WO2021/168074
is modified to include a piperazine- or piperazine-containing group covalently attached to the -LP-E group as described herein. [0137] In embodiments, the compound is selected from any of the following compounds of Table A2, or a pharmaceutically acceptable salt thereof. In embodiments, an E moiety is selected from those described in Table D, where
shows the point of covalent attachment to moiety LP. In embodiments, -LP-E is according to any of substructures (D1)-(D49) as described herein. Table A2. Exemplary Compounds Comprising Class A Ligands
Exemplary Compounds Comprising a Class B Ligand [0138] In embodiments, the invention features compounds comprising a Class B ligand. In embodiments, a compound of the invention as described herein comprises or is derived from a Class B ligand, wherein said ligand is according to or derived from any one of Formulas (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII), and (XIV) of PCT/US22/21999 such as any one of Compounds (1)-(71), or a pharmaceutically acceptable salt thereof. [0139] Certain exemplary structure features are described herein. Exemplary structural formulae and compounds can feature any combination of features as described herein.
[0140] In embodiments of compounds comprising or derived from a Class B Ligand, E and LP are according to any embodiments described herein, as well as any combinations thereof. [0141] In one embodiment, the invention features a compound having a structure according to Formula (BI),
or a pharmaceutically acceptable salt thereof, wherein A1 is independently phenylene or 5- or 6-membered heteroarylene; A2 is independently phenyl, naphthyl, or a 5- to 13-membered heteroaryl; X1 is independently O or X1A; X1A is a covalent bond, S, NR4, C1-6 alkylene, C2-6 alkenylene, or C2-6 alkynylene; each of X2 and X3 is independently N or CR1B; L1 is independently a covalent bond or C1-6 alkylene; L2 is independently a covalent bond, C2-6 alkenylene, C2-6 alkynylene, C3-6 cycloalkylene, 3- to 10-membered heterocyclylene, phenylene, or 5- or 6-membered heteroarylene; each R1A and R1B is independently H, OH, CN, halogen, C1-6 aliphatic, C1-6 alkoxy, NR6R7, C(O)R8, CO2R8, C(O)NR6R7, NR9C(O)R8, NR9CO2R8, NR9C(O)NR6R7, or R10; each R2, when present, is independently OH, CN, halogen, C1-6 aliphatic, C1-6 alkoxy, NR6R7, C(O)R8, CO2R8, C(O)NR6R7, NR9C(O)R8, NR9CO2R8, NR9C(O)NR6R7, R10, OR10, CH2R10, CH2CH2R10, OCH2R10, or OCH2CH2R10; each R3, when present, is independently –LP-E, OH, CN, halogen, C1-6 aliphatic, C1-6 alkoxy, NR6R7, C(O)R8, CO2R8, C(O)NR6R7, NR9C(O)R8, NR9CO2R8, NR9C(O)NR6R7, R10, OR10, CH2R10, CH2CH2R10, OCH2R10, or OCH2CH2R10, and where valency permits when R3 is not –LP-E, R3 optionally further comprises –LP-E; LP is a linker; E is an E3 ubiquitin ligase ligand; each R4 is independently H, a N-protecting group, or C1-6 alkyl; R5 is hydrogen;
each R6, R7, and R9 is independently H or C1-6 alkyl; or R6 and R7, together with the nitrogen atom to which they are attached, form a 3- to 10-membered heterocyclyl, or R6 and R9, together with the atoms to which they are attached, form a 3- to 10-membered heterocyclyl; R8 is independently C1-6 aliphatic, C3-C10 cycloaliphatic, 3- to 10-membered heterocyclyl, phenyl, naphthyl, or a 5- to 12-membered heteroaryl, or R8 and R9, together with the atoms to which they are attached, form a 3- to 10-membered heterocyclyl; R10 is independently C3-C10 cycloaliphatic, 3- to 10-membered heterocyclyl, phenyl, naphthyl, or a 5- to 12-membered heteroaryl; each of n and o is independently 0, 1, or 2; and wherein the compound comprises one and only one LP-E moiety. In embodiments, when X1 is O, and both of X2 and X3 are not N, then A2 is naphthyl or a bicyclic 8- to 12-membered heteroaryl. In embodiments, X2 is N. In embodiments, X2 is CR1B (e.g., CH). In embodiments, X3 is N. In embodiments, X3 is CR1B (e.g., CH). In embodiments, each of X2 and X3 is N. In embodiments, each of X2 and X3 is CR1B. In embodiments, each of X2 and X3 is CH. In embodiments, one of X2 and X3 is N, and the other is CR1B (e.g., CH). In embodiments, at least one of X2 and X3 is N. In embodiments, X1 is X1A. In embodiments, X1A is a covalent bond. In embodiments, X1A is S or NR4. In embodiments, X1A is C1-6 alkylene, C2-6 alkenylene, or C2-6 alkynylene. In embodiments, L1 is a covalent bond. In embodiments, L1 is unsubstituted branched C1-6 alkylene, or linear C1-6 alkylene optionally comprising a -OH substituent. In embodiments, X1 is X1A, wherein X1A is a covalent bond, C1-6 alkylene, C2-6 alkenylene, or C2-6 alkynylene;
L1 is independently a covalent bond or C1-6 alkylene; L2 is independently a covalent bond, C2-6 alkenylene, C2-6 alkynylene, C3-6 cycloalkylene, 3- to 10-membered heterocyclylene, phenylene, or 5- or 6-membered heteroarylene; and where at least one of X1A, L1, and L2 is a covalent bond. In embodiments, one X1A and L1 is a covalent bond and the other is C1-6 alkylene; and L2 is a covalent bond. In embodiments, each of L1 and L2 is a covalent bond. In embodiments, each of X1A and L2 is a covalent bond. In embodiments, each of X1A and L1 is a covalent bond. In embodiments, X2 is N. In embodiments, X2 is CR1B (e.g., CH). In embodiments, X3 is N. In embodiments, X3 is CR1B (e.g., CH). In embodiments, each of X2 and X3 is N. In embodiments, each of X2 and X3 is CR1B. In embodiments, each of X2 and X3 is CH. In embodiments, one of X2 and X3 is N, and the other is CR1B (e.g., CH). In embodiments, at least one of X2 and X3 is N. In embodiments, A1 is phenylene. In embodiments, A1 is unsubstituted phenylene. In embodiments, A1 is substituted phenylene (e.g., comprising 1 or 2 substituents as described herein). In embodiments, A1 is 5- or 6-membered heteroarylene. Examplary 5- to 6-membered heteroarylene includes but is not limited to pyridylene, pyrimidylene, pyrazolylene, thiazolylene, oxazolylene, and imidazolylene. In embodiments, A1 is unsubstituted 5- or 6- membered heteroarylene. In embodiments, A1 is substituted 5- or 6-membered heteroarylene (e.g., comprising 1 or 2 substituents as described herein). In embodiments, A1 is pyrazolylene. In embodiments, A1 is unsubstituted pyrazolylene. In embodiments, A1 is substituted pyrazolylene (e.g., comprising 1 or 2 substituents as described herein). In embodiments, A1 is N-substituted pyrazolylene (e.g., N-methyl pyrazolylene). In embodiments, A2 is phenyl. In embodiments, A2 is unsubstituted phenyl. In embodiments, A2 is substituted phenyl (e.g., comprising 1 or 2 substituents as described herein).
In embodiments, A2 is naphthyl. In embodiments, A2 is unsubstituted naphthyl. In embodiments, A2 is substituted naphthyl (e.g., comprising 1 or 2 substituents as described herein). In embodiments, A2 is 5- to 13-membered heteroaryl (e.g., monocyclic or bicyclic heteroaryl). In embodiments, A2 is a monocyclic 5- to 6-membered heteroaryl. Examplary monocyclic 5- to 6-membered heteroaryls include but are not limited to pyridyl, pyrimidyl, pyrazolyl, thiazolyl, oxazolyl, and imidazolyl. In embodiments, A2 is a bicyclic 8- to 12-membered heteroaryl (e.g., nitrogen-containing, bicyclic 8- to 12-membered heteroaryl). Examplary bicyclic 8- to 12-membered heteroaryls include but are not limited to indolyl, benzimidazolyl, indazolyl, isoindolyl, pyrrolopyrimidyl, pyrrolopyridinyl, pyrazolopyrimidyl, pyrazolopyridinyl, benzotriazolyl, quinolyl, and isoquinolyl. In embodiments, A2 is pyrazolyl. In embodiments, A2 is unsubstituted 5- to 13-membered heteroaryl (e.g., unsubstituted monocyclic or bicyclic heteroaryl). In embodiments, A2 is unsubstituted monocyclic 5- to 6-membered heteroaryls. In embodiments, A2 is unsubstituted pyridyl, unsubstituted pyrimidyl, unsubstituted pyrazolyl, unsubstituted thiazolyl, unsubstituted oxazolyl, or unsubstituted imidazolyl. In embodiments, A2 is unsubstituted bicyclic 8- to 12-membered heteroaryl (e.g., unsubstituted nitrogen-containing, bicyclic 8- to 12-membered heteroaryl). In embodiments, A2 is unsubstituted indolyl, unsubstituted benzimidazolyl, unsubstituted indazolyl, unsubstituted isoindolyl, unsubstituted pyrrolopyrimidyl, unsubstituted pyrrolopyridinyl, unsubstituted pyrazolopyrimidyl, unsubstituted pyrazolopyridinyl, unsubstituted benzotriazolyl, unsubstituted quinolyl, or unsubstituted isoquinolyl. In embodiments, A2 is unsubstituted pyrazolyl. In embodiments, A2 is substituted 5- to 13-membered heteroaryl (e.g., substituted monocyclic or bicyclic heteroaryl comprising 1 or 2 substituents as described herein). In embodiments, A2 is substituted monocyclic 5- to 6-membered heteroaryls. In embodiments, A2 is substituted pyridyl, substituted pyrimidyl, substituted pyrazolyl, substituted thiazolyl, substituted oxazolyl, or substituted imidazolyl. In embodiments, A2 is substituted bicyclic 8- to 12- membered heteroaryl (e.g., substituted nitrogen-containing, bicyclic 8- to 12-membered heteroaryl). In embodiments, A2 is substituted indolyl, substituted benzimidazolyl, substituted indazolyl, substituted isoindolyl, substituted pyrrolopyrimidyl, substituted pyrrolopyridinyl, substituted pyrazolopyrimidyl, substituted pyrazolopyridinyl, substituted benzotriazolyl, substituted quinolyl, or substituted isoquinolyl. Examplary substituent groups include but are
not limited to methyl, halogen (e.g. F, Cl, Br, or I), and CN. In embodiments, A2 is substituted pyrazolyl (e.g, N-substituted pyrazolyl such as N-methyl pyrazolyl). In embodiments, when X1 is O, and both of X2 and X3 are not N, then A2 is naphthyl or a bicyclic 8- to 12-membered heteroaryl. In embodiments, X1 is not O. In embodiments, R1A is H. In embodiments, R1A is OH. In embodiments, R1A is CN. In embodiments, R1A is halogen (e.g., F, Cl, Br, or I). In embodiments, R1A is C1-6 aliphatic. In embodiments, R1A is unsubstituted C1-6 aliphatic. In embodiments, R1A is substituted C1-6 aliphatic (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R1A is C1-6 alkoxy. In embodiments, R1A is unsubstituted C1-6 alkoxy. In embodiments, R1A is substituted C1-6 alkoxy (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R1A is NR6R7. In embodiments, R1A is C(O)R8. In embodiments, R1A is CO2R8. In embodiments, R1A is C(O)NR6R7. In embodiments, R1A is NR9C(O)R8. In embodiments, R1A is NR9CO2R8. In embodiments, R1A is NR9C(O)NR6R7. In embodiments, R1A is R10. In embodiments, R1A is CH3, CH2F, CHF2, or CF3. In embodiments, R1A is CH3. In embodiments, R1A is CH2F, CHF2, or CF3. In embodiments, R1B is H. In embodiments, R1B is OH. In embodiments, R1B is CN. In embodiments, R1B is halogen (e.g., F, Cl, Br, or I). In embodiments, R1B is C1-6 aliphatic. In embodiments, R1B is unsubstituted C1-6 aliphatic. In embodiments, R1B is substituted C1-6 aliphatic (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R1B is C1-6 alkoxy. In embodiments, R1B is unsubstituted C1-6 alkoxy. In embodiments, R1B is substituted C1-6 alkoxy (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R1B is NR6R7. In embodiments, R1B is C(O)R8. In embodiments, R1B is CO2R8. In embodiments, R1B is C(O)NR6R7. In embodiments, R1B is NR9C(O)R8. In embodiments, R1B is NR9CO2R8. In embodiments, R1B is NR9C(O)NR6R7. In embodiments, R1B is R10. In embodiments, R2 is OH. In embodiments, R2 is CN. In embodiments, R2 is halogen (e.g., F, Cl, Br, or I). In embodiments, R2 is C1-6 aliphatic (e.g., methyl). In embodiments, R2 is unsubstituted C1-6 aliphatic (e.g., methyl). In embodiments, R2 is substituted C1-6 aliphatic (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R2 is C1-6 alkoxy. In embodiments, R2 is unsubstituted C1-6 alkoxy. In embodiments, R2 is substituted C1-6 alkoxy
(e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R2 is NR6R7. In embodiments, R2 is C(O)R8. In embodiments, R2 is CO2R8. In embodiments, R2 is C(O)NR6R7. In embodiments, R2 is NR9C(O)R8. In embodiments, R2 is NR9CO2R8. In embodiments, R2 is NR9C(O)NR6R7. In embodiments, R2 is R10. In embodiments, R2 is OR10. In embodiments, R2 is CH2R10. In embodiments, R2 is CH2CH2R10. In embodiments, R2 is OCH2R10. In embodiments, R2 is OCH2CH2R10. In embodiments, R2 is methyl. In embodiments, R3 is–LP-E. In embodiments, R3 is not –LP-E. In embodiments, R3 further comprises -LP-E. In embodiments, R3 is OH. In embodiments, R3 is CN. In embodiments, R3 is halogen (e.g., F, Cl, Br, or I). In embodiments, R3 is C1-6 aliphatic. In embodiments, R3 is unsubstituted C1-6 aliphatic. In embodiments, R3 is substituted C1-6 aliphatic (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R3 is C1-6 alkoxy. In embodiments, R3 is unsubstituted C1-6 alkoxy. In embodiments, R3 is substituted C1-6 alkoxy (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R3 is NR6R7. In embodiments, R3 is C(O)R8. In embodiments, R3 is CO2R8. In embodiments, R3 is C(O)NR6R7. In embodiments, R3 is NR9C(O)R8. In embodiments, R3 is NR9CO2R8. In embodiments, R3 is NR9C(O)NR6R7. In embodiments, R3 is R10. In embodiments, R3 is OR10. In embodiments, R3 is CH2R10. In embodiments, R3 is CH2CH2R10. In embodiments, R3 is OCH2R10. In embodiments, R3 is OCH2CH2R10. In embodiments, R3 is is halogen. In embodiments, R3 is NR6R7, where R6 and R7, together with the nitrogen atom to which they are attached, form a 5- to 6-membered heterocyclyl. In embodiments, R3 is NR6R7, wherein each R6 and R7 is independently C1-C6 alkyl (e.g., one R6 and R7 is unsubstituted C1-C6 alkyl, and the other is C1-C6 alkyl comprising an amino group, a monoalkylamino group, or a dialkylamino group). In embodiments, R3 is unsubstituted or substituted phenyl or pyridyl. In embodiments, R3 is unsubstituted or substituted phenyl. In embodiments, R3 is unsubstituted or substituted pyridyl. In embodiments, R3 is unsubstituted or substituted pyrrolidine, morpholine, piperidine, or piperazine.
In embodiments, R3 is C(O)R8, wherein R8 is unsubstituted or substituted pyrrolidine, morpholine, piperidine, or piperazine. In embodiments, R3 is R10, OR10, CH2R10, CH2CH2R10, or OCH2CH2R10, wherein R10 is unsubstituted or substituted pyrrolidine, morpholine, piperidine, or piperazine. In embodiments, R3 is an unsubstituted group. In embodiments, R3 is a group comprising 1, 2, 3, or 4 substituent groups. In embodiments, a substituent group is selected from halogen (e.g., F, Cl, Br, or I), C1-6 aliphatic (e.g., methyl, monofluoromethyl, difluoromethyl, trifluoromethyl, ethyl, monofluoroethyl, propyl (e.g., n- propyl or isopropyl), butyl (e.g., n-butyl, sec-butyl, isobutyl, or tert-butyl)), amino (_NH2), monoalkylamino (e.g., -NHCH3), dialkylamino (e.g., -N(CH3)2), oxo (=O), C3-6 cycloaliphatic (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), or 3- to 6-membered heterocyclyl (e.g., oxetanyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholino), pyridyl, or phenyl. In embodiments, a cyclic group (e.g., a C3-6 cycloaliphatic, a 3- to 6-membered heterocyclyl, a pyridyl, or a phenyl) comprises 1, 2, or 3 substituent groups (e.g., 1, 2, or 3 substituent groups selected from halogen (e.g., F, Cl, Br, or I), C1-6 aliphatic (e.g., methyl, monofluoromethyl, difluoromethyl, trifluoromethyl, ethyl, monofluoroethyl, propyl (e.g., n-propyl or isopropyl), butyl (e.g., n-butyl, sec-butyl, isobutyl, or tert-butyl)), amino (_NH2), monoalkylamino (e.g., -NHCH3), dialkylamino (e.g., -N(CH3)2), and oxo (=O). In embodiments, R4 is H. In embodiments, R4 is an N-protecting group (e.g., an amide group, a carbamate group, or a sulfonamide group). In embodiments, R4 is C1-6 alkyl. In embodiments, a C1-6 alkyl is unsubstituted. In embodiments, a C1-6 alkyl is substituted (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R5 is H. In embodiments, R6 is H. In embodiments, R6 is C1-6 alkyl. In embodiments, a C1-6 alkyl is unsubstituted. In embodiments, a C1-6 alkyl is substituted (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R7 is H. In embodiments, R7 is C1-6 alkyl. In embodiments, a C1-6 alkyl is unsubstituted. In embodiments, a C1-6 alkyl is substituted (e.g., comprising 1, 2, or 3 substituent groups).
In embodiments, R9 is H. In embodiments, R9 is C1-6 alkyl. In embodiments, a C1-6 alkyl is unsubstituted. In embodiments, a C1-6 alkyl is substituted (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R6 and R7, together with the nitrogen atom to which they are attached, form a 3- to 10-membered heterocyclyl (e.g., monocyclic or bicyclic heterocyclyl). In embodiments, a 3- to 10-membered heterocyclyl is unsubstituted. In embodiments, a 3- to 10-membered heterocyclyl is substituted (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R6 and R9, together with the atoms to which they are attached, form a 3- to 10-membered heterocyclyl (e.g., monocyclic or bicyclic heterocyclyl). In embodiments, a 3- to 10-membered heterocyclyl is unsubstituted. In embodiments, a 3- to 10-membered heterocyclyl is substituted (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R8 is C1-6 aliphatic. In embodiments, R8 is C3-C10 cycloaliphatic (e.g., monocyclic or bicyclic cycloaliphatic). In embodiments, R8 is 3- to 10-membered heterocyclyl (e.g., monocyclic or bicyclic heterocyclyl). In embodiments, R8 is phenyl. In embodiments, R8 is naphthyl. In embodiments, R8 is 5- to 12-membered heteroaryl (e.g., monocyclic or bicyclic heteroaryl). In embodiments, R8 is unsubstituted C1-6 aliphatic. In embodiments, R8 is unsubstituted C3-C10 cycloaliphatic. In embodiments, R8 is unsubstituted 3- to 10-membered heterocyclyl. In embodiments, R8 is unsubstituted phenyl. In embodiments, R8 is unsubstituted naphthyl. In embodiments, R8 is unsubstituted 5- to 12-membered heteroaryl. In embodiments, R8 is substituted C1-6 aliphatic. In embodiments, R8 is substituted C3-C10 cycloaliphatic. In embodiments, R8 is substituted 3- to 10-membered heterocyclyl. In embodiments, R8 is substituted phenyl. In embodiments, R8 is substituted naphthyl. In embodiments, R8 is substituted 5- to 12-membered heteroaryl. In embodiments, a substituted group comprises 1, 2, or 3 substituent groups as described herein. In embodiments, R8 and R9, together with the atoms to which they are attached, form a 3- to 10-membered heterocyclyl (e.g., monocyclic or bicyclic heterocyclyl). In embodiments, a 3- to 10-membered heterocyclyl is unsubstituted. In embodiments, a 3- to 10-membered heterocyclyl is substituted (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R10 is C3-C10 cycloaliphatic (e.g., monocyclic or bicyclic cycloaliphatic). In embodiments, R10 is 3- to 10-membered heterocyclyl (e.g., monocyclic or bicyclic
heterocyclyl). In embodiments, R10 is phenyl. In embodiments, R10 is naphthyl. In embodiments, R10 is 5- to 12-membered heteroaryl (e.g., monocyclic or bicyclic heteroaryl). In embodiments, R10 is unsubstituted C3-C10 cycloaliphatic. In embodiments, R10 is unsubstituted 3- to 10-membered heterocyclyl. In embodiments, R10 is unsubstituted phenyl. In embodiments, R10 is unsubstituted naphthyl. In embodiments, R10 is unsubstituted 5- to 12- membered heteroaryl. In embodiments, R10 is substituted C3-C10 cycloaliphatic. In embodiments, R10 is substituted 3- to 10-membered heterocyclyl. In embodiments, R10 is substituted phenyl. In embodiments, R10 is substituted naphthyl. In embodiments, R10 is substituted 5- to 12-membered heteroaryl. In embodiments, a substituted group comprises 1, 2, or 3 substituent groups as described herein. In embodiments, n is 0. In embodiments, n is 1. In embodiments, n is 2. In embodiments, n is 1 or 2. In embodiments, o is 0. In embodiments, o is 1. In embodiments, o is 2. In embodiments, o is 1 or 2. [0142] In embodiments, a compound of the invention comprising a Class B ligand has a structure selected from the following formulas selected from Table B1. In embodiments, an E moiety is selected from those described in Table D, where
shows the point of covalent attachment to moiety LP. In embodiments, -LP-E is according to any of substructures (D1)- (D49) as described herein. In embodiments, -LP-E is according to any of substructures (D1)’- (D49)’ as described herein. Table B1. Exemplary Formulas Comprising Class B Ligands
or a pharmaceutically acceptable salt thereof. [0143] In embodiments, the compound is according to Formula (BIX), (BX), or (BXI), or a pharmaceutically acceptable salt thereof, wherein L1 is C1-C6 alkylene optionally substituted by 1, 2, or 3 R13; each R13 is independently unsubstituted C1-C3 alkyl; and R1A is independently unsubstitued C1-C6 alkyl or C1-C6 haloalkyl. [0144] In embodiments, the compound is according to Formula (BXII), or a pharmaceutically acceptable salt thereof, wherein R1A is independently unsubstitued C1-C6 alkyl or C1-C6 haloalkyl. [0145] In embodiments, the compound is according to Formula (BXIII) or (BXIV), or a pharmaceutically acceptable salt thereof, wherein L1 is C1-C6 alkylene optionally substituted by 1 or 2 R13; each R13 is independently unsubstituted C1-C3 alkyl; and R1A is independently unsubstitued C1-C6 alkyl or C1-C6 haloalkyl. [0146] In embodiments, L1 is selected from: –(CH2)3–; –(CH2)4–;
wherein a carbon marked by an asterisk (*) is racemic or has the (R)- or (S)- stereochemistry. In embodiments, a carbon marked by an asterisk (*) is racemic. In embodiments, a carbon marked by an asterisk (*) has the (R)-stereochemistry. In embodiments, a carbon marked by an asterisk (*) has the (S)-stereochemistry. [0001] In embodiments, -L1-L2-X1- or -L1-L2-X1A- is [0002] In embodiments, -L1-L2-X1- or -L1-L2-X1A- is [0003] In embodiments, -L1-L2-X1- or -L1-L2-X1A- is [0004] In embodiments, -L1-L2-X1- or -L1-L2-X1A- is
[0005] In embodiments, -L1-L2-X1- or -L1-L2-X1A- is substructure (S1). In embodiments, - L1-L2-X1- or -L1-L2-X1A- is substructure (S2). In embodiments, -L1-L2-X1- or -L1-L2-X1A- is substructure (S3). In embodiments, -L1-L2-X1- or -L1-L2-X1A- is substructure (S4). In embodiments, -L1-L2-X1- or -L1-L2-X1A- is substructure (S5). In embodiments, -L1-L2-X1- or - L1-L2-X1A- is substructure (S6). In embodiments, -L1-L2-X1- or -L1-L2-X1A- is substructure (S7). In embodiments, -L1-L2-X1- or -L1-L2-X1A- is substructure (S8). [0147] In embodiments, the compound comprises a ligand formed from any one Compounds (1)-(71) of PCT/US22/21999, or a pharmaceutically acceptable salt thereof.
[0148] In embodiments, the compound comprises a ligand derived from any one of Compounds (1)-(71) of PCT/US22/21999, or a pharmaceutically acceptable salt thereof. In embodiments, the compound of PCT/US22/21999 is modified to include a piperazine- or piperazine-containing group covalently attached to the -LP-E group as described herein. [0149] In embodiments, the compound is selected from any of the following compounds of Table B2, or a pharmaceutically acceptable salt thereof. In embodiments, an E moiety is selected from those described in Table D, where
shows the point of covalent attachment to moiety LP. In embodiments, -LP-E is according to any of substructures (D1)-(D49) as described herein. Table B2. Exemplary Compounds Comprising Class B Ligands
Exemplary Compounds Comprising a Class C Ligand [0150] In embodiments, the invention features compounds comprising a Class C ligand. In embodiments, a compound of the invention as described herein comprises or is derived from a Class C ligand, wherein said ligand is according to or derived from any one of Formulas (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII), (XIV), (XV), (XVI), (XVII), (XVIII), (XIX), (XX), (XXI), (XXII), and (XXIII) as described in PCT/US22/28755, such as any one of Compounds (1)-(169), or a pharmaceutically acceptable salt thereof. [0151] Certain exemplary structure features are described herein. Exemplary structural formulae and compounds can feature any combination of features as described herein. [0152] In embodiments of compounds comprising or derived from a Class C Ligand, E and LP are according to any embodiments described herein, as well as any combinations thereof.
[0153] In one embodiment, the invention features a compound having a structure according to Formula (CI),
or a pharmaceutically acceptable salt thereof, wherein X2 is independently N or CR5; each of X3 and X4 is independently a covalent bond, O, S, NR6, C(O)NR6, NR6C(O), NR6C(O)NR6, or (C(R7)2)q; L1 is independently a covalent bond, C1-6 heteroalkylene, C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C3-6 cycloalkylene, 3- to 10-membered heterocyclylene, phenylene, naphthylene, or 5- to 10-membered heteroarylene; each R1 is independently LP-E,
(Substructure A), OH, CN, halogen, C1-6 aliphatic, C1-6 alkoxy, NR8R9, C(O)R10, CO2R10, C(O)NR8R9, NR11C(O)R10, NR11CO2R10, NR11C(O)NR8R9, or (CH2)rR12, or two R1 or two R2, together to which the atoms they are attached form a 5- to 10-membered ring, and where valency permits when R1 is not –LP-E, R1 optionally further comprises –LP-E; each R2 is independently LP-E,
(Substructure A), OH, CN, halogen, C1-6 aliphatic, C1-6 alkoxy, NR8R9, C(O)R10, CO2R10, C(O)NR8R9, NR11C(O)R10, NR11CO2R10, NR11C(O)NR8R9, or (CH2)rR12, or two R1 or two R2, together to which the atoms they are attached form a 5- to 10-membered ring, and where valency permits when R2 is not –LP-E, R2 optionally further comprises –LP-E; LP is a linker; E is an E3 ubiquitin ligase ligand; L2 is independently a covalent bond, O, NRL, C(O), C(O)NRL, NRLC(O), CRL 2;
RL is independently H or C1-6 alkyl; A is independently phenyl, naphthyl, 5- to 13-membered heteroaryl, C3-C10 cycloaliphatic, or 3- to 10-membered heterocyclyl; B is independently phenyl, naphthyl, 5- to 13-membered heteroaryl, C3-C10 cycloaliphatic, or 3- to 10-membered heterocyclyl; C is independently 5- or 6-membered heteroaryl; each R3 is independently OH, CN, halogen, C1-6 aliphatic, C1-6 alkoxy, NR8R9, C(O)R10, CO2R10, C(O)NR8R9, NR11C(O)R10, NR11CO2R10, NR11C(O)NR8R9, or (CH2)rR12; each R4 is independently –LP-E, H, OH, CN, halogen, C1-6 aliphatic, C1-6 alkoxy, NR8R9, C(O)R10, CO2R10, C(O)NR8R9, NR11C(O)R10, NR11CO2R10, NR11C(O)NR8R9, NR11(CH2)sNR8R9, (CH2)tNR8R9, (CH2)tOH, (CH2)tOCH3, O(CH2)tOH, O(CH2)tOCH3, O(CH2)rR12, or (CH2)rR12; or R4 and R6 or R4 and R7, together with the atoms to which they are attached, form a 5- to 6-membered ring, and where valency permits when R4 is not –LP-E, R4 optionally further comprises –LP-E; each R5 is independently H, OH, CN, halogen, C1-6 aliphatic, C1-6 alkoxy, NR8R9, C(O)R10, CO2R10, C(O)NR8R9, NR11C(O)R10, NR11CO2R10, NR11C(O)NR8R9, or (CH2)rR12; each R6 is independently H, a N-protecting group, or C1-6 alkyl; or R6 and R4, together with the atoms to which they are attached, form a 5- to 6-membered ring; each R7 is independently H or C1-6 alkyl; or two R7 on the same carbon combine to from an oxo (=O) group; or R7 and R4, together with the atoms to which they are attached, form a 5- to 6-membered ring; each R8, R9, and R11 is independently H or C1-6 alkyl; or R8 and R9, together with the nitrogen atom to which they are attached, form a 3- to 10-membered heterocyclyl, or R8 and R11, together with the atoms to which they are attached, form a 3- to 10-membered heterocyclyl; each R10 is independently C1-6 aliphatic, C3-C10 cycloaliphatic, 3- to 10-membered heterocyclyl, phenyl, naphthyl, or a 5- to 12-membered heteroaryl; or R10 and R11, together with the atoms to which they are attached, form a 3- to 10-membered heterocyclyl; each R12 is independently C3-C10 cycloaliphatic, 3- to 10-membered heterocyclyl, phenyl, naphthyl, or a 5- to 12-membered heteroaryl; each m, n, and o is independently 0, 1, or 2; each p is independently 0, 1, 2; 3, or 4; each q is independently 1 or 2; each r is independently an integer of 0-4;
each s is independently an integer of 2-6; each t is independently an integer of 1-6; and wherein the compound comprises one and only one LP-E moiety. In embodiments, each R4 is independently H, OH, CN, halogen, C1-6 aliphatic, C1-6 alkoxy, NR8R9, C(O)R10, CO2R10, C(O)NR8R9, NR11C(O)R10, NR11CO2R10, NR11C(O)NR8R9, NR11(CH2)sNR8R9, (CH2)tNR8R9, or (CH2)rR12; or R4 and R6, or R4 and R7, together with the atoms to which they are attached, form a 5- to 6-membered ring. In embodiments, m is 0. In embodiments, m is 1. In embodiments, m is 2. In embodiments, m is 1 or 2. In embodiments, n is 0. In embodiments, n is 1. In embodiments, n is 2. In embodiments, n is 1 or 2. In embodiments, m is not 0. In embodiments, n is not 0. In embodiments, at least one m or n is not 0. In embodiments, m is 1, and n is 0. In embodiments, n is 1, and m is 0. In embodiments, p is 0. In embodiments, p is 1. In embodiments, p is 2. In embodiments, p is 3. In embodiments, p is 4. In embodiments, R1 is present. In embodiments, R2 is present. In embodiments, at least one of R1 and R2 is present. In embodiments, one of R1 and R2 is present. In embodiments, no more than one of R1 and R2 is present. In embodiments, one of R1 and R2 is present and is Substructure A (
) or halogen (e.g., F, Cl, Br, or I). In embodiments, one of R1 and R2 is present and is Substructure A (
). In embodiments, Substructure A (
) is not present. In embodiments, one Substructure A group is present. In embodiments, no more than one Substructure A is present. In embodiments, two Substructure A groups are present (e.g., two Substructure A groups with identical or different structures). In embodiments, more than two Substructure A groups are present (e.g., more than two Substructure A groups with identical or different structures). In embodiments, no more than one Substructure A group is present.
In embodiments, C is 5- or 6-membered N-containing heteroaryl. In embodiments, C is pyridyl, pyrimidyl, pyrazolyl, pyrrolyl, thiazolyl, oxazolyl, or imidazolyl. In embodiments, A is pyridyl, pyrimidyl, pyrazolyl, pyrrolyl, thiazolyl, oxazolyl, or imidazolyl. In embodiments, B is pyridyl, pyrimidyl, pyrazolyl, pyrrolyl, thiazolyl, oxazolyl, or imidazolyl. In embodiments, each of A and B is pyrazolyl. In embodiments, In embodiments, A is pyridyl or pyrimidyl. In embodiments, X1 is N. In embodiments, X2 is CR5 (e.g., CH). In embodiments, X2 is N. In embodiments, X2 is CR5 (e.g., CH). In embodiments, X3 is a covalent bond. In embodiments, X3 is O. In embodiments, X3 is S. In embodiments, X3 is NR6, C(O)NR6, NR6C(O), or NR6C(O)NR6. In embodiments, R6 is H. In embodiments, R6 is an N-protecting group (e.g., an amide group, a carbamate group, or a sulfonamide group). In embodiments, R6 is C1-6 alkyl. In embodiments, a C1-6 alkyl is unsubstituted. In embodiments, a C1-6 alkyl is substituted (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, X3 is (C(R7)2)q. In embodiments, q is 1. In embodiments, q is 2. In embodiments, R7 is H. In embodiments, R7 is C1-6 alkyl. In embodiments, a C1-6 alkyl is unsubstituted. In embodiments, a C1-6 alkyl is substituted (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, two R7 on the same carbon combine to from an oxo (=O) group. In embodiments, X3 is C(O), CH2, CHCH3, or C(CH3)2. In embodiments, X4 is a covalent bond. In embodiments, X4 is O. In embodiments, X4 is S. In embodiments, X4 is NR6, C(O)NR6, NR6C(O), or NR6C(O)NR6. In embodiments, R6 is H. In embodiments, R6 is an N-protecting group (e.g., an amide group, a carbamate group, or a sulfonamide group). In embodiments, R6 is C1-6 alkyl. In embodiments, a C1-6 alkyl is
unsubstituted. In embodiments, a C1-6 alkyl is substituted (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, X4 is (C(R7)2)q. In embodiments, q is 1. In embodiments, q is 2. In embodiments, R7 is H. In embodiments, R7 is C1-6 alkyl. In embodiments, a C1-6 alkyl is unsubstituted. In embodiments, a C1-6 alkyl is substituted (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, two R7 on the same carbon combine to from an oxo (=O) group. In embodiments, X4 is C(O), CH2, CHCH3, or C(CH3)2. In embodiments, X3 is O and X4 is O. In embodiments, X2 is CH, X3 is O, and X4 is O. In embodiments, X1 is N. In embodiments, R6 and R4, together with the atoms to which they are attached, form a 5- to 6-membered ring. In embodiments, a 5- to 6-membered ring has a structure of where the M ring is the newly-formed A
ring. In embodiments, L is a covalent bond. In embodiments, LA is an alkylene (e.g., -CH2-). In embodiments, an alkylene is unsubstituted. In embodiments, an alkylene is substituted (e.g., comprising 1 or 2 substituent groups). In embodiments, R7 and R4, together with the atoms to which they are attached, form a 5- to 6-membered ring. In embodiments, a 5- to 6-membered ring has a structure of where the M ring is the newly-formed ring. In embodiments, LA is a
covalent bond. In embodiments, LA is an alkylene (e.g., -CH2-). In embodiments, an alkylene is unsubstituted. In embodiments, an alkylene is substituted (e.g., comprising 1 or 2 substituent groups). In embodiments, X3 and X4 are the same. In embodiments, X3 and X4 are different. In embodiments, X3 and X4 are both O. In embodiments, L1 is a covalent bond.
In embodiments, L1 is a C1-6 heteroalkylene (e.g., comprises 1, 2, or 3 heteroatoms that are independently oxygen or nitrogen). In embodiments, L1 is a branched C1-6 heteroalkylene. In embodiments, L1 is a linear C1-6 heteroalkylene. In embodiments, L1 is unsubstituted C1-6 heteroalkylene. In embodiments, L1 is unsubstituted branched C1-6 heteroalkylene. In embodiments, L1 is unsubstituted linear C1-6 heteroalkylene. In embodiments, L1 is substituted C1-6 heteroalkylene (e.g., comprising 1, 2, or 3 substituent groups such as OH, oxo (=O), or unsubstituted C1-3 alkyl). In embodiments, L1 is substituted branched C1-6 heteroalkylene (e.g., comprising 1, 2, or 3 substituent groups such as OH, oxo (=O), or unsubstituted C1-3 alkyl). In embodiments, L1 is substituted linear C1-6 heteroalkylene (e.g., comprising 1, 2, or 3 substituent groups such as OH, oxo (=O), or unsubstituted C1-3 alkyl). In embodiments, a C1-6 heteroalkylene is -O(CH2)u-, - (CH2)uO-, -O(CH2)uO-, -OCH2OCH2CH2OCH2–, -CH2OCH2CH2O-, -OCH2CH2OCH2- , -NH(CH2)u-, - (CH2)uNH-, or -NH(CH2)uNH-, and wherein u is an integer of 1-4. In embodiments, u is 1. In embodiments, u is 2. In embodiments, u is 3. In embodiments, u is 4. In embodiments, L1 is a C1-6 alkylene (e.g., CH2, (CH2)2, (CH2)3, (CH2)4, (CH2)5, or (CH2)6). In embodiments, L1 is a branched C1-6 alkylene. In embodiments, L1 is a linear C1-6 alkylene. In embodiments, L1 is unsubstituted C1-6 alkylene. In embodiments, L1 is unsubstituted branched C1-6 alkylene. In embodiments, L1 is unsubstituted linear C1-6 alkylene. In embodiments, L1 is substituted C1-6 alkylene (e.g., comprising 1, 2, or 3 substituent groups such as OH, oxo (=O), or unsubstituted C1-3 alkyl). In embodiments, L1 is substituted branched C1-6 alkylene (e.g., comprising 1, 2, or 3 substituent groups such as OH, oxo (=O), or unsubstituted C1-3 alkyl). In embodiments, L1 is substituted linear C1-6 alkylene (e.g., comprising 1, 2, or 3 substituent groups such as OH, oxo (=O), or unsubstituted C1-3 alkyl). In embodiments, L1 is unsubstituted C1-6 alkylene. In embodiments, L1 is unsubstituted branched C2-6 alkylene. In embodiments, L1 is unsubstituted linear C2-6 alkylene. In embodiments, L1 is a C2-6 alkenylene (e.g., C2H4, C3H6, C4H8, C5H10, or C6H12). In embodiments, L1 is unsubstituted C2-6 alkenylene. In embodiments, L1 is substituted C2-6 alkenylene (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, L1 is a C2-6 alkynylene (e.g., C2H2, C3H4, C4H6, C5H8, or C6H10). In embodiments, L1 is unsubstituted C2-6 alkynylene. In embodiments, L1 is substituted C2-6 alkynylene (e.g., comprising 1, 2, or 3 substituent groups).
In embodiments, L1 is a C3-6 cycloalkylene (e.g., cyclopropylene, cyclobutylene, cyclopentylene, or cyclohexylene). In embodiments, L1 is unsubstituted C3-6 cycloalkylene. In embodiments, L1 is substituted C3-6 cycloalkylene (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, the sp3 carbon of a L1 group has the (R)-configuration. In embodiments, the sp3 carbon of a L1 group has the (S)-configuration. In embodiments, L1 is a 3- to 10-membered heterocyclylene (e.g., monocyclic or bicyclic heterocyclylene). In embodiments, L1 is unsubstituted 3- to 10-membered heterocyclylene. In embodiments, L1 is substituted 3- to 10-membered heterocyclylene (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, L1 is a phenylene or naphthylene. In embodiments, L1 is unsubstituted phenylene or unsubstituted naphthylene. In embodiments, L1 is substituted phenylene or substituted naphthylene (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, L1 is a 5- to 10-membered heteroarylene. In embodiments, L1 is unsubstituted 5- to 10-membered heteroarylene. In embodiments, L1 is substituted 5- to 10-membered heteroarylene (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, L1 is an unsubstituted linear C4-6 alkylene or an unsubstituted branched C4-6 alkylene. In embodiments, L1 is -(CH2)3-. In embodiments, L1 is -CH(CH3)CH2CH2-. In embodiments, L1 is
In embodiments, L1 is
where * denotes the point of covalent attachment to X4, and ** denotes the point of covalent attachment to X3. In embodiments, -X4-L1-X3- is -O-L1-O-. In embodiments, -X4-L1-X3- is -O(CH2)3O-. In embodiments, -X4-L1-X3- is -OCH(CH3)CH2CH2O-.
In embodiments, -X4-L1-X3- is
In embodiments, X4-L1-X3 forms or comprises a urea group (e.g., NHC(O)NH). In embodiments, X3 and/or X4 is NR6C(O)NR6. In embodiments, one of X3 and X4 is NR6C(O)NR6. In embodiments, X4-L1-X3 forms or comprises a carboxamide group (e.g., C(O)NH or NH(CO)). In embodiments, X3 and/or X4 is C(O)NR6 or NR6C(O). In embodiments, one of X3 and X4 is C(O)NR6 or NR6C(O). In embodiments, X4-L1-X3 is -CHR7-O(C1-2 alkylene)-OCHR7- or -CHR7-O(C1-2 alkylene)-O-. In embodiments, B is phenyl. In embodiments, B is naphthyl. In embodiments, B is 5- to 13- membered heteroaryl (e.g., monocyclic or bicyclic heteroaryl). In embodiments, B is a bicyclic 8- to 12-membered heteroaryl (e.g., nitrogen-containing, bicyclic 8- to 12-membered heteroaryl). In embodiments, B is a monocyclic 5- to 6-membered heteroaryl. Examplary monocyclic 5- to 6-membered heteroaryls include but are not limited to pyridyl, pyrimidyl, pyrazolyl, pyrrolyl, thiazolyl, oxazolyl, and imidazolyl. In embodiments, B is phenyl or 5- to 6-membered heteroaryl. In embodiments, B is phenyl, pyridyl, pyrimidyl, pyrazolyl, pyrrolyl, thiazolyl, oxazolyl, or imidazolyl. In embodiments, B is pyrazolyl. In embodiments, B is unsubstituted phenyl. In embodiments, B is unsubstituted naphthyl. In embodiments, B is unsubstituted 5- to 13-membered heteroaryl (e.g., unsubstituted monocyclic or bicyclic heteroaryl). In embodiments, B is unsubstituted bicyclic 8- to 12- membered heteroaryl (e.g., unsubstituted nitrogen-containing, bicyclic 8- to 12-membered heteroaryl). In embodiments, B is unsubstituted monocyclic 5- to 6-membered heteroaryls. In embodiments, B is unsubstituted pyridyl, unsubstituted pyrimidyl, unsubstituted pyrazolyl, unsubstituted pyrrolyl, unsubstituted thiazolyl, unsubstituted oxazolyl, or unsubstituted imidazolyl. In embodiments, B is substituted phenyl (e.g., comprising 1 or 2 substituents as described herein). In embodiments, B is substituted naphthyl (e.g., comprising 1 or 2 substituents as described herein). In embodiments, B is substituted 5- to 13-membered heteroaryl (e.g., substituted monocyclic or bicyclic heteroaryl comprising 1 or 2 substituents as described herein). B is substituted bicyclic 8- to 12-membered heteroaryl (e.g., substituted nitrogen-
containing, bicyclic 8- to 12-membered heteroaryl). In embodiments, B is substituted monocyclic 5- to 6-membered heteroaryls. In embodiments, B is substituted pyridyl, substituted pyrimidyl, substituted pyrazolyl, substituted pyrrolyl, substituted thiazolyl, substituted oxazolyl, or substituted imidazolyl. In embodiments, B is substituted pyrazolyl (e.g., N-substituted pyrazolyl such as N-methyl pyrazolyl). In embodiments, B is substituted with one or more R3 groups as described herein (e.g., methyl, halogen, or CN). In embodiments, B is
where * denotes the point of covalent attachment to C, and ** denotes the point of covalent attachment to X3. In embodiments, C is 5- or 6-membered heteroaryl. In embodiments, C is 5- or 6-membered N-containing heteroaryl. Examplary 5- or 6-membered heteroaryls include but are not limited to pyridyl, pyrimidyl, pyrazolyl, pyrrolyl, thiazolyl, oxazolyl, and imidazolyl. In embodiments, C is pyridyl or pyrimidyl. In embodiments, C is pyrazolyl or thiazolyl. In embodiments, C is unsubstituted 5- or 6-membered heteroaryl. In embodiments, C is unsubstituted 5- or 6-membered N-containing heteroaryl. Examplary unsubstituted 5- or 6-membered heteroaryls include but are not limited to unsubstituted pyridyl, unsubstituted pyrimidyl, unsubstituted pyrazolyl, unsubstituted pyrrolyl, unsubstituted thiazolyl, unsubstituted oxazolyl, and unsubstituted imidazolyl. In embodiments, C is unsubstituted pyridyl or pyrimidyl. In embodiments, C is unsubstituted pyrazolyl or thiazolyl. In embodiments, C is substituted 5- or 6-membered heteroaryl (e.g., comprising 1 or 2 substituents as described herein). In embodiments, C is substituted 5- or 6-membered N- containing heteroaryl (e.g., comprising 1 or 2 substituents as described herein). In embodiments, C is substituted pyridyl, substituted pyrimidyl, substituted pyrazolyl, substituted pyrrolyl, substituted thiazolyl, substituted oxazolyl, or substituted imidazolyl. In embodiments, C is substituted pyridyl (e.g., substituted with Substructure A). In embodiments, C is substituted pyrimidyl (e.g., substituted with Substructure A). In embodiments, C is substituted pyrazolyl (e.g., N-substituted pyrazolyl such as N-methyl pyrazolyl). In embodiments, C is substituted thiazolyl (e.g., methyl substituted thiazolyl). In embodiments, C is substituted with one or more R1 groups as described herein (e.g., Substructure A or methyl).
In embodiments, A is pyrazolyl, B is pyrazolyl, and C is pyridyl or pyrimidyl. In embodiments, A and B are substituted. In embodiments, m is 0. In embodiments, m is 1. In embodiments, m is 2. In embodiments, m is 1 or 2. In embodiments, m is not 0. In embodiments, R1 is present. In embodiments, R1 is
(Substructure A). In embodiments, L2 is independently a covalent bond, O, NRL, C(O), C(O)NRL, NRLC(O), CRL 2, wherein RL is independently H or C1-6 alkyl. In embodiments, RL is unsubstituted C1-6 alkyl. In embodiments, RL is substituted C1-6 alkyl (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, L2 is covalent bond. In embodiments, each R4 is independently H, OH, CN, halogen, C1-6 aliphatic, C1-6 alkoxy, NR8R9, C(O)R10, CO2R10, C(O)NR8R9, NR11C(O)R10, NR11CO2R10, NR11C(O)NR8R9, NR11(CH2)sNR8R9, (CH2)tNR8R9, or (CH2)rR12. In embodiments, p is 0. In embodiments, p is 1. In embodiments, p is 2. In embodiments, R4 is–LP-E. In embodiments, R4 is not –LP-E. In embodiments, R4 further comprises -LP-E. In embodiments, R1 is–LP-E. In embodiments, R1 is not –LP-E. In embodiments, R1 further comprises -LP-E. In embodiments, R1 is OH. In embodiments, R1 is CN. In embodiments, R1 is halogen (e.g., F, Cl, Br, or I). In embodiments, R1 is C1-6 aliphatic. In embodiments, R1 is unsubstituted C1-6 aliphatic. In embodiments, R1 is substituted C1-6 aliphatic (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R1 is C1-6 alkoxy. In embodiments, R1 is unsubstituted C1-6 alkoxy. In embodiments, R1 is substituted C1-6 alkoxy (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R1 is NR8R9. In embodiments, R1 is C(O)R10. In embodiments, R1 is CO2R10. In embodiments, R1 is C(O)NR8R9. In embodiments, R1 is NR11C(O)R10. In embodiments, R1 is NR11CO2R10. In embodiments, R1 is NR11C(O)NR8R9. In embodiments, R1 is (CH2)rR12. In embodiments, r is 0. In embodiments, r is 1. In embodiments, r is 2. In embodiments, r is 3. In embodiments, r is 4. In embodiments, r is 0 or 1. In embodiments, R1 is halogen (e.g., F, Cl, Br, or I). In embodiments, n is 0. In embodiments, n is 1. In embodiments, n is 2. In embodiments, n is 1 or 2.
In embodiments, n is not 0. In embodiments, R2 is present. In embodiments, R2 is
(Substructure A). In embodiments, L2 is independently a covalent bond, O, NRL, C(O), C(O)NRL, NRLC(O), CRL2, wherein RL is independently H or C1-6 alkyl. In embodiments, RL is unsubstituted C1-6 alkyl. In embodiments, RL is substituted C1-6 alkyl (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, L2 is covalent bond. In embodiments, each R4 is independently H, OH, CN, halogen, C1-6 aliphatic, C1-6 alkoxy, NR8R9, C(O)R10, CO2R10, C(O)NR8R9, NR11C(O)R10, NR11CO2R10, NR11C(O)NR8R9, NR11(CH2)sNR8R9, (CH2)tNR8R9, or (CH2)rR12. In embodiments, p is 0. In embodiments, p is 1. In embodiments, p is 2. In embodiments, R4 is–LP-E. In embodiments, R4 is not –LP-E. In embodiments, R4 further comprises -LP-E. In embodiments, R2 is–LP-E. In embodiments, R2 is not –LP-E. In embodiments, R2 further comprises -LP-E. In embodiments, R2 is OH. In embodiments, R2 is CN. In embodiments, R2 is halogen (e.g., F, Cl, Br, or I). In embodiments, R2 is C1-6 aliphatic. In embodiments, R2 is unsubstituted C1-6 aliphatic. In embodiments, R2 is substituted C1-6 aliphatic (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R2 is C1-6 alkoxy. In embodiments, R2 is unsubstituted C1-6 alkoxy. In embodiments, R2 is substituted C1-6 alkoxy (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R2 is NR8R9. In embodiments, R2 is C(O)R10. In embodiments, R2 is CO2R10. In embodiments, R2 is C(O)NR8R9. In embodiments, R2 is NR11C(O)R10. In embodiments, R2 is NR11CO2R10. In embodiments, R2 is NR11C(O)NR8R9. In embodiments, R2 is (CH2)rR12. In embodiments, r is 0. In embodiments, r is 1. In embodiments, r is 2. In embodiments, r is 3. In embodiments, r is 4. In embodiments, r is 0 or 1. In embodiments, R2 is halogen (e.g., F, Cl, Br, or I). In embodiments, R1 is present. In embodiments, R2 is present. In embodiments, one of R1 and R2 is present. In embodiments, one of R1 and R2 is present and is Substructure A (
) or halogen (e.g., F, Cl, Br, or I). In embodiments, one of R1 and R2 is present and is Substructure A (
). In embodiments, two R1 or two R2, together to which the atoms they are attached form a 5- to 10-membered ring (e.g., 5- to 10-membered carbocyclic, heterocyclic, aryl, or heteroaryl ring). In embodiments, o is 0. In embodiments, o is 1. In embodiments, o is 2. In embodiments, o is 1 or 2. In embodiments, o is 0 or 1. In embodiments, o is not 0. In embodiments, R3 is present. In embodiments, R3 is OH. In embodiments, R3 is CN. In embodiments, R3 is halogen (e.g., F, Cl, Br, or I). In embodiments, R3 is C1-6 aliphatic. In embodiments, R3 is unsubstituted C1-6 aliphatic. In embodiments, R3 is substituted C1-6 aliphatic (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R3 is C1-6 alkoxy. In embodiments, R3 is unsubstituted C1-6 alkoxy. In embodiments, R3 is substituted C1-6 alkoxy (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R3 is NR8R9. In embodiments, R3 is C(O)R10. In embodiments, R3 is CO2R10. In embodiments, R3 is C(O)NR8R9. In embodiments, R3 is NR11C(O)R10. In embodiments, R3 is NR11CO2R10. In embodiments, R3 is NR11C(O)NR8R9. In embodiments, R3 is (CH2)rR12. In embodiments, r is 0. In embodiments, r is 1. In embodiments, r is 2. In embodiments, r is 3. In embodiments, r is 4. In embodiments, r is 0 or 1. In embodiments, R3 is methyl, halogen, or CN. In embodiments, R3 is methyl. In embodiments, R5 is H. In embodiments, R5 is OH. In embodiments, R5 is CN. In embodiments, R5 is halogen (e.g., F, Cl, Br, or I). In embodiments, R5 is C1-6 aliphatic. In embodiments, R5 is unsubstituted C1-6 aliphatic. In embodiments, R5 is substituted C1-6 aliphatic (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R5 is C1-6 alkoxy. In embodiments, R5 is unsubstituted C1-6 alkoxy. In embodiments, R5 is substituted C1-6 alkoxy (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R5 is NR8R9. In embodiments, R5 is C(O)R10. In embodiments, R5 is CO2R10. In embodiments, R5 is C(O)NR8R9. In embodiments, R5 is NR11C(O)R10. In embodiments, R5 is NR11CO2R10. In embodiments, R5 is NR11C(O)NR8R9.
In embodiments, R5 is (CH2)rR12. In embodiments, r is 0. In embodiments, r is 1. In embodiments, r is 2. In embodiments, r is 3. In embodiments, r is 4. In embodiments, r is 0 or 1. In embodiments, R8 is H. In embodiments, R8 is C1-6 alkyl. In embodiments, a C1-6 alkyl is unsubstituted. In embodiments, a C1-6 alkyl is substituted (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R9 is H. In embodiments, R9 is C1-6 alkyl. In embodiments, a C1-6 alkyl is unsubstituted. In embodiments, a C1-6 alkyl is substituted (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R11 is H. In embodiments, R11 is C1-6 alkyl. In embodiments, a C1-6 alkyl is unsubstituted. In embodiments, a C1-6 alkyl is substituted (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R8 and R9, together with the nitrogen atom to which they are attached, form a 3- to 10-membered heterocyclyl. In embodiments, a 3- to 10-membered heterocyclyl is unsubstituted. In embodiments, a 3- to 10-membered heterocyclyl is unsubstituted (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R8 and R11, together with the atoms to which they are attached, form a 3- to 10-membered heterocyclyl. In embodiments, a 3- to 10-membered heterocyclyl is unsubstituted. In embodiments, a 3- to 10-membered heterocyclyl is unsubstituted (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R10 is C1-6 aliphatic. In embodiments, R10 is C3-C10 cycloaliphatic (e.g., monocyclic or bicyclic cycloaliphatic). In embodiments, R10 is 3- to 10-membered heterocyclyl (e.g., monocyclic or bicyclic heterocyclyl). In embodiments, R10 is phenyl. In embodiments, R10 is naphthyl. In embodiments, R10 is 5- to 12-membered heteroaryl (e.g., monocyclic or bicyclic heteroaryl). In embodiments, R10 is unsubstituted C1-6 aliphatic. In embodiments, R10 is unsubstituted C3- C10 cycloaliphatic. In embodiments, R10 is unsubstituted 3- to 10-membered heterocyclyl. In embodiments, R10 is unsubstituted phenyl. In embodiments, R10 is unsubstituted naphthyl. In embodiments, R10 is unsubstituted 5- to 12-membered heteroaryl. In embodiments, R10 is substituted C1-6 aliphatic. In embodiments, R10 is substituted C3-C10 cycloaliphatic. In embodiments, R10 is substituted 3- to 10-membered heterocyclyl. In
embodiments, R10 is substituted phenyl. In embodiments, R10 is substituted naphthyl. In embodiments, R10 is substituted 5- to 12-membered heteroaryl. In embodiments, a substituted group comprises 1, 2, or 3 substituent groups as described herein. In embodiments, R10 and R11, together with the atoms to which they are attached, form a 3- to 10-membered heterocyclyl. In embodiments, a 3- to 10-membered heterocyclyl is unsubstituted. In embodiments, a 3- to 10-membered heterocyclyl is substituted (e.g., comprising 1, 2, or 3 substituent groups). In embodiments, R12 is C3-C10 cycloaliphatic (e.g., monocyclic or bicyclic cycloaliphatic). In embodiments, R12 is 3- to 10-membered heterocyclyl (e.g., monocyclic or bicyclic heterocyclyl). In embodiments, R12 is phenyl. In embodiments, R12 is naphthyl. In embodiments, R12 is 5- to 12-membered heteroaryl (e.g., monocyclic or bicyclic heteroaryl). In embodiments, R12 is unsubstituted C3-C10 cycloaliphatic. In embodiments, R12 is unsubstituted 3- to 10-membered heterocyclyl. In embodiments, R12 is unsubstituted phenyl. In embodiments, R12 is unsubstituted naphthyl. In embodiments, R12 is unsubstituted 5- to 12- membered heteroaryl. In embodiments, R12 is substituted C3-C10 cycloaliphatic. In embodiments, R12 is substituted 3- to 10-membered heterocyclyl. In embodiments, R12 is substituted phenyl. In embodiments, R12 is substituted naphthyl. In embodiments, R12 is substituted 5- to 12-membered heteroaryl. In embodiments, a substituted group comprises 1, 2, or 3 substituent groups as described herein. [0154] In embodiments, a compound of the invention comprising a Class C ligand has a structure selected from the following formulas selected from Table C1. In embodiments, an E moiety is selected from those described in Table D, where
shows the point of covalent attachment to moiety LP. In embodiments, -LP-E is according to any of substructures (D1)-
(D49) as described herein. In embodiments, -LP-E is according to any of substructures (D1)’- (D49)’ as described herein. Table C1. Exemplary Formulas Comprising Class C Ligands
or a pharmaceutically acceptable salt thereof, wherein R4A is a first R4 group, R4B is a second R4 group, R4C is a third R4 group, R4D is a fourth R4 group, preferably R4 is unsubstituted C1-6 alkyl if one or more of R4A, R4B, and R4C is also present; and p is 0 or 1. [0155] In embodiments, the compound comprises a ligand formed from any one Compounds (1)-(169) of PCT/US22/28755, or a pharmaceutically acceptable salt thereof. [0156] In embodiments, the compound comprises a ligand derived from any one of Compounds (1)-(169) of PCT/US22/28755, or a pharmaceutically acceptable salt thereof. In embodiments, the compound of PCT/US22/28755 is modified to include a piperazine- or piperazine-containing group covalently attached to the -LP-E group as described herein. [0157] In embodiments, the compound is selected from any of the following compounds of Table C2 and C3, or a pharmaceutically acceptable salt thereof. In embodiments, an E moiety is selected from those described in Table D, where
shows the point of covalent
attachment to moiety LP. In embodiments, -LP-E is according to any of substructures (D1)- (D49) as described herein. Table C2. Exemplary Compounds Comprising Class C Ligands
Exemplary LP and E Groups [0158] Exemplary linkers (LP) and E3 ubiquitin ligase ligands (E) suitable for inclusion in the compounds of the invention include any known in the art. Exemplary structures for LP and/or E include those described in the below, each of which is incorporated by reference in its entirety. [0159] In embodiments, a linker LP is a covalent bond. [0160] In embodiments, a linker LP comprises a heterocycyl directly attached to the Ligand or attached to Ligand via a methylene (CH2) moiety. In embodiments, a linker LP comprises a substructure F1
or a substructure F2
where * indicates the point of covalent attachment to the Ligand. [0161] In embodiments, a linker LP comprises a C1-C20 alkylene. [0162] In embodiments, a linker LP is a C1-C20 alkylene. [0163] In embodiments, a linker LP comprises an unsubstituted C1-C20 alkylene. In embodiments, a linker LP comprises an unsubstituted C2-C10 alkylene. In embodiments, a linker LP comprises an unsubstituted, linear C2-C10 alkylene. In embodiments, a linker LP is comprises unsubstituted C3-C10 alkylene. [0164] In embodiments, a linker LP is an unsubstituted C1-C20 alkylene. In embodiments, a linker LP is an unsubstituted C2-C10 alkylene. In embodiments, a linker LP is an unsubstituted, linear C2-C10 alkylene. In embodiments, a linker LP is an unsubstituted C3-C10 alkylene. [0165] In embodiments, a linker LP comprises a C1-C20 alkylene comprising an oxo (=O) substituent (e.g., a C1-C20 alkylene comprising 1, 2, or 3 oxo (=O) substituents as valency permits). [0166] In embodiments, a linker LP is a C1-C20 alkylene comprising an oxo (=O) substituent (e.g., a C1-C20 alkylene comprising 1, 2, or 3 oxo (=O) substituents as valency permits). [0167] In embodiments, a linker LP comprises a C2-C20 heteroalkylene. [0168] In embodiments, a linker LP is a C2-C20 heteroalkylene. [0169] In embodiments, a linker LP comprises an unsubstituted C2-C20 heteroalkylene. In embodiments, a linker LP comprises an unsubstituted C2-C10 heteroalkylene. In embodiments,
a linker LP comprises an unsubstituted, linear C2-C10 heteroalkylene. In embodiments, a linker LP comprises an unsubstituted C3-C10 heteroalkylene. [0170] In embodiments, a linker LP is an unsubstituted C2-C20 heteroalkylene. In embodiments, a linker LP is an unsubstituted C2-C10 heteroalkylene. In embodiments, a linker LP is an unsubstituted, linear C2-C10 heteroalkylene. In embodiments, a linker LP is an unsubstituted C3-C10 heteroalkylene. [0171] In embodiments, a linker LP comprises a C2-C20 heteroalkylene comprising an oxo (=O) substituent (e.g., a C2-C20 heteroalkylene comprising 1, 2, or 3 oxo (=O) substituents as valency permits). [0172] In embodiments, a linker LP is a C2-C20 heteroalkylene comprising an oxo (=O) substituent (e.g., a C2-C20 heteroalkylene comprising 1, 2, or 3 oxo (=O) substituents as valency permits). [0173] In embodiments, a linker LP comprises a C2-C20 monoalkynylene. [0174] In embodiments, a linker LP is a C2-C20 monoalkynylene. [0175] In embodiments, a linker LP comprises an unsubstituted C2-C20 monoalkynylene. In embodiments, a linker LP comprises an unsubstituted C2-C10 monoalkynylene. In embodiments, a linker LP comprises an unsubstituted, linear C2-C10 monoalkynylene. In embodiments, a linker LP comprises an unsubstituted, branched C4-C10 monoalkynylene. [0176] In embodiments, a linker LP is an unsubstituted C2-C20 monoalkynylene. In embodiments, a linker LP is an unsubstituted C2-C10 monoalkynylene. In embodiments, a linker LP is an unsubstituted, linear C2-C10 monoalkynylene. In embodiments, a linker LP is an unsubstituted, branched C4-C10 monoalkynylene. [0177] In embodiments, a linker LP comprises a C3-C20 monoalkynylene comprising an oxo (=O) substituent (e.g., a C3-C20 heteroalkylene comprising 1, 2, or 3 oxo (=O) substituents as valency permits). [0178] In embodiments, a linker LP is a C3-C20 monoalkynylene comprising an oxo (=O) substituent (e.g., a C3-C20 monoalkynylene comprising 1, 2, or 3 oxo (=O) substituents as valency permits). [0179] In embodiments, a linker LP comprises one or more ethyleneglycol moieties. In embodiments, a linker LP comprises 1, 2, 3, 4, or 5 ethyleneglycol repeating units. In
embodiments, a linker LP further comprises an oxo (=O) subsitutent (e.g., comprising 1, 2, or 3 oxo (=O) substituents as valency permits). [0180] In embodiments, a linker LP comprises (1) an alkylene moiety (CH2), (CH2)2, (CH2)3, (CH2)4, (CH2)5, (CH2)6, (CH2)7, (CH2)8, (CH2)9, or (CH2)10; and (2) substructure F1 or substructure F2. [0181] In embodiments, a linker LP is (CH2), (CH2)2, (CH2)3, (CH2)4, (CH2)5, (CH2)6, (CH2)7, (CH2)8, (CH2)9, or (CH2)10. [0182] In embodiments, a linker LP comprises –O(CH2CH2O)2(CH2)2-, -O(CH2CH2O)(CH2)2-, -O(CH2CH2O)3(CH2)2-, -O(CH2CH2O)4(CH2)2-, or -O(CH2CH2O)5(CH2)2-. [0183] In embodiments, a linker LP comprises (1) –O(CH2CH2O)2(CH2)2-, -O(CH2CH2O)(CH2)2-, -O(CH2CH2O)3(CH2)2-, -O(CH2CH2O)4(CH2)2-, or -O(CH2CH2O)5(CH2)2-; and (2) substructure F1 or substructure F2. [0184] In embodiments, a linker LP is –O(CH2CH2O)2(CH2)2-, -O(CH2CH2O)(CH2)2-, -O(CH2CH2O)3(CH2)2-, -O(CH2CH2O)4(CH2)2-, or -O(CH2CH2O)5(CH2)2-. [0185] In embodiments, a linker LP comprises –O(CH2CH2O)CH2C(O)-, –O(CH2CH2O)2CH2C(O)-, –O(CH2CH2O)3CH2C(O)-, –O(CH2CH2O)4CH2C(O)-, or – O(CH2CH2O)5CH2C(O)-. [0186] In embodiments, a linker LP comprises: (1) –O(CH2CH2O)CH2C(O)-, –O(CH2CH2O)2CH2C(O)-, –O(CH2CH2O)3CH2C(O)-, –O(CH2CH2O)4CH2C(O)-, or – O(CH2CH2O)5CH2C(O)-; and (2) substructure F1 or substructure F2. [0187] In embodiments, a linker LP is –O(CH2CH2O)CH2C(O)-, –O(CH2CH2O)2CH2C(O)-, –O(CH2CH2O)3CH2C(O)-, –O(CH2CH2O)4CH2C(O)-, or – O(CH2CH2O)5CH2C(O)-. [0188] In embodiments, a linker LP comprises -NHC(O)CH2O(CH2CH2O)(CH2)2-, -NHC(O)CH2O(CH2CH2O)2(CH2)2-, -NHC(O)CH2O(CH2 CH2O)3(CH2)2-, -NHC(O)CH2O(CH2CH2O)4(CH2)2-, or -NHC(O)CH2O(CH2CH2O)5(CH2)2-. [0189] In embodiments, a linker LP comprises: (1) -NHC(O)CH2O(CH2CH2O)(CH2)2-, -NHC(O)CH2O(CH2CH2O)2(CH2)2-, -NHC(O)CH2O(CH2
CH2O)3(CH2)2-, -NHC(O)CH2O(CH2CH2O)4(CH2)2-, or -NHC(O)CH2O(CH2CH2O)5(CH2)2-; and (2) substructure F1 or substructure F2. [0190] In embodiments, a linker LP is -NHC(O)CH2O(CH2CH2O)(CH2)2-, -NHC(O)CH2O(CH2CH2O)2(CH2)2-, -NHC(O)CH2O(CH2 CH2O)3(CH2)2-, -NHC(O)CH2O(CH2CH2O)4(CH2)2-, or -NHC(O)CH2O(CH2CH2O)5(CH2)2-. [0191] In embodiments, a linker LP comprises -NHC(O)CH2O(CH2CH2O)(CH2)2C(O)-, -NHC(O)CH2O(CH2CH2O)2(CH2)2C(O)-, -NHC(O) CH2O(CH2CH2O)3(CH2)2C(O)-, -NHC(O)CH2O(CH2CH2O)4(CH2)2C(O)-, or -NHC(O)CH2O(CH2CH2O)5(CH2)2C(O)-. [0192] In embodiments, a linker LP comprises (1) -NHC(O)CH2O(CH2CH2O)(CH2)2C(O)-, -NHC(O)CH2O(CH2CH2O)2(CH2)2C(O)-, -NHC(O) CH2O(CH2CH2O)3(CH2)2C(O)-, -NHC(O)CH2O(CH2CH2O)4(CH2)2C(O)-, or -NHC(O)CH2O(CH2CH2O)5(CH2)2C(O)-; and (2) substructure F1 or substructure F2. [0193] In embodiments, a linker LP is: -NHC(O)CH2O(CH2CH2O)(CH2)2C(O)-, -NHC(O)CH2O(CH2CH2O)2(CH2)2C(O)-, -NHC(O) CH2O(CH2CH2O)3(CH2)2C(O)-, -NHC(O)CH2O(CH2CH2O)4(CH2)2C(O)-, or -NHC(O)CH2O(CH2CH2O)5(CH2)2C(O)-. [0194] In embodiments, a linker LP comprises –NH(CH2)C(O)-, -NH(CH2)2C(O)-, -NH(CH2)3C(O)-, -NH(CH2)4C(O)-, or -NH(CH2)5C(O)-. [0195] In embodiments, a linker LP comprises: (1) –NH(CH2)C(O)-, -NH(CH2)2C(O)-, -NH(CH2)3C(O)-, -NH(CH2)4C(O)-, or -NH(CH2)5C(O)-; and (2) substructure F1 or substructure F2. [0196] In embodiments, a linker LP is –NH(CH2)C(O)-, -NH(CH2)2C(O)-, -NH(CH2)3C(O)-, -NH(CH2)4C(O)-, or -NH(CH2)5C(O)-. [0197] In embodiments, a linker LP comprises -(NHCH2C(O)NH)(CH2)(NHCH2C(O)-, -(NHCH2C(O)NH)(CH2)2(NHCH2C(O)-, - (NHCH2C(O)NH)(CH2)3(NHCH2C(O)-, -(NHCH2C(O)NH)(CH2)4(NHCH2C(O)-, or -(NHCH2C(O)NH)(CH2)5(NHCH2C(O)-. [0198] In embodiments, a linker LP comprises: (1) -(NHCH2C(O)NH)(CH2)(NHCH2C(O)-, -(NHCH2C(O)NH)(CH2)2(NHCH2C(O)-, -(NHC
H2C(O)NH)(CH2)3(NHCH2C(O)-, -(NHCH2C(O)NH)(CH2)4(NHCH2C(O)-, or -(NHCH2C(O)NH)(CH2)5(NHCH2C(O)-; and (2) substructure F1 or substructure F2. [0199] In embodiments, a linker LP is -(NHCH2C(O)NH)(CH2)(NHCH2C(O)-, -(NHCH2C(O)NH)(CH2)2(NHCH2C(O)-, -(NHCH2 C(O)NH)(CH2)3(NHCH2C(O)-, -(NHCH2C(O)NH)(CH2)4(NHCH2C(O)-, or -(NHCH2C(O)NH)(CH2)5(NHCH2C(O)-. [0200] In embodiments, a linker LP comprises –NH(CH2)C(O)-, -NH(CH2)2C(O)-, -NH(CH2)3C(O)-, -NH(CH2)4C(O)-, or -NH(CH2)5C(O)-. [0201] In embodiments, a linker LP comprises: (1) –NH(CH2)C(O)-, -NH(CH2)2C(O)-, -NH(CH2)3C(O)-, -NH(CH2)4C(O)-, or -NH(CH2)5C(O)-; and (2) substructure F1 or substructure F2. [0202] In embodiments, a linker LP is –NH(CH2)C(O)-, -NH(CH2)2C(O)-, -NH(CH2)3C(O)-, -NH(CH2)4C(O)-, or -NH(CH2)5C(O)-. [0203] In embodiments, a linker LP comprises -NHC(O)CH2O(CH2)2C(O)-, -NHC(O)CH2O(CH2)3C(O)-, -NHC(O)CH2O(CH2)4C (O)-, -NHC(O)CH2O(CH2)5C(O)-, or -NHC(O)CH2O(CH2)6C(O)-. [0204] In embodiments, a linker LP comprises: (1) -NHC(O)CH2O(CH2)2C(O)-, -NHC(O)CH2O(CH2)3C(O)-, -NHC(O)CH2O(CH2)4C(O)-, - NHC(O)CH2O(CH2)5C(O)-, or -NHC(O)CH2O(CH2)6C(O)-; and (2) substructure F1 or substructure F2. [0205] In embodiments, a linker LP is -NHC(O)CH2O(CH2)2C(O)-, -NHC(O)CH2O(CH2)3C(O)-, -NHC(O)CH2O(CH2)4C(O)-, -N HC(O)CH2O(CH2)5C(O)-, or -NHC(O)CH2O(CH2)6C(O)-. [0206] In embodiments, a linker LP comprises -≡-(CH2)-, -≡-(CH2)2-, -≡-(CH2)3-, -≡-(CH2)4-, -≡-(CH2)5-, -≡-(CH2)6, -≡-(CH2)7, or -≡-(CH2)8. [0207] In embodiments, a linker LP comprises: (1) -≡-(CH2)-, -≡-(CH2)2-, -≡-(CH2)3-, -≡-(CH2)4-, -≡-(CH2)5-, -≡-(CH2)6, -≡-(CH2)7, or -≡-(CH2)8; and (2) substructure F1 or substructure F2. [0208] In embodiments, a linker LP is -≡-(CH2)-, -≡-(CH2)2-, -≡-(CH2)3-, -≡-(CH2)4-, -≡-(CH2)5-, -≡-(CH2)6, -≡-(CH2)7, or -≡-(CH2)8.
[0209] In embodiments, a linker LP comprises -≡-(CH2)OCH2CH2OCH2C(O)-, -≡-(CH2)NHCH2CH2NHCH2C(O)-, or -≡-(CH2)OCH2CH2NHC(O)CH2-. [0210] In embodiments, a linker LP comprises: (1) -≡-(CH2)OCH2CH2OCH2C(O)-, -≡-(CH2)NHCH2CH2NHCH2C(O)-, or -≡-(CH2)OCH2CH2NHC(O)CH2-; and (2) substructure F1 or substructure F2. [0211] In embodiments, a linker LP is -≡-(CH2)OCH2CH2OCH2C(O)-, -≡-(CH2)NHCH2CH2NHCH2C(O)-, or -≡-(CH2)OCH2CH2NHC(O)CH2-. [0212] In embodiments, an E moiety is selected from those described in Table D, where
shows the point of covalent attachment to moiety LP. Table D. Exemplary E Moieties
[0213] In embodiments, an LP-E moiety is selected from those described in Table E1. Table E1. Exemplary LP-E Moieties
[0214] In embodiments, an LP-E moiety is selected from those described in Table E2.
Table E2. Exemplary LP-E Moieties
[0215] In embodiments, an LP-E moiety is selected from those described in Table E3. Table E3. Exemplary LP-E Moieties
Additional Exemplary LP-E Moieties [0216] In certain embodiments, an LP-E moiety comprises, corresponds to, or is derived from that present in ARV-110, ARV-471, AC682, ARV-766, CC-94676, DT2216, FHD-609, KT- 474, KT-413, KT-333, NX-2127, NX-5948, CFT8634, CFT8919, or CG001419, including any fragments thereof. In certain embodiments, an LP-E moiety comprises, corresponds to, or is derived from that present in BGB-16673, HK29116, LNK-01002, AC682, HP618, or GT- 20029, including fragments thereof. Exemplary Group 1 [0217] In certain embodiments, LP-E moieties include any of those described in WO2021121261, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described at pages 28-30 of WO2021121261. [0218] In certain embodiments, LP-E moieties include any of those described in US20190106417, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0219] In certain embodiments, LP-E moieties include any of those described in WO2018119441, which is incorporated herein by reference in its entirety, as well any moieties
corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0220] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in WO2022047145A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0221] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20220259154A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0222] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20220162163A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0223] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20220144809A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0224] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20220127279A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0225] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20220089570A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
[0226] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20210187108A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0227] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20210145832A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0228] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20210040081A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0229] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20200392131A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0230] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20200155690A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0231] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20180346461A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0232] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20180237418A1, which is incorporated herein by reference in its entirety, as
well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0233] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20180193470, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0234] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20180155322A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0235] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20180147202A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0236] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20180072711A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0237] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20170327469A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0238] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20160272639A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E
comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0239] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20160214972A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0240] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20160058872A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0241] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20160045607A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0242] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20210220475A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0243] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20180193470A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, E
comprises, corresponds to, or is derived from a moiety described therein (e.g., those described at paragraphs [0654]-[0953] of US20180193470A1such as Formulas (a)-(f):
wherein: W of Formulas (a) through (e) is independently selected from the group CH2, CHR, C═O, SO2, NH, and N-alkyl; X of Formulas (a) through (e) is independently selected from the group O, S and H2; Y of Formulas (a) through (e) is independently selected from the group CH2, —C═CR′, NH, N-alkyl, N-aryl, N-hetaryl, N-cycloalkyl, N-heterocyclyl, O, and S; Z of Formulas (a) through (e) is independently selected from the group O, and S or H2 except that both X and Z cannot be H2; G and G′ of Formulas (a) through (e) are independently selected from the group H, alkyl (linear, branched, optionally substituted), OH, R′OCOOR,
R′OCONRR″, CH2-heterocyclyl optionally substituted with R′, and benzyl optionally substituted with R′; Q1-Q4 of Formulas (a) through (e) represent a carbon C substituted with a group independently selected from R′, N or N-oxide; A of Formulas (a) through (e) is independently selected from the group H, alkyl (linear, branched, optionally substituted), cycloalkyl, Cl and F; R of Formulas (a) through (e) comprises, but is not limited to: —CONR′R″, — OR′, —NR′R″, —SR′, —SO2R′, —SO2NR′R″, —CR′R″—, —CR′NR′R″—, —aryl, —hetaryl, —alkyl, —cycloalkyl, —heterocyclyl, —P(O)(OR′)R″, —P(O)R′R″, — OP(O)(OR′)R″, —OP(O)R′R″, —Cl, —F, —Br, —I, —CF3, —CN, — NR′SO2NR′R″, —NR′CONR′R″, —CONR′COR″, —NR′C(═N—CN)NR′R″, — C(═N—CN)NR′R″, —NR′C(═N—CN)R″, —NR′C(═C—NO2)NR′R″, — SO2NR′COR″, —NO2, —CO2R′, —C(C═N—OR′)R″, —CR′═CR′R″, —CCR′, — S(C═O)(C═N—R′)R″, —SF5 and —OCF3 R′ and R″ of Formulas (a) through (e) are independently selected from a bond, H, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclic, —C(═O)R, heterocyclyl, each of which is optionally substituted; n of Formulas (a) through (e) is an integer from 1-10; of Formulas (a) through (e) represents a bond that may be stereospecific ((R) or (S)) or non-stereospecific; and Rn of Formulas (a) through (e) comprises 1-4 independent functional groups or atoms, for example, O, N or S, and optionally, one of which is modified to be covalently joined to a PTM, a chemical linker group (L), a ULM, CLM (or CLM′) or combination thereof. [0244] In embodiments, LP comprises, corresponds to, or is derived from a moiety described therein (e.g., those described at paragraphs [0954]-[0993] of US20180193470A1, include those described at paragraphs [0969]-[0977], particularly those described at paragraphs [0975]-[0977]). For example, a linker LP may be described by: one or more covalently connected structural units (e.g., —AL 1... (AL)q- or -(AL)q-), wherein A1 is a group coupled to the ligand moiety, and (AL)q is a group coupled to the E moiety. [0245] In certain embodiments, the linker group L is selected from -(AL)q-, wherein
(AL)q is a group which is connected to at least one of a ULM, a PTM moiety, or a combination thereof; q of the linker is an integer greater than or equal to 1; each AL q is independently selected from the group consisting of, a bond, CRL1RL2, O, S, SO, SO2, NRL3, SO2NRL3, SONRL3, CONRL3, NRL3CONRL4, NRL3SO2NRL4, CO, CRL1═CRL2, C≡C, SiRL1RL2, P(O)RL1, P(O)ORL1, NRL3C(═NCN)NRL4, NRL3C(═NCN), NRL3C(═CNO2)NRL4, C3-11cycloalkyl optionally substituted with 0-6 RL1 and/or RL2 groups, C5-13 spirocycloalkyl optionally substituted with 0-9 RL1 and/or RL2 groups, C3-11heterocyclyl optionally substituted with 0-6 RL1 and/or RL2 groups, C5-13 spiroheterocycloalkyl optionally substituted with 0-8 RL1 and/or RL2 groups, aryl optionally substituted with 0-6 RL1 and/or RL2 groups, heteroaryl optionally substituted with 0-6 RL1 and/or RL2 groups, where RL1 or RL2, each independently are optionally linked to other groups to form cycloalkyl and/or heterocyclyl moiety, optionally substituted with 0-4 RL5 groups; and RL1, RL2, RL3, RL and RL5 are, each independently, H, halo, C1-8alkyl, OC1- 8alkyl, SC1-8alkyl, NHC1-8alkyl, N(C1-8alkyl)2, C3-11cycloalkyl, aryl, heteroaryl, C3- 11heterocyclyl, OC1-8cycloalkyl, SC1-8cycloalkyl, NHC1-8cycloalkyl, N(C1- 8cycloalkyl)2, N(C1-8cycloalkyl)(C1-8alkyl), OH, NH2, SH, SO2C1-8alkyl, P(O)(OC1- 8alkyl)(C1-8alkyl), P(O)(OC1-8alkyl)2, CC—C1-8alkyl, CCH, CH═CH(C1-8alkyl), C(C1- 8alkyl)═CH(C1-8alkyl), C(C1-8alkyl)═C(C1-8alkyl)2, Si(OH)3, Si(C1-8alkyl)3, Si(OH)(C1- 8alkyl)2, COC1-8alkyl, CO2H, halogen, CN, CF3, CHF2, CH2F, NO2, SF5, SO2NHC1- 8alkyl, SO2N(C1-8alkyl)2, SONHC1-8alkyl, SON(C1-8alkyl)2, CONHC1-8alkyl, CON(C1- 8alkyl)2, N(C1-8alkyl)CONH(C1-8alkyl), N(C1-8alkyl)CON(C1-8alkyl)2, NHCONH(C1- 8alkyl), NHCON(C1-8alkyl)2, NHCONH2, N(C1-8alkyl)SO2NH(C1-8alkyl), N(C1-8alkyl) SO2N(C1-8alkyl)2, NH SO2NH(C1-8alkyl), NH SO2N(C1-8alkyl)2, NH SO2NH2. [0246] In certain embodiments, q of the linker is an integer greater than or equal to 0. In certain embodiments, q is an integer greater than or equal to 1. [0247] In certain embodiments, e.g., where q of the linker is greater than 2, (AL)q is a group which is connected to ULM, and AL 1 and (AL)q are connected via structural units of the linker (L). [0248] In certain embodiments, e.g., where q of the linker is 2, (AL)q is a group which is connected to AL 1 and to a ULM.
[0249] In certain embodiments, e.g., where q of the linker is 1, the structure of the linker group L is -AL 1-, and AL 1 is a group which is connected to a ULM moiety and a PTM moiety. [0250] In certain embodiments, the linker (L) comprises a group represented by a general structure selected from the group consisting of: —NR(CH2)n-(lower alkyl)-, —NR(CH2)n-(lower alkoxyl)-, —NR(CH2)n- (lower alkoxyl)-OCH2—, —NR(CH2)n-(lower alkoxyl)-(lower alkyl)-OCH2—, — NR(CH2)n-(cycloalkyl)-(lower alkyl)-OCH2-, —NR(CH2)n-(hetero cycloalkyl)-, — NR(CH2CH2O)n-(lower alkyl)-O—CH2—, NR(CH2CH2O)n-(hetero cycloalkyl)-O— CH2—, —NR(CH2CH2O)n—Aryl-O—CH2—, —NR(CH2CH2O)n-(hetero aryl)-O— CH2—, —NR(CH2CH2O)n-(cyclo alkyl)-O-(hetero aryl)-O—CH2—, — NR(CH2CH2O)n-(cyclo alkyl)-O-Aryl-O—CH2—, —NR(CH2CH2O)n-(lower alkyl)- NH-Aryl-O—CH2—, NR(CH2CH2O)n-(lower alkyl)-O-Aryl-CH2, —NR(CH2CH2O)n- cycloalkyl-O-Aryl-, NR(CH2CH2O)n-cycloalkyl-O-(hetero aryl)l-, —NR(CH2CH2)n- (cycloalkyl)-O-(heterocycle)-CH2, —NR(CH2CH2)n-(heterocycle)-(heterocycle)-CH2, —N(R1R2)-(heterocycle)-CH2; where n of the linker can be 0 to 10; R of the linker can be H, lower alkyl; R1 and R2 of the linker can form a ring with the connecting N. [0251] In certain embodiments, an LP-E moiety comprises, corresponds to, or is derived from that present in ARV-471, including any fragments thereof. In embodiments, an LP-E moiety has a structure according to (D46), (D46)’, or (D46)”.
[0252] In certain embodiments, an LP-E moiety comprises, corresponds to, or is derived from that present in ARV-110, including any fragments thereof. In embodiments, an LP-E moiety has a structure according to (D47), (D47)’, or (D47)”.
[0253] In certain embodiments, an LP-E moiety comprises, corresponds to, or is derived from that present in ARV-771 or ARV-766, including any fragments thereof.
Exemplary Group 2 [0254] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20220274993A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0255] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20220054453A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0256] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20210395273A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0257] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20210228562A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0258] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20220281831A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0259] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20210002296A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E
comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0260] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US11318205B1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0261] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US11117889B1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0262] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20200010468A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0263] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in WO2022178532A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety having the following structure:
, wherein L is a covalent bond or a bivalent, saturated or partially unsaturated, straight or branched C1-50 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by –Cy-, -O-, -N(R)-, –Si(R)2–, –Si(OH)(R)–, –Si(OH)2–, –P(O)(OR)–, –P(O)(R)–, –
P(O)(NR2)–, -S-, - OC(O)-, -C(O)O-, -C(O)-, -S(O)-, -S(O)2-, -N(R)S(O)2-, -S(O)2N(R)-, - N(R)C(O)-, -C(O)N(R)-, - OC(O)N(R)-, –N(R)C(O)O-,
wherein each –Cy– is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 4-11 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-11 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8- 10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or an 8-10 membered bicyclic heteroarylenyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein r is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; X1 is a bivalent moiety selected from a covalent bond, –CH2–, –CHCF3–, –SO2–, – S(O)–, –P(O)R–, – P(O)OR–, –P(O)NR2–, –C(O)–, –C(S)–, or ; X2 is a carbon atom or silicon atom; X3 is a bivalent moiety selected from –CR2–, –NR–, –O–, –S–, or –Si(R2)–; R1 is hydrogen, deuterium, halogen, –CN, –OR, –SR, –S(O)R, –S(O)2R, –N(R)2, –P(O)(OR)2, – P(O)(NR2)OR, –P(O)(NR2)2, –Si(OH)2R, –Si(OH)(R)2, –Si(R)3, or an optionally substituted C1-4 aliphatic; each R2 is independently hydrogen, deuterium, –R6, halogen, –CN, –NO2, –OR, -SR, - N(R)2, - Si(R)3, -S(O)2R, -S(O)2N(R)2, -S(O)R, -C(O)R, -C(O)OR, –C(O)N(R)2, - C(O)N(R)OR, - C(R)2N(R)C(O)R, -C(R)2N(R)C(O)N(R)2, -OC(O)R, -OC(O)N(R)2, -
OP(O)R2, -OP(O)(OR)2, - OP(O)(OR)(NR2), -OP(O)(NR2)2-, -N(R)C(O)OR, -N(R)C(O)R, - N(R)C(O)N(R)2, –N(R)S(O)2R, - NP(O)R2, -N(R)P(O)(OR)2, -N(R)P(O)(OR)(NR2), - N(R)P(O)(NR2)2, or –N(R)S(O)2R; Ring B is a fused ring selected from 6-membered aryl, 6-membered heteroaryl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 5 to 7- membered saturated or partially unsaturated carbocyclyl, 5 to 7-membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or 5-membered heteroaryl with 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur; R3 is selected from hydrogen, halogen, –OR, –N(R)2, or –SR; each R4 is independently hydrogen, –R6, halogen, –CN, –NO2, –OR, - SR, -NR2, - S(O)2R, -S(O)2NR2, -S(O)R, -C(O)R, -C(O)OR, – C(O)NR2, -C(O)N(R)OR, -OC(O)R, - OC(O)NR2, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR2, or –N(R)S(O)2R; R5 is hydrogen, C1-4 aliphatic, or –CN; each R6 is independently an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; L1 is a covalent bond or a C1-3 bivalent straight or branched saturated or unsaturated hydrocarbon chain wherein 1-2 methylene units of the chain are independently and optionally replaced with -O-, -C(O)- , -C(S)-, -C(R)2-, -CF(R)-, -C(F)2-, -N(R)-, -S-, -S(O)2- or -(C)=CH- ; m is 0, 1, 2, 3 or 4; each R is independently hydrogen, or an optionally substituted group selected from C1– 6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or: two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring
having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur; and Ring A is a bi- or tricyclic ring that is:
. [0264] Where a point of attachment of –(R2)m is depicted on Ring B, it is intended, and one of ordinary skill in the art would appreciate, that the point of attachment of –(R2)m may be on Ring A and may also be at any available carbon or nitrogen atom on Ring A including the ring to which Ring B is fused. Where - R2 is attached to a nitrogen atom bound to R4 or R5, R4 or R5 is absent and -R2 takes the place of the R4 or R5 group. [0265] In some embodiments, L is a covalent bond. In some embodiments, each –Cy– is independently an optionally substituted bivalent phenylenyl. In some embodiments, each – Cy– is independently an optionally substituted 8-10 membered bicyclic arylenyl. In some embodiments, each –Cy– is independently an optionally substituted 4-7 membered saturated or partially unsaturated carbocyclylenyl. In some embodiments, each –Cy– is independently an optionally substituted 4-7 membered saturated or partially unsaturated spiro carbocyclylenyl. In some embodiments, each –Cy– is independently an optionally substituted 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl. In some embodiments, each –Cy– is independently an optionally substituted 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each –Cy– is independently an optionally substituted 4-7 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each –Cy– is independently an optionally substituted 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each –Cy– is independently an optionally substituted 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each –Cy– is independently an optionally
substituted 8-10 membered bicyclic heteroarylenyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur. [0266] In embodiments, a linker is as described at, e.g., paragraphs [00478]-[0486] and Table 1 or Table B of WO2022178532A1 (e.g., exemplified linkers (1)-(650) of Table B). [0267] In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety found in any of the exemplary compounds of Table 1 of WO2022178532A1 (e.g., a moiety found in any of Compounds I-1 to I-100 as described therein). [0268] In certain embodiments, an LP-E moiety comprises, corresponds to, or is derived from that present in KT-474, including any fragments thereof. [0269] In certain embodiments, an LP-E moiety comprises, corresponds to, or is derived from that present in KT-413, including any fragments thereof. [0270] In certain embodiments, an LP-E moiety comprises, corresponds to, or is derived from that present in KT-333, including any fragments thereof. Exemplary Group 3 [0271] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20220098194A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0272] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in WO2022081927A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0273] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in WO2022081925A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
[0274] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in WO2022081928A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0275] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US11407732B1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0276] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in WO2022032132A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0277] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in WO2022032026A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0278] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in WO2021255213A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0279] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in WO2021255212A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0280] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20210198256A1, which is incorporated herein by reference in its entirety, as
well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0281] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in WO2021127561A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0282] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20210070763A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0283] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in WO2021083949A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0284] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in WO2021086785A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0285] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20210032245A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0286] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20210009559A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E
comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0287] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20200361930A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0288] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20220251061A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0289] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US10905768B1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0290] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in WO2020181232A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0291] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20200207733A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0292] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US11254672B2, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof.
[0293] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20200207783A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0294] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in WO2020132561A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0295] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20200140456A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0296] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US10849982B2, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0297] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20190076539A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0298] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20190070185A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0299] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US11185592B2, which is incorporated herein by reference in its entirety, as well
any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0300] In embodiments, a linker LP moiety is a chain of 2 to 14, 15, 16, 17, 18 or 20 or more carbon atoms of which one or more carbons can be replaced by a heteroatom such as O, N, S, or P. In certain embodiments the chain has 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 contiguous atoms in the chain. For example, the chain may include 1 or more ethylene glycol units that can be contiguous, partially contiguous or non-contiguous (for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 ethylene glycol units). In certain embodiments, the chain has at least 1, 2, 3, 4, 5, 6, 7, or 8 contiguous chains which can have branches which can be independently alkyl, heteroalkyl, aryl, heteroaryl, alkenyl, or alkynyl, aliphatic, heteroaliphatic, cycloalkyl or heterocyclic substituents. [0301] In embodiments, a linker LP moiety can include or be comprised of one or more of ethylene glycol, propylene glycol, lactic acid and/or glycolic acid. In general, propylene glycol adds hydrophobicity, while propylene glycol adds hydrophilicity. Lactic acid segments tend to have a longer half-life than glycolic acid segments. Block and random lactic acid-co-glycolic acid moieties, as well as ethylene glycol and propylene glycol, are known in the art to be pharmaceutically acceptable and can be modified or arranged to obtain the desired half-life and hydrophilicity. In certain aspects, these units can be flanked or interspersed with other moieties, such as aliphatic, including alkyl, heteroaliphatic, aryl, heteroaryl, heterocyclic, cycloalkyl, etc., as desired to achieve the appropriate drug properties. [0302] In embodiments, a linker LP moiety is selected from the following formulas:
wherein: X1 and X2 are independently selected from bond, NH, NR25, CH2, CHR25, C(R25)2, O, and S; R20, R21, R22, R23, and R24 are independently selected from bond, alkyl, —C(O)— — C(O)O—, —OC(O)—, —C(O)alkyl, —C(O)Oalkyl, —C(S)—, —SO2—, —S(O)—, — C(S)—, —C(O)NH—, —NHC(O)—, —N(alkyl)C(O)—, —C(O)N(alkyl)-, —O—, —S—, — NH—, —N(alkyl)-, —CH(—O—R26)—, —CH(—NHR25)—, —CH(—NH2)—, —CH(— NR25 2)—, —C(—O—R26)alkyl-, —C(—NHR25)alkyl-, —C(—NH2)alkyl-, —C(— NR25 2)alkyl-, —C(R4R4)—, -alkyl(R27)-alkyl(R28)—, —C(R27R28)—, —P(O)(OR26)O—, — P(O)(OR26)—, —NHC(O)NH—, —N(R25)C(O)N(R25)—, —N(H)C(O)N(R25)—, polyethylene glycol, poly(lactic-co-glycolic acid), alkene, haloalkyl, alkoxy, and alkyne; or R20, R21, R22, R23, and R24 can in addition to those above be independently selected from heteroarylalkyl, aryl, arylalkyl, heterocycle, aliphatic, heteroaliphatic, heteroaryl, polypropylene glycol, lactic acid, glycolic acid, carbocycle, or —O—(CH2)1-12—O—, — NH—(CH2)1-12—NH—, —NH—(CH2)1-12—O—, or —O—(CH2)1-12—NH—, —S—(CH2)1- 12—O—, —O—(CH2)1-12—S—, —S—(CH2)1-12—S—, —S—(CH2)1-12—NH—, —NH— (CH2)1-12—S—, (and wherein the 1-12 can be independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12, and wherein one or more of the CH2 or NH can be modified by substitution of a H for a methyl, ethyl, cyclopropyl, F (if on carbon), etc, as described herein), and optionally, a heteroatom, heteroalkyl, aryl, heteroaryl or cycloaliphatic group is interspersed in the chain).
Certain nonlimiting examples include —O—CH(CH3)—CH(CH3)CH—O—, —O—CH2— CH(CH3)CH—O—, —O—CH(CH3)—CH2CH—O—, etc. each of which R20, R21, R22, R23, and R24 is optionally substituted with one or more substituents selected from R101 or alternatively as described in Section 1. Definitions; R25 is selected at each instance from: alkyl, —C(O)H, —C(O)OH, —C(O)alkyl, — C(O)Oalkyl, alkenyl, or alkynyl or alternatively can be aliphatic, heteroaliphatic, aryl, heteroaryl or heterocyclic; R26 is hydrogen, alkyl, silane, arylalkyl, heteroarylalkyl, alkene, and alkyne; or in addition to these can also be selected from aryl, heteroaryl, heterocyclic, aliphatic and heteroaliphatic; R27 and R28 are independently selected from hydrogen, alkyl, amine, or together with the carbon atom to which they are attached, form C(O), C(S), C═CH2, a C3- C6 spirocarbocycle, or a 4-, 5-, or 6-membered spiroheterocycle comprising 1 or 2 heteroatoms selected from N and O, or form a 1 or 2 carbon bridged ring; R101 is independently selected at each occurrence from hydrogen, alkyl, alkene, alkyne, haloalkyl, alkoxy, hydroxyl, aryl, heteroaryl, heterocycle, arylalkyl, heteroarylalkyl, heterocycloalkyl, aryloxy, heteroaryloxy, CN, —COOalkyl, COOH, NO2, F, Cl, Br, I, CF3, NH2, NHalkyl, N(alkyl)2, NR25R25, NHR25, aliphatic, heteroaliphatic, and COR4; and R4 is selected from hydrogen, alkyl, aliphatic, heteroaliphatic, aryl, heteroaryl, carbocyclic, hydroxyl, alkoxy, amine, —NHalkyl, or —Nalkyl2. [0303] In embodiments, a linker LP moiety is an optionally substituted (poly)ethylene glycol having at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, ethylene glycol units, or optionally substituted alkyl groups interspersed with optionally substituted, O, N, S, P or Si atoms. In certain embodiments, the Linker is flanked, substituted, or interspersed with an aryl, phenyl, benzyl, alkyl, alkylene, or heterocycle group. In certain embodiments, the Linker may be asymmetric or symmetrical. In some embodiments, the Linker is a substituted or unsubstituted polyethylene glycol group ranging in size from about 1 to about 12 ethylene glycol units, between 1 and about 10 ethylene glycol units, about 2 about 6 ethylene glycol units, between about 2 and 5 ethylene glycol units, between about 2 and 4 ethylene glycol units. In any of the embodiments of the
compounds described herein, the linker LP moiety may be any suitable moiety as described herein. [0304] In embodiments, the linker LP moiety is selected from: —NR61(CH2)n1-(lower alkyl)-, —NR61(CH2)n1-(lower alkoxyl)-, —NR61(CH2)n1-(lower alkoxyl)-OCH2—, —NR61(CH2)n1- (lower alkoxyl)-(lower alkyl)-OCH2—, —NR61(CH2)n1-(cycloalkyl)-(lower alkyl)-OCH2—, —NR61(CH2)n1-(heterocycloalkyl)-, —NR61(CH2CH2O)n1-(lower alkyl)-O—CH2—, — NR61(CH2CH2O)n1-(heterocycloalkyl)-O—CH2—, —NR61(CH2CH2O)n1-Aryl-O—CH2—, — NR61(CH2CH2O)n1-(heteroaryl)-O—CH2—, —NR61(CH2CH2O)n1-(cycloalkyl)-O-(heteroaryl)- O—CH2—, —NR61(CH2CH2O)n1-(cycloalkyl)-O-Aryl-O—CH2—, —NR61(CH2CH2O)n1- (lower alkyl)-NH-Aryl-O— CH2—, —NR61(CH2CH2O)n1-(lower alkyl)-O-Aryl-CH2, — NR61(CH2CH2O)n-cycloalkyl-O-Aryl-, —NR61(CH2CH2O)n1-cycloalkyl-O-heteroaryl-, — NR61(CH2CH2)n1-(cycloalkyl)-O-(heterocycle)-CH2, —NR61(CH2CH2)n1-(heterocycle)- (heterocycle)-CH2, and —NR61-(heterocycle)-CH2; wherein n1 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and R61 is H, methyl, or ethyl. [0305] In embodiments, the linker LP moiety is selected from: —N(R61)—(CH2)m1—O(CH2)n2—O(CH2)o1—O(CH2)p1—O(CH2)q1—O(CH2)r1—OCH2—O— (CH2)m1—O(CH2)n2—O(CH2)o1—O(CH2)p1—O(CH2)q1—O(CH2)r1—OCH2—, —O— (CH2)m1—O(CH2)n2—O(CH2)o1—O(CH2)p1—O(CH2)q1—O(CH2)r1—O—; —N(R61)—(CH2)m1—O(CH2)n2—O(CH2)o1—O(CH2)p1—O(CH2)q1—O(CH2)r1—O—; —(CH2)m1—O(CH2)n2—O(CH2)o1—O(CH2)p1—O(CH2)q1—O(CH2)r1—O—; —(CH2)m1—O(CH2)n2—O(CH2)o1—O(CH2)p1—O(CH2)q1—O(CH2)r1—OCH2—; —O(CH2)m1O(CH2)n2O(CH2)p1O(CH2)q1OCH2—; and —O(CH2)m1O(CH2)n2O(CH2)p1O(CH2)q1OCH2—; wherein m1, n2, o1, p1, q1, and r1 are independently 1, 2, 3, 4, or 5; and R61 is H, methyl, or ethyl. [0306] In certain embodiments, a LP moiety includes any of the strctures described in US11185592B2 at cols.97-148. [0307] In certain embodiments, an E moiety includes any of the strctures described in US11185592B2 as the fragments according to Formula (I) and Formula (II) cols.61-74 or according to Formula III and IV at cols.74-84.
[0308] In certain embodiments, LP-E moieties include any of the PROTAC degraders described in US20200308171A1, which is incorporated herein by reference in its entirety, as well any moieties corresponding to LP and/or E described therein. In embodiments, -LP-E comprises, corresponds to, or is derived from a moiety described therein, including any fragments thereof. [0309] For example, LP, E, and/or LP-E moieties include those according to the following formula, where Y is covalently attached to the the Ligand moiety,
Y is absent or heterocyclyl (e.g., pyrrolidinyl); and L is selected from the group consisting of i) —C(═O)—(CH2)2-10—NH—, in particular —C(═O)—(CH2)5—NH—; ii) —(CH2)2-10—NH—, in particular —(CH2)6—NH—, —(CH2)5—NH— or — (CH2)4—NH—; iii) —(CH2)2-10-heterocyclyl-, in particular a. —(CH2)2-10-piperidyl-, in particular —(CH2)4-piperidyl-, —(CH2)3- piperidyl- or —(CH2)2-piperidyl-; or b. —(CH2)2-10-azetidinyl-, in particular —(CH2)3-azetidinyl- or —(CH2)2- azetidinyl-; iv) —C(═O)-heterocyclyl-(CH2)2-10—NH—, in particular —C(═O)-piperazinyl- (CH2)2-10—NH—, more particular —C(═O)-piperazinyl-(CH2)4—NH—; v) —(CH2)2-10—O-heterocyclyl-, in particular a. —(CH2)2-10—O-piperidyl-, in particular —(CH2)3—O-piperidyl-; or b. —(CH2)2-10—O-azetidinyl-, in particular —(CH2)3—O-azetidinyl-; and vi) —(CH2)2-10—C3-6cycloalkyl-, in particular —(CH2)3-cyclohexyl; [0310] In certain embodiments, an LP-E moiety comprises, corresponds to, or is derived from that present in CFT8919, including any fragments thereof.
[0311] In certain embodiments, an LP-E moiety comprises, corresponds to, or is derived from that present in CFT8634, including any fragments thereof. In embodiments, an LP-E moiety has a structure according to (D48), (D48)’, or (D48)”.
Exemplary Group 4 [0312] In certain embodiments, an LP-E moiety comprises, corresponds to, or is derived from that present in DT2216, including any fragments thereof. [0313] In certain embodiments, an LP-E moiety comprises, corresponds to, or is derived from that present in AC682, including any fragments thereof. [0314] In certain embodiments, an LP-E moiety comprises, corresponds to, or is derived from that present in CC-94676, including any fragments thereof. [0315] In certain embodiments, an LP-E moiety comprises, corresponds to, or is derived from that present in FHD-609, including any fragments thereof. [0316] In certain embodiments, an LP-E moiety comprises, corresponds to, or is derived from that present in NX-2127, including any fragments thereof. [0317] In certain embodiments, an LP-E moiety comprises, corresponds to, or is derived from that present in NX-5948, including any fragments thereof.
[0318] In certain embodiments, an LP-E moiety comprises, corresponds to, or is derived from that present in CG001419, including any fragments thereof. Deuterated Compounds [0319] Compounds described herein can comprise atoms that exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominately found in nature. The term “isotopologue” refers to a species that has the same chemical structure and formula as a specific compound provided herein, with the exception of the positions of isotopic substitution and/or level of isotopic enrichment at one or more positions, e.g., hydrogen vs. deuterium. The present invention is meant to include all suitable isotopic variations of the compounds of the compounds described herein. For example, different isotopic forms of hydrogen (H) include protium (1H), deuterium (2H), and tritium (3H), as well as compositions enriched in isotopologues of any compound described herein. [0320] In embodiments, one or more of the hydrogens of the compounds described herein is replaced by a deuterium. When a position is designated as “H” or “hydrogen”, the position is understood to have hydrogen at its natural abundance isotopic composition. When a position is designated as “2H” or “deuterium”, the position is understood to have deuterium at an abundance that is at least 3340 times greater than the natural abundance of deuterium, which is 0.015% (i.e., the term “2H” or “deuterium” indicates at least 50.1% incorporation of deuterium). Accordingly, the invention also features compositions enriched in deuterated compounds. [0321] In embodiments, compositions of any compound provided herein may have an isotopic enrichment factor for each deuterium present at a site designated as a potential site of deuteration on the compound of at least 3500 (52.5% deuterium incorporation), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
Synthetic Methods [0322] Compounds described herein can be prepared according to methods known in the art. For example, the exemplary synthetic methods described in the instant Examples can be used to prepare still other compounds of the invention. [0323] Accordingly, disclosed compounds can generally be synthesized by an appropriate combination of generally well known synthetic methods. Techniques useful in synthesizing these chemical entities are both readily apparent and accessible to those of skill in the relevant art, based on the instant disclosure. Many of the optionally substituted starting compounds and other reactants are commercially available, e.g., from Aldrich Chemical Company (Milwaukee, Wis.) or can be readily prepared by those skilled in the art using commonly employed synthetic methodology. [0324] Pharmaceutical Compositions [0325] In another exemplary aspect, the invention features pharmaceutical compositions comprising any compound herein, or a pharmaceutically acceptable form thereof. In embodiments, a pharmaceutical composition comprises a therapeutically effective amount of any compound described herein, or any pharmaceutically acceptable form thereof. [0326] In embodiments, a pharmaceutically acceptable form of a compound includes any pharmaceutically acceptable salts, hydrates, solvates, isomers, prodrugs, and isotopically labeled derivatives thereof. [0327] In embodiments, a pharmaceutical composition comprises any compound described herein, or a pharmaceutically acceptable salt thereof. [0328] In embodiments, a pharmaceutical composition comprises a pharmaceutically acceptable excipient. [0329] For the purposes of the present invention the term “excipient” and “carrier” are used interchangeably throughout the description of the present invention and said terms are defined herein as, “ingredients which are used in the practice of formulating a safe and effective pharmaceutical composition.” [0330] The formulator will understand that excipients are used primarily to serve in delivering a safe, stable, and functional pharmaceutical, serving not only as part of the overall vehicle for delivery but also as a means for achieving effective absorption by the recipient of the active
ingredient. An excipient may fill a role as simple and direct as being an inert filler, or an excipient as used herein may be part of a pH stabilizing system or coating to insure delivery of the ingredients safely to the stomach. The formulator can also take advantage of the fact the compounds of the present invention have improved cellular potency, pharmacokinetic properties, as well as improved oral bioavailability. [0331] Accordingly, in some embodiments, provided herein are pharmaceutical compositions comprising one or more compounds as disclosed herein, or a pharmaceutically acceptable form thereof (e.g., pharmaceutically acceptable salts, hydrates, solvates, isomers, prodrugs, and isotopically labeled derivatives), and one or more pharmaceutically acceptable excipients, carriers, including inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants. In some embodiments, a pharmaceutical composition described herein includes a second active agent such as an additional therapeutic agent, (e.g., a chemotherapeutic). [0332] Accordingly, the present teachings also provide pharmaceutical compositions that include at least one compound described herein, or any pharmaceutically salt thereof thereof, and one or more pharmaceutically acceptable carriers, excipients, or diluents. Examples of such carriers are well known to those skilled in the art and can be prepared in accordance with acceptable pharmaceutical procedures, such as, for example, those described in Remington’s Pharmaceutical Sciences, 17th edition, ed. Alfonoso R. Gennaro, Mack Publishing Company, Easton, PA (1985), the entire disclosure of which is incorporated by reference herein for all purposes. As used herein, “pharmaceutically acceptable” refers to a substance that is acceptable for use in pharmaceutical applications from a toxicological perspective and does not adversely interact with the active ingredient. Accordingly, pharmaceutically acceptable carriers are those that are compatible with the other ingredients in the composition and are biologically acceptable. Supplementary active ingredients can also be incorporated into the pharmaceutical compositions. [0333] Compounds of the present teachings can be administered orally or parenterally, neat or in combination with conventional pharmaceutical carriers. Applicable solid carriers can include one or more substances which can also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents, or encapsulating materials. The compounds can be formulated in conventional manner, for example, in a manner similar to that used for known 5-hydroxytryptamine receptor 7 activity modulators. Pharmaceutical compositions in the form of oral formulations containing a
compound disclosed herein can comprise any conventionally used oral form, including tablets, capsules, buccal forms, troches, lozenges and oral liquids, suspensions or solutions. In powders, the carrier can be a finely divided solid, which is an admixture with a finely divided compound. In tablets, a compound disclosed herein can be mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets can contain up to 99 % of the compound. [0334] Capsules can contain mixtures of one or more compound(s) disclosed herein with inert filler(s) and/or diluent(s) such as pharmaceutically acceptable starches (e.g., corn, potato or tapioca starch), sugars, artificial sweetening agents, powdered celluloses (e.g., crystalline and microcrystalline celluloses), flours, gelatins, gums, and the like. [0335] Useful tablet formulations can be made by conventional compression, wet granulation or dry granulation methods and utilize pharmaceutically acceptable diluents, binding agents, lubricants, disintegrants, surface modifying agents (including surfactants), suspending or stabilizing agents, including, but not limited to, magnesium stearate, stearic acid, sodium lauryl sulfate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, microcrystalline cellulose, sodium carboxymethyl cellulose, carboxymethylcellulose calcium, polyvinylpyrrolidine, alginic acid, acacia gum, xanthan gum, sodium citrate, complex silicates, calcium carbonate, glycine, sucrose, sorbitol, dicalcium phosphate, calcium sulfate, lactose, kaolin, mannitol, sodium chloride, low melting waxes, and ion exchange resins. Surface modifying agents include nonionic and anionic surface modifying agents. Representative examples of surface modifying agents include, but are not limited to, poloxamer 188, benzalkonium chloride, calcium stearate, cetostearl alcohol, cetomacrogol emulsifying wax, sorbitan esters, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, magnesium aluminum silicate, and triethanolamine. Oral formulations described herein herein can utilize standard delay or time-release formulations to alter the absorption of the compound(s). An oral formulation can also consist of administering a compound disclosed herein in water or fruit juice, containing appropriate solubilizers or emulsifiers as needed. [0336] Liquid carriers can be used in preparing solutions, suspensions, emulsions, syrups, elixirs, and for inhaled delivery. A compound of the present teachings can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, or a mixture of both, or a pharmaceutically acceptable oils or fats. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity
regulators, stabilizers, and osmo-regulators. Examples of liquid carriers for oral and parenteral administration include, but are not limited to, water (particularly containing additives as described herein, e.g., cellulose derivatives such as a sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g., glycols) and their derivatives, and oils (e.g., fractionated coconut oil and arachis oil). For parenteral administration, the carrier can be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration. The liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellants. [0337] Liquid pharmaceutical compositions, which are sterile solutions or suspensions, can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. Compositions for oral administration can be in either liquid or solid form. [0338] In embodiments, a pharmaceutical composition is in unit dosage form, for example, as tablets, capsules, powders, solutions, suspensions, emulsions, granules, or suppositories. In such form, the pharmaceutical composition can be sub-divided in unit dose(s) containing appropriate quantities of the compound. The unit dosage forms can be packaged compositions, for example, packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids. Alternatively, the unit dosage form can be a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form. Such unit dosage form can contain from about 1 mg/kg of compound to about 500 mg/kg of compound, and can be given in a single dose or in two or more doses. Such doses can be administered in any manner useful in directing the compound(s) to the recipient’s bloodstream, including orally, via implants, parenterally (including intravenous, intraperitoneal and subcutaneous injections), rectally, vaginally, and transdermally. [0339] When administered for the treatment or inhibition of a particular disease state or disorder, it is understood that an effective dosage can vary depending upon the particular compound utilized, the mode of administration, and severity of the condition being treated, as well as the various physical factors related to the individual being treated. In therapeutic applications, a compound of the present teachings can be provided to a patient already suffering from a disease in an amount sufficient to cure or at least partially ameliorate the symptoms of the disease and its complications. The dosage to be used in the treatment of a specific individual typically must be subjectively determined by the attending physician. The
variables involved include the specific condition and its state as well as the size, age and response pattern of the patient.
[0340] In some cases it may be desirable to administer a compound directly to the airways of the patient, using devices such as, but not limited to, metered dose inhalers, breath-operated inhalers, multidose dry-powder inhalers, pumps, squeeze-actuated nebulized spray dispensers, aerosol dispensers, and aerosol nebulizers. For administration by intranasal or intrabronchial inhalation, the compounds of the present teachings can be formulated into a liquid composition, a solid composition, or an aerosol composition. The liquid composition can include, by way of illustration, one or more compounds of the present teachings dissolved, partially dissolved, or suspended in one or more pharmaceutically acceptable solvents and can be administered by, for example, a pump or a squeeze-actuated nebulized spray dispenser. The solvents can be, for example, isotonic saline or bacteriostatic water. The solid composition can be, by way of illustration, a powder preparation including one or more compounds of the present teachings intermixed with lactose or other inert powders that are acceptable for intrabronchial use, and can be administered by, for example, an aerosol dispenser or a device that breaks or punctures a capsule encasing the solid composition and delivers the solid composition for inhalation. The aerosol composition can include, by way of illustration, one or more compounds of the present teachings, propellants, surfactants, and co-solvents, and can be administered by, for example, a metered device. The propellants can be a chlorofluorocarbon (CFC), a hydrofluoroalkane (HFA), or other propellants that are physiologically and environmentally acceptable.]
[0341] Compounds described herein can be administered parenterally or intraperitoneally. Solutions or suspensions of these compounds or a pharmaceutically acceptable salts, hydrates, or esters thereof can be prepared in water suitably mixed with a surfactant such as hydroxylpropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations typically contain a preservative to inhibit the growth of microorganisms.
[0342] The pharmaceutical forms suitable for injection can include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In some embodiments, the form can sterile and its viscosity permits it to flow through a syringe. The form preferably is stable under the conditions of manufacture and storage and can be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example,
water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils. [0343] Compounds described herein can be administered transdermally, i.e., administered across the surface of the body and the inner linings of bodily passages including epithelial and mucosal tissues. Such administration can be carried out using the compounds of the present teachings including pharmaceutically acceptable salts, hydrates, or esters thereof, in lotions, creams, foams, patches, suspensions, solutions, and suppositories (rectal and vaginal). [0344] Transdermal administration can be accomplished through the use of a transdermal patch containing a compound, such as a compound disclosed herein, and a carrier that can be inert to the compound, can be non-toxic to the skin, and can allow delivery of the compound for systemic absorption into the blood stream via the skin. The carrier can take any number of forms such as creams and ointments, pastes, gels, and occlusive devices. The creams and ointments can be viscous liquid or semisolid emulsions of either the oil-in-water or water-in- oil type. Pastes comprised of absorptive powders dispersed in petroleum or hydrophilic petroleum containing the compound can also be suitable. A variety of occlusive devices can be used to release the compound into the blood stream, such as a semi-permeable membrane covering a reservoir containing the compound with or without a carrier, or a matrix containing the compound. Other occlusive devices are known in the literature. [0345] Compounds described herein can be administered rectally or vaginally in the form of a conventional suppository. Suppository formulations can be made from traditional materials, including cocoa butter, with or without the addition of waxes to alter the suppository’s melting point, and glycerin. Water-soluble suppository bases, such as polyethylene glycols of various molecular weights, can also be used. [0346] Lipid formulations or nanocapsules can be used to introduce compounds of the present teachings into host cells either in vitro or in vivo. Lipid formulations and nanocapsules can be prepared by methods known in the art. [0347] To increase the effectiveness of compounds of the present teachings, it can be desirable to combine a compound with other agents effective in the treatment of the target disease. For example, other active compounds (i.e., other active ingredients or agents) effective in treating the target disease can be administered with compounds of the present teachings. The other agents can be administered at the same time or at different times than the compounds disclosed herein.
Kits [0348] In some embodiments, provided herein are kits. The kits can include a compound or pharmaceutically acceptable form thereof, or pharmaceutical composition as described herein, in suitable packaging, and written material that can include instructions for use, discussion of clinical studies, listing of side effects, and the like. Kits are well suited for the delivery of solid oral dosage forms such as tablets or capsules. Such kits can also include information, such as scientific literature references, package insert materials, clinical trial results, and/or summaries of these and the like, which indicate or establish the activities and/or advantages of the pharmaceutical composition, and/or which describe dosing, administration, side effects, drug interactions, or other information useful to the health care provider. Such information can be based on the results of various studies, for example, studies using experimental animals involving in vivo models and studies based on human clinical trials. Therapeutic Methods [0349] Compounds of the present teachings can be useful for the treatment or inhibition of a pathological condition or disorder in a mammal, for example, a human subject. The present teachings accordingly provide methods of treating or inhibiting a pathological condition or disorder by providing to a mammal a compound of the present teachings (including its pharmaceutically acceptable salt) or a pharmaceutical composition that includes one or more compounds of the present teachings in combination or association with pharmaceutically acceptable carriers. Compounds of the present teachings can be administered alone or in combination with other therapeutically effective compounds or therapies for the treatment or inhibition of the pathological condition or disorder. [0350] Accordingly, compounds described herein can be particularly useful in treating diseases or disorders associated with defects in various components of signal transduction pathways and which are responsive to modulation (e.g., inhibition) of protein kinases. In embodiments, a compound described herein modulates (e.g., inhibitors) a protein kinase that is abl, Akt, bcr-abl, Blk, Brk, c-kit, c-met, c-src, CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, cRaf1, CSK, EGFR, ErbB2, ErbB3, ErbB4, Erk, Pak, fes, FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, Fgr, flt-1, Fps, Frk, Fyn, Hck, IGF-1R, INS-R, Jak, KDR, Lck, Lyn, MEK, p38, PDGFR, PIK, PKC, PYK2, ros, tie, tie2, TRK or Zap70. In embodiments, a compound described herein modulates (e.g., inhibits) a wild-type form of a
kinase (e.g., EGFR). In embodiments, a compound described herein modulates (e.g., inhibits) a mutant form of a kinase (e.g., EGFR). [0351] In embodiments, a compound described herein, or any pharmaceutically acceptable form thereof such as a pharmaceutically acceptable salt thereof, modulates (e.g., inhibits) a kinase that is a tyrosine kinase (e.g., KIT, erb2, PDGFR, EGFR, VEGFR, src, or abl). [0352] In embodiments, a compound described herein, or any pharmaceutically acceptable form thereof such as a pharmaceutically acceptable salt thereof, modulates (e.g., inhibits) a kinase that is a serine/threonine kinase (e.g., mTorC1, mTorC2, ATM, ATR, DNA-PK, or Akt). [0353] In embodiments, a compound described herein, or any pharmaceutically acceptable form thereof such as a pharmaceutically acceptable salt thereof, can be used to treat or prevent a disease or disorder that is responsive to modulation (e.g., inhibition) of a protein kinase (e.g., abl, Akt, bcr-abl, Blk, Brk, c-kit, c-met, c-src, CDK1, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, cRaf1, CSK, EGFR, ErbB2, ErbB3, ErbB4, Erk, Pak, fes, FGFR1, FGFR2, FGFR3, FGFR4, FGFR5, Fgr, flt-1, Fps, Frk, Fyn, Hck, IGF-1R, INS-R, Jak, KDR, Lck, Lyn, MEK, p38, PDGFR, PIK, PKC, PYK2, ros, tie, tie2, TRK or Zap70). [0354] In embodiments, a compound described herein, or any pharmaceutically acceptable form thereof such as a pharmaceutically acceptable salt thereof, can be used to treat or prevent a disease or disorder that is responsive to modulation (e.g., inhibition) of a tyrosine kinase (e.g., KIT, erb2, PDGFR, EGFR, VEGFR, src, or abl). [0355] In embodiments, a compound described herein, or any pharmaceutically acceptable form thereof such as a pharmaceutically acceptable salt thereof, can be used to treat or prevent a disease or disorder that is responsive to modulation (e.g., inhibition) of a serine/threonine kinase (e.g., mTorC1, mTorC2, ATM, ATR, DNA-PK, or Akt). [0356] In embodiments, a compound described herein modulates (e.g., inhibits) a wild-type form of a kinase (e.g., EGFR). In embodiments, a compound described herein modulates (e.g., inhibits) a mutant form of a kinase (e.g., EGFR). Selective Inhibition of Kinases [0357] The term "selective inhibition" or "selectively inhibit" as applied to a biologically active agent refers to the agent’s ability to selectively reduce the target signaling activity as compared to off-target signaling activity, via direct or interact interaction with the target.
[0358] In some embodiments, a compound described herein, or any pharmaceutically acceptable salt thereof, selectively inhibits a kinase or kinase form over other kinases or other kinase forms. In embodiments, a compound selectively inhibits a mutant kinase form over the wild-type of the same kinase. [0359] In embodiments, a compound described herein, or any pharmaceutically acceptable salt thereof, selectively inhibits a kinase (e.g., EGFR) over other kinases. [0360] In embodiments, a compound described herein, or any pharmaceutically acceptable salt thereof, selectively inhibits a kinase form (e.g., mutant EGFR) over other kinase forms (e.g., wild-type EGFR). [0361] By way of non-limiting example, the ratio of selectivity can be greater than a factor of about 10, greater than a factor of about 20, greater than a factor of about 30, greater than a factor of about 40, greater than a factor of about 50, greater than a factor of about 60, greater than a factor of about 70, greater than a factor of about 80, greater than a factor of about 100, greater than a factor of about 120, or greater than a factor of about 150, where selectivity can be measured by in vitro assays known in the art. Non-limiting examples of assays to measure selectivity include enzymatic assays, cellular proliferation assays, and EGFR phosphorylation assays. In one embodiment, selectivity can be determined by cellular proliferation assays. In another embodiment, selectivity can be determined by EGFR phosphorylation assays. In some embodiments, the mutant EGFR inhibitory activity of a compound as disclosed herein can be less than about 1000 nM, less than about 100 nM, less than about 50 nM, less than about 30 nM, or less than about 10 nM. [0362] In embodiments, the IC50 of a kinase inhibitor compound can be less than about 100 nM, less than about 50 nM, less than about 10 nM, less than about 1 nM, less than about 0.5 nM, or less than about 1 pM. [0363] Determination of IC50 values can be performed according to methods known in the art. [0364] In embodiments, a compound described herein, or any pharmaceutically acceptable form thereof such as a pharmaceutically acceptable salt thereof, can be used to treat or prevent a disease or disorder that is cancer, an inflammatory disorder, a metabolic disorder, vascular disease, or neuronal disease.
[0365] Compounds described herein, or any pharmaceutically acceptable form thereof, or any pharmaceutical composition thereof, can be useful for treating diseases and disorders associated with abnormal cell proliferation.
[0366] In embodiments, a compound described herein, or a pharmaceutically acceptable form thereof (e.g., a pharmaceutically acceptable salt thereof), or a pharmaceutical composition thereof, can be used to treat cancer.
Cancer
[0367] The compositions and methods provided herein can potentially be useful for the treatment of cancer including tumors such as astrocytic, breast, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatocellular, laryngeal, lung, oral, ovarian, prostate and thyroid carcinomas and sarcomas.
[0368] In embodiments, a cancer is a cardiac cancer such as sarcoma (angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma, lipoma or teratoma.
[0369] In embodiments, a cancer is a lung cancer such as bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, or mesothelioma.
[0370] In embodiments, a cancer is a gastrointestinal cancer such as: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma).
[0371] In embodiments, a cancer is a cancer of the genitourinary tract such as: kidney (adenocarcinoma, Wilm's tumor (nephroblastoma), lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma).
[0372] In embodiments a cancer is a liver cancer such as hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma.
[0373] In embodiments, a cancer is a bone cancer such as: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell tumors.
[0374] In embodiments a cancer is a cancer of the central nervous system (CNS) such as: skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), spinal cord neurofibroma, meningioma, glioma, sarcoma).
[0375] In embodiments, a cancer is a gynecological cancer such as: uterus (endometrial carcinoma), cervix (cervical carcinoma, pre -tumor cervical dysplasia), ovaries (ovarian carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), fallopian tubes (carcinoma).
[0376] In embodiments, a cancer is a hematological cancer such as: blood (myeloid leukemia (acute and chronic), acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma, myelodysplasia syndrome), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma).
[0377] In embodiments, a cancer is a skin cancer such as: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, keloids, psoriasis.
[0378] In embodiments, a cancer is a cancer of the adrenal glands such as neuroblastoma.
Thus, the term "cancerous cell" as provided herein, includes a cell afflicted by any one of or related to the above identified conditions.
[0379] In embodiments, a cancer is an EGFR-driven cancer (e.g., as described herein). In embodiments, an EGFR-driven cancer is non-small cell lung cancer (NSCLC), squamous cell carcinoma, adenocarcinoma, adenocarcinoma, bronchioloalveolar carcinoma (BAC), BAC with focal invasion, adenocarcinoma with BAC features, and large cell carcinoma; neural tumors, such as glioblastomas; pancreatic cancer; head and neck cancers (e.g., squamous cell carcinoma); breast cancer; colorectal cancer; epithelial cancer, including squamous cell carcinoma; ovarian cancer; prostate cancer; or adenocarcinomas.
[0380] In embodiments, a cancer is an EGFR mutant cancer (e.g., as described herein). In embodiments, an EGFR mutant cancer is non-small cell lung cancer (NSCLC), squamous cell carcinoma, adenocarcinoma, adenocarcinoma, bronchioloalveolar carcinoma (BAC), BAC with focal invasion, adenocarcinoma with BAC features, and large cell carcinoma; neural tumors, such as glioblastomas; pancreatic cancer; head and neck cancers (e.g., squamous cell carcinoma); breast cancer; colorectal cancer; epithelial cancer, including squamous cell carcinoma; ovarian cancer; prostate cancer; or adenocarcinomas.
[0381] In one embodiment, the compositions and methods provided herein are useful for the treatment of lung cancer and pancreatic cancer, most specifically, non-small cell lung cancer (NSCLC).
[0382] In embodiments, a cancer is refractory to TKI therapies (e.g., erlotinib, gefitinib, dacomitinib, afatinib, osimertinib).
Lung Cancer
[0383] In embodiments, a cancer is a lung cancer.
[0384] Lung cancer is the most common cause of cancer mortality globally and the second most common cancer in both men and women. About 14% of all new cancers are lung cancers. In the United States (US), there are projected to be 222,500 new cases of lung cancer (116,990 in men and 105,510 in women) and 155,870 deaths from lung cancer (84,590 in men and 71,280 in women) in 2017.
[0385] The two major forms of lung cancer are non-small cell lung cancer (NSCLC) and small cell lung cancer. NSCLC is a heterogeneous disease that consists of adenocarcinoma, large-cell carcinoma, and squamous cell carcinoma (sqNSCLC), and comprises approximately 80% to 85% of all lung cancers. Squamous cell carcinoma of the lung accounts for 20% to 30% of NSCLC. Despite advances in early detection and standard treatment, NSCLC is often
diagnosed at an advanced stage, has poor prognosis, and is the leading cause of cancer deaths worldwide. [0386] Platinum-based doublet therapy, maintenance chemotherapy, and anti-angiogenic agents in combination with chemotherapy have contributed to improved patient outcomes in advanced NSCLC. [0387] In embodiments, an advanced lung cancer is stage III cancer or stage IV cancer. In embodiments, an advanced lung cancer is stage III cancer. In embodiments, an advanced lung cancer is stage IV cancer. In embodiments, an advanced lung cancer is locally advanced. In embodiments, an advanced lung cancer is metastatic. [0388] In embodiments, a lung cancer is small cell lung cancer (SCLC). [0389] In embodiments, a lung cancer is non-small cell lung cancer (NSCLC) such as adenocarcinoma, large-cell carcinoma, or squamous cell carcinoma (sqNSCLC). In embodiments, a NSCLC is lung adenocarcinoma. In embodiments, a NSCLC is large cell carcinoma of the lung. In embodiments, a NSCLC is squamous cell carcinoma of the lung (sqNSCLC). [0390] In embodiments, a lung cancer (e.g., NSCLC) is an EGFR-mutant lung cancer (e.g., EGFR-mutant NSCLC). In embodiments, a cancer is NSCLC (e.g., advanced NSCLC) with an identified EGFR mutation. EGFR Driven and EGFR Mutant Cancers [0391] The invention features compounds which can be useful for treating patients who have an EGFR-driven cancer, including cancers which are, or have become, refractory to erlotinib, gefitinib, dacomitinib, afatinib, osimertinib , or cancers which bear an EGFR mutation identified herein, by administering a compound of formula (I) to a subject. [0392] EGFR-driven cancers which can be treated using the compositions and method of the invention include, for example, EGFR mutants including one or more deletions, substitutions, or additions in the amino acid or nucleotide sequences of EGFR, or fragments thereof. [0393] An EGFR-driven cancer may result from an EGFR fusion. For example, the N-terminal of EGFR can be linked to various fusion partners such as RAD51. Cancers (e.g., lung cancers) characterized by an EGFR-fusion (e.g., an EGFR-RAD51 fusion) may be particularly suitable for therapy using any compound described herein, or any pharmaceutically acceptable form (e.g., a pharmaceutically acceptable salt) thereof.
[0394] Mutations in EGFR can occur in any part of the EGFR sequence. Generally, EGFR mutants arise from mutations in the kinase domain (i.e., exons 18-24 in the EGFR sequence) or in the extracellular domain (i.e., exons 2-16 in the EGFR sequence). [0395] A mutation in EGFR can be an activating mutation, which lead to a ligand- independent activation of TK activity. A mutation in EGFR can also be a resistance mutation, which can confer resistance to TKI therapies such as resistance to one or more of erlotinib, gefitinib, dacomitinib, afatinib, or osimertinib. [0396] For example, mutations typically occur in the kinase domain, including one or more of a point mutation in exon 18 (e.g., L688P, V689M, P694L/S, N700D, L703V, E709K/Q/A/G/V, I715S, L718P, G719C/A/S/R, or S720P/F), a deletion in exon 19 that may or may not include an insertion (e.g., delG719, delE746_E749, delE746_A750, delE746_A750insRP, delE746_A750insQP, delE746_T751, delE746_T751insA/I/V, delE746_T751insVA, delE746_S752, delE746_S752insA/V/D, delE746_P53insLS, delL747_E749, delL747_A750, delL747_A750insP, delL747_T751, delL747_T751insP/S/Q, delL747_T751insPI, delL747_S752, delL747_S752insQ, delL747_P753, delL747_P753insS/Q, delL747_L754insSR, delE749_A750, delE749_A750insRP, delE749_T751, delT751_I759, delT751_I759insS/N, or delS752_I759), a duplication in exon 19 (e.g., K739_I44dupKIPVAI), a point mutation in exon 19 (e.g., L730F, W731Stop, P733L, G735S, V742A, E746V/K, A750P, T751I, S752Y, P753S, A754P, or D761Y), an in-frame insertion in exon 20 (e.g., D761_E762insEAFQ, A767_S768insTLA, V769_D770insY, V769_D770insCV, V769_D770insASV, D770_N771insD/G, D770_N771insNPG, D770_N771insSVQ, P772_H773insN/V, P772_H773insYNP, or V774_C775insHV), a deletion in exon 20 that may or may not include an insertion (e.g., delM766_A767, delM766_A767insAI, delA767_V769, delD770, or delP772_H773insNP), a duplication in exon 20 (e.g., S768_D770dupSVD, A767_V769dupASV, or H773dupH), a point mutation in exon 20 (e.g., D761N, A763V, V765A/M, S768I, V769L/M, S768I, P772R, N771T, H773R/Y/L, V774M, R776G/H/C, G779S/F, T783A, T784F, L792P, L798H/F, T790M, R803W, K806E, or L814P), or a point mutation in exon 21 (e.g., G810S, N826S, L833V, H835L, L838V, A839T, K846R, T847I, H850N, V851I/A, I853T, L858M/R, A859T, L861Q/R, G863D, A864T, E866K, or G873E). [0397] In lung cancer, activation mutants are typical.
[0398] In embodiments, a mutation is a resistance mutation. In particular, drug resistance in 50% of lung cancers arises from the T790M point mutation. Other exemplary resistance mutation include point mutations such as: C797X (e.g., C797S, C797G, or C797N); G796X (e.g., G796R, G796S, or G796D); L792X (e.g. L792H, L792F, L792R, or L792Y); G724S; L718X (e.g., L718P, L718Q, or L718V); S768I; or G719A. [0399] In glioblastoma, mutations typically, but not exclusively, occur in the extracellular domain, including EGFR variant I (EGFRvI) lacking the extracellular domain and resembling the v-erbB oncoprotein; EGFRvII lacking 83 amino acids from domain IV; and EGFRvIII lacking amino acids 30-297 from domains I and II, which is the most common amplification and is reported in 30-50% of glioblastomas and 5% of squamous cell carcinoma. Other mutations for glioblastoma include one or more of point mutations in exon 2 (e.g., D46N or G63R), exon 3 (e.g., R108K in domain I), exon 7 (e.g., T263P or A289D/T/V in domain II), exon 8 (e.g., R324L or E330K), exon 15 (e.g., P596L or G598V in domain IV), or exon 21 (L861Q in the kinase domain). [0400] EGFR mutants also include those with a combination of two or more mutations, as described herein. Exemplary combinations include S768I and G719A; S768I and V769L; H773R and W731Stop; R776G and L858R; R776H and L861Q; T790M and L858R; T790M and delE746_A750; R803W and delE746_T751insVA; delL747_E749 and A750P; delL747_S752 and E746V; delL747_S752 and P753S; P772_H773insYNP and H773Y; P772_H773insNP and H773Y; and D770_N771insG and N771T. Other exemplary combinations include any including T790M (e.g., T790M and L858R or T790M and delE746_A750. [0401] EGFR mutants can be either activation mutants or resistant mutants. Activation mutants include those with substitutions that increase drug sensitivity (e.g., G719C/S/A, delE746_A750, or L858R). Resistant mutants include those with substitutions that increase drug resistance (e.g., T790M or any combination including T790M). [0402] In embodiments, an EGFR mutation is a deletion in exon19 (del19). In embodiments, an EGFR mutation is a T790M mutation. In embodiments, an EGFR mutation is a L858R mutation. In embodiments, an EGFR mutation is a C797S mutation. In embodiments, an EGFR-driven cancer (e.g., non-small cell lung cancer) is characterized by at least one of these mutations. In embodiments, an EGFR-driven cancer (e.g., non-small cell lung cancer) is
characterized by at least two of these mutations. In embodiments, an EGFR-driven cancer (e.g., non-small cell lung cancer) is characterized by at least three of these mutations. [0403] EGFR-driven cancers include those having any mutant described herein. For example, EGFRvIII is commonly found in glioblastoma and has also been reported in breast, ovarian, prostate, and lung carcinomas. Exemplary EGFR-driven cancers: glioblastoma, lung cancer (e.g., squamous cell carcinoma, non-small cell lung cancer, adenocarcinoma, bronchioloalveolar carcinoma (BAC), BAC with focal invasion, adenocarcinoma with BAC features, and large cell carcinoma), pancreatic cancer, head and neck cancers (e.g., squamous cell carcinoma), breast cancer, colorectal cancer, epithelial cancer (e.g., squamous cell carcinoma), ovarian cancer, and prostate cancer. [0404] In particular, the invention described herein would benefit patient populations having higher risk for TKI-resistant mutations. About 8,000 to 16,000 new cases per year can be estimated based on: incidence of non-small cell lung cancer (about 160,000 new cases in the U.S.), the response to erlotinib in the general population (about 10%, resulting in a sensitive population of 16,000), the presence of activation mutations (10-20% in white and 30-40% in Asian population, resulting in a sensitive population of 16,000-32,000), acquisition of secondary resistance (most if not all patients, resulting in a sensitive population of 16,000- 32,000), and percentage of patients carrying the T790M point mutations (about 50%, resulting in a sensitive population of 8,000-16,000). Patients having TKI-resistant mutations include those patients having cancers resistant to one or more of erlotinib, gefitinib, dacomitinib, afatinib, osimertinib, CL-387,785, BIBW 2992 (CAS Reg. No.439081-18-2), CI-1033, neratinib (HKI-272), MP-412 (AV-412), PF-299804, AEE78, and XL64. [0405] In particular, the inventions relate to treatment of EGFR-driven cancers having the T790M point mutation. Generally, irreversible inhibitors (e.g., CI-1033, neratinib (HKI-272), and PF-299804) are less potent in cell lines having the T790M mutation and do not inhibit T790M at clinically achievable concentrations. Since the ATP Km of T790M and WT are similar, concentrations that inhibit the mutant will inhibit the WT and result in gastrointestinal and cutaneous events. [0406] An EGFR mutant also includes other amino acid and nucleotide sequences of EGFR with one or more deletions, substitutions, or additions, such as point mutations, that retain or increase tyrosine kinase or phosphorylation activity. Where the mutant is a protein or polypeptide, preferable substitutions are conservative substitutions, which are substitutions
between amino acids similar in properties such as structural, electric, polar, or hydrophobic properties. For example, the substitution can be conducted between basic amino acids (e.g., Lys, Arg, and His), or between acidic amino acids (e.g., Asp and Glu), or between amino acids having non-charged polar side chains (e.g., Gly, Asn, Gln, Ser, Thr, Tyr, and Cys), or between amino acids having hydrophobic side chains (e.g., Ala, Val, Leu, Ile, Pro, Phe, and Met), or between amino acids having branched side chains (e.g., Thr, Val, Leu, and Ile), or between amino acids having aromatic side chains (e.g., Tyr, Trp, Phe, and His). [0407] Where the mutant is a nucleic acid, the DNA encoding an EGFR mutant protein may comprise a nucleotide sequence capable of hybridizing to a complement sequence of the nucleotide sequence encoding an EGFR mutant, as defined herein, under stringent conditions. As used herein, the stringent conditions include low, medium or high stringent conditions. An example of the stringent conditions includes hybridization at approximately 42-55°C in approximately 2-6 x SSC, followed by wash at approximately 50-65°C in approximately 0.1-1 x SSC containing approximately 0.1-0.2% SDS, where 1 x SSC is a solution containing 0.15 M NaCl and 0.015 M Na citrate, pH 7.0. Wash can be performed once or more. In general, stringent conditions may be set at a temperature approximately 5°C lower than a melting temperature (Tm) of a specific nucleotide sequence at defined ionic strength and pH. [0408] The amino acid and nucleotide sequences of EGFR and DNAs encoding them are available from known databases such as NCBI GenBank (USA), EMBL (Europe), etc. For example, GenBank accession numbers for EGFR [Homo sapiens] include MIM131550, AAI28420, NM_005228, NP_005219.2, and GeneID: 1956. EGFR-Selective Inhibition [0409] In some embodiments, a compound described herein, or any pharmaceutically acceptable salt thereof, selectively inhibits EGFR (including any mutant EGFR described herein) over other kinases. [0410] In some embodiments, a compound described herein, or any pharmaceutically acceptable salt thereof, selectively inhibits mutant EGFR (e.g., any mutant EGFR described herein) over wild-type EGFR. In embodiments, a compound described herein selectively inhibits EGFR characterized by a mutation that is: a deletion in exon19 (del19), a T790M mutation, a L858R mutation, and/or a C797S mutation, or any combination thereof. Such
inhibitors can be effective in ameliorating diseases and disorders associated with mutant EGFR activity. [0411] By way of non-limiting example, the ratio of selectivity can be greater than a factor of about 10, greater than a factor of about 20, greater than a factor of about 30, greater than a factor of about 40, greater than a factor of about 50, greater than a factor of about 60, greater than a factor of about 70, greater than a factor of about 80, greater than a factor of about 100, greater than a factor of about 120, or greater than a factor of about 150, where selectivity can be measured by in vitro assays known in the art. Non-limiting examples of assays to measure selectivity include enzymatic assays, cellular proliferation assays, and EGFR phosphorylation assays. In one embodiment, selectivity can be determined by cellular proliferation assays. In another embodiment, selectivity can be determined by EGFR phosphorylation assays. In some embodiments, the mutant EGFR inhibitory activity of a compound as disclosed herein can be less than about 1000 nM, less than about 100 nM, less than about 50 nM, less than about 30 nM, or less than about 10 nM. [0412] In embodiments, the IC50 of a subject compound for mutant EGFR inhibition can be less than about 100 nM, less than about 50 nM, less than about 10 nM, less than about 1 nM, less than about 0.5 nM, or less than about 1 pM. Characterization of EGFR-driven Cancers [0413] The compositions and methods of the invention can be used to treat subjects having an EGFR-driven cancer (i.e., cancers characterized by EGFR mutant expression or overexpression). EGFR mutant expression or overexpression can be determined in a diagnostic or prognostic assay by evaluating levels of EGFR mutants in biological sample, or secreted by the cell (e.g., via an immunohistochemistry assay using anti-EGFR antibodies or anti-p-EGFR antibodies; FACS analysis, etc.). Alternatively, or additionally, one can measure levels of EGFR mutant-encoding nucleic acid or mRNA in the cell, e.g., via fluorescent in situ hybridization using a nucleic acid based probe corresponding to an EGFR mutant-encoding nucleic acid or the complement thereof; (FISH; see WO98/45479, published October, 1998), Southern blotting, Northern blotting, or polymerase chain reaction (PCR) techniques, such as real time quantitative PCR (RT-PCR). One can also study EGFR mutant expression by measuring shed antigen in a biological sample, such as serum, e.g., using antibody-based assays (see also, e.g., U.S. Patent No.4,933,294, issued June 12, 1990; WO91/05264, published April 18, 1991; U.S. Patent 5,401,638, issued March 28, 1995; and Sias et al., J.
Immunol. Methods 132:73 (1990)). Aside from the above assays, various in vivo assays are available to the skilled practitioner. For example, one can expose cells within the body of the mammal to an antibody which is optionally labeled with a detectable label, e.g., a radioactive isotope, and binding of the antibody to cells in the mammal can be evaluated, e.g., by external scanning for radioactivity or by analyzing a biopsy taken from a mammal previously exposed to the antibody. [0414] Examples of biological properties that can be measured in isolated cells include mRNA expression, protein expression, and DNA quantification. Additionally, the DNA of cells isolated by the methods of the invention can be sequenced, or certain sequence characteristics (e.g., polymorphisms and chromosomal abnormalities) can be identified using standard techniques, e.g., FISH or PCR. The chemical components of cells, and other analytes, may also be assayed after isolation. Cells may also be assayed without lysis, e.g., using extracellular or intracellular stains or by other observation, e.g., morphology or growth characteristics in various media. [0415] While any hybridization technique can be used to detect the gene rearrangements, one preferred technique is fluorescent in situ hybridization (FISH). FISH is a cytogenetic technique which can be used to detect and localize the presence or absence of specific DNA or RNA sequences on chromosomes. FISH incorporates the use of fluorescently labeled nucleic acid probes which bind only to those parts of the chromosome with which they show a high degree of sequence similarity. Fluorescence microscopy can be used to find out where the fluorescent probe bound to the chromosome. The basic steps of FISH are outlined below. Exemplary FISH probes include Vysis EGFR SpectrumOrange/ CEP SpectrumGreen Probe (Abbott, Downers Grove, IL), which hybridizes to band 7p12; and ZytoLight SPEC EGFR/CEN 7 Dual Color Probe (ZytoVision), which hybridizes to the alpha-satellite sequences of the centromere of chromosome 7. [0416] For FISH, a probe is constructed that is long enough to hybridize specifically to its target (and not to similar sequences in the genome), but not too large to impede the hybridization process. Probes are generally labeled with fluorophores, with targets for antibodies, with biotin, or any combination thereof. This can be done in various ways, for example using random priming, nick translation, and PCR using tagged nucleotides. [0417] Generally, a sample or aliquot of a population of cells is used for FISH analysis. For example, in one method of preparation, cells are trypsinized to disperse into single cells,
cytospun onto glass slides, and then fixed with paraformaldehyde before storing in 70% ethanol. For preparation of the chromosomes for FISH, the chromosomes are firmly attached to a substrate, usually glass. After preparation, the probe is applied to the chromosome RNA and starts to hybridize. In several wash steps, all unhybridized or partially hybridized probes are washed away. If signal amplification is necessary to exceed the detection threshold of the microscope (which depends on many factors such as probe labeling efficiency, the kind of probe, and the fluorescent dye), fluorescent tagged antibodies or strepavidin are bound to the tag molecules, thus amplifying the fluorescence. [0418] An epifluorescence microscope can be used for observation of the hybridized sequences. The white light of the source lamp is filtered so that only the relevant wavelengths for excitation of the fluorescent molecules arrive onto the sample. Emission of the fluorochromes happens, in general, at larger wavelengths, which allows one to distinguish between excitation and emission light by mean of another optical filter. With a more sophisticated filter set, it is possible to distinguish between several excitation and emission bands, and thus between several fluorochromes, which allows observation of many different probes on the same strand. [0419] Depending on the probes used, FISH can have resolution ranging from huge chromosomes or tiny (~100 kilobase) sequences. The probes can be quantified simply by counting dots or comparing color. [0420] Allele-specific quantitative real time-PCR may also be used to identify a nucleic acid encoding a mutant EGFR protein (see, for e.g., Diagnostic Innovations DxS BCR-ABL T3151 Mutation Test Kit, and Singer et al., Methods in Molec. Biol.181:145 (2001)). This technique utilizes Taq DNA polymerase, which is extremely effective at distinguishing between a match and a mismatch at the 3’-end of the primer (when the 3’-base is mismatched, no efficient amplification occurs). Using this technique, the 3’-end of the primer may be designed to specifically hybridize to a nucleic acid sequence that corresponds to a codon that encodes a mutant amino acid in an EGFR mutant, as described herein. In this way, the specific mutated sequences can be selectively amplified in a patient sample. This technique further utilizes a Scorpion probe molecule, which is a bifunctional molecule containing a PCR primer, a fluorophore, and a quencher. The fluorophore in the probe interacts with a quencher, which reduces fluorescence. During a PCR reaction, when the Scorpion probe binds to the amplicon, the fluorophore and quencher in the Scorpion probe become separated, which leads to an
increase in fluorescence from the reaction tube. Any of the primers described herein may be used in allele-specific quantitative real time PCR. [0421] A biological sample can be analyzed to detect a mutation in an EGFR gene, or expression levels of an EGFR gene, by methods that are known in the art. For example, methods such as direct nucleic acid sequencing, altered hybridization, aberrant electrophoretic gel migration, binding or cleavage mediated by mismatch binding proteins, single-strand conformational polymorphism (SSCP) analysis, or restriction fragment length polymorphism (RFLP) analysis of PCR products derived from a patient sample can be used to detect a mutation in an EGFR gene; ELISA can be used to measure levels of EGFR polypeptide; and PCR can be used to measure the level of an EGFR nucleic acid molecule. [0422] Any of these techniques may be used to facilitate detection of a mutation in a candidate gene, and each is well known in the art; examples of particular techniques are described, without limitation, in Orita et al. (Proc. Natl. Acad. Sci. USA 86:2766 (1989)) and Sheffield et al. (Proc. Natl. Acad. Sci. USA 86:232 (1989)). Furthermore, expression of the candidate gene in a biological sample (e.g., a biopsy) may be monitored by standard Northern blot analysis or may be aided by PCR (see, e.g., Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY (1995); PCR Technology: Principles and Applications for DNA Amplification, H.A. Ehrlich, Ed., Stockton Press, NY; Yap et al., Nucl. Acids. Res.19:4294 (1991)). [0423] One skilled in the art may identify in a nucleic acid or protein sequence a residue (e.g., amino acid or nucleotide) or codon that corresponds to a residue or codon in wild-type EGFR or EGFR mutants using a number of sequence alignment software programs (e.g., NCBI BLAST website). Such software programs may allow for gaps in the alignment of the compared sequences. Using such software, one skilled in the art may identify a nucleotide, amino acid, or amino acid that corresponding to a specific nucleotide, amino acid, or codon in wild-type EGFR or EGFR mutants. [0424] Levels of EGFR expression (e.g., DNA, mRNA, or protein) in a biological sample can be determined by using any of a number of standard techniques that are well known in the art or described herein. Exemplary biological samples include plasma, blood, sputum, pleural effusion, bronchoalveolar lavage, or biopsy, such as a lung biopsy and lymph node biopsy. For example, EGFR expression in a biological sample (e.g., a blood or tissue sample) from a patient can be monitored by standard northern blot analysis or by quantitative PCR (see, e.g.,
Ausubel et al., supra; PCR Technology: Principles and Applications for DNA Amplification, H.A. Ehrlich, Ed., Stockton Press, NY; Yap et al., Nucl. Acids. Res.19:4294 (1991)). Combination Therapies [0425] In some embodiments, provided herein are methods for combination therapies in which an agent known to modulate other pathways, or other components of the same pathway, or even overlapping sets of target enzymes are used in combination with a compound as provided herein, or a pharmaceutically acceptable form (e.g., pharmaceutically acceptable salts, hydrates, solvates, isomers, prodrugs, and isotopically labeled derivatives) thereof. In one aspect, such therapy includes, but is not limited to, the combination of the subject compound with chemotherapeutic agents, therapeutic antibodies, and radiation treatment, to provide a synergistic or additive therapeutic effect. [0426] When administered as a combination, the therapeutic agents can be formulated as separate compositions that are administered at the same time or sequentially at different times, or the therapeutic agents can be given as a single composition. The phrase “combination therapy", in referring to the use of a disclosed compound together with another pharmaceutical agent, means the coadministration of each agent in a substantially simultaneous manner as well as the administration of each agent in a sequential manner, in either case, in a regimen that will provide beneficial effects of the drug combination. Coadministration includes, inter alia, the simultaneous delivery, e.g., in a single tablet, capsule, injection or other dosage form having a fixed ratio of these active agents, as well as the simultaneous delivery in multiple, separate dosage forms for each agent respectively. Thus, the administration of disclosed compounds can be in conjunction with additional therapies known to those skilled in the art in the prevention or treatment of cancer, such as radiation therapy or cytostatic agents, cytotoxic agents, other anti-cancer agents and other drugs to amerliorate symptoms of the cancer or side effects of any of the drugs. [0427] In some embodiments, treatment can be provided in combination with one or more other cancer therapies, include surgery, radiotherapy (e.g., gamma-radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, and systemic radioactive isotopes, etc.), endocrine therapy, biologic response modifiers (e.g., interferons, interleukins, and tumor necrosis factor (TNF)), hyperthermia, cryotherapy, agents to attenuate any adverse effects (e.g., antiemetics), and other cancer chemotherapeutic drugs. The other
agent(s) can be administered using a formulation, route of administration and dosing schedule the same or different from that used with the compounds provided herein.
[0428] In embodiments, combination therapy comprises administration of a compound described herein, or any pharmaceutically acceptable form thereof (e.g., any pharmaceutically acceptable salt thereof), or a pharmaceutical composition thereof, in combination with anticancer drugs (e.g., antiproliferative agents, anti-angiogenic agents and other chemotherapeutic agents).
[0429] In embodiments, combination therapy comprises administration of a compound described herein, or any pharmaceutically acceptable form thereof (e.g., any pharmaceutically acceptable salt thereof), or a pharmaceutical composition thereof, in combination with an amount of an anti-cancer agent (e.g., a chemotherapeutic agent).
[0430] From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.
[0431] All references, patents or applications, U.S. or foreign, cited in the application are hereby incorporated by reference as if written herein in their entireties. Where any inconsistencies arise, material literally disclosed herein controls.
Claims
CLAIMS What is claimed is: 1. A compound of Formula (AI):
or a pharmaceutically acceptable salt thereof, wherein: A is C6-10 arylene, 5-12-membered heteroarylene, or 5-12-membered heterocycloalkylene; X1 is N or CRX; X2 is N or CRX; X3 is N or CRX”; X4 is N or CRX”; X6 is N or CRX’; X7 is N or CRX’; ------ represents an optional double bond between X7 and X4 or X4 and X6, wherein one and only one double bond is present; X5 is a covalent bond, CH2, O, NR4, C(O)NR4, or NR4C(O); L1 is a covalent bond or C(R5)2, and L2 is C1-4 alkylene, or L1 and L2 combine to form a C3-6 cycloalkyl or a 4- to 6-membered heterocycloalkyl; R1 is –LP-E, halogen, C1-6 alkyl, C3-7 cycloalkyl, C6-10 aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocycloalkyl, CN, NR6R7, NR6C(O)R7, NR6C(O)NH2, OR8, or C(O)NR6R7, and where valency permits when R1 is not –LP-E, R1 optionally further comprises -LP-E; R2 is absent, H, C1-6 alkyl, halogen, CN, or C1-6 alkoxy; each R3, when present, is independently OH, CN, halogen, C1-6 alkyl, or C1-6 alkoxy; n is 0, 1, or 2;
each RX is independently H, ORX1, CN, halogen, or C1-6 alkyl, wherein RX1 is H or C1- 6 alkyl; each RX’ is independently H, ORX1, CN, halogen, or C1-6 alkyl, wherein RX1 is H or C1- 6 alkyl, or RX’ is absent if the carbon to which it is attached is part of a double bond; each RX” is independently –LP-E, H, ORX1, CN, halogen, or C1-6 alkyl optionally comprising -LP-E, and wherein RX1 is H or C1-6 alkyl optionally comprising –LP-E; LP is a linker; E is an E3 ubiquitin ligase ligand; each R4 and R5 is independently H or C1-6 alkyl; each R6 and R7 is independently H, C1-6 alkyl, C3-7 cycloalkyl, or 3- to 10-membered heterocycloalkyl; or R6 and R7 together with the nitrogen atom to which they are attached form a 3- to 8-membered heterocycloalkyl ring; and R8 is independently H, C1-6 alkyl, or 4- to 6-membered heterocycloalkyl; and wherein the compound comprises one and only one LP-E moiety.
2. A compound of Formula (BI):
or a pharmaceutically acceptable salt thereof, wherein A1 is independently phenylene or 5- or 6-membered heteroarylene; A2 is independently phenyl, naphthyl, or a 5- to 13-membered heteroaryl; X1 is independently O or X1A; X1A is a covalent bond, S, NR4, C1-6 alkylene, C2-6 alkenylene, or C2-6 alkynylene; each of X2 and X3 is independently N or CR1B; L1 is independently a covalent bond or C1-6 alkylene; L2 is independently a covalent bond, C2-6 alkenylene, C2-6 alkynylene, C3-6 cycloalkylene, 3- to 10-membered heterocyclylene, phenylene, or 5- or 6-membered heteroarylene; each R1A and R1B is independently H, OH, CN, halogen, C1-6 aliphatic, C1-6 alkoxy, NR6R7, C(O)R8, CO2R8, C(O)NR6R7, NR9C(O)R8, NR9CO2R8, NR9C(O)NR6R7, or R10;
each R2, when present, is independently OH, CN, halogen, C1-6 aliphatic, C1-6 alkoxy, NR6R7, C(O)R8, CO2R8, C(O)NR6R7, NR9C(O)R8, NR9CO2R8, NR9C(O)NR6R7, R10, OR10, CH2R10, CH2CH2R10, OCH2R10, or OCH2CH2R10; each R3, when present, is independently –LP-E, OH, CN, halogen, C1-6 aliphatic, C1-6 alkoxy, NR6R7, C(O)R8, CO2R8, C(O)NR6R7, NR9C(O)R8, NR9CO2R8, NR9C(O)NR6R7, R10, OR10, CH2R10, CH2CH2R10, OCH2R10, or OCH2CH2R10, and where valency permits when R3 is not –LP-E, R3 optionally further comprises –LP-E; LP is a linker; E is an E3 ubiquitin ligase ligand; each R4 is independently H, a N-protecting group, or C1-6 alkyl; R5 is hydrogen; each R6, R7, and R9 is independently H or C1-6 alkyl; or R6 and R7, together with the nitrogen atom to which they are attached, form a 3- to 10-membered heterocyclyl, or R6 and R9, together with the atoms to which they are attached, form a 3- to 10-membered heterocyclyl; R8 is independently C1-6 aliphatic, C3-C10 cycloaliphatic, 3- to 10-membered heterocyclyl, phenyl, naphthyl, or a 5- to 12-membered heteroaryl, or R8 and R9, together with the atoms to which they are attached, form a 3- to 10-membered heterocyclyl; R10 is independently C3-C10 cycloaliphatic, 3- to 10-membered heterocyclyl, phenyl, naphthyl, or a 5- to 12-membered heteroaryl; each of n and o is independently 0, 1, or 2; wherein X1 is O, and both of X2 and X3 are not N, then A2 is naphthyl or a bicyclic 8- to 12-membered heteroaryl; and wherein the compound comprises one and only one LP-E moiety. 3. A compound of Formula (CI):
or a pharmaceutically acceptable salt thereof, wherein X2 is independently N or CR5; each of X3 and X4 is independently a covalent bond, O, S, NR6, C(O)NR6, NR6C(O), NR6C(O)NR6, or (C(R7)2)q; L1 is independently a covalent bond, C1-6 heteroalkylene, C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, C3-6 cycloalkylene, 3- to 10-membered heterocyclylene, phenylene, or 5- to 10-membered heteroarylene; each R1 is independently LP-E,
(Substructure A), OH, CN, halogen, C1-6 aliphatic, C1-6 alkoxy, NR8R9, C(O)R10, CO2R10, C(O)NR8R9, NR11C(O)R10, NR11CO2R10, NR11C(O)NR8R9, or (CH2)rR12, or two R1 or two R2, together to which the atoms they are attached form a 5- to 10-membered ring, and where valency permits when R1 is not –LP-E, R1 optionally further comprises –LP-E; each R2 is independently LP-E,
(Substructure A), OH, CN, halogen, C1-6 aliphatic, C1-6 alkoxy, NR8R9, C(O)R10, CO2R10, C(O)NR8R9, NR11C(O)R10, NR11CO2R10, NR11C(O)NR8R9, or (CH2)rR12, or two R1 or two R2, together to which the atoms they are attached form a 5- to 10-membered ring, and where valency permits when R2 is not –LP-E, R2 optionally further comprises –LP-E; LP is a linker; E is an E3 ubiquitin ligase ligand; L2 is independently a covalent bond, O, NRL, C(O), C(O)NRL, NRLC(O), CRL 2; RL is independently H or C1-6 alkyl; A is independently phenyl, naphthyl, 5- to 13-membered heteroaryl, C3-C10 cycloaliphatic, or 3- to 10-membered heterocyclyl; B is independently phenyl, naphthyl, 5- to 13-membered heteroaryl, C3-C10 cycloaliphatic, or 3- to 10-membered heterocyclyl; C is independently 5- or 6-membered heteroaryl; each R3 is independently OH, CN, halogen, C1-6 aliphatic, C1-6 alkoxy, NR8R9, C(O)R10, CO2R10, C(O)NR8R9, NR11C(O)R10, NR11CO2R10, NR11C(O)NR8R9, or (CH2)rR12; each R4 is independently –LP-E, H, OH, CN, halogen, C1-6 aliphatic, C1-6 alkoxy, NR8R9, C(O)R10, CO2R10, C(O)NR8R9, NR11C(O)R10, NR11CO2R10, NR11C(O)NR8R9,
NR11(CH2)sNR8R9, (CH2)tNR8R9, (CH2)tOH, (CH2)tOCH3, O(CH2)tOH, O(CH2)tOCH3, O(CH2)rR12, or (CH2)rR12; or R4 and R6 or R4 and R7, together with the atoms to which they are attached, form a 5- to 6-membered ring, and where valency permits when R4 is not –LP-E, R4 optionally further comprises –LP-E; each R5 is independently H, OH, CN, halogen, C1-6 aliphatic, C1-6 alkoxy, NR8R9, C(O)R10, CO2R10, C(O)NR8R9, NR11C(O)R10, NR11CO2R10, NR11C(O)NR8R9, or (CH2)rR12; each R6 is independently H, a N-protecting group, or C1-6 alkyl; or R6 and R4, together with the atoms to which they are attached, form a 5- to 6-membered ring; each R7 is independently H or C1-6 alkyl; or two R7 on the same carbon combine to from an oxo (=O) group; or R7 and R4, together with the atoms to which they are attached, form a 5- to 6-membered ring; each R8, R9, and R11 is independently H or C1-6 alkyl; or R8 and R9, together with the nitrogen atom to which they are attached, form a 3- to 10-membered heterocyclyl, or R8 and R11, together with the atoms to which they are attached, form a 3- to 10-membered heterocyclyl; each R10 is independently C1-6 aliphatic, C3-C10 cycloaliphatic, 3- to 10-membered heterocyclyl, phenyl, naphthyl, or a 5- to 12-membered heteroaryl, or R10 and R11, together with the atoms to which they are attached, form a 3- to 10-membered heterocyclyl; each R12 is independently C3-C10 cycloaliphatic,
3- to 10-membered heterocyclyl, phenyl, naphthyl, or a 5- to 12-membered heteroaryl; each m, n, and o, is independently 0, 1, or 2; each p is independently 0, 1, 2; 3, or 4; each q is independently 1 or 2; each r is independently an integer of 0-4; each s is independently an integer of 2-6; each t is independently an integer of 1-6; and wherein the compound comprises one and only one LP-E moiety.
5. The compound of claim 4, wherein: L1-L2-X5 when present is CH(CH3)-(CH2)2-O, CH(CH3)-(CH2)3-O, CH(CH2CH3)-(CH2)2-O, C(CH3)2-(CH2)2-O, (CH2)3-O, CH2-CH(CH3)CH2-O, CH2-
CH2CH(CH3)-O, CH(CH3)-(CH2)2-NH, CH(CH3)-(CH2)2-NCH3, CH(CH3)-(CH2)3- NH, CH(CH3)-(CH2)3-NCH3, CH(CH3)-(CH2)3, or CH(CH3)-(CH2)4, or L1-L2-X5 is
6. The compound of claim 4 or 5, wherein R2 is H or unsubstituted C1-6 alkyl; or R2 is unsubstituted C1-6 alkyl or C1-6 alkyl substituted by a group that is unsubstituted C3-6 cycloalkyl.
7. The compound of claim 1, selected from the group consisting of the compounds of Table A2, or a pharmaceutically acceptable salt thereof:
9. The compound of claim 7, wherein: (a) the compound is according to Formula (BIX), (BX), or (BXI), or a pharmaceutically acceptable salt thereof, wherein L1 is C1-C6 alkylene optionally substituted by 1, 2, or 3 R13; each R13 is independently unsubstituted C1-C3 alkyl; and R1A is independently unsubstitued C1-C6 alkyl or C1-C6 haloalkyl; (b) the compound is according to Formula (BXII), or a pharmaceutically acceptable salt thereof, wherein R1A is independently unsubstitued C1-C6 alkyl or C1-C6 haloalkyl; or (c) the compound is according to Formula (BXIII) or (BXIV), or a pharmaceutically acceptable salt thereof, wherein L1 is C1-C6 alkylene optionally substituted by 1 or 2 R13; each R13 is independently unsubstituted C1-C3 alkyl; and R1A is independently unsubstitued C1-C6 alkyl or C1-C6 haloalkyl.
10. The compound of claim 2, selected from the group consisting of the compounds of Table B2, or a pharmaceutically acceptable salt thereof.
11. The compound of claim 3, having a structure selected from the following formulas:
or a pharmaceutically acceptable salt thereof, wherein
R4A is a first R4 group, R4B is a second R4 group, R4C is a third R4 group, R4D is a fourth R4 group, preferably R4 is unsubstituted C1-6 alkyl if one or more of R4A, R4B, and R4C is also present; and p is 0 or 1.
12. The compound of claim 3, selected from the group consisting of the compounds of Table C2 and Table C3, or a pharmaceutically acceptable salt thereof.
14. The compound of any one of claims 1-13, wherein a linker LP is a covalent bond.
15. The compound of any one of claims 1-13, wherein a linker LP comprises a C1-C20 alkylene, a C2-C20 heteroalkylene, a C2-C20 monoalkynylene, and/or one or more ethyleneglycol moieties.
16. The compound of claim 15, wherein a linker LP comprises one or more oxo (=O) substituents as valency permits.
17. The compound of any one of claims 1-13 and 15-16, wherein linker LP comprises a heterocyclyl moiety that is attached to the EGFR ligand moiety of the compound via a covalent bond or via a CH2 or C(O) linker.
19. The compound of any one of claims 1-13 and 15-16, wherein linker LP does not comprise a heterocyclyl moiety that is attached to the EGFR ligand moiety of the compound via a covalent bond or via a CH2 or C(O) linker.
20. The compound of any one of claims 1-12, wherein –LP-E comprises a structure or is a structure selected from the group consisting of:
22. A pharmaceutical composition comprising a compound according to any one of claims 1-21, or a pharmaceutically acceptable salt thereof.
23. A method of treating cancer comprising administering to a human in need thereof an effective amount of a compound according to any one of claims 1-21 or a pharmaceutically acceptable salt thereof in a pharmaceutical composition.
24. The method of claim 23, wherein said cancer is a lung cancer.
25. The method of claim 23 or 24, wherein said cancer is non-small cell lung cancer.
26. The method of any one of claims 23-25, wherein said cancer is an EGFR-driven cancer.
27. The method of any one of claims 23-26, wherein said cancer is characterized by an EGFR mutation.
28. The method of claim 27, wherein said EGFR mutation is a resistance mutation.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263410823P | 2022-09-28 | 2022-09-28 | |
US63/410,823 | 2022-09-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024073507A1 true WO2024073507A1 (en) | 2024-04-04 |
Family
ID=88689857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/075262 WO2024073507A1 (en) | 2022-09-28 | 2023-09-27 | Macrocyclic compounds and uses thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024073507A1 (en) |
Citations (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4933294A (en) | 1984-01-30 | 1990-06-12 | Icrf Patents Limited | Method of detecting truncated epidermal growth factor receptors |
WO1991005264A1 (en) | 1989-09-29 | 1991-04-18 | Oncogenetics Partners | Detection and quantification of neu related proteins in the biological fluids of humans |
US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
WO1998045479A1 (en) | 1997-04-04 | 1998-10-15 | Albany Medical College | Method for assessing prostate cancer |
US20160045607A1 (en) | 2014-08-11 | 2016-02-18 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
US20160214972A1 (en) | 2015-01-20 | 2016-07-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
US20160272639A1 (en) | 2015-03-18 | 2016-09-22 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
US20170327469A1 (en) | 2015-01-20 | 2017-11-16 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
US20180072711A1 (en) | 2016-09-15 | 2018-03-15 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
US20180147202A1 (en) | 2015-06-05 | 2018-05-31 | Arvinas, Inc. | TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE |
US20180155322A1 (en) | 2016-12-01 | 2018-06-07 | Arvinas, Inc. | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
WO2018119441A1 (en) | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Egfr proteolysis targeting chimeric molecules and associated methods of use |
US20180237418A1 (en) | 2017-01-26 | 2018-08-23 | Arvinas, Inc. | Modulators of estrogen receptor proteolysis and associated methods of use |
US20190070185A1 (en) | 2013-03-15 | 2019-03-07 | G1 Therapeutics, Inc. | Hspc-sparing treatments for rb-positive abnormal cellular proliferation |
US20190076539A1 (en) | 2016-05-10 | 2019-03-14 | C4 Theraprutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
US20190106417A1 (en) | 2016-04-22 | 2019-04-11 | Dana-Farber Cancer Institute, Inc. | Bifunctional molecules for degradation of egfr and methods of use |
US20200010468A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
US20200140456A1 (en) | 2017-06-20 | 2020-05-07 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
US20200155690A1 (en) | 2014-04-14 | 2020-05-21 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
WO2020132561A1 (en) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Targeted protein degradation |
US20200207733A1 (en) | 2017-09-04 | 2020-07-02 | C4 Therapeutics, Inc. | Dihydroquinolinones for medical treatment |
US20200207783A1 (en) | 2017-09-04 | 2020-07-02 | C4 Therapeutics, Inc. | Glutarimides for medical treatment |
WO2020181232A1 (en) | 2019-03-06 | 2020-09-10 | C4 Therapeutics, Inc. | Heterocyclic compounds for medical treatment |
US20200308171A1 (en) | 2017-12-18 | 2020-10-01 | Hoffmann-La Roche Inc. | Bifunctional inhibitors with egfr having a e3 ubiquitin ligase moiety |
US20200361930A1 (en) | 2018-02-05 | 2020-11-19 | Hoffmann-La Roche Inc. | Bifunctional molecules that degrade egfr |
US10849982B2 (en) | 2016-05-10 | 2020-12-01 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
US20210002296A1 (en) | 2018-01-12 | 2021-01-07 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
US20210009559A1 (en) | 2018-03-26 | 2021-01-14 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
US10905768B1 (en) | 2016-05-10 | 2021-02-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
US20210032245A1 (en) | 2018-04-16 | 2021-02-04 | C4 Therapeutics, Inc. | Spirocyclic compounds |
US20210070763A1 (en) | 2018-06-04 | 2021-03-11 | C4 Therapeutics, Inc. | Spirocyclic compounds |
WO2021086785A1 (en) | 2019-10-28 | 2021-05-06 | F. Hoffmann-La Roche Ag | Bifunctional compounds |
WO2021083949A1 (en) | 2019-10-29 | 2021-05-06 | F. Hoffmann-La Roche Ag | Bifunctional compounds for the treatment of cancer |
WO2021127561A1 (en) | 2019-12-20 | 2021-06-24 | C4 Therapeutics, Inc. | Isoindolinone and indazole compounds for the degradation of egfr |
US20210187108A1 (en) | 2015-08-19 | 2021-06-24 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
WO2021121261A1 (en) | 2019-12-16 | 2021-06-24 | 北京泰德制药股份有限公司 | Compound for inhibiting and inducing degradation of egfr kinase |
US20210198256A1 (en) | 2018-09-04 | 2021-07-01 | C4 Therapeutics, Inc. | Compounds for the degradation of brd9 or mth1 |
US20210228562A1 (en) | 2019-12-17 | 2021-07-29 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
WO2021168074A1 (en) | 2020-02-18 | 2021-08-26 | Theseus Pharmaceuticals, Inc. | Macrocyclic compounds and uses thereof |
US11117889B1 (en) | 2018-11-30 | 2021-09-14 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
US11185592B2 (en) | 2016-05-10 | 2021-11-30 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
WO2021255212A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Braf degraders |
WO2021255213A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Heterobifunctional compounds as degraders of braf |
US20210395273A1 (en) | 2020-06-03 | 2021-12-23 | Kymera Therapeutics, Inc. | Crystalline forms of irak degraders |
WO2022032132A1 (en) | 2020-08-07 | 2022-02-10 | C4 Therapeutics, Inc. | Advantageous therapies for disorders mediated by ikaros or aiolos |
WO2022032026A1 (en) | 2020-08-05 | 2022-02-10 | C4 Therapeutics, Inc. | Compounds for targeted degradation of ret |
US11254672B2 (en) | 2017-09-04 | 2022-02-22 | C4 Therapeutics, Inc. | Dihydrobenzimidazolones for medical treatment |
US20220054453A1 (en) | 2020-07-30 | 2022-02-24 | Kymera Therapeutics, Inc. | Methods of treating mutant lymphomas |
WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
US20220089570A1 (en) | 2014-04-14 | 2022-03-24 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
US20220098194A1 (en) | 2020-03-05 | 2022-03-31 | C4 Therapeutics, Inc. | Compounds for targeted degradation of brd9 |
WO2022081925A1 (en) | 2020-10-14 | 2022-04-21 | C4 Therapeutics, Inc. | Tricyclic ligands for degradation of ikzf2 or ikzf4 |
WO2022081927A1 (en) | 2020-10-14 | 2022-04-21 | C4 Therapeutics, Inc. | Tricyclic compounds to degrade neosubstrates for medical therapy |
WO2022081928A1 (en) | 2020-10-14 | 2022-04-21 | C4 Therapeutics, Inc. | Tricyclic heterobifunctional compounds for degradation of targeted proteins |
US20220127279A1 (en) | 2015-07-10 | 2022-04-28 | Arvinas Operations, Inc. | Mdm2-based modulators of proteolysis and associated methods of use |
US11318205B1 (en) | 2017-12-26 | 2022-05-03 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
US20220144809A1 (en) | 2020-11-06 | 2022-05-12 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor and associated methods of use |
US20220162163A1 (en) | 2015-07-13 | 2022-05-26 | Arvinas Operations, Inc. | Alanine-based modulators of proteolysis and associated methods of use |
US11407732B1 (en) | 2019-04-12 | 2022-08-09 | C4 Therapeutics, Inc. | Tricyclic degraders of Ikaros and Aiolos |
US20220251061A1 (en) | 2017-11-16 | 2022-08-11 | C4 Therapeutics, Inc. | Degraders and degrons for targeted protein degradation |
US20220259154A1 (en) | 2016-10-11 | 2022-08-18 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
WO2022178532A1 (en) | 2021-02-19 | 2022-08-25 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
US20220274993A1 (en) | 2021-02-15 | 2022-09-01 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
US20220281831A1 (en) | 2019-07-15 | 2022-09-08 | Kymera Therapeutics, Inc. | Fused-glutarimide crbn ligands and uses thereof |
-
2023
- 2023-09-27 WO PCT/US2023/075262 patent/WO2024073507A1/en unknown
Patent Citations (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4933294A (en) | 1984-01-30 | 1990-06-12 | Icrf Patents Limited | Method of detecting truncated epidermal growth factor receptors |
US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
WO1991005264A1 (en) | 1989-09-29 | 1991-04-18 | Oncogenetics Partners | Detection and quantification of neu related proteins in the biological fluids of humans |
WO1998045479A1 (en) | 1997-04-04 | 1998-10-15 | Albany Medical College | Method for assessing prostate cancer |
US20190070185A1 (en) | 2013-03-15 | 2019-03-07 | G1 Therapeutics, Inc. | Hspc-sparing treatments for rb-positive abnormal cellular proliferation |
US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
US20200155690A1 (en) | 2014-04-14 | 2020-05-21 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
US20220089570A1 (en) | 2014-04-14 | 2022-03-24 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
US20160045607A1 (en) | 2014-08-11 | 2016-02-18 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
US20170327469A1 (en) | 2015-01-20 | 2017-11-16 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
US20160214972A1 (en) | 2015-01-20 | 2016-07-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
US20180346461A1 (en) | 2015-01-20 | 2018-12-06 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
US20200392131A1 (en) | 2015-03-18 | 2020-12-17 | Arvinas Operations, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
US20160272639A1 (en) | 2015-03-18 | 2016-09-22 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
US20180147202A1 (en) | 2015-06-05 | 2018-05-31 | Arvinas, Inc. | TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE |
US20210145832A1 (en) | 2015-06-05 | 2021-05-20 | Arvinas Operations, Inc. | TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE |
US20220127279A1 (en) | 2015-07-10 | 2022-04-28 | Arvinas Operations, Inc. | Mdm2-based modulators of proteolysis and associated methods of use |
US20220162163A1 (en) | 2015-07-13 | 2022-05-26 | Arvinas Operations, Inc. | Alanine-based modulators of proteolysis and associated methods of use |
US20210187108A1 (en) | 2015-08-19 | 2021-06-24 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
US20190106417A1 (en) | 2016-04-22 | 2019-04-11 | Dana-Farber Cancer Institute, Inc. | Bifunctional molecules for degradation of egfr and methods of use |
US20190076539A1 (en) | 2016-05-10 | 2019-03-14 | C4 Theraprutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
US10905768B1 (en) | 2016-05-10 | 2021-02-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
US10849982B2 (en) | 2016-05-10 | 2020-12-01 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
US11185592B2 (en) | 2016-05-10 | 2021-11-30 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
US20210040081A1 (en) | 2016-09-15 | 2021-02-11 | Arvinas Operations, Inc. | Indole derivatives as estrogen receptor degraders |
US20180072711A1 (en) | 2016-09-15 | 2018-03-15 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
US20220259154A1 (en) | 2016-10-11 | 2022-08-18 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
US20180155322A1 (en) | 2016-12-01 | 2018-06-07 | Arvinas, Inc. | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
US20210220475A1 (en) | 2016-12-23 | 2021-07-22 | Arvinas Operations, Inc. | Egfr proteolysis targeting chimeric molecules and associated methods of use |
US20180193470A1 (en) | 2016-12-23 | 2018-07-12 | Arvinas, Inc. | Egfr proteolysis targeting chimeric molecules and associated methods of use |
WO2018119441A1 (en) | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Egfr proteolysis targeting chimeric molecules and associated methods of use |
US20180237418A1 (en) | 2017-01-26 | 2018-08-23 | Arvinas, Inc. | Modulators of estrogen receptor proteolysis and associated methods of use |
US20200140456A1 (en) | 2017-06-20 | 2020-05-07 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
US20200207783A1 (en) | 2017-09-04 | 2020-07-02 | C4 Therapeutics, Inc. | Glutarimides for medical treatment |
US11254672B2 (en) | 2017-09-04 | 2022-02-22 | C4 Therapeutics, Inc. | Dihydrobenzimidazolones for medical treatment |
US20200207733A1 (en) | 2017-09-04 | 2020-07-02 | C4 Therapeutics, Inc. | Dihydroquinolinones for medical treatment |
US20220251061A1 (en) | 2017-11-16 | 2022-08-11 | C4 Therapeutics, Inc. | Degraders and degrons for targeted protein degradation |
US20200308171A1 (en) | 2017-12-18 | 2020-10-01 | Hoffmann-La Roche Inc. | Bifunctional inhibitors with egfr having a e3 ubiquitin ligase moiety |
US11318205B1 (en) | 2017-12-26 | 2022-05-03 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
US20210002296A1 (en) | 2018-01-12 | 2021-01-07 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
US20200361930A1 (en) | 2018-02-05 | 2020-11-19 | Hoffmann-La Roche Inc. | Bifunctional molecules that degrade egfr |
US20210009559A1 (en) | 2018-03-26 | 2021-01-14 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
US20210032245A1 (en) | 2018-04-16 | 2021-02-04 | C4 Therapeutics, Inc. | Spirocyclic compounds |
US20210070763A1 (en) | 2018-06-04 | 2021-03-11 | C4 Therapeutics, Inc. | Spirocyclic compounds |
US20200010468A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
US20210198256A1 (en) | 2018-09-04 | 2021-07-01 | C4 Therapeutics, Inc. | Compounds for the degradation of brd9 or mth1 |
US11117889B1 (en) | 2018-11-30 | 2021-09-14 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
WO2020132561A1 (en) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Targeted protein degradation |
WO2020181232A1 (en) | 2019-03-06 | 2020-09-10 | C4 Therapeutics, Inc. | Heterocyclic compounds for medical treatment |
US11407732B1 (en) | 2019-04-12 | 2022-08-09 | C4 Therapeutics, Inc. | Tricyclic degraders of Ikaros and Aiolos |
US20220281831A1 (en) | 2019-07-15 | 2022-09-08 | Kymera Therapeutics, Inc. | Fused-glutarimide crbn ligands and uses thereof |
WO2021086785A1 (en) | 2019-10-28 | 2021-05-06 | F. Hoffmann-La Roche Ag | Bifunctional compounds |
WO2021083949A1 (en) | 2019-10-29 | 2021-05-06 | F. Hoffmann-La Roche Ag | Bifunctional compounds for the treatment of cancer |
EP4079735A1 (en) * | 2019-12-16 | 2022-10-26 | Beijing Tide Pharmaceutical Co., Ltd. | Compound for inhibiting and inducing degradation of egfr kinase |
WO2021121261A1 (en) | 2019-12-16 | 2021-06-24 | 北京泰德制药股份有限公司 | Compound for inhibiting and inducing degradation of egfr kinase |
US20210228562A1 (en) | 2019-12-17 | 2021-07-29 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
WO2021127561A1 (en) | 2019-12-20 | 2021-06-24 | C4 Therapeutics, Inc. | Isoindolinone and indazole compounds for the degradation of egfr |
WO2021168074A1 (en) | 2020-02-18 | 2021-08-26 | Theseus Pharmaceuticals, Inc. | Macrocyclic compounds and uses thereof |
US20220098194A1 (en) | 2020-03-05 | 2022-03-31 | C4 Therapeutics, Inc. | Compounds for targeted degradation of brd9 |
US20210395273A1 (en) | 2020-06-03 | 2021-12-23 | Kymera Therapeutics, Inc. | Crystalline forms of irak degraders |
WO2021255213A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Heterobifunctional compounds as degraders of braf |
WO2021255212A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Braf degraders |
US20220054453A1 (en) | 2020-07-30 | 2022-02-24 | Kymera Therapeutics, Inc. | Methods of treating mutant lymphomas |
WO2022032026A1 (en) | 2020-08-05 | 2022-02-10 | C4 Therapeutics, Inc. | Compounds for targeted degradation of ret |
WO2022032132A1 (en) | 2020-08-07 | 2022-02-10 | C4 Therapeutics, Inc. | Advantageous therapies for disorders mediated by ikaros or aiolos |
WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
WO2022081925A1 (en) | 2020-10-14 | 2022-04-21 | C4 Therapeutics, Inc. | Tricyclic ligands for degradation of ikzf2 or ikzf4 |
WO2022081927A1 (en) | 2020-10-14 | 2022-04-21 | C4 Therapeutics, Inc. | Tricyclic compounds to degrade neosubstrates for medical therapy |
WO2022081928A1 (en) | 2020-10-14 | 2022-04-21 | C4 Therapeutics, Inc. | Tricyclic heterobifunctional compounds for degradation of targeted proteins |
US20220144809A1 (en) | 2020-11-06 | 2022-05-12 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor and associated methods of use |
US20220274993A1 (en) | 2021-02-15 | 2022-09-01 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
WO2022178532A1 (en) | 2021-02-19 | 2022-08-25 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
Non-Patent Citations (11)
Title |
---|
"GenBank", Database accession no. NP_005219.2 |
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY |
AUSUBEL ET AL.: "Current Protocols in Molecular Biology", 1995, JOHN WILEY & SONS |
BURKE ET AL.: "Overcoming Cancer Drug Resistance Utilizing PROTAC Technology", FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, vol. 10, 872729, 25 April 2022 (2022-04-25), pages 1 - 22, XP093104187, DOI: http://dx.doi.org/10.3389/fcell.2022.872729 * |
CHONG ET AL., NATURE MED, vol. 19, no. 11, 2013, pages 1389 - 1400 |
CIECHANOVER A. ET AL., BIOESSAYS, vol. 22, 2000, pages 442 - 451 |
S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19 |
SHEFFIELD ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 2766 |
SIAS ET AL., J., vol. 132, 1990, pages 3 |
SINGER ET AL., METHODS IN MOLEC. BIOL., vol. 181, 2001, pages 145 |
YAP ET AL., NUCL. ACIDS. RES., vol. 19, 1991, pages 4294 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI448464B (en) | Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) | |
TWI642667B (en) | Pyridino pyrimidine derivatives, preparation method and medical use thereof | |
KR20230067635A (en) | Indole derivatives as RAS inhibitors in the treatment of cancer | |
US8541403B2 (en) | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency | |
US20230148005A1 (en) | Macrocyclic compounds and uses thereof | |
CN116209438A (en) | Treatment of malignant diseases with SHP2 mutations using SOS1 inhibitors | |
KR20100044816A (en) | Phthalazinone derivatives as inhibitors of parp-1 | |
WO2011130661A1 (en) | Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp) | |
WO2012166151A1 (en) | Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml) | |
WO2022217042A1 (en) | Naphthyl-substituted quinoline-4(1h)-ones and related compounds and their use in treating medical conditions | |
IL306067A (en) | Macrocyclic egfr inhibitors for the treatment of cancer | |
WO2024073507A1 (en) | Macrocyclic compounds and uses thereof | |
WO2022036313A1 (en) | Pyrimidinyl sulfonamides as inhibitors of ack1/tnk1 tyrosine kinase | |
EP3878841B1 (en) | Indazole kinase inhibitor and use thereof | |
AU2022359282A1 (en) | Combinations of kras g12d inhibitors with pi3ka inhibitors and related methods of treatment | |
WO2023215471A1 (en) | Tetrahydroisoquinoline heterobifunctional bcl-xl degraders | |
CN117580841A (en) | Macrocyclic compounds and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23800661 Country of ref document: EP Kind code of ref document: A1 |